

disorders related to the secreted proteins. The proteins, and polynucleotide sequences may be useful for treating disorders of the immune system, hyperproliferative disorders, infectious disease, regeneration of tissues, for chemotaxis and for screening molecules that bind to the proteins. The proteins or polynucleotide sequences may be used as food additives or preservatives, to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, co-factors or other nutritional components. Agonists or antagonists of the proteins may be used to prevent scar tissue growth during wound healing, and hyper-vascular diseases. AAA39043 to AAA39051 and AAB08890 are sequences used in the exemplification of the present invention

Sequence 327 AA;
Query Match 99.6%; Score 1692; DB 3; Length 327;
Best Local Similarity 99.7%; Pred. No. 7.4e-114;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Y 1 MABELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
b 1 MABELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
Y 61 FVQPGKPISESHPTLYFTNGHLVPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
b 61 FVQPGKPISESHPTLYFTNGHLVPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
Y 121 CQVNNPPDFYTNGLINLTVLPSPNPLCSQSGTSGVSTALRCSSSEGAPKPVYNNV 180
b 121 CQVNNPPDFYTNGLINLTVLPSPNPLCSQSGTSGVSTALRCSSSEGAPKPVYNNV 180
Y 181 RLGTPTTSPSGMWQDEVSGQLILTNLSLTSSGTYRCVATNQMSASCCELLTSLVTEPPQG 240
b 181 RLGTPTTSPSGMWQDEVSGQLILTNLSLTSSGTYRCVATNQMSASCCELLTSLVTEPPQG 240
Y 241 RVAGALIGVLLGLVLLSVAAFLVRFQERKPKKPKETTYGGSGLREDALAPGISEHTCMRA 300
b 241 RVAGALIGVLLGLVLLSVAAFLVRFQERKPKKPKETTYGGSGLREDALAPGISEHTCMRA 300
Y 301 DSSKGFLEPSSASTVTTTTSKLPMMV 327
b 301 DSSKGFLEPSSASTVTTTTSKLPMMV 327

RESULT 2
AA87251
ID AAY87251 standard; protein; 327 AA.
XX AAY87251;
XX 11-MAY-2000 (first entry)
XX Human signal peptide containing protein HSPP-28 SEQ ID NO:28.
DE Human; signal peptide-containing protein; HSPP; diagnosis; cancer;
XX inflammation; cardiovascular disease; anticancer; anti-inflammatory;
KW antimicrobial; neurotropic; neuroprotective; cardiovascular; hepatotropic;
KW antiaesthetic; gene therapy; cell proliferation; neurological disorder;
KW reproductive disorder; developmental disorder; arteriosclerosis;
KW cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;
KW parkinson's disease; infection; Alzheimer's disease; schizophrenia;
KW muscular dystrophy.
XX Homo sapiens.
XX OS
XX WO200000610-A2.
XX PN
XX 06-JAN-2000.
XX PD
XX 25-JUN-1999; 99WO-US014484.
XX PF
XX 26-JUN-1998; 98US-0090762P.
XX

31-JUL-1998; 98US-0094983P.
PR 01-OCT-1998; 98US-0102686P.
PR 11-DEC-1998; 98US-0112129P.
XX (INCY-) INCYTE PHARM INC.
XX Lal P, Tang YT, Gorgone GA, Corley MC, Guegler KJ, Baughn MR;
PI Akerblom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL;
PI Bandman O;
XX WPI; 2000-160673/14.
DR N-PSDB; AAZ98136.
XX New human signal peptide-containing proteins useful in treatment,
PT prevention and diagnosis of e.g. cancer, inflammation and cardiovascular
PT disease.
XX Claim 1; Page 177-178; 327pp; English.
PS

AAZ98109 to AAZ98242 encode AAY87224 to AAY87357 which represent the human signal peptide-containing proteins HSPP-1 to HSPP-134. HSPPs have anticancer, anti-inflammatory, antimicrobial, neurotropic, hepatotropic, neuroprotective, cardiovascular and antiaesthetic activities, and can be used in gene therapy. HSPPs can be used to treat or prevent disorders associated with decreased activity or function of HSPP. Antagonists of HSPP are used to treat or prevent disorders associated with increased activity or function of HSPP. Such diseases include cell proliferation (including cancer), inflammation, cardiovascular, neurological, reproductive or developmental disorders, (e.g. arteriosclerosis, cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia, asthma, Crohn's disease, microbial or other infections, congestive or ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSPP nucleic acids can be used for the recombinant production of HSPP, for detecting HSPP in standard hybridisation and amplification assays (for diagnosis and monitoring), in gene therapy, as antisense, triplex-forming or ribozyme therapeutics, for detecting related sequences or genetic variations, and for chromosomal mapping. HSPP are also used to raise specific antibodies (Ab) and to screen for agonists and antagonists (potential therapeutic agents). Ab are used to diagnose, or monitor, HSPP-related diseases (in usual immunoassays), as therapeutic antagonists, in competitive drug screens, and for purification of HSPP from natural sources

XX Sequence 327 AA;
SQ Query Match 99.5%; Score 1691; DB 3; Length 327;
Best Local Similarity 99.7%; Pred. No. 8.8e-114;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 MABELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
DB 1 MABELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
QY 61 FVQPGKPISESHPTLYFTNGHLVPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
DB 61 FVQPGKPISESHPTLYFTNGHLVPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
QY 121 CQVNNPPDFYTNGLINLTVLPSPNPLCSQSGTSGVSTALRCSSSEGAPKPVYNNV 180
DB 121 CQVNNPPDFYTNGLINLTVLPSPNPLCSQSGTSGVSTALRCSSSEGAPKPVYNNV 180
QY 181 RLGTPTTSPSGMWQDEVSGQLILTNLSLTSSGTYRCVATNQMSASCCELLTSLVTEPPQG 240
DB 181 RLGTPTTSPSGMWQDEVSGQLILTNLSLTSSGTYRCVATNQMSASCCELLTSLVTEPPQG 240
QY 241 RVAGALIGVLLGLVLLSVAAFLVRFQERKPKKPKETTYGGSGLREDALAPGISEHTCMRA 300
DB 241 RVAGALIGVLLGLVLLSVAAFLVRFQERKPKKPKETTYGGSGLREDALAPGISEHTCMRA 300
QY 301 DSSKGFLEPSSASTVTTTTSKLPMMV 327
DB 301 DSSKGFLEPSSASTVTTTTSKLPMMV 327

This Page Blank (uspto)

DT	25-OCT-2004 (TrEMBLrel. 28, Last annotation update)	
DE	V-set and immunoglobulin domain containing 2 (CTH Variant).	
GN	Name=V8IG2; ORFNames=UNQ2770;	
OS	Homo sapiens (Human).	
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
OX	NCBI_TaxID=9606;	
RN	[1]	
RP	SEQUENCE FROM N.A.	
RC	TISSUE=Colon;	
EX	MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;	
RA	Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,	
RA	Klausner R.D., Collins F.S., Wagner L., Shemen C.M., Schuler G.D.,	
RA	Altshul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,	
RA	Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P.,	
RA	Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,	
RA	Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,	
RA	Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,	
RA	Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,	
RA	Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,	
RA	Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,	
RA	Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,	
RA	Fahy J., Helton E., Kettner M., Madan A., Rodriguez S., Sanchez A.,	
RA	Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,	
RA	Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,	
RA	Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,	
RA	Krzywiecki M.I., Skalska J., Smallic D.E., Schnerch A., Schein J.E.,	
RA	Jones S.J., Marra M.A.;	
RT	"Generation and initial analysis of more than 15,000 full-length human	
RT	and mouse cDNA sequences."	
RL	Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).	
RN	[2]	
RP	SEQUENCE FROM N.A.	
RC	TISSUE=Colon;	
RA	Director MGC Project;	
RA	Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.	
RN	[3]	
RP	SEQUENCE FROM N.A.	
RX	MEDLINE=22987296; PubMed=12975309; DOI=10.1101/gr.1293003;	
RA	Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D., Brush J.,	
RA	Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,	
RA	Eaton D., Foster J., Grimaldi C., Gu Q., Hass P.E., Heldeng S.,	
RA	Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,	
RA	Lewis L., Liao D., Mark M., Robbie B., Sanchez C., Schoenfeld J.,	
RA	Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,	
RA	Vandlen R., Watanabe C., Wiedand D., Woods K., Xie M.H., Yansura D.,	
RA	Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A., Wood W.I.,	
RA	Godowski P.;	
RT	"The secreted protein discovery initiative (SPDI), a large-scale	
RT	effort to identify novel human secreted and transmembrane proteins: a	
RT	bioinformatics assessment."	
RL	Genome Res. 13:2265-2270 (2003).	
DR	EMBL; BC007313; AA07313.1; -	
DR	EMBL; AY358897; AA089256.1; -	
DR	HSSP; 088792; 1P97.	
DR	GO; GO:0004872; F:receptor activity; IEA.	
DR	InterPro; IPR007110; Ig-like.	
DR	Pfam; PF00047; Ig; 1.	
DR	PROSITE; PS00835; IG-LIKE; 2.	
SQ	SEQUENCE 327 AA; 34348 MW; CP395ACTEF951AC1 CRC64;	
Query Match	99.2%; Score 1155; DB 2; Length 327;	
Best Local Similarity	100.0%; Pred. No. 2.1e-83;	
Matches 220; Conservative	0; Mismatches 0; Indels 0; Gaps 0;	
Qy	1 VEVKVTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISSEHPILYFTNGHLY 60	
Db	24 VEVKVTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISSEHPILYFTNGHLY 83	
Qy	61 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGYTLCOVNNPPDFYTNGLGLNLTVLV 120	
Db	84 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGYTLCOVNNPPDFYTNGLGLNLTVLV 143	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	144 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 203	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRVA 220	
Db	204 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRVA 243	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy	121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180	
Db	143 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 202	
Qy	181 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 219	
Db	203 LTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQGRV 241	
Qy</		

This Page Blank (uspto)

Db 1 MAELPGPLCCAGLGLCLSLAVENKVPTEPLSTPLGKTAELICTTSTVSDSFALEWS 60
QY 61 FVQPKPISESHPILYFTNGHLYPTGSKSRVSLLONPPTVGATLKLTDVHPDSTGYL 120
Db 61 FVQPKPISESHPILYFTNGHLYPTGSKSRVSLLONPPTVGATLKLTDVHPDSTGYL 120
QY 121 CQVNNPDPFYNGLGLNLTLVLPSPNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYVNW 180
Db 121 CQVNNPDPFYNGLGLNLTLVLPSPNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYVNW 180
QY 181 RLGTFTPTSPGSMQVDSVQGLILTNLSLTSSGTYRCVATNQMSASCELTLSTVTSQ 240
Db 181 RLGTFTPTSPGSMQVDSVQGLILTNLSLTSSGTYRCVATNQMSASCELTLSTVTSQ 240
QY 241 RVREL 245
Db 241 RVREL 245

RESULT 5

US-10-227-884-236
Sequence 236, Application US/10227884
Publication No. US20030027988A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Deenoyers, Luc
APPLICANT: Gerritsen, Mary
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Smith, Victoria
APPLICANT: Stephan, Jean-Philippe P.
APPLICANT: Watanabe, Colin L.
APPLICANT: Wood, William I.
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P3530P1C79
CURRENT APPLICATION NUMBER: US/10/227,884
CURRENT FILING DATE: 2002-08-26
PRIOR APPLICATION NUMBER: 10/119,480
PRIOR FILING DATE: 2002-04-09
PRIOR APPLICATION NUMBER: 60/059113
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/062287
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/063549
PRIOR FILING DATE: 1997-10-28
PRIOR APPLICATION NUMBER: 60/064103
PRIOR FILING DATE: 1997-10-31
PRIOR APPLICATION NUMBER: 60/069873
PRIOR FILING DATE: 1997-12-17
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079656
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: 60/079728
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/081819
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081955
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082804
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/084441
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/085323
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085579
PRIOR FILING DATE: 1998-05-15

PRIOR APPLICATION NUMBER: 60/086392
PRIOR FILING DATE: 1998-05-22
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089905
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090691
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/095302
PRIOR FILING DATE: 1998-08-04
PRIOR APPLICATION NUMBER: 60/095318
PRIOR FILING DATE: 1998-08-04
PRIOR APPLICATION NUMBER: 60/095916
PRIOR FILING DATE: 1998-08-10
PRIOR APPLICATION NUMBER: 60/096146
PRIOR FILING DATE: 1998-08-11
PRIOR APPLICATION NUMBER: 60/096791
PRIOR FILING DATE: 1998-08-17
PRIOR APPLICATION NUMBER: 60/097986
PRIOR FILING DATE: 1998-08-26
PRIOR APPLICATION NUMBER: 60/098544
PRIOR FILING DATE: 1998-08-31
PRIOR APPLICATION NUMBER: 60/099596
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099803
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099811
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099812
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099816
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/100038
PRIOR FILING DATE: 1998-09-11
PRIOR APPLICATION NUMBER: 60/100385
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100390
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100627
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100848
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100919
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/101477
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101738
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101741
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101786
PRIOR FILING DATE: 1998-09-25
PRIOR APPLICATION NUMBER: 60/101916
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101922
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/106178
PRIOR FILING DATE: 1998-10-28
PRIOR APPLICATION NUMBER: 60/106248
PRIOR FILING DATE: 1998-10-29
PRIOR APPLICATION NUMBER: 60/106464

This Page Blank (uspto)

;; PRIOR FILING DATE: 1998-10-30
;; PRIOR APPLICATION NUMBER: 60/106905
;; PRIOR FILING DATE: 1998-11-03
;; PRIOR APPLICATION NUMBER: 60/108787
;; PRIOR FILING DATE: 1998-11-17
;; PRIOR APPLICATION NUMBER: 60/108801
;; PRIOR FILING DATE: 1998-11-17
;; PRIOR APPLICATION NUMBER: 60/108849
;; PRIOR FILING DATE: 1998-11-18
;; PRIOR APPLICATION NUMBER: 60/112422
;; PRIOR FILING DATE: 1998-12-15
;; PRIOR APPLICATION NUMBER: 60/113296
;; PRIOR FILING DATE: 1998-12-22
;; PRIOR APPLICATION NUMBER: 60/113605
;; PRIOR FILING DATE: 1998-12-23
;; PRIOR APPLICATION NUMBER: 60/113621
;; PRIOR FILING DATE: 1998-12-23
;; PRIOR APPLICATION NUMBER: 60/115558
;; PRIOR FILING DATE: 1999-01-12
;; PRIOR APPLICATION NUMBER: 60/115565
;; PRIOR FILING DATE: 1999-01-12
;; PRIOR APPLICATION NUMBER: 60/115733
;; PRIOR FILING DATE: 1999-01-12
;; PRIOR APPLICATION NUMBER: 60/119549
;; PRIOR FILING DATE: 1999-02-10
;; PRIOR APPLICATION NUMBER: 60/123618
;; PRIOR FILING DATE: 1999-03-10
;; PRIOR APPLICATION NUMBER: 60/125259
;; PRIOR FILING DATE: 1999-03-19
;; PRIOR APPLICATION NUMBER: 60/125775
;; PRIOR FILING DATE: 1999-03-23
;; PRIOR APPLICATION NUMBER: 60/126773
;; PRIOR FILING DATE: 1999-03-29
;; PRIOR APPLICATION NUMBER: 60/127887
;; PRIOR FILING DATE: 1999-04-05
;; PRIOR APPLICATION NUMBER: 60/130232
;; PRIOR FILING DATE: 1999-04-21
;; PRIOR APPLICATION NUMBER: 60/131022
;; PRIOR FILING DATE: 1999-04-26
;; PRIOR APPLICATION NUMBER: 60/131270
;; PRIOR FILING DATE: 1999-04-27
;; PRIOR APPLICATION NUMBER: 60/131291
;; PRIOR FILING DATE: 1999-04-27
;; PRIOR APPLICATION NUMBER: 60/131445
;; PRIOR FILING DATE: 1999-04-28
;; PRIOR APPLICATION NUMBER: 60/134287
;; PRIOR FILING DATE: 1999-05-14
;; PRIOR APPLICATION NUMBER: 60/140650
;; PRIOR FILING DATE: 1999-06-22
;; PRIOR APPLICATION NUMBER: 60/140723
;; PRIOR FILING DATE: 1999-06-22
;; PRIOR APPLICATION NUMBER: 60/141037
;; PRIOR FILING DATE: 1999-06-23
;; PRIOR APPLICATION NUMBER: 60/144758
;; PRIOR FILING DATE: 1999-07-20
;; PRIOR APPLICATION NUMBER: 60/145698
;; PRIOR FILING DATE: 1999-07-26
;; PRIOR APPLICATION NUMBER: 60/146222
;; PRIOR FILING DATE: 1999-07-28
;; PRIOR APPLICATION NUMBER: 60/146963
;; PRIOR FILING DATE: 1999-08-03
;; PRIOR APPLICATION NUMBER: 60/149320
;; PRIOR FILING DATE: 1999-08-17
;; PRIOR APPLICATION NUMBER: 60/149638
;; PRIOR FILING DATE: 1999-08-17
;; PRIOR APPLICATION NUMBER: 60/151733
;; PRIOR FILING DATE: 1999-08-31
;; PRIOR APPLICATION NUMBER: 60/164418
;; PRIOR FILING DATE: 1999-11-09
;; PRIOR APPLICATION NUMBER: 60/166361
;; PRIOR FILING DATE: 1999-11-16
;; PRIOR APPLICATION NUMBER: 60/169445
;; PRIOR FILING DATE: 1999-12-07

;; PRIOR APPLICATION NUMBER: 60/169495
;; PRIOR FILING DATE: 1999-12-07
;; PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.3%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCAGLIGFLCGLAVEVVKVPTPEPLSTPLGKTAELTCTYSTVSVDGSALEWS 60
DB 1 MAELPGPFLCAGLIGFLCGLAVEVVKVPTPEPLSTPLGKTAELTCTYSTVSVDGSALEWS 60

QY 61 FVQPKDISSEHPILYFTNGHLVPTGSKSRVSLLOQNPPTVGATLKLTDVHPSDTGYL 120
DB 61 FVQPKDISSEHPILYFTNGHLVPTGSKSRVSLLOQNPPTVGATLKLTDVHPSDTGYL 120

QY 121 CQVNNPDPFTNGGLINLTVLPSPNPLCSQSGTSGGSTARLRCSSSEGAPKPVYNNV 180
DB 121 CQVNNPDPFTNGGLINLTVLPSPNPLCSQSGTSGGSTARLRCSSSEGAPKPVYNNV 180

QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLSTVTEPSQ 240
DB 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLSTVTEPSQ 240

QY 241 RVA 243
DB 241 RVA 243

RESULT 6

US-10-230-163-236
;; Sequence 236, Application US/10230163
;; Publication No. US20030036635A1
;; GENERAL INFORMATION:
;; APPLICANT: Baker, Kevin P.
;; APPLICANT: Desnoyers, Luc
;; APPLICANT: Gerritsen, Mary
;; APPLICANT: Goddard, Audrey
;; APPLICANT: Godowski, Paul J.
;; APPLICANT: Grimaldi, J. Christopher
;; APPLICANT: Gurney, Austin L.
;; APPLICANT: Smith, Victoria
;; APPLICANT: Stephan, Jean-Philippe F.
;; APPLICANT: Watanabe, Colin L.
;; APPLICANT: Wood, William I.
;; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;; TITLE OF INVENTION: ACIDS ENCODING THE SAME
;; FILE REFERENCE: P3530PIC96
;; CURRENT APPLICATION NUMBER: US/10/230,163
;; CURRENT FILING DATE: 2002-08-28
;; PRIOR APPLICATION NUMBER: 10/119,480
;; PRIOR FILING DATE: 2002-04-09
;; PRIOR APPLICATION NUMBER: 60/059113
;; PRIOR FILING DATE: 1997-09-17
;; PRIOR APPLICATION NUMBER: 60/062287
;; PRIOR FILING DATE: 1997-10-17
;; PRIOR APPLICATION NUMBER: 60/063549
;; PRIOR FILING DATE: 1997-10-28
;; PRIOR APPLICATION NUMBER: 60/064103
;; PRIOR FILING DATE: 1997-10-31
;; PRIOR APPLICATION NUMBER: 60/069873
;; PRIOR FILING DATE: 1997-12-17
;; PRIOR APPLICATION NUMBER: 60/078910
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/079294
;; PRIOR FILING DATE: 1998-03-25
;; PRIOR APPLICATION NUMBER: 60/079656
;; PRIOR FILING DATE: 1998-03-26
;; PRIOR APPLICATION NUMBER: 60/079728
;; PRIOR FILING DATE: 1998-03-27
;; PRIOR APPLICATION NUMBER: 60/081819
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081955

This Page Blank (uspto)

GenCore version 5.1.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.
OM protein - protein search, using sw model
Run on: August 4, 2005, 06:13:42 ; Search time 66.0997 Seconds
(without alignments)
1447.018 Million cell updates/sec

Title: US-10-607-565-83_COPY_1_245
Perfect score: 1286
Sequence: 1 MAELPGPFLCGALLGFLCLS.....ASCELTSLVTPSQGRVABL 245
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5
Searched: 1752860 seqs, 390397842 residues
Total number of hits satisfying chosen parameters: 1752860

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA:*

1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US10E_PUBCOMB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US10F_PUBCOMB.pep.*
19: /cgn2_6/ptodata/1/pubpaa/US11A_PUBCOMB.pep.*
20: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
21: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
22: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES				Description	
Result No.	Score	Query Match %	Length DB ID		
1	1286	100.0	245	9	US-09-820-893-98
2	1286	100.0	245	15	US-10-607-565-98
3	1286	100.0	246	9	US-09-820-893-83
4	1286	100.0	246	15	US-10-607-565-83
5	1277	99.3	327	14	US-10-227-884-236
6	1277	99.3	327	14	US-10-230-163-236
7	1277	99.3	327	14	US-10-230-338-236
8	1277	99.3	327	14	US-10-218-631-236
9	1277	99.3	327	14	US-10-230-414-236
10	1277	99.3	327	14	US-10-232-224-236
11	1277	99.3	327	14	US-10-216-159A-236

12	1277	99.3	327	14	US-10-218-849-236	Sequence 236, App
13	1277	99.3	327	14	US-10-227-873-236	Sequence 236, App
14	1277	99.3	327	14	US-10-227-883-236	Sequence 236, App
15	1277	99.3	327	14	US-10-219-076-236	Sequence 236, App
16	1277	99.3	327	14	US-10-230-434-236	Sequence 236, App
17	1277	99.3	327	14	US-10-219-003-236	Sequence 236, App
18	1277	99.3	327	14	US-10-219-075-236	Sequence 236, App
19	1277	99.3	327	14	US-10-219-464-236	Sequence 236, App
20	1277	99.3	327	14	US-10-219-466-236	Sequence 236, App
21	1277	99.3	327	14	US-10-219-479-236	Sequence 236, App
22	1277	99.3	327	14	US-10-219-481-236	Sequence 236, App
23	1277	99.3	327	14	US-10-230-260-236	Sequence 236, App
24	1277	99.3	327	14	US-10-232-231-236	Sequence 236, App
25	1277	99.3	327	14	US-10-232-233-236	Sequence 236, App
26	1277	99.3	327	14	US-10-216-165-236	Sequence 236, App
27	1277	99.3	327	14	US-10-218-956-236	Sequence 236, App
28	1277	99.3	327	14	US-10-219-488-236	Sequence 236, App
29	1277	99.3	327	14	US-10-219-478-236	Sequence 236, App
30	1277	99.3	327	14	US-10-219-536-236	Sequence 236, App
31	1277	99.3	327	14	US-10-233-205-236	Sequence 236, App
32	1277	99.3	327	14	US-10-219-072-236	Sequence 236, App
33	1277	99.3	327	14	US-10-219-470-236	Sequence 236, App
34	1277	99.3	327	14	US-10-219-474-236	Sequence 236, App
35	1277	99.3	327	14	US-10-219-524-236	Sequence 236, App
36	1277	99.3	327	14	US-10-219-528-236	Sequence 236, App
37	1277	99.3	327	14	US-10-227-881-236	Sequence 236, App
38	1277	99.3	327	14	US-10-227-882-236	Sequence 236, App
39	1277	99.3	327	14	US-10-230-436-236	Sequence 236, App
40	1277	99.3	327	14	US-10-232-225-236	Sequence 236, App
41	1277	99.3	327	14	US-10-232-227-236	Sequence 236, App
42	1277	99.3	327	14	US-10-232-229-236	Sequence 236, App
43	1277	99.3	327	14	US-10-232-234-236	Sequence 236, App
44	1277	99.3	327	14	US-10-232-236-236	Sequence 236, App
45	1277	99.3	327	14	US-10-232-238-236	Sequence 236, App

ALIGNMENTS

RESULT 1
US-09-820-893-98
; Sequence 98, Application US/09820893
; Patent No. US20020076705A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human Secreted Proteins
; FILE REFERENCE: PZ033PI
; CURRENT APPLICATION NUMBER: US/09/820,893
; CURRENT FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 09/531,119
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: 60/102,895
; PRIOR FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 98
; LENGTH: 245
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-820-893-98

Query Match				100.0%	Score 1286;	DB 9;	Length 245;
Best Local Similarity				100.0%	Pred. No. 1.1e-96;		
Matches 245;				Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	MAELPGPFLCGALLGFLCLSGLAVEKVPTEPLSTPLGKTABLTCTYSTVSGDSFALEWS	60				
DB	1	MAELPGPFLCGALLGFLCLSGLAVEKVPTEPLSTPLGKTABLTCTYSTVSGDSFALEWS	60				
QY	61	FVQPGKPISSEHPILFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSTGTYL	120				
DB	61	FVQPGKPISSEHPILFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSTGTYL	120				

Qy	121	CQVNNPPDPYTNGLGLINLTVLPSPNPLCSQSGTQSVGGSTALRCSSSGAPKPYVNV	180
Db	121	CQVNNPPDPYTNGLGLINLTVLPSPNPLCSQSGTQSVGGSTALRCSSSGAPKPYVNV	180
Qy	181	RLGTFPTPSPGSMQDEVSGQLITNLSTSGTYRCVATNQMSASCELLT	240
Db	181	RLGTFPTPSPGSMQDEVSGQLITNLSTSGTYRCVATNQMSASCELLT	240
Qy	241	RVABL	245
Db	241	RVABL	245

```

RESULT 2
US-10-607-565-98
; Sequence 98, Application US/10607566
; Publication No. US20040048294A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human Secreted Proteins
; FILE REFERENCE: P2033P1
; CURRENT APPLICATION NUMBER: US/10/607,565
; CURRENT FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: US/09/531,119
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/101,546
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/102,895
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 98
; LENGTH: 245
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-607-565-98

```

[illegible]

```

RESULT 3
US-09-820-893-83
; Sequence 83, Application US/09820893
; Patent No. US20020076705A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human Secreted Proteins
; FILE REFERENCE: P2033P1
; CURRENT APPLICATION NUMBER: US/09/820,893
; CURRENT FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 09/531,119

```

```

; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: 60/102,895
; PRIOR FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 83
; LENGTH: 246
; TYPE: PR1
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (246)
; OTHER INFORMATION: Xaa equals stop translation
US-09-820-893-83

```

Query Match	100.0%;	Score 1286;	DB 9;	Length 246;
Best Local Similarity	100.0%;	Pred. No. 1.1e-96;		
Matches 245;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0
Qy	1	MAELPGGFCLGALIGFLCLSGLA	VEVKVPEPLSTPLGKTAELTCTYSTSVGDS	FALEWS 60
Db	1	MAELPGGFCLGALLGFLCLSGLA	VEVKVPEPLSTPLGKTAELTCTYSTSVGDS	FALEWS 60
Qy	61	FVQGRKDISSEHPILYETNGHLY	PTGSKSRVSILOHPPTVGVA	TLKLTLDVHPSDTGYL 120
Db	61	FVQGRKDISSEHPILYETNGHLY	PTGSKSRVSILOHPPTVGVA	TLKLTLDVHPSDTGYL 120
Qy	121	CQVNNPPDYFTNGLGLNLNLTVL	VPSPNPLCSQSGQTSVGGSTAL	RCSSEGAPKPVYNNV 180
Db	121	CQVNNPPDYFTNGLGLNLNLTVL	VPSPNPLCSQSGQTSVGGSTAL	RCSSEGAPKPVYNNV 180
Qy	181	RLGTFPPSPGSMVQDEVSGOLIL	TNLSSTSGGYRCVATNQMSAS	CELTLSVTEPSQG 240
Db	181	RLGTFPPSPGSMVQDEVSGOLIL	TNLSSTSGGYRCVATNQMSAS	CELTLSVTEPSQG 240
Qy	241	RVAEL 245		
Db	241	RVAEL 245		

```

RESULT 4
US-10-607-565-83
; Sequence 83, Application US/10607565
; Publication No. US20040048294A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human Secreted Proteins
; FILE REFERENCE: P2033P1
; CURRENT APPLICATION NUMBER: US/10/607,565
; CURRENT FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: US/09/531,119
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/101,546
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/102,895
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: PatentIn ver. 2.0
; SEQ ID NO 83
; LENGTH: 246
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (246)
; OTHER INFORMATION: Xaa equals stop translation
US-10-607-565-83

```

```

Query Match      100.0%; Score 1286; DB 15; Length 246;
Best Local Similarity 100.0%; Pred. No. 1.1e-96;
Matches 245; Conservative 0; Mismatches 0; Indels 0; Gaps 0
Qy 1 MAELPGPFLCGALGFLCLSGLAVEVKVPTPLCTPLCKTAEELCTCTYSTVGDSFALEWS 60

```

Db 1 MASELPGLCGALLGFLCLSGLAVERKVPTEPLSTPLGKTAELTCTVSTVGDSFALEWS 60
Qy 61 FVOPGKPISSHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTVDVHPSDGTGYL 120
Db 61 FVOPGKPISSHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTVDVHPSDGTGYL 120
Qy 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSGAPKPVYNNV 180
Db 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSGAPKPVYNNV 180
Qy 181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTTCRCVATNMGSAACELTLVTPBSQG 240
Db 181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTTCRCVATNMGSAACELTLVTPBSQG 240
Qy 241 RVAEL 245
Db 241 RVAEL 245

RESULT 5

US-10-227-884-236

; Sequence 236, Application US/10227884

; Publication No. US20030027988A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Desnoyers, Luc

; APPLICANT: Gerritsen, Mary

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, J. Christopher

; APPLICANT: Gurney, Austin L.

; APPLICANT: Smith, Victoria

; APPLICANT: Stephan, Jean-Philippe F.

; APPLICANT: Watanabe, Colin L.

; APPLICANT: Wood, William I.

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE OF INVENTION: ACIDS ENCODING THE SAME

; FILE REFERENCE: P3530P1C79

; CURRENT APPLICATION NUMBER: US/10/227,884

; CURRENT FILING DATE: 2002-08-26

; PRIOR APPLICATION NUMBER: 10/119,480

; PRIOR FILING DATE: 2002-04-09

; PRIOR APPLICATION NUMBER: 60/059113

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/062287

; PRIOR FILING DATE: 1997-10-17

; PRIOR APPLICATION NUMBER: 60/063549

; PRIOR FILING DATE: 1997-10-28

; PRIOR APPLICATION NUMBER: 60/064103

; PRIOR FILING DATE: 1997-10-31

; PRIOR APPLICATION NUMBER: 60/069873

; PRIOR FILING DATE: 1997-12-17

; PRIOR APPLICATION NUMBER: 60/078910

; PRIOR FILING DATE: 1998-03-20

; PRIOR APPLICATION NUMBER: 60/079294

; PRIOR FILING DATE: 1998-03-25

; PRIOR APPLICATION NUMBER: 60/079656

; PRIOR FILING DATE: 1998-03-26

; PRIOR APPLICATION NUMBER: 60/079728

; PRIOR FILING DATE: 1998-03-27

; PRIOR APPLICATION NUMBER: 60/081819

; PRIOR FILING DATE: 1998-04-15

; PRIOR APPLICATION NUMBER: 60/081955

; PRIOR FILING DATE: 1998-04-15

; PRIOR APPLICATION NUMBER: 60/082804

; PRIOR FILING DATE: 1998-04-22

; PRIOR APPLICATION NUMBER: 60/084441

; PRIOR FILING DATE: 1998-05-06

; PRIOR APPLICATION NUMBER: 60/085323

; PRIOR FILING DATE: 1998-05-13

; PRIOR APPLICATION NUMBER: 60/085579

; PRIOR FILING DATE: 1998-05-15

; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464

```
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/115558
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115565
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115733
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/119549
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/123618
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/125259
; PRIOR FILING DATE: 1999-03-19
; PRIOR APPLICATION NUMBER: 60/125775
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 60/126773
; PRIOR FILING DATE: 1999-03-29
; PRIOR APPLICATION NUMBER: 60/127887
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 60/130232
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: 60/131022
; PRIOR FILING DATE: 1999-04-26
; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14
; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/144758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07

; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match          99.3%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAELPGPFLCGALIGFLCGLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
   |||||
Db 1 MAELPGPFLCGALIGFLCGLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
   |||||

Qy 61 FVQPKPISESHPILYFTNGHLYPTGSKSKVSVLLQNPPTVGVATLKLTDVHPSDTGYL 120
   |||||
Db 61 FVQPKPISESHPILYFTNGHLYPTGSKSKVSVLLQNPPTVGVATLKLTDVHPSDTGYL 120
   |||||

Qy 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKEVYNWV 180
   |||||
Db 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKEVYNWV 180
   |||||

Qy 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGSASCELTLVTEPSQG 240
   |||||
Db 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGSASCELTLVTEPSQG 240
   |||||

Qy 241 RVA 243
   |||
Db 241 RVA 243
   |||

RESULT 6
US-10-230-163-236
; Sequence 236, Application US/10230163
; Publication No. US20030036635A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C96
; CURRENT APPLICATION NUMBER: US/10/230,163
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
```


, PRIOR FILING DATE: 1998-04-15
 , PRIOR APPLICATION NUMBER: 60/082804
 , PRIOR FILING DATE: 1998-04-22
 , PRIOR APPLICATION NUMBER: 60/084441
 , PRIOR FILING DATE: 1998-05-06
 , PRIOR APPLICATION NUMBER: 60/085323
 , PRIOR FILING DATE: 1998-05-13
 , PRIOR APPLICATION NUMBER: 60/085579
 , PRIOR FILING DATE: 1998-05-15
 , PRIOR APPLICATION NUMBER: 60/086392
 , PRIOR FILING DATE: 1998-05-22
 , PRIOR APPLICATION NUMBER: 60/089532
 , PRIOR FILING DATE: 1998-06-17
 , PRIOR APPLICATION NUMBER: 60/089538
 , PRIOR FILING DATE: 1998-06-17
 , PRIOR APPLICATION NUMBER: 60/089905
 , PRIOR FILING DATE: 1998-06-18
 , PRIOR APPLICATION NUMBER: 60/090472
 , PRIOR FILING DATE: 1998-06-24
 , PRIOR APPLICATION NUMBER: 60/090557
 , PRIOR FILING DATE: 1998-06-24
 , PRIOR APPLICATION NUMBER: 60/090691
 , PRIOR FILING DATE: 1998-06-25
 , PRIOR APPLICATION NUMBER: 60/090695
 , PRIOR FILING DATE: 1998-06-25
 , PRIOR APPLICATION NUMBER: 60/091982
 , PRIOR FILING DATE: 1998-07-07
 , PRIOR APPLICATION NUMBER: 60/095302
 , PRIOR FILING DATE: 1998-08-04
 , PRIOR APPLICATION NUMBER: 60/095318
 , PRIOR FILING DATE: 1998-08-04
 , PRIOR APPLICATION NUMBER: 60/095916
 , PRIOR FILING DATE: 1998-08-10
 , PRIOR APPLICATION NUMBER: 60/096146
 , PRIOR FILING DATE: 1998-08-11
 , PRIOR APPLICATION NUMBER: 60/096791
 , PRIOR FILING DATE: 1998-08-17
 , PRIOR APPLICATION NUMBER: 60/097986
 , PRIOR FILING DATE: 1998-08-26
 , PRIOR APPLICATION NUMBER: 60/098544
 , PRIOR FILING DATE: 1998-08-31
 , PRIOR APPLICATION NUMBER: 60/099596
 , PRIOR FILING DATE: 1998-09-09
 , PRIOR APPLICATION NUMBER: 60/099598
 , PRIOR FILING DATE: 1998-09-09
 , PRIOR APPLICATION NUMBER: 60/099803
 , PRIOR FILING DATE: 1998-09-10
 , PRIOR APPLICATION NUMBER: 60/099811
 , PRIOR FILING DATE: 1998-09-10
 , PRIOR APPLICATION NUMBER: 60/099812
 , PRIOR FILING DATE: 1998-09-10
 , PRIOR APPLICATION NUMBER: 60/099816
 , PRIOR FILING DATE: 1998-09-10
 , PRIOR APPLICATION NUMBER: 60/100038
 , PRIOR FILING DATE: 1998-09-11
 , PRIOR APPLICATION NUMBER: 60/100385
 , PRIOR FILING DATE: 1998-09-15
 , PRIOR APPLICATION NUMBER: 60/100390
 , PRIOR FILING DATE: 1998-09-15
 , PRIOR APPLICATION NUMBER: 60/100627
 , PRIOR FILING DATE: 1998-09-16
 , PRIOR APPLICATION NUMBER: 60/100848
 , PRIOR FILING DATE: 1998-09-18
 , PRIOR APPLICATION NUMBER: 60/100919
 , PRIOR FILING DATE: 1998-09-17
 , PRIOR APPLICATION NUMBER: 60/101477
 , PRIOR FILING DATE: 1998-09-23
 , PRIOR APPLICATION NUMBER: 60/101738
 , PRIOR FILING DATE: 1998-09-24
 , PRIOR APPLICATION NUMBER: 60/101741
 , PRIOR FILING DATE: 1998-09-24
 , PRIOR APPLICATION NUMBER: 60/101786
 , PRIOR FILING DATE: 1998-09-25

, PRIOR APPLICATION NUMBER: 60/101916
 , PRIOR FILING DATE: 1998-09-24
 , PRIOR APPLICATION NUMBER: 60/101922
 , PRIOR FILING DATE: 1998-09-24
 , PRIOR APPLICATION NUMBER: 60/106178
 , PRIOR FILING DATE: 1998-10-28
 , PRIOR APPLICATION NUMBER: 60/106248
 , PRIOR FILING DATE: 1998-10-29
 , PRIOR APPLICATION NUMBER: 60/106464
 , PRIOR FILING DATE: 1998-10-30
 , PRIOR APPLICATION NUMBER: 60/106905
 , PRIOR FILING DATE: 1998-11-03
 , PRIOR APPLICATION NUMBER: 60/108787
 , PRIOR FILING DATE: 1998-11-17
 , PRIOR APPLICATION NUMBER: 60/108801
 , PRIOR FILING DATE: 1998-11-17
 , PRIOR APPLICATION NUMBER: 60/108849
 , PRIOR FILING DATE: 1998-11-18
 , PRIOR APPLICATION NUMBER: 60/112422
 , PRIOR FILING DATE: 1998-12-15
 , PRIOR APPLICATION NUMBER: 60/113296
 , PRIOR FILING DATE: 1998-12-22
 , PRIOR APPLICATION NUMBER: 60/113605
 , PRIOR FILING DATE: 1998-12-23
 , PRIOR APPLICATION NUMBER: 60/113621
 , PRIOR FILING DATE: 1998-12-23
 , PRIOR APPLICATION NUMBER: 60/115558
 , PRIOR FILING DATE: 1999-01-12
 , PRIOR APPLICATION NUMBER: 60/115565
 , PRIOR FILING DATE: 1999-01-12
 , PRIOR APPLICATION NUMBER: 60/115733
 , PRIOR FILING DATE: 1999-01-12
 , PRIOR APPLICATION NUMBER: 60/119549
 , PRIOR FILING DATE: 1999-02-10
 , PRIOR APPLICATION NUMBER: 60/123618
 , PRIOR FILING DATE: 1999-03-10
 , PRIOR APPLICATION NUMBER: 60/125259
 , PRIOR FILING DATE: 1999-03-19
 , PRIOR APPLICATION NUMBER: 60/125775
 , PRIOR FILING DATE: 1999-03-23
 , PRIOR APPLICATION NUMBER: 60/126773
 , PRIOR FILING DATE: 1999-03-29
 , PRIOR APPLICATION NUMBER: 60/127887
 , PRIOR FILING DATE: 1999-04-05
 , PRIOR APPLICATION NUMBER: 60/130232
 , PRIOR FILING DATE: 1999-04-21
 , PRIOR APPLICATION NUMBER: 60/131022
 , PRIOR FILING DATE: 1999-04-26
 , PRIOR APPLICATION NUMBER: 60/131270
 , PRIOR FILING DATE: 1999-04-27
 , PRIOR APPLICATION NUMBER: 60/131291
 , PRIOR FILING DATE: 1999-04-27
 , PRIOR APPLICATION NUMBER: 60/131445
 , PRIOR FILING DATE: 1999-04-28
 , PRIOR APPLICATION NUMBER: 60/134287
 , PRIOR FILING DATE: 1999-05-14
 , PRIOR APPLICATION NUMBER: 60/140650
 , PRIOR FILING DATE: 1999-06-22
 , PRIOR APPLICATION NUMBER: 60/140723
 , PRIOR FILING DATE: 1999-06-22
 , PRIOR APPLICATION NUMBER: 60/141037
 , PRIOR FILING DATE: 1999-06-23
 , PRIOR APPLICATION NUMBER: 60/144758
 , PRIOR FILING DATE: 1999-07-20
 , PRIOR APPLICATION NUMBER: 60/145698
 , PRIOR FILING DATE: 1999-07-26
 , PRIOR APPLICATION NUMBER: 60/146222
 , PRIOR FILING DATE: 1999-07-28
 , PRIOR APPLICATION NUMBER: 60/146963
 , PRIOR FILING DATE: 1999-08-03
 , PRIOR APPLICATION NUMBER: 60/149320
 , PRIOR FILING DATE: 1999-08-17
 , PRIOR APPLICATION NUMBER: 60/149638

```
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match          99.3%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYL 120
Db 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYL 120
QY 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
Db 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
QY 181 RLGTPTPSGSMQVDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLVSVPESQ 240
Db 181 RLGTPTPSGSMQVDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLVSVPESQ 240
QY 241 RVA 243
Db 241 RVA 243

RESULT 7
US-10-230-338-236
; Sequence 236, Application US/10230338
; Publication No. US2003004934A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C92
; CURRENT APPLICATION NUMBER: US/10/230,338
; PRIOR FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
```

```
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-230-338-236

Query Match          99.3%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYL 120
Db 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYL 120
QY 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
Db 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
QY 181 RLGTPTPSGSMQVDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLVSVPESQ 240
Db 181 RLGTPTPSGSMQVDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLVSVPESQ 240
QY 241 RVA 243
Db 241 RVA 243

RESULT 8
US-10-218-631-236
; Sequence 236, Application US/10218631
; Publication No. US20030045687A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C14
; CURRENT APPLICATION NUMBER: US/10/218,631
; PRIOR FILING DATE: 2002-08-12
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
```

; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-631-236

Query Match 99.3%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGPFLLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
Db 1 MAELPGPFLLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGVA TLKLDVHPSDTGTYL 120
Db 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGVA TLKLDVHPSDTGTYL 120
QY 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAKPKYNNW 180
Db 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAKPKYNNW 180
QY 181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTVCVATNMGASCELTL SVTSPSQ 240
Db 181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTVCVATNMGASCELTL SVTSPSQ 240
QY 241 RVA 243
Db 241 RVA 243

RESULT 9
US-10-230-414-236
; Sequence 236, Application US/10230414
; Publication No. US20030050448A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC98
; CURRENT APPLICATION NUMBER: US/10/230,414
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17

; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-230-414-236

Query Match 99.3%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGPFLLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
Db 1 MAELPGPFLLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGVA TLKLDVHPSDTGTYL 120
Db 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGVA TLKLDVHPSDTGTYL 120
QY 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAKPKYNNW 180
Db 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAKPKYNNW 180
QY 181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTVCVATNMGASCELTL SVTSPSQ 240
Db 181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTVCVATNMGASCELTL SVTSPSQ 240
QY 241 RVA 243
Db 241 RVA 243

RESULT 10
US-10-232-224-236
; Sequence 236, Application US/10232224
; Publication No. US20030065147A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC111
; CURRENT APPLICATION NUMBER: US/10/232,224
; CURRENT FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873

```

; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-232-224-236

Query Match          99.3%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0

Qy      1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVGDSPALEWS 60
      |||||
Db      1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVGDSPALEWS 60
      |||||

Qy      61 FVQPGKPISESHPILYFTNGHLYPTGSKSKVSLLLQNPPTVGVAATKLTDVHPSDTGYL 120
      |||||
Db      61 FVQPGKPISESHPILYFTNGHLYPTGSKSKRVSLLLQNPPTVGVAATKLTDVHPSDTGYL 120
      |||||

Qy      121 CQVNNPPDFYFNGLGLINLTVLVPPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
      |||||
Db      121 CQVNNPPDFYFNGLGLINLTVLVPPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
      |||||

Qy      181 RLGTFTPTSPGSMVQDEYSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSVTEPSQG 240
      |||||
Db      181 RLGTFTPTSPGSMVQDEYSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSVTEPSQG 240
      |||||

Qy      241 RVA 243
      |||||
Db      241 RVA 243
      |||||

```

RESULT 11
US-10-216-159A-236
; Sequence 236, Application US/10216159A
; Publication No. US20030069397A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530PlC6
; CURRENT APPLICATION NUMBER: US/10/216,159A
; CURRENT FILING DATE: 2002-08-09
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; CURRENT APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; CURRENT APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; CURRENT APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; CURRENT APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31

```

; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-216-159A-236

Query Match          99.3%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0

Qy      1  MAELPGFPGCALGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSPALEWS 60
      |||
Db      1  MAELPGFPGCALGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSPALEWS 60
      |||

Qy      61  FVQPGKPISESHPILYFTNGHLHYPTGSKSRVSLQLQNPTVGVAATKLTDVHPSTGTYL 120
      |||
Db      61  FVQPGKPISESHPILYFTNGHLHYPTGSKSRVSLQLQNPTVGVAATKLTDVHPSTGTYL 120
      |||

Qy      121  CQVNNPPDFYFTNGLGLNLTVLVPSPNPLCSQSGOTSVGGSTALRCSSEGAPKPVYNNV 180
      |||
Db      121  CQVNNPPDFYFTNGLGLNLTVLVPSPNPLCSQSGOTSVGGSTALRCSSEGAPKPVYNNV 180
      |||

Qy      181  RLGTFFTPSPGSMQVDEVSGQLILTNLSLTSSGTYRCVATNQMGASACELTILSVTEPSQG 240
      |||
Db      181  RLGTFFTPSPGSMQVDEVSGQLILTNLSLTSSGTYRCVATNQMGASACELTILSVTEPSQG 240
      |||

Qy      241  RVA 243
      |||
Db      241  RVA 243
      |||

```

```

RESULT 12
US-10-218-849-236
; Sequence 236, Application US/10218849
; Publication No. US20030073814A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530P1C11
; CURRENT APPLICATION NUMBER: US/10/218,849
; CURRENT FILING DATE: 2002-08-12
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-849-236
Query Match
99.3%; Score 1277; DB 14; Length 327;

```

Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	MAELPGPFLCGALGFLCLSGLAWEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS	60
Db	1	MAELPGPFLCGALGFLCLSGLAWEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS	60
QY	61	FVQPGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYL	120
Db	61	FVQPGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYL	120
QY	121	QVNNPPDFYFTNGHLYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYL	180
Db	121	QVNNPPDFYFTNGHLYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYL	180
QY	181	RLGTFTPPSPGSMVQDEVSQGLITNLISLTSSGTYRCVATNMGASCELTLSTVTPSQ	240
Db	181	RLGTFTPPSPGSMVQDEVSQGLITNLISLTSSGTYRCVATNMGASCELTLSTVTPSQ	240
QY	241	RVA 243	
Db	241	RVA 243	

RESULT 13

US-10-227-873-236
; Sequence 236, Application US/10227873
; Publication No. US20030073816A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P35301C72
; CURRENT APPLICATION NUMBER: US/10/227,873
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06

; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178

; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/115558
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115565
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115733
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/119549
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/123618
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/125259
; PRIOR FILING DATE: 1999-03-19
; PRIOR APPLICATION NUMBER: 60/125775
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 60/126773
; PRIOR FILING DATE: 1999-03-29
; PRIOR APPLICATION NUMBER: 60/127887
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 60/130232
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: 60/131022
; PRIOR FILING DATE: 1999-04-26
; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14
; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/144758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09

; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835
; PRIOR APPLICATION NUMBER: 60/169835
Query Match 99.3%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MAELPGPFLCGALLGFLCISGLAVEVKVPTPLSTPLGKTAELTCTYSTVGDSPALEWS 60
Db 1 MAELPGPFLCGALLGFLCISGLAVEVKVPTPLSTPLGKTAELTCTYSTVGDSPALEWS 60
Qy 61 FVQPKPISESHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYL 120
Db 61 FVQPKPISESHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYL 120
Qy 121 QVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYVNW 180
Db 121 QVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYVNW 180
Qy 181 RLGTFTPTSPGSMVQDEVSGOLILTNLSLTSSGTVCVATNMGASCELTLVTEPSQG 240
Db 181 RLGTFTPTSPGSMVQDEVSGOLILTNLSLTSSGTVCVATNMGASCELTLVTEPSQG 240
Qy 241 RVA 243
Db 241 RVA 243
RESULT 14
US-10-227-883-236
; Sequence 236, Application US/10227883
; Publication No. US20030073817A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C78
; CURRENT APPLICATION NUMBER: US/10/227,883
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728

PRIOR APPLICATION NUMBER:	60/101741
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/101786
PRIOR FILING DATE:	1998-09-25
PRIOR APPLICATION NUMBER:	60/101916
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/101922
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/106178
PRIOR FILING DATE:	1998-10-28
PRIOR APPLICATION NUMBER:	60/106248
PRIOR FILING DATE:	1998-10-29
PRIOR APPLICATION NUMBER:	60/106464
PRIOR FILING DATE:	1998-10-30
PRIOR APPLICATION NUMBER:	60/106905
PRIOR FILING DATE:	1998-11-03
PRIOR APPLICATION NUMBER:	60/108787
PRIOR FILING DATE:	1998-11-17
PRIOR APPLICATION NUMBER:	60/108801
PRIOR FILING DATE:	1998-11-17
PRIOR APPLICATION NUMBER:	60/108849
PRIOR FILING DATE:	1998-11-18
PRIOR APPLICATION NUMBER:	60/112422
PRIOR FILING DATE:	1998-12-15
PRIOR APPLICATION NUMBER:	60/113296
PRIOR FILING DATE:	1998-12-22
PRIOR APPLICATION NUMBER:	60/113605
PRIOR FILING DATE:	1998-12-23
PRIOR APPLICATION NUMBER:	60/113621
PRIOR FILING DATE:	1998-12-23
PRIOR APPLICATION NUMBER:	60/115558
PRIOR FILING DATE:	1999-01-12
PRIOR APPLICATION NUMBER:	60/115565
PRIOR FILING DATE:	1999-01-12
PRIOR APPLICATION NUMBER:	60/115733
PRIOR FILING DATE:	1999-01-12
PRIOR APPLICATION NUMBER:	60/119549
PRIOR FILING DATE:	1999-02-10
PRIOR APPLICATION NUMBER:	60/123618
PRIOR FILING DATE:	1999-03-10
PRIOR APPLICATION NUMBER:	60/125259
PRIOR FILING DATE:	1999-03-19
PRIOR APPLICATION NUMBER:	60/125775
PRIOR FILING DATE:	1999-03-23
PRIOR APPLICATION NUMBER:	60/126773
PRIOR FILING DATE:	1999-03-29
PRIOR APPLICATION NUMBER:	60/127887
PRIOR FILING DATE:	1999-04-05
PRIOR APPLICATION NUMBER:	60/130232
PRIOR FILING DATE:	1999-04-21
PRIOR APPLICATION NUMBER:	60/131022
PRIOR FILING DATE:	1999-04-26
PRIOR APPLICATION NUMBER:	60/131270
PRIOR FILING DATE:	1999-04-27
PRIOR APPLICATION NUMBER:	60/131291
PRIOR FILING DATE:	1999-04-27
PRIOR APPLICATION NUMBER:	60/131445
PRIOR FILING DATE:	1999-04-28
PRIOR APPLICATION NUMBER:	60/140723
PRIOR FILING DATE:	1999-06-22
PRIOR APPLICATION NUMBER:	60/143287
PRIOR FILING DATE:	1999-05-14
PRIOR APPLICATION NUMBER:	60/140650
PRIOR FILING DATE:	1999-06-22
PRIOR APPLICATION NUMBER:	60/140723
PRIOR FILING DATE:	1999-06-22
PRIOR APPLICATION NUMBER:	60/145698
PRIOR FILING DATE:	1999-07-26
PRIOR APPLICATION NUMBER:	60/146222
PRIOR FILING DATE:	1999-07-28
PRIOR APPLICATION NUMBER:	60/146963

```
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1998-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1998-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1998-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1998-12-07
; PRIOR APPLICATION NUMBER: 60/169835
```

```
Query Match          99.3%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAELPGFLCGALLGFLCLSLGLAVEVKVPTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGFLCGALLGFLCLSLGLAVEVKVPTPLGKTAELTCTYSTSVGDSFALEWS 60

Qy 61 FVQPKPISESHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYL 120
Db 61 FVQPKPISESHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYL 120

Qy 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSOGQTSVGGSTALRCSSEGAPKPVYNNV 180
Db 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSOGQTSVGGSTALRCSSEGAPKPVYNNV 180

Qy 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPSQG 240
Db 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPSQG 240

Qy 241 RVA 243
Db 241 RVA 243
```

```
RESULT 15
US-10-219-076-236
; Sequence 236, Application US/10219076
; Publication No. US20030078379A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe P.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC62
; CURRENT APPLICATION NUMBER: US/10/219,076
; CURRENT FILING DATE: 2002-08-14
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
```

```
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 245
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
; US-10-219-076-236
```

```
Query Match          99.3%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAELPGFLCGALLGFLCLSLGLAVEVKVPTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGFLCGALLGFLCLSLGLAVEVKVPTPLGKTAELTCTYSTSVGDSFALEWS 60

Qy 61 FVQPKPISESHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYL 120
Db 61 FVQPKPISESHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYL 120

Qy 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSOGQTSVGGSTALRCSSEGAPKPVYNNV 180
Db 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSOGQTSVGGSTALRCSSEGAPKPVYNNV 180

Qy 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPSQG 240
Db 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPSQG 240

Qy 241 RVA 243
Db 241 RVA 243
```

Search completed: August 4, 2005, 06:47:29
Job time : 67.0997 secs

GenCore version 5.1.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 4, 2005, 05:56:06 ; Search time 61.3592 Seconds
(without alignments)
1852.722 Million cell updates/sec

Title: US-10-607-565-83_COPY_24_245

Perfect score: 1164

Sequence: 1 VEVKVTPLSTPLGKTAEL.....ASCELTLSVTEPSQGRVAEL 222

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Uniprot_03:*

1: uniprot_eprot:*

2: uniprot_trembl:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1155	99.2	287	Q9NX42	Q9NX42 homo sapien
2	1155	99.2	324	Q96IQ7	Q96IQ7 homo sapien
3	1145	98.4	325	Q95791	Q95791 homo sapien
4	982	84.4	304	Q9CVA4	Q9CVA4 mus musculus
5	960	82.5	328	Q9Z109	Q9Z109 mus musculus
6	656	56.4	248	Q9D0T4	Q9D0T4 mus musculus
7	352	30.2	259	Q7Z2Q1	Q7Z2Q1 homo sapien
8	352	30.2	387	Q86XK7	Q86XK7 homo sapien
9	352	30.2	412	Q6WZS4	Q6WZS4 homo sapien
10	332.5	28.6	407	Q9D2J4	Q9D2J4 mus musculus
11	329.5	28.3	430	Q8N4F1	Q8N4F1 homo sapien
12	316	27.1	318	Q91664	Q91664 xenopus lae
13	311.5	26.8	335	Q9PWR4	Q9PWR4 gallus gall
14	311.5	26.8	335	Q9YGH1	Q9YGH1 gallus gall
15	303.5	26.1	335	Q9YGV5	Q9YGV5 gallus gall
16	299	25.7	432	Q6DDE7	Q6DDE7 xenopus lae
17	289.5	24.9	323	Q8NDD2	Q8NDD2 homo sapien
18	286.5	24.6	181	Q91665	Q91665 xenopus lae
19	281	24.1	319	A33 HUMAN	Q99795 homo sapien
20	269.5	23.2	300	Q9D9J0	Q9D9J0 mus musculus
21	267.5	23.0	372	Q90Y50	Q90Y50 brachydanio
22	266.5	22.9	300	Q9DA22	Q9DA22 mus musculus
23	264.5	22.7	332	Q6F359	Q6F359 xenopus tro
24	264	22.7	319	A33 MOUSE	Q9JKA5 mus musculus
25	261.5	22.5	406	Q8N7T8	Q8N7T8 homo sapien
26	260.5	22.4	442	Q6NW88	Q6NW88 brachydanio
27	254.5	21.9	319	Q9TU80	Q9TU80 canis famill
28	249.5	21.4	394	Q9Z5F2	Q9Z5F2 mus musculus
29	248.5	21.3	352	Q91W66	Q91W66 mus musculus
30	248.5	21.3	365	1 CXAR MOUSE	P97792 mus musculus
31	248.5	21.3	365	2 Q9DBJ8	Q9DBJ8 mus musculus

```

32 243.5 20.9 394 2 Q6AYD4 Q6ayd4 rattus norv
33 240.5 20.7 344 2 Q9R067 Q9r067 rattus norv
34 240.5 20.7 358 2 Q9R066 Q9r066 rattus norv
35 237 20.4 298 2 Q804R4 Q804r4 brachydanio
36 236.5 20.3 344 2 Q9UKV4 Q9ukv4 homo sapien
37 236.5 20.3 365 1 CXAR HUMAN P78310 homo sapien
38 233.5 20.1 319 2 Q9TU79 Q9tu79 sus scrofa
39 233.5 20.1 365 2 Q8MMV3 Q8mmv3 bos taurus
40 229.5 19.7 390 2 Q95K13 Q95k13 macaca fasc
41 225.5 19.4 373 2 Q8R373 Q8r373 mus musculus
42 224.5 19.3 372 2 Q8KI60 Q8ki60 rattus norv
43 224.5 19.3 373 2 Q9H6B4 Q9h6b4 mus sapien
44 221.5 19.0 373 2 Q920S5 Q920s5 mus musculus
45 221 19.0 332 2 Q640U3 Q640u3 xenopus tro

```

ALIGNMENTS

RESULT 1

```

Q9NX42
ID Q9NX42 PRELIMINARY; PRT; 284 AA.
AC Q9NX42;
DT 01-OCT-2000 (Tremblrel. 15, Created)
DT 01-OCT-2000 (Tremblrel. 15, Last sequence update)
DT 01-OCT-2003 (Tremblrel. 25, Last annotation update)
DE Hypothetical protein FLJ20453.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Watanabe K., Kumagai A., Itakura S., Yamazaki M., Tashiro H., Ota T.,
RA Suzuki Y., Ohyashi M., Nishi T., Shibahara T., Tanaka T.,
RA Nakamura Y., Isegai T., Sugano S.;
RL Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK000460; BAA91179.1; -
DR HSP; O88792; 1F97.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003598; IG_C2.
DR Pfam; PF00047; IG; 1.
DR SMART; SM00408; IGC2; 1.
DR PROSITE; PS50835; IG LIKE; 2.
SQ SEQUENCE 284 AA; 29829 MW; 1F9E09C60856B9A9 CRC64;

```

```

Query Match 99.2%; Score 1155; DB 2; Length 284;
Best Local Similarity 100.0%; Pred. No. 1.8e-83;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEVKVTPLSTPLGKTAELCTYSTSVGDSFALEWSFVQPKPISESPILYFTNGHLY 60
Db 24 VEVKVTPLSTPLGKTAELCTYSTSVGDSFALEWSFVQPKPISESPILYFTNGHLY 83
QY 61 PTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYLCQVNNPPDFYTNGLGLNLTLV 120
Db 84 PTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYLCQVNNPPDFYTNGLGLNLTLV 143
QY 121 PPSNPLCSQSGTSGVGGTALRCSSEGAPKPVYNNVRLGTPTPTSPGSMQDEVSGQLI 180
Db 144 PPSNPLCSQSGTSGVGGTALRCSSEGAPKPVYNNVRLGTPTPTSPGSMQDEVSGQLI 203
QY 181 LTNLSTSGTVRCVATNMGSGASCELTLSVTEPSQGRVA 220
Db 204 LTNLSTSGTVRCVATNMGSGASCELTLSVTEPSQGRVA 243

```

RESULT 2

```

Q96IQ7 PRELIMINARY; PRT; 327 AA.
ID Q96IQ7
AC Q96IQ7;
DT 01-DEC-2001 (Tremblrel. 19, Created)
DT 01-DEC-2001 (Tremblrel. 19, Last sequence update)

```

```

DE 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
GN Name=VSG2; ORFNames=UNQ2770;
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Colon;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Klausner R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Strausberg R.D., Collins F.S., Wagner L., Shemen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Bueow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Datchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Colon;
RA Director MGC Project;
RL Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=22887296; PubMed=12975309; DOI=10.1101/gr.1293003;
RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D., Brush J.,
RA Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA Eaton D., Foster J., Grimaldi C., Gu Q., Hass P.E., Haldens S.,
RA Huang A., Kim H.S., Klinowski L., Jin Y., Johnson S., Lee J.,
RA Lewis L., Liao D., Mark M., Robbie E., Sanchez C., Schoenfeld J.,
RA Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA Vandlen R., Watanabe C., Wleand D., Woods K., Xie M.H., Yansura D.,
RA Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A., Wood W.I.,
RA Godowski P.;
RT "The secreted protein discovery initiative (SPDI), a large-scale
effort to identify novel human secreted and transmembrane proteins: a
bioinformatics assessment.";
RL Genome Res. 13:2265-2270(2003).
DR EMBL; BC007313; AA07313.1; -.
DR EMBL; AY358897; AA089256.1; -.
DR HSSP; O88792; 1F97.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR007110; IG-like.
DR Pfam; PF00047; ig; 1.
DR PROSITE; PS50835; IG LIKE; 2.
SQ SEQUENCE 327 AA; 34348 MW; CF395AC7EP951AC1 CRC64;

Query Match 99.2%; Score 1155; DB 2; Length 327;
Best Local Similarity 100.0%; Pred. No. 2.1e-83;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEVKVTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
DB 24 VEVKVTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 83

QY 61 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTVLV 120
DB 84 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTVLV 143

25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
GN Name=VSG2; ORFNames=UNQ2770;
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Colon;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Klausner R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Strausberg R.D., Collins F.S., Wagner L., Shemen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Bueow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Datchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Colon;
RA Director MGC Project;
RL Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=95077161; PubMed=9862345;
DOI=10.1002/(SICI)1521-4141(199812)28:12<4094::AID-IMMU4094>3.3.CO;2-U;
Chretien I., Marcuz A., Courtet M., Katevuo K., Vainio O., Heath J.K.,
White S.J., Du Pasquier L.;
"CTX, a Xenopus thymocyte receptor, defines a molecular family
conserved throughout vertebrates.";
Eur. J. Immunol. 28:4094-4104(1998).
DR EMBL; AF061022; AAD17522.1; -.
DR HSSP; O88792; 1F97.
DR GO; GO:0005887; C:integral to plasma membrane; TAS.
DR GO; GO:0005624; C:membrane fraction; TAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003598; IG_c2.
DR Pfam; PF00047; ig; 1.
DR SMART; SMO0408; IGC2; 1.
DR PROSITE; PS50835; IG LIKE; 2.
SQ SEQUENCE 325 AA; 34329 MW; B7B5B664CBCFF4BE CRC64;

Query Match 98.4%; Score 1145; DB 2; Length 325;
Best Local Similarity 99.1%; Pred. No. 1.3e-82;
Matches 217; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEVKVTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
DB 23 VEVKVTPEPLSTPLGKTAELTCTYSTVSGDTFALEWSFVQPKPISESHPILYFTNGHLY 82

61 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTVLV 120
83 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTVLV 142

121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVVNWRLGTFPTPSPGSMVQDEVSGQLI 180
143 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVVNWRLGTFPTPSPGSMVQDEVSGQLI 202

25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
GN Name=VSG2; ORFNames=UNQ2770;
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Colon;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Klausner R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Strausberg R.D., Collins F.S., Wagner L., Shemen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Bueow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Datchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Colon;
RA Director MGC Project;
RL Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=95077161; PubMed=9862345;
DOI=10.1002/(SICI)1521-4141(199812)28:12<4094::AID-IMMU4094>3.3.CO;2-U;
Chretien I., Marcuz A., Courtet M., Katevuo K., Vainio O., Heath J.K.,
White S.J., Du Pasquier L.;
"CTX, a Xenopus thymocyte receptor, defines a molecular family
conserved throughout vertebrates.";
Eur. J. Immunol. 28:4094-4104(1998).
DR EMBL; AF061022; AAD17522.1; -.
DR HSSP; O88792; 1F97.
DR GO; GO:0005887; C:integral to plasma membrane; TAS.
DR GO; GO:0005624; C:membrane fraction; TAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003598; IG_c2.
DR Pfam; PF00047; ig; 1.
DR SMART; SMO0408; IGC2; 1.
DR PROSITE; PS50835; IG LIKE; 2.
SQ SEQUENCE 325 AA; 34329 MW; B7B5B664CBCFF4BE CRC64;

Query Match 98.4%; Score 1145; DB 2; Length 325;
Best Local Similarity 99.1%; Pred. No. 1.3e-82;
Matches 217; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEVKVTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
DB 23 VEVKVTPEPLSTPLGKTAELTCTYSTVSGDTFALEWSFVQPKPISESHPILYFTNGHLY 82

61 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTVLV 120
83 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTVLV 142

121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVVNWRLGTFPTPSPGSMVQDEVSGQLI 180
143 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVVNWRLGTFPTPSPGSMVQDEVSGQLI 202

25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
GN Name=VSG2; ORFNames=UNQ2770;
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Colon;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Klausner R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Strausberg R.D., Collins F.S., Wagner L., Shemen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Bueow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Datchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Colon;
RA Director MGC Project;
RL Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=95077161; PubMed=9862345;
DOI=10.1002/(SICI)1521-4141(199812)28:12<4094::AID-IMMU4094>3.3.CO;2-U;
Chretien I., Marcuz A., Courtet M., Katevuo K., Vainio O., Heath J.K.,
White S.J., Du Pasquier L.;
"CTX, a Xenopus thymocyte receptor, defines a molecular family
conserved throughout vertebrates.";
Eur. J. Immunol. 28:4094-4104(1998).
DR EMBL; AF061022; AAD17522.1; -.
DR HSSP; O88792; 1F97.
DR GO; GO:0005887; C:integral to plasma membrane; TAS.
DR GO; GO:0005624; C:membrane fraction; TAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003598; IG_c2.
DR Pfam; PF00047; ig; 1.
DR SMART; SMO0408; IGC2; 1.
DR PROSITE; PS50835; IG LIKE; 2.
SQ SEQUENCE 327 AA; 34348 MW; CF395AC7EP951AC1 CRC64;

Query Match 99.2%; Score 1155; DB 2; Length 327;
Best Local Similarity 100.0%; Pred. No. 2.1e-83;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEVKVTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
DB 24 VEVKVTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 83

QY 61 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTVLV 120
DB 84 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTVLV 143
```


QY 117 TVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVVNWVRL-GTFPTPSPGSMVQDEV 175
Db 118 SVLVKPSKPLCSVQGRPETGHTISLCSALGTPSPVYVWHKLEGRDIVPVKNEF--NPT 175
QY 176 SQGLILTNLSLTSSGTYRCVATNMGASCELTLSVTBPSQ 217
Db 176 TGLVIGNLTNFEQGYOCTAINRLGNSSCEIDLTSSHPEVG 217

RESULT 8

Q6XK7 PRELIMINARY; PRT; 387 AA.
AC Q6XK7;
DT 01-JUN-2003 (TREMELrel. 24, Created)
DT 01-JUN-2003 (TREMELrel. 24, Last sequence update)
DT 25-OCT-2004 (TREMELrel. 28, Last annotation update)
DE V-set and immunoglobulin domain containing 1 (Hypothetical protein DKFP686I1638).
GN Name=VSI61; Synonyms=DKFP686I1638;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Testis;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny K.C., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Testis;
RA Director MGC Project;
RL Submitted (JAN-2003) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RC TISSUE=Testis;
RA The German cDNA Consortium;
RA Ottenwaelder B., Obermaier B., Deutschenbaur S., Schaipp A.,
RA Mewes H.W., Weil B., Amid C., Osanger A., Fobo G., Han M., Wiemann S.;
RL Submitted (SEP-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC043216; AAH43216.1; -.
DR EMBL; BX648658; CAH56142.1; -.
DR HSSP; P06907; 1NEU.
DR GO; GO:0016020; C:membrane; IEA.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003598; IG_c2.
DR InterPro; IPR000920; Myelin_P0.
DR Pfam; PF00047; ig; 1.
DR PRINTS; PR00213; MYELINP0.
DR SMART; SM00408; IGC2; 2.
DR SMART; SM00409; IG; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
KW Hypothetical protein.
FT NON_TER 1
SQ SEQUENCE 387 AA; 41811 MW; F5D39F3B21FF1D0D CRC64;

Query Match 30.2%; Score 352; DB 2; Length 387;
Best Local Similarity 34.2%; Pred. No. 9.5e-20;
Matches 76; Conservative 47; Mismatches 85; Indels 14; Gaps 7;
QY 1 VEVKPTPEPLSTPLGKTAELTCTYSTVG--DSFALEWSFVQPGKPISESHPI-LYFT-N 56
Db 22 VQVTIPDGFVNVTVGSGNVTLICIIYTTTASREQSIQMSFFHK----KEMEPISIFYSQG 77
QY 57 GHLVPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTGTLYCQVNNPPDFYTNGLGLINL 116
Db 78 GOAVAIGQFKDIRITGSNDP---GNASITISHMQPADSGIYICDVNNPPDFLQNGQILNV 134
QY 117 TVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVVNWVRL-GTFPTPSPGSMVQDEV 175
Db 135 SVLVKPSKPLCSVQGRPETGHTISLCSALGTPSPVYVWHKLEGRDIVPVKNEF--NPT 192
QY 176 SQGLILTNLSLTSSGTYRCVATNMGASCELTLSVTBPSQ 217
Db 193 TGLVIGNLTNFEQGYOCTAINRLGNSSCEIDLTSSHPEVG 234
RESULT 9
Q6MZS4 PRELIMINARY; PRT; 412 AA.
AC Q6MZS4;
DT 05-JUL-2004 (TREMELrel. 27, Created)
DT 05-JUL-2004 (TREMELrel. 27, Last sequence update)
DT 05-JUL-2004 (TREMELrel. 27, Last annotation update)
DE Hypothetical protein DKFP686A1239 (Fragment).
GN Name=DKFP686A1239;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Human testis;
RG The German Human cDNA Consortium;
RA Ottenwaelder B., Obermaier B., Deutschenbaur S., Mewes H.W., Weil B.,
RA Amid C., Osanger A., Fobo G., Han M., Wiemann S.;
RL Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX640913; CAH45954.1; -.
DR GO; GO:0016020; C:membrane; IEA.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003598; IG_c2.
DR InterPro; IPR003596; IG_V.
DR InterPro; IPR000920; Myelin_P0.
DR Pfam; PF00047; ig; 1.
DR PRINTS; PR00213; MYELINP0.
DR SMART; SM00409; IG; 2.
DR SMART; SM00408; IGC2; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
KW Hypothetical protein.
FT NON_TER 1
SQ SEQUENCE 412 AA; 44702 MW; C1B4E005F0882C45 CRC64;

Query Match 30.2%; Score 352; DB 2; Length 412;
Best Local Similarity 34.2%; Pred. No. 1e-19;
Matches 76; Conservative 47; Mismatches 85; Indels 14; Gaps 7;
QY 1 VEVKPTPEPLSTPLGKTAELTCTYSTVG--DSFALEWSFVQPGKPISESHPI-LYFT-N 56
Db 47 VQVTIPDGFVNVTVGSGNVTLICIIYTTTASREQSIQMSFFHK----KEMEPISIFYSQG 102
QY 57 GHLVPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTGTLYCQVNNPPDFYTNGLGLINL 116
Db 103 GOAVAIGQFKDIRITGSNDP---GNASITISHMQPADSGIYICDVNNPPDFLQNGQILNV 159
QY 117 TVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVVNWVRL-GTFPTPSPGSMVQDEV 175
Db 160 SVLVKPSKPLCSVQGRPETGHTISLCSALGTPSPVYVWHKLEGRDIVPVKNEF--NPT 217

Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S., Krzywinski M.I., Skalska U., Smalls D.E., Schnerch A., Schein J.E., Jones S.J., Marra M.A.;
 "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences";
Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 [2]
 RN SEQUENCE FROM N.A.
 RP TISSUE=Brain;
 RC Strausberg R.;
 RA Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
 RL EMBL; BC034411; AAH34411.1; -;
 DR HSP; P78310; IEA;
 DR Genew; HGNC:16689; IGSF11.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003598; Ig_c2.
 DR Pfam; PF00047; Ig; 1.
 DR SMART; SM00408; IGc2; 1.
 DR PROSITE; PS0835; IG_LIKE; 2.
 SQ SEQUENCE 430 AA; 46245 MW; E53FC71BC1D0D49D CRC64;

Query Match 28.3%; Score 329.5; DB 2; Length 430;
 Best Local Similarity 34.7%; Pred. No. 6.5e-18;
 Matches 75; Conservative 35; Mismatches 101; Indels 5; Gaps 5;

QY 1 VEVKVPTPELPSTPLGKTAAELTCVTYSTVG-DSPALEWSFYQPKPISESHPILYFTNGHL 59
 :|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||:
 Db 22 LEVSSEPGSIQVARGQTAVLPCTFTTSAALINLVIV-MVTPLSNANQPEGVILYQGQM 80
 :|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||:

QY 60 YPTGSK-SKEVSLLONPPTVGATLKLTDVHPSDTGTYLCQVANPPDFYTNGLINLTV 118
 :|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||:
 Db 81 FDGAPRPHRGVGFGTWPATNV-SIFNTQLSDTGTYQCVLNNLPDIGGRNIGVTGLTV 139
 :|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||:

QY 119 LVPPSPLCSQSOGTSVGGSTALRCSSSEGAKPVYNWRLGTPTTPSGSMVQDEYSQ 178
 |||||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||:
 Db 140 LVPPSAPHCHIQSQSDIGSDVILLCSSEGIPTYLWEKLDN-TLKLPTATQDQVGT 198
 :|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||:

QY 179 LIITNLSLTSSGYRCVATNQMSGASCELTLSVTEP 214
 :|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||:
 Db 199 VTRINSALSGLYQCVASNAGTGTCLLDLQVISP 234

RESULT 12
 Q91664 PRELIMINARY; PRT; 318 AA.
 ID Q91664 AC Q91664;
 DT 01-NOV-1996 (TrEMBLrel. 01, Created)
 DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE CTX.
 OS Xenopus laevis (African clawed frog).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae; Pipidae;
 OC Xenoportinae; Xenopus.
 ON NCBI_TaxID=8355;
 RX [1]
 RN SEQUENCE FROM N.A.
 RP STRAIN=ff; TISSUE=Thymus;
 RX MEDLINE=96210130; PubMed=8625968;
 RA Chretien I., Robert J., Marcuz A., Garcia-Sanz J.A., Courtet M., Du Pasquier L.;
 "CTX, a novel molecule specifically expressed on the surface of cortical thymocytes in Xenopus";
 Eur. J. Immunol. 26:780-791(1996).
 DR EMBL; U43330; AAC59899.1; -;
 DR HSP; P78310; IKAC.
 DR Pfam; PF00047; Ig; 1.
 DR SMART; SM00409; IG; 2.
 DR PROSITE; PS0835; IG_LIKE; 2.
 SQ SEQUENCE 318 AA; 34429 MW; 6231D24B0B806C09 CRC64;

Query Match 27.1%; Score 316; DB 2; Length 318;
 Best Local Similarity 35.2%; Pred. No. 5.3e-17;

```
Q9YGH1
ID Q9YGH1 PRELIMINARY; PRT; 335 AA.
AC Q9YGH1
DT 01-MAY-1999 (Tremblrel. 10, Created)
DT 01-MAY-1999 (Tremblrel. 10, Last sequence update)
DT 01-OCT-2003 (Tremblrel. 25, Last annotation update)
DE Cht1 thymocyte antigen precursor.
GN Name=Cht1;
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]_TaxID=9031;
RP SEQUENCE FROM N.A.
RC STRAIN=RPRL line 0; TISSUE=Thymus;
RA Katevuo K.H., Boyd R., Gobel T.T., Bean A., Dunon D., Imhof B.A.,
RA Vainio O.;
RL Submitted (JUN-1997) to the EMBL/GenBank/DBJ databases.
DR EMBL, Y14063; CAA74390.1; -.
DR HSSP; P78310; IKAC.
DR InterPro; IPR007110; Ig-like.
DR pfam; PF00047; Ig_v.
DR SMART; SM00406; Igv; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
KW Signal.
FT SIGNAL.
FT CHAIN.
FT CHAIN.
SQ SEQUENCE 335 AA; 36553 MW; AA640C5CD02CB16D CRC64;

Query Match 26.8%; Score 311.5; DB 2; Length 335;
Best Local Similarity 33.5%; Pred. No. 1.3e-16;
Matches 71; Conservative 43; Mismatches 89; Indels 9; Gaps 5;

QY 1 VEVKVPTEPLSTPLGKTAEITCTYSTS--VGDSFALEWSFVQPGKPISESHPILYFTNGH 58
Db 22 VVVTVPKTVNVKGTGNATLLCTYTSSQPLG-NFFIQWSFYSAKE--SQLHTIYYISEGQ 78

QY 59 LYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSTGTLYLCOVNNPPDPFTYNGLGLINLTV 118
Db 79 SYSYGEFKDRITAATSP---GNASITISNMQPSDTGTCVFSPQDDAGOSQKSIVNV 135

QY 119 LVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTTSPGSMVQDEVSQ 178
Db 136 LVKPSKPFCKIEGTPEKGHLIYLLCKDQGLSHPTRYWKVDE-NLTLPVTEYFNPDTGI 194

QY 179 LILTNLSLTSSGTYRCVATNOMGSASCELTL 210
Db 195 LYIGNLTTFETGCHYRCIASNMGSTCELDLT 226

RESULT 15
Q9YGV5
ID Q9YGV5 PRELIMINARY; PRT; 335 AA.
AC Q9YGV5;
DT 01-MAY-1999 (Tremblrel. 10, Created)
DT 01-MAY-1999 (Tremblrel. 10, Last sequence update)
DT 01-OCT-2003 (Tremblrel. 25, Last annotation update)
DE Cht1.
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]_TaxID=9031;
RP SEQUENCE FROM N.A.
EX MEDLINE=90077161; PubMed=9862345;
RX DOI=10.1002/(SICI)1521-4141(199812)28:12<4094::AID-IMMU4094>3.3.CO;2-U;
RA Chretien I., Marcuz A., Courtet M., Katevuo K., Vainio O., Heath J.K.,
RA White S.J., Du Pasquier L.;
RT "CTX, a Xenopus thymocyte receptor, defines a molecular family
conserved throughout vertebrates.";
RT
```

```
RL Eur. J. Immunol. 28:4094-4104 (1998).
DR EMBL; AF061023; AADI7523.1; -.
DR HSSP; P78310; IKAC.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR pfam; PF00047; Ig; 1.
DR SMART; SM00406; Igv; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
SQ SEQUENCE 335 AA; 36561 MW; 071A3133CE6DCA0 CRC64;

Query Match 26.1%; Score 303.5; DB 2; Length 335;
Best Local Similarity 33.0%; Pred. No. 5.5e-16;
Matches 70; Conservative 43; Mismatches 90; Indels 9; Gaps 5;

QY 1 VEVKVPTEPLSTPLGKTAEITCTYSTS--VGDSFALEWSFVQPGKPISESHPILYFTNGH 58
Db 22 VVVTVPKTVNVKGTGNATLLCTYTSSQPLG-NFFIQWSFYSAKE--SQLHTIYYISEGQ 78

QY 59 LYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSTGTLYLCOVNNPPDPFTYNGLGLINLTV 118
Db 79 SYSYGEFKDRITAATSP---GNASITISNMQPSDTGTCVFSPQDDAGOSQKSIVNV 135

QY 119 LVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTTSPGSMVQDEVSQ 178
Db 136 LVKPSKPFCKIEGTPEKGHLIYLLCKDQGLSHPTRYWKVDE-NLTLPVTEYFNPDTGI 194

QY 179 LILTNLSLTSSGTYRCVATNOMGSASCELTL 210
Db 195 LYIGNLTTFETGCHYRCIASNMGSTCELDLT 226
```

Search completed: August 4, 2005, 06:13:31
Job time : 62.3592 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.
OM protein - protein search, using sw model
Run on: August 4, 2005, 06:13:42 ; Search time 59.8944 Seconds
(without alignments)
1447.018 Million cell updates/sec

Title: US-10-607-565-83_COPY_24_245
Perfect score: 1164
Sequence: 1 VEVKVTPEPLSTPLGKTAEI.....ASCELTSLVTPSQGRVABL 222

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1752860 seqs, 390397842 residues
Total number of hits satisfying chosen parameters: 1752860

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA:*

1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09C_NEW_PUB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US10E_PUBCOMB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US10E_NEW_PUB.pep.*
19: /cgn2_6/ptodata/1/pubpaa/US11A_PUBCOMB.pep.*
20: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
21: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
22: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1164	100.0	245	9	US-09-820-893-98
2	1164	100.0	245	15	US-10-607-565-98
3	1164	100.0	246	9	US-09-820-893-83
4	1164	100.0	246	15	US-10-607-565-83
5	1155	99.2	326	15	US-10-443-108-4
6	1155	99.2	327	14	US-10-227-884-236
7	1155	99.2	327	14	US-10-230-163-236
8	1155	99.2	327	14	US-10-230-338-236
9	1155	99.2	327	14	US-10-218-631-236
10	1155	99.2	327	14	US-10-230-414-236
11	1155	99.2	327	14	US-10-232-224-236

12	1155	99.2	327	14	US-10-216-159A-236	Sequence 236, App
13	1155	99.2	327	14	US-10-218-849-236	Sequence 236, App
14	1155	99.2	327	14	US-10-227-873-236	Sequence 236, App
15	1155	99.2	327	14	US-10-227-883-236	Sequence 236, App
16	1155	99.2	327	14	US-10-219-076-236	Sequence 236, App
17	1155	99.2	327	14	US-10-230-434-236	Sequence 236, App
18	1155	99.2	327	14	US-10-219-003-236	Sequence 236, App
19	1155	99.2	327	14	US-10-219-075-236	Sequence 236, App
20	1155	99.2	327	14	US-10-219-464-236	Sequence 236, App
21	1155	99.2	327	14	US-10-219-466-236	Sequence 236, App
22	1155	99.2	327	14	US-10-219-479-236	Sequence 236, App
23	1155	99.2	327	14	US-10-219-481-236	Sequence 236, App
24	1155	99.2	327	14	US-10-230-260-236	Sequence 236, App
25	1155	99.2	327	14	US-10-232-231-236	Sequence 236, App
26	1155	99.2	327	14	US-10-232-233-236	Sequence 236, App
27	1155	99.2	327	14	US-10-216-165-236	Sequence 236, App
28	1155	99.2	327	14	US-10-218-956-236	Sequence 236, App
29	1155	99.2	327	14	US-10-219-468-236	Sequence 236, App
30	1155	99.2	327	14	US-10-219-478-236	Sequence 236, App
31	1155	99.2	327	14	US-10-219-536-236	Sequence 236, App
32	1155	99.2	327	14	US-10-233-205-236	Sequence 236, App
33	1155	99.2	327	14	US-10-219-072-236	Sequence 236, App
34	1155	99.2	327	14	US-10-219-470-236	Sequence 236, App
35	1155	99.2	327	14	US-10-219-524-236	Sequence 236, App
36	1155	99.2	327	14	US-10-219-528-236	Sequence 236, App
37	1155	99.2	327	14	US-10-227-880-236	Sequence 236, App
38	1155	99.2	327	14	US-10-227-881-236	Sequence 236, App
39	1155	99.2	327	14	US-10-227-882-236	Sequence 236, App
40	1155	99.2	327	14	US-10-230-436-236	Sequence 236, App
41	1155	99.2	327	14	US-10-232-223-236	Sequence 236, App
42	1155	99.2	327	14	US-10-232-225-236	Sequence 236, App
43	1155	99.2	327	14	US-10-232-227-236	Sequence 236, App
44	1155	99.2	327	14	US-10-232-229-236	Sequence 236, App
45	1155	99.2	327	14	US-10-232-229-236	Sequence 236, App

ALIGNMENTS

RESULT 1
US-09-820-893-98
; Sequence 98, Application US/09820893
; Patent No. US20020076705A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human Secreted Proteins
; FILE REFERENCE: PZ033PI
; CURRENT APPLICATION NUMBER: US/09/820,893
; CURRENT FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 09/531,119
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: 60/102,895
; PRIOR FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 98
; LENGTH: 245
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-820-893-98

Query Match	100.0%	Score 1164;	DB 9;	Length 245;
Best Local Similarity	100.0%	Pred. No. 1.7e-88;		
Matches 222;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	VEVKVTEPLSTPLGKTAEICTYSTVGDSPALEWSFVQPGKPISSEHPILYFTNGHLY	60	
Db	24	VEVKVTEPLSTPLGKTAEICTYSTVGDSPALEWSFVQPGKPISSEHPILYFTNGHLY	83	
QY	61	PTGSKSKRVSLQLQNPPVTGVATLKLTDVHPSTGTLYLCQVNNPPDPFYTNGLGLINLTVLV	120	
Db	84	PTGSKSKRVSLQLQNPPVTGVATLKLTDVHPSTGTLYLCQVNNPPDPFYTNGLGLINLTVLV	143	

Qy	121	PPSNPLCSQSGQTSVGGSTALRCSSEBAPKPVNVNRLGTFPPSPGSMVQDEVSGQL	180
Db	144	PPSNPLCSQSGQTSVGGSTALRCSSEBAPKPVNVNRLGTFPPSPGSMVQDEVSGQL	203
Qy	181	LTNLSLTSSGTYRCVATNMQSGASCELTLSVTEPSQGRVREL	222
Db	204	LTNLSLTSSGTYRCVATNMQSGASCELTLSVTEPSQGRVREL	245

```

RESULT 2
US-10-607-565-98
; Sequence 98, Application US/10607565
; Publication No. US20040048294A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human Secreted Proteins
; FILE REFERENCE: P2033P1
; CURRENT APPLICATION NUMBER: US/10/607,565
; CURRENT FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: US/09/531,119
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/101,546
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/102,895
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 98
; LENGTH: 245
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-607-565-98

```

Query Match	100.0%	Score 1164;	DB 15;	Length 245;
Best Local Similarity	100.0%;	Prod. No. 1.7e-88;		
Matches 222;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1	VEVKVPEPLSTPLGKTAELTCTYSTSVGDSFALEWSPVQPKPISSEHPILFTNGHLY	60	
Db	24	VEVKVPEPLSTPLGKTAELTCTYSTSVGDSFALEWSPVQPKPISSEHPILFTNGHLY	83	
Qy	61	PTGSKSRVSLQLQNPPTVGVAATLKLTVHPESDCTYILCQVNNPPDFYTNGLGLINLTVLY	120	
Db	84	PTGSKSRVSLQLQNPPTVGVAATLKLTVHPESDCTYILCQVNNPPDFYTNGLGLINLTVLY	143	
Qy	121	PPSNPLCSQSGQTSVGGSTALRCSSSEGAKPKVYNWVRLGTFPTPPSPGSMVQDEVSGLI	180	
Db	144	PPSNPLCSQSGQTSVGGSTALRCSSSEGAKPKVYNWVRLGTFPTPPSPGSMVQDEVSGLI	203	
Qy	181	LTNLSLTSSGTYRCVATNQMSGASCELTSLVTEPSQGRVAEL	222	
Db	204	LTNLSLTSSGTYRCVATNQMSGASCELTSLVTEPSQGRVAEL	245	

```

; ORGANISM: Homo sapiens
;
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (246)
; OTHER INFORMATION: Xaa equals stop translation
US-09-820-893-83

Query Match          100.0%;   Score 1164;   DB 9;   Length 246;
Best Local Similarity 100.0%;   Pred. No. 1.8e-88;
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1  VEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
      |||||
Db 24 VEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 83

Qy 61  PTGSKSRVSLQNPPTVGVATLKLTDVHPSDGTGYLCQVNNPPDFYTNGLGLINLTVL 120
      |||||
Db 84  PTGSKSRVSLQNPPTVGVATLKLTDVHPSDGTGYLCQVNNPPDFYTNGLGLINLTVL 143

Qy 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLTFTPTPPSGSMVQDEVSGQLI 180
      |||||
Db 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLTFTPTPPSGSMVQDEVSGQLI 203

Qy 181 LTNLSTSSGTYRCVATNQMSGASCELTLSVTEPSSQGRVAEL 222
      |||||
Db 204 LTNLSTSSGTYRCVATNQMSGASCELTLSVTEPSSQGRVAEL 245

```

RESULT 4
US-10-607-565-83
; Sequence 83, Application US/10607565
; Publication No. US20040048294A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human Secreted Proteins
; FILE REFERENCE: P2033P1
; CURRENT APPLICATION NUMBER: US/10/607,565
; CURRENT FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: US/09/531,119
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/101,546
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/102,895
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: PatentIn ver. 2.0
; SEQ ID NO 83
; LENGTH: 246
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (246)
; OTHER INFORMATION: Xaa equals stop translation
US-10-607-565-83

	Query Match	100.0%;	Score 1164;	DB 15;	Length 246;
	Best Local Similarity	100.0%;	Pred. No. 1.8e-88;		
	Matches 222;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1	VEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPGKPISESHPILYFTNGHLY	60		
Db	24	VEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPGKPISESHPILYFTNGHLY	83		
Qy	61	PTGSKSRVLLQNPPTVGVA TLKLTVDHPSDGTYLQVNNPPDFYTNGLGLINLTVLV	120		
Db	84	PTGSKSRVLLQNPPTVGVA TLKLTVDHPSDGTYLQVNNPPDFYTNGLGLINLTVLV	143		
Qy	121	PPSNPLCSQSGQTSVGGSTALRCSSESGAKPKVYNNWRLGTFPTPSGSMVQDEVSGQLI	180		
Db	144	PPSNPLCSQSGQTSVGGSTALRCSSESGAKPKVYNNWRLGTFPTPSGSMVQDEVSGQLI	203		
Qy	181	LTNLSTLSSGTYRCVATNQMSGASCELTLTSVTTPSQGRVAEL	222		

Db 204 LTNLSTSSGTRCVATNMGASCSCLTSLVTEPSQGRVAEL 245
|||||

RESULT 5
US-10-443-108-4
; Sequence 4, Application US/10443108
; Publication No. US20040005615A1
; GENERAL INFORMATION:
; APPLICANT: LI, JING
; APPLICANT: MU, DAVID
; APPLICANT: YANG, JIANXIN
; TITLE OF INVENTION: AMPLIFICATION AND OVEREXPRESSION OF ONCOGENES
; FILE REFERENCE: 38002-0049
; CURRENT APPLICATION NUMBER: US/10/443,108
; CURRENT FILING DATE: 2003-05-22
; PRIOR APPLICATION NUMBER: 60/398,099
; PRIOR FILING DATE: 2002-07-25
; PRIOR APPLICATION NUMBER: 60/382,606
; PRIOR FILING DATE: 2002-05-24
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 326
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-443-108-4

Query Match 99.2%; Score 1155; DB 15; Length 326;
Best Local Similarity 100.0%; Pred. No. 1.4e-87;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
DB 23 VEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 82
QY 61 PTGSKSKRVSLQLQNPPTGVATLKLTDVHPSDTGYLCQVNNPPDFYTNGLGLINLTVLV 120
DB 83 PTGSKSKRVSLQLQNPPTGVATLKLTDVHPSDTGYLCQVNNPPDFYTNGLGLINLTVLV 142
QY 121 PPSNPLCSQSGQTSVCGSTALRCSSEGAPKPVYNNVRLGTPTTPSPGSMVDQVSGQLI 180
DB 143 PPSNPLCSQSGQTSVCGSTALRCSSEGAPKPVYNNVRLGTPTTPSPGSMVDQVSGQLI 202
QY 181 LTNLSTSSGTRCVATNMGASCSCLTSLVTEPSQGRVA 220
DB 203 LTNLSTSSGTRCVATNMGASCSCLTSLVTEPSQGRVA 242
|||||

RESULT 6
US-10-227-884-236
; Sequence 236, Application US/10227884
; Publication No. US20030027988A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530P1C79
; CURRENT APPLICATION NUMBER: US/10/227,884
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113

; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10

1	PRIOR APPLICATION NUMBER: 60/100318	1	PRIOR FILING DATE: 1998-09-11
2	PRIOR APPLICATION NUMBER: 60/100385	2	PRIOR FILING DATE: 1998-09-15
3	PRIOR APPLICATION NUMBER: 60/100390	3	PRIOR FILING DATE: 1998-09-15
4	PRIOR APPLICATION NUMBER: 60/100627	4	PRIOR FILING DATE: 1998-09-16
5	PRIOR APPLICATION NUMBER: 60/100848	5	PRIOR FILING DATE: 1998-09-18
6	PRIOR APPLICATION NUMBER: 60/100919	6	PRIOR FILING DATE: 1998-09-17
7	PRIOR APPLICATION NUMBER: 60/101477	7	PRIOR FILING DATE: 1998-09-23
8	PRIOR APPLICATION NUMBER: 60/101738	8	PRIOR FILING DATE: 1998-09-24
9	PRIOR APPLICATION NUMBER: 60/101741	9	PRIOR FILING DATE: 1998-09-24
10	PRIOR APPLICATION NUMBER: 60/101786	10	PRIOR FILING DATE: 1998-09-25
11	PRIOR APPLICATION NUMBER: 60/101916	11	PRIOR FILING DATE: 1998-09-24
12	PRIOR APPLICATION NUMBER: 60/101922	12	PRIOR FILING DATE: 1998-09-24
13	PRIOR APPLICATION NUMBER: 60/106178	13	PRIOR FILING DATE: 1998-10-28
14	PRIOR APPLICATION NUMBER: 60/106248	14	PRIOR FILING DATE: 1998-10-29
15	PRIOR APPLICATION NUMBER: 60/106464	15	PRIOR FILING DATE: 1998-10-30
16	PRIOR APPLICATION NUMBER: 60/106905	16	PRIOR FILING DATE: 1998-11-03
17	PRIOR APPLICATION NUMBER: 60/108787	17	PRIOR FILING DATE: 1998-11-17
18	PRIOR APPLICATION NUMBER: 60/108801	18	PRIOR FILING DATE: 1998-11-17
19	PRIOR APPLICATION NUMBER: 60/108849	19	PRIOR FILING DATE: 1998-11-18
20	PRIOR APPLICATION NUMBER: 60/112422	20	PRIOR FILING DATE: 1998-12-15
21	PRIOR APPLICATION NUMBER: 60/113296	21	PRIOR FILING DATE: 1998-12-22
22	PRIOR APPLICATION NUMBER: 60/113605	22	PRIOR FILING DATE: 1999-01-12
23	PRIOR APPLICATION NUMBER: 60/115733	23	PRIOR FILING DATE: 1999-01-12
24	PRIOR APPLICATION NUMBER: 60/113621	24	PRIOR FILING DATE: 1999-01-12
25	PRIOR APPLICATION NUMBER: 60/115558	25	PRIOR FILING DATE: 1999-01-12
26	PRIOR APPLICATION NUMBER: 60/123618	26	PRIOR FILING DATE: 1999-03-10
27	PRIOR APPLICATION NUMBER: 60/125259	27	PRIOR FILING DATE: 1999-03-19
28	PRIOR APPLICATION NUMBER: 60/125775	28	PRIOR FILING DATE: 1999-03-23
29	PRIOR APPLICATION NUMBER: 60/126773	29	PRIOR FILING DATE: 1999-03-29
30	PRIOR APPLICATION NUMBER: 60/127887	30	PRIOR FILING DATE: 1999-04-05
31	PRIOR APPLICATION NUMBER: 60/130232	31	PRIOR FILING DATE: 1999-04-21
32	PRIOR APPLICATION NUMBER: 60/131022	32	PRIOR FILING DATE: 1999-04-26
33	PRIOR APPLICATION NUMBER: 60/131270	33	PRIOR FILING DATE: 1999-04-27
34	PRIOR APPLICATION NUMBER: 60/131291	34	PRIOR FILING DATE: 1999-04-27
35	PRIOR APPLICATION NUMBER: 60/131445	35	

:	PRIOR FILING DATE:	1999-04-28
:	PRIOR APPLICATION NUMBER:	60/134287
:	PRIOR FILING DATE:	1999-05-14
:	PRIOR APPLICATION NUMBER:	60/140650
:	PRIOR FILING DATE:	1999-06-22
:	PRIOR APPLICATION NUMBER:	60/140723
:	PRIOR FILING DATE:	1999-06-22
:	PRIOR APPLICATION NUMBER:	60/141037
:	PRIOR FILING DATE:	1999-06-23
:	PRIOR APPLICATION NUMBER:	60/144758
:	PRIOR FILING DATE:	1999-07-20
:	PRIOR APPLICATION NUMBER:	60/145698
:	PRIOR FILING DATE:	1999-07-26
:	PRIOR APPLICATION NUMBER:	60/146222
:	PRIOR FILING DATE:	1999-07-28
:	PRIOR APPLICATION NUMBER:	60/146963
:	PRIOR FILING DATE:	1999-08-03
:	PRIOR APPLICATION NUMBER:	60/149320
:	PRIOR FILING DATE:	1999-08-17
:	PRIOR APPLICATION NUMBER:	60/149638
:	PRIOR FILING DATE:	1999-08-17
:	PRIOR APPLICATION NUMBER:	60/151733
:	PRIOR FILING DATE:	1999-08-31
:	PRIOR APPLICATION NUMBER:	60/164418
:	PRIOR FILING DATE:	1999-11-09
:	PRIOR APPLICATION NUMBER:	60/166361
:	PRIOR FILING DATE:	1999-11-16
:	PRIOR APPLICATION NUMBER:	60/169445
:	PRIOR FILING DATE:	1999-12-07
:	PRIOR APPLICATION NUMBER:	60/169495
:	PRIOR FILING DATE:	1999-12-07
:	PRIOR APPLICATION NUMBER:	60/169835
Query Match 99.2%; Score 1155; DB 14; Length 327;		
Best Local Similarity 100.0%; Pred. No. 1.4e-87;		
Matches	220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	1	VEVKVTEPLSTPLGKTAELTCTYSTSVGDSPFALEWSFVOPGKPISSEHPILYFTNGHLY 60
Dd	24	VEVKVTEPLSTPLGKTAELTCTYSTSVGDSPFALEWSFVOPGKPISSEHPILYFTNGHLY 83
Qy	61	PTGSCKSRVSLQLONPPTVGATLKLTDVHPSDGTGYLCQQNNPPDFVTNGLGINLTVLV 120
Dd	84	PTGSCKSRVSLQLQNPPTVGVATLKLTDVHPSDGTGYLCQQNNPPDFFYTNGLGLINLTVLV 143
Qy	121	PPSNPLCSGGQTSGVGSALTALRCCSSSEGAPKPKYNWVRGLTFTPPSGMVQEVSQOLI 180
Dd	144	PPSNPLCSGGQTSGVGSALTALRCCSSEGAPKPKYNWVRGLTFFTPSPSGMVQEVSQOLI 203
Qy	181	LTNLSITSGETRCVATNQMSGASCELTIVTSVPESQRVA 220
Dd	204	LTNLSITSSGETRCVATNQMSGASCETIIVTSFPESGRVA 243

```

RESULT 7
US-10-230-163-236
; Sequence 236, Application US/10230163
; Publication No. US20030036635A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530P1C96

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
2220
2221
2222

; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14
; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/14758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.2%; Score 1155; DB 14; Length 327;

Best Local Similarity 100.0%; Pred. No. 1.4e-87;

Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 VEKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPIYFTNGHLY 60
Db 24 VEKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPIYFTNGHLY 83
Qy 61 PTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYLCQVNNPDPFYTNGLGLNLTVLV 120
Db 84 PTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYLCQVNNPDPFYTNGLGLNLTVLV 143
Qy 121 PPSNPLCSQSGQTSVGGSTALRCSSESGAPKPVYNNWRLGTFPTPSPGSMVQDEVSGQLI 180
Db 144 PPSNPLCSQSGQTSVGGSTALRCSSESGAPKPVYNNWRLGTFPTPSPGSMVQDEVSGQLI 203
Qy 181 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 220
Db 204 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 243

RESULT 8

US-10-230-338-236

; Sequence 236, Application US/10230338

; Publication No. US2003004934A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Deenoyers, Luc

; APPLICANT: Gerritsen, Mary

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, J. Christopher

; APPLICANT: Gurney, Austin L.

; APPLICANT: Smith, Victoria

; APPLICANT: Stephan, Jean-Philippe F.

; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C92
; CURRENT APPLICATION NUMBER: US/10/230,338
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-230-338-236

Query Match 99.2%; Score 1155; DB 14; Length 327;

Best Local Similarity 100.0%; Pred. No. 1.4e-87;

Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 VEKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPIYFTNGHLY 60
Db 24 VEKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPIYFTNGHLY 83
Qy 61 PTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYLCQVNNPDPFYTNGLGLNLTVLV 120
Db 84 PTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTYLCQVNNPDPFYTNGLGLNLTVLV 143
Qy 121 PPSNPLCSQSGQTSVGGSTALRCSSESGAPKPVYNNWRLGTFPTPSPGSMVQDEVSGQLI 180
Db 144 PPSNPLCSQSGQTSVGGSTALRCSSESGAPKPVYNNWRLGTFPTPSPGSMVQDEVSGQLI 203
Qy 181 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 220
Db 204 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 243

RESULT 9

US-10-218-631-236

; Sequence 236, Application US/10218631

; Publication No. US20030045687A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Deenoyers, Luc

; APPLICANT: Gerritsen, Mary

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, J. Christopher

; APPLICANT: Gurney, Austin L.

; APPLICANT: Smith, Victoria

; APPLICANT: Stephan, Jean-Philippe F.

; APPLICANT: Watanabe, Colin L.

; APPLICANT: Wood, William I.

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

```
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530P1C14
; CURRENT APPLICATION NUMBER: US/10/218,631
; CURRENT FILING DATE: 2002-08-12
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-631-236

Query Match          99.2%; Score 1155; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-87;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISEHPILYFTNGHLY 60
Db 24 VEKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISEHPILYFTNGHLY 83

QY 61 PTGSKSKRVLLQNPPPTGVATLKLTDVHPSTGTLYLCQVNNPPDPYTNGLGLINLTVLV 120
Db 84 PTGSKSKRVLLQNPPPTGVATLKLTDVHPSTGTLYLCQVNNPPDPYTNGLGLINLTVLV 143

QY 121 PPSNPLCSGGTSGVSTALRCSSSEGAPKPVYNNVRLGTPTTSPGSMVQDEVSGQLI 180
Db 144 PPSNPLCSGGTSGVSTALRCSSSEGAPKPVYNNVRLGTPTTSPGSMVQDEVSGQLI 203

QY 181 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 220
Db 204 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 243

RESULT 10
US-10-230-414-236
; Sequence 236, Application US/10230414
; Publication No. US20030050448A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C98
; CURRENT APPLICATION NUMBER: US/10/230,414
```

```
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-230-414-236

Query Match          99.2%; Score 1155; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-87;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISEHPILYFTNGHLY 60
Db 24 VEKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISEHPILYFTNGHLY 83

QY 61 PTGSKSKRVLLQNPPPTGVATLKLTDVHPSTGTLYLCQVNNPPDPYTNGLGLINLTVLV 120
Db 84 PTGSKSKRVLLQNPPPTGVATLKLTDVHPSTGTLYLCQVNNPPDPYTNGLGLINLTVLV 143

QY 121 PPSNPLCSGGTSGVSTALRCSSSEGAPKPVYNNVRLGTPTTSPGSMVQDEVSGQLI 180
Db 144 PPSNPLCSGGTSGVSTALRCSSSEGAPKPVYNNVRLGTPTTSPGSMVQDEVSGQLI 203

QY 181 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 220
Db 204 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 243

RESULT 11
US-10-232-224-236
; Sequence 236, Application US/10232224
; Publication No. US20030065147A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C11
; CURRENT APPLICATION NUMBER: US/10/232,224
; CURRENT FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
```

```
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-232-224-236

Query Match          99.2%; Score 1155; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-87;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEVKPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
Db 24 VEVKPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 83

QY 61 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGYLCOVNNPPDFYTNGLGLNLTVLV 120
Db 84 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGYLCOVNNPPDFYTNGLGLNLTVLV 143

QY 121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTPPSGSMVQDEVSGOLI 180
Db 144 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTPPSGSMVQDEVSGOLI 203

QY 181 LTNLSTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 220
Db 204 LTNLSTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 243

RESULT 12
US-10-216-159A-236
; Sequence 236, Application US/10216159A
; Publication No. US20030069397A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC6
; CURRENT FILING DATE: 2002-08-09
; PRIOR APPLICATION NUMBER: US/10/216,159A
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
```

```
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-216-159A-236

Query Match          99.2%; Score 1155; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-87;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEVKPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
Db 24 VEVKPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 83

QY 61 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGYLCOVNNPPDFYTNGLGLNLTVLV 120
Db 84 PTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGYLCOVNNPPDFYTNGLGLNLTVLV 143

QY 121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTPPSGSMVQDEVSGOLI 180
Db 144 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTPPSGSMVQDEVSGOLI 203

QY 181 LTNLSTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 220
Db 204 LTNLSTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 243

RESULT 13
US-10-218-849-236
; Sequence 236, Application US/10218849
; Publication No. US20030073814A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC11
; CURRENT FILING DATE: 2002-08-12
; PRIOR APPLICATION NUMBER: US/10/218,849
; PRIOR FILING DATE: 2002-08-12
; Remaining Prior Application data removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-849-236
```



```
Query Match          99.2%; Score 1155; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-87;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 VEKVTPELSTPLGKTAELTCTYSTVSGDSPALEWSFVQPKPISESHPILYFTNGHLY 60
Db      24 VEKVTPELSTPLGKTAELTCTYSTVSGDSPALEWSFVQPKPISESHPILYFTNGHLY 83

QY      61 PTGSKSKRYVLLQNPPTVGATIKLTDVHPSDTGTLYLCVNNPPDPFTYTNGLGLINLTVLV 120
Db      84 PTGSKSKRYVLLQNPPTVGATIKLTDVHPSDTGTLYLCVNNPPDPFTYTNGLGLINLTVLV 143

QY     121 PRSNPLCSGGTSTVCGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 180
Db     144 PRSNPLCSGGTSTVCGSTALRCSSSEGAPKPVYNNVRLGTFPTSPGSMVQDEVSGQLI 203

QY     181 LTNLSLTSSGTVRCVATNMGNSASCELTLSVTEPSQGRVA 220
Db     204 LTNLSLTSSGTVRCVATNMGNSASCELTLSVTEPSQGRVA 243

RESULT 14
US-10-227-873-236
; Sequence 236, Application US/10227873
; Publication No. US20030073816A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C72
; CURRENT APPLICATION NUMBER: US/10/227,873
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
```

```
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
```

```
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/115558
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115565
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115733
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/119549
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/123618
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/125259
; PRIOR FILING DATE: 1999-03-19
; PRIOR APPLICATION NUMBER: 60/125775
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 60/126773
; PRIOR FILING DATE: 1999-03-29
; PRIOR APPLICATION NUMBER: 60/127887
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 60/130232
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: 60/131022
; PRIOR FILING DATE: 1999-04-26
; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14
; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/144758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
```

```
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match          99.2%; Score 1155; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-87;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEVKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPGKPISESHPILYFTNGHLY 60
   |||||
Db 24 VEVKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPGKPISESHPILYFTNGHLY 83
   |||||

QY 61 PTGSKSRVSLLONPPTVGATLKLTDVHPSDTGTLYLCQVNNPDPFYTNGLINLTVLV 120
   |||||
Db 84 PTGSKSRVSLLONPPTVGATLKLTDVHPSDTGTLYLCQVNNPDPFYTNGLINLTVLV 143
   |||||

QY 121 PPSNPLCSQSQTSTVGGSTALRCSSESGAPKPVVNWRLGTFTPTSPGSMVQDEVSGOLI 180
   |||||
Db 144 PPSNPLCSQSQTSTVGGSTALRCSSESGAPKPVVNWRLGTFTPTSPGSMVQDEVSGOLI 203
   |||||

QY 181 LTNLSTLTSSGTYRCVATNQMSASCELTLSVTEPSQGRVA 220
   |||||
Db 204 LTNLSTLTSSGTYRCVATNQMSASCELTLSVTEPSQGRVA 243
   |||||

RESULT 15
US-10-227-883-236
; Sequence 236, Application US/10227883
; Publication No. US20030073817A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Deenoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C78
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
```

1	PRIOR FILING DATE: 1998-09-24
2	PRIOR APPLICATION NUMBER: 60/106178
3	PRIOR FILING DATE: 1998-10-28
4	PRIOR APPLICATION NUMBER: 60/106248
5	PRIOR FILING DATE: 1998-10-29
6	PRIOR APPLICATION NUMBER: 60/106464
7	PRIOR FILING DATE: 1998-10-30
8	PRIOR APPLICATION NUMBER: 60/106905
9	PRIOR FILING DATE: 1998-11-03
10	PRIOR APPLICATION NUMBER: 60/108787
11	PRIOR FILING DATE: 1998-11-17
12	PRIOR APPLICATION NUMBER: 60/108801
13	PRIOR FILING DATE: 1998-11-17
14	PRIOR APPLICATION NUMBER: 60/108849
15	PRIOR FILING DATE: 1998-11-18
16	PRIOR APPLICATION NUMBER: 60/112422
17	PRIOR FILING DATE: 1998-12-15
18	PRIOR APPLICATION NUMBER: 60/113296
19	PRIOR FILING DATE: 1998-12-22
20	PRIOR APPLICATION NUMBER: 60/113605
21	PRIOR FILING DATE: 1998-12-23
22	PRIOR APPLICATION NUMBER: 60/113621
23	PRIOR FILING DATE: 1998-12-23
24	PRIOR APPLICATION NUMBER: 60/115558
25	PRIOR FILING DATE: 1999-01-12
26	PRIOR APPLICATION NUMBER: 60/115565
27	PRIOR FILING DATE: 1999-01-12
28	PRIOR APPLICATION NUMBER: 60/115733
29	PRIOR FILING DATE: 1999-01-12
30	PRIOR APPLICATION NUMBER: 60/119549
31	PRIOR FILING DATE: 1999-02-10
32	PRIOR APPLICATION NUMBER: 60/123618
33	PRIOR FILING DATE: 1999-03-10
34	PRIOR APPLICATION NUMBER: 60/125259
35	PRIOR FILING DATE: 1999-03-19
36	PRIOR APPLICATION NUMBER: 60/125775
37	PRIOR FILING DATE: 1999-03-23
38	PRIOR APPLICATION NUMBER: 60/126773
39	PRIOR FILING DATE: 1999-03-29
40	PRIOR APPLICATION NUMBER: 60/127887
41	PRIOR FILING DATE: 1999-04-05
42	PRIOR APPLICATION NUMBER: 60/130232
43	PRIOR FILING DATE: 1999-04-21
44	PRIOR APPLICATION NUMBER: 60/131022
45	PRIOR FILING DATE: 1999-04-26
46	PRIOR APPLICATION NUMBER: 60/131270
47	PRIOR FILING DATE: 1999-04-27
48	PRIOR APPLICATION NUMBER: 60/131291
49	PRIOR FILING DATE: 1999-04-27
50	PRIOR APPLICATION NUMBER: 60/131445
51	PRIOR FILING DATE: 1999-04-28
52	PRIOR APPLICATION NUMBER: 60/134287
53	PRIOR FILING DATE: 1999-05-14
54	PRIOR APPLICATION NUMBER: 60/140650
55	PRIOR FILING DATE: 1999-06-22
56	PRIOR APPLICATION NUMBER: 60/140723
57	PRIOR FILING DATE: 1999-06-22
58	PRIOR APPLICATION NUMBER: 60/141037
59	PRIOR FILING DATE: 1999-06-23
60	PRIOR APPLICATION NUMBER: 60/144758
61	PRIOR FILING DATE: 1999-07-20
62	PRIOR APPLICATION NUMBER: 60/145698
63	PRIOR FILING DATE: 1999-07-26
64	PRIOR APPLICATION NUMBER: 60/146222
65	PRIOR FILING DATE: 1999-07-28
66	PRIOR APPLICATION NUMBER: 60/146963
67	PRIOR FILING DATE: 1999-08-03
68	PRIOR APPLICATION NUMBER: 60/149320
69	PRIOR FILING DATE: 1999-08-17
70	PRIOR APPLICATION NUMBER: 60/149638
71	PRIOR FILING DATE: 1999-08-17
72	PRIOR APPLICATION NUMBER: 60/151733
73	PRIOR FILING DATE: 1999-08-31

; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.2%; Score 1155; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-87;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEVKVTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPGKPISESHPILYFTNGHLY 60
DB 24 VEVKVTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPGKPISESHPILYFTNGHLY 83

QY 61 PTGSKSKRVSLLLQNPTVGVATLKLTDVHPSPDTGYLCOVANNPPDFYTNGLGLINLTLVLV 120
DB 84 PTGSKSKRVSLLLQNPTVGVATLKLTDVHPSPDTGYLCOVANNPPDFYTNGLGLINLTLVLV 143

QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKEVYNWVRLGTFTPTSPGSMVQDEVSGQLI 180
DB 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKEVYNWVRLGTFTPTSPGSMVQDEVSGQLI 203

QY 181 LTNLSITSSGTYRCVATNQMSASCELTLISVTEPSQGRVA 220
DB 204 LTNLSITSSGTYRCVATNQMSASCELTLISVTEPSQGRVA 243

Search completed: August 4, 2005, 06:47:30
Job time : 60.8944 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 4, 2005, 05:53:15 ; Search time 67.7067 Seconds
(without alignments)
1268.128 Million cell updates/sec

Title: US-10-607-565-83_COPY_24_245
Perfect score: 1164
Sequence: 1 VEVKVPTEPLSTPLGKTAE.....ASCELTSLVTEPSQGRVDEL 222

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_16Dec04:*
1: Geneseqp1980s:*
2: Geneseqp1990s:*
3: Geneseqp2000s:*
4: Geneseqp2001s:*
5: Geneseqp2002s:*
6: Geneseqp2003as:*
7: Geneseqp2003bs:*
8: Geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1164	100.0	245	3 AAB08940	Aab08940 Human sec
2	1164	100.0	246	3 AAB08926	Aab08926 Human sec
3	1155	99.2	326	8 ADF83097	Adf83097 Human cor
4	1155	99.2	327	3 AAY87251	Aay87251 Human sig
5	1155	99.2	327	3 AAY94857	Aay94857 Human pro
6	1155	99.2	327	4 AAY97585	Aay97585 Human sec
7	1155	99.2	327	5 AAB90354	Aab90354 Human pol
8	1155	99.2	327	5 AAU83709	Aau83709 Human PRO
9	1155	99.2	327	6 ABU80856	Abu80856 Human PRO
10	1155	99.2	327	6 ABO33822	Abu33822 Novel hum
11	1155	99.2	327	6 ABU82165	Abu82165 Novel hum
12	1155	99.2	327	6 ABJ72345	Abj72345 Human PRO
13	1155	99.2	327	6 ABJ72473	Abj72473 Human PRO
14	1155	99.2	327	6 ABO34368	Abu34368 Human sec
15	1155	99.2	327	7 ABJ72175	Abj72175 Human mem
16	1155	99.2	327	7 ADB83726	Adb83726 Novel hum
17	1155	99.2	327	7 ADB80832	Adb80832 Novel hum
18	1155	99.2	327	7 ADB73373	Adb73373 Novel hum
19	1155	99.2	327	7 ADB78455	Adb78455 Novel hum
20	1155	99.2	327	7 ADB85103	Adb85103 Human PRO
21	1155	99.2	327	7 ADB78209	Adb78209 Novel hum
22	1155	99.2	327	7 ADB87275	Adb87275 Human PRO
23	1155	99.2	327	7 ADB84857	Adb84857 Human PRO
24	1155	99.2	327	7 ADB83972	Adb83972 Novel hum
25	1155	99.2	327	7 ADB73127	Adb73127 Novel hum

ALIGNMENTS

RESULT 1

AAB08940

ID AAB08940 standard; protein; 245 AA.

AC AAB08940;

DT 30-AUG-2000 (first entry)

DE Human secreted protein sequence encoded by gene 13 SEQ ID NO:97.

KW Human; secreted protein; cytostatic; anti-proliferative; vulnary;
KW immunosuppressive; antibacterial; diagnosis; immune system; chemotaxis;
KW hyperproliferative disorder; infectious disease; tissue regeneration;
KW screening; food additive; preservative; wound healing;
KW hyper-vascular disease; chromosome 11.

OS Homo sapiens.

XX WO200017222-A1.

XX 30-MAR-2000.

XX 22-SEP-1999; 99WO-US022012.

XX 23-SEP-1998; 98US-0101546P.

XX 02-OCT-1998; 98US-0102895P.

XX (HUMA-) HUMAN GENOME SCI INC.

PI Ruben SM, Rosen CA, Duan RD, Shi Y, Lafleur DW, Young PE, Ni J;

PI Komatsoulis G, Endress GA, Soppet DR;

XX WPI; 2000-283538/24.

PT Human secreted proteins and coding sequences useful in diagnostic and
therapeutic methods for disorders such as immune system or proliferative
disorders, related to the proteins.

PS Disclosure; Page 40; 416pp; English.

CC The polynucleotide sequences given in AAA39052 to AAA39088 encode the
human secreted proteins given in AAB08891 to AAB08984. The human secreted
proteins can have activities based on the tissues and cells they are
expressed in. Examples of the activities are: cytostatic; anti-
proliferative; immunosuppressive; antibacterial; and vulnary. The
secreted proteins and their related polynucleotide sequences are useful
for diagnostic and therapeutic methods useful for diagnosing and treating
disorders related to the secreted proteins. The proteins, and

CC polynucleotide sequences may be useful for treating disorders of the
CC immune system, hyperproliferative disorders, infectious disease,
CC regeneration of tissues, for chemotaxis and for screening molecules that
CC bind to the proteins. The proteins or polynucleotide sequences may be
CC used as food additives or preservatives, to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, co-factors or other nutritional components. Agonists or
CC antagonists of the proteins may be used to prevent scar tissue growth
CC during wound healing, and hyper-vascular diseases. AAA39043 to AAA39051
CC and AAB08890 are sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 245 AA;
Query Match 100.0%; Score 1164; DB 3; Length 245;
Best Local Similarity 100.0%; Pred. No. 2e-81;
Matches 222; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VEVKVPTEPLSTPLGKTAEALTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
DB 24 VEVKVPTEPLSTPLGKTAEALTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 83
QY 61 PTGSKSKRVSLLOQPPTVGATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTVLV 120
DB 84 PTGSKSKRVSLLOQPPTVGATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTVLV 143
QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRLGTPTTPSPGSMVQDEVSGQLI 180
DB 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRLGTPTTPSPGSMVQDEVSGQLI 203
QY 181 LTNLSLTSSGTYRCVATNQMSASCELTLSVTEPSQGRVAEL 222
DB 204 LTNLSLTSSGTYRCVATNQMSASCELTLSVTEPSQGRVAEL 245
RESULT 2
AAB08926
ID AAB08926 standard; protein; 245 AA.
AC AAB08926;
XX
DT 30-AUG-2000 (first entry)
XX
DE Human secreted protein sequence encoded by gene 13 SEQ ID NO:83.
XX
KW Human; secreted protein; cytostatic; anti-proliferative; vulnerary;
KW immunosuppressive; antibacterial; diagnosis; immune system; chemotaxis;
KW hyperproliferative disorder; infectious disease; tissue regeneration;
KW screening; food additive; preservative; wound healing;
KW hyper-vascular disease; chromosome 11.
XX
OS Homo sapiens.
XX
PN WO200017222-A1.
XX
PD 30-MAR-2000.
XX
PF 22-SEP-1999; 99WO-US022012.
XX
PR 23-SEP-1998; 98US-0101546P.
PR 02-OCT-1998; 98US-0102895P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Rosen CA, Duan RD, Shi Y, Lafleur DW, Young PE, Ni J;
PI Komatsoulis G, Endress GA, Soppet DR;
XX
DR WPI; 2000-283538/24.
DR N-PSDB; AAA39087.
XX
PT Human secreted proteins and coding sequences useful in diagnostic and
PT therapeutic methods for disorders such as immune system or proliferative
PT disorders, related to the proteins.

XX Claim 11; Page 376-377; 416pp; English.
XX
CC The polynucleotide sequences given in AAA39052 to AAA39088 encode the
CC human secreted proteins given in AAB08891 to AAB08984. The human secreted
CC proteins can have activities based on the tissues and cells they are
CC expressed in. Examples of the activities are: cytostatic; anti-
CC proliferative; immunosuppressive; antibacterial; and vulnerary. The
CC secreted proteins and their related polynucleotide sequences are useful
CC for diagnostic and therapeutic methods useful for diagnosing and treating
CC disorders related to the secreted proteins. The proteins and
CC polynucleotide sequences may be useful for treating disorders of the
CC immune system, hyperproliferative disorders, infectious disease,
CC regeneration of tissues, for chemotaxis and for screening molecules that
CC bind to the proteins. The proteins or polynucleotide sequences may be
CC used as food additives or preservatives, to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, co-factors or other nutritional components. Agonists or
CC antagonists of the proteins may be used to prevent scar tissue growth
CC during wound healing, and hyper-vascular diseases. AAA39043 to AAA39051
CC and AAB08890 are sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 246 AA;
Query Match 100.0%; Score 1164; DB 3; Length 246;
Best Local Similarity 100.0%; Pred. No. 2e-81;
Matches 222; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VEVKVPTEPLSTPLGKTAEALTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
DB 24 VEVKVPTEPLSTPLGKTAEALTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 83
QY 61 PTGSKSKRVSLLOQPPTVGATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTVLV 120
DB 84 PTGSKSKRVSLLOQPPTVGATLKLTDVHPSDTGYLCQVNNPPDFYTNGLINLTVLV 143
QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRLGTPTTPSPGSMVQDEVSGQLI 180
DB 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRLGTPTTPSPGSMVQDEVSGQLI 203
QY 181 LTNLSLTSSGTYRCVATNQMSASCELTLSVTEPSQGRVAEL 222
DB 204 LTNLSLTSSGTYRCVATNQMSASCELTLSVTEPSQGRVAEL 245
RESULT 3
ADF83097
ID ADF83097 standard; protein; 326 AA.
XX
AC ADF83097;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human corticol thymocyte receptor CTXL, overexpressed in cancer.
XX
KW Human; corticol thymocyte receptor; receptor; CTXL; cancer; cytostatic;
KW vaccine; gene therapy.
XX
OS Homo sapiens.
XX
PN WO2003100000-A2.
XX
PD 04-DEC-2003.
XX
PF 22-MAY-2003; 2003WO-US016049.
XX
PR 24-MAY-2002; 2002US-0382606P.
PR 25-JUL-2002; 2002US-0398099P.
XX
PA (TULA-) TULARIK INC.
XX
PI Li J, Mu D, Yang J;

XX WPI; 2004-035118/03.
 DR N-PSDB; ADF93096.
 DR GENBANK; XP_035095.
 XX
 PT Diagnosing a cancer in a mammal comprises determining RecQL5, CTXL,
 PT USP13, MCL1, or Pellino 1 gene copy number in a biological sample from a
 PT region of the mammal that is suspected to be precancerous or cancerous.
 XX
 XX Claim 54; SEQ ID NO 4; 174pp; English.
 XX
 CC The present sequence is the protein sequence of human cortical thymocyte
 CC receptor (Xenopus laevis cts)-like (CTXL), previously known as a cortical
 CC thymocyte marker in frogs, and a member of the immunoglobulin superfamily
 CC having features of both antigen-specific receptors and adhesion
 CC molecules. The invention is based on the finding of the overexpression of
 CC CTXL and other genes (RecQL5, USP13, MCL1 and Pellino1) in certain
 CC cancers, including breast cancer, colon cancer, lung cancer and ovarian
 CC cancer, and the frequent amplification of these genes in cancer cells.
 CC The genes, and their expression products, can be used diagnostically or
 CC as targets for cancer therapy. They can also be used to identify and
 CC design compounds useful in the diagnosis, prevention and therapy of
 CC tumours and cancers, in vaccine development, and in methods for
 CC determining the efficacy of a treatment regime. A claimed method for
 CC inhibiting cancer or precancerous growth, especially in colon, ovarian or
 CC breast tissue, uses an inhibitor that interacts with CTXL DNA or RNA. The
 CC inhibitor is a small interfering RNA (siRNA), microRNA (miRNA), an
 CC antisense RNA, and antisense DNA, a decoy molecule, a decoy DNA, a
 CC ribozyme or small molecule.
 XX
 SQ Sequence 326 AA;

Query Match 99.2%; Score 1155; DB 8; Length 326;
 Best Local Similarity 100.0%; Pred. No. 1.4e-80;
 Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 VEVKPTPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPIFYNGHLY 60
 Db 23 VEVKPTPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPIFYNGHLY 82
 QY 61 PTGSKSKRVLLQNPPPTGVATLKLTDVHPSDTGYLQVNNPPDPYTNGLINLTVLV 120
 Db 83 PTGSKSKRVLLQNPPPTGVATLKLTDVHPSDTGYLQVNNPPDPYTNGLINLTVLV 142
 QY 121 PPSNPLCSQSGTSTVGGSTALRCSSEGAPKPVYNNVRLGTPTPSPGSMWQDEVSGQLI 180
 Db 143 PPSNPLCSQSGTSTVGGSTALRCSSEGAPKPVYNNVRLGTPTPSPGSMWQDEVSGQLI 202
 QY 181 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 220
 Db 203 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 242

RESULT 4
 AAY87251
 ID AAY87251 standard; protein; 327 AA.
 AC AAY87251;
 XX
 XX 11-MAY-2000 (first entry)
 XX
 XX Human signal peptide containing protein HSP-28 SEQ ID NO:28.
 KW Human; signal peptide-containing protein; HSP; diagnosis; cancer;
 KW inflammation; cardiovascular disease; anticancer; anti-inflammatory;
 KW antimicrobial; neurotropic; neuroprotective; cardiovascular; hepatotropic;
 KW antitastmatic; gene therapy; cell proliferation; neurological disorder;
 KW reproductive disorder; developmental disorder; arteriosclerosis;
 KW cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;
 KW asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;
 KW Parkinson's disease; Huntington's disease; ovulatory defect;
 KW muscular dystrophy.
 XX

OS Homo sapiens.
 XX WO200000610-A2.
 PN
 XX
 PD 06-JAN-2000.
 XX
 XX 25-JUN-1999; 99WO-US014484.
 XX
 PR 26-JUN-1998; 98US-0090762P.
 PR 31-JUL-1998; 98US-0094983P.
 PR 01-OCT-1998; 98US-0102686P.
 PR 11-DEC-1998; 98US-0112129P.
 XX
 PA (INCY-) INCYTE PHARM INC.
 XX
 PI Lal P, Tang YT, Gorgone GA, Corley NC, Guegler KJ, Baughn MR;
 PI Akerdlom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL;
 PI Bandman O;
 XX
 XX WPI; 2000-160673/14.
 DR N-PSDB; AAZ98136.
 XX
 PT New human signal peptide-containing proteins useful in treatment,
 PT prevention and diagnosis of e.g. cancer, inflammation and cardiovascular
 PT disease.
 XX
 XX Claim 1; Page 177-178; 327pp; English.
 XX
 CC AAZ98109 to AAZ98242 encode AAY87224 to AAY87357 which represent the
 CC human signal peptide-containing proteins HSP-1 to HSP-134. HSPs have
 CC anticancer, anti-inflammatory, antimicrobial, neurotropic, hepatotropic,
 CC neuroprotective, cardiovascular and antitastmatic activities, and can be
 CC used in gene therapy. HSPs can be used to treat or prevent disorders
 CC associated with decreased activity or function of HSP. Antagonists of
 CC HSP are used to treat or prevent disorders associated with increased
 CC activity or function of HSP. Such diseases include cell proliferation
 CC (including cancer), inflammation, cardiovascular, neurological,
 CC reproductive or developmental disorders, (e.g. arteriosclerosis,
 CC cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia, or
 CC asthma, Crohn's disease, microbial or other infections, congestive or
 CC ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's
 CC diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSP
 CC nucleic acids can be used for the recombinant production of HSP, for
 CC detecting HSP in standard hybridisation and amplification assays (for
 CC diagnosis and monitoring), in gene therapy, as antisense, triplex-forming
 CC or ribozyme therapeutics, for detecting related sequences or genetic
 CC variations, and for chromosomal mapping. HSP are also used to raise
 CC specific antibodies (Ab) and to screen for agonists and antagonists
 CC (potential therapeutic agents). Ab are used to diagnose, or monitor, HSP
 CC -related diseases (in usual immunoassays), as therapeutic antagonists, in
 CC competitive drug screens, and for purification of HSP from natural
 CC sources
 XX
 SQ Sequence 327 AA;

Query Match 99.2%; Score 1155; DB 3; Length 327;
 Best Local Similarity 100.0%; Pred. No. 1.4e-80;
 Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 VEVKPTPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPIFYNGHLY 60
 Db 24 VEVKPTPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPIFYNGHLY 83
 QY 61 PTGSKSKRVLLQNPPPTGVATLKLTDVHPSDTGYLQVNNPPDPYTNGLINLTVLV 120
 Db 84 PTGSKSKRVLLQNPPPTGVATLKLTDVHPSDTGYLQVNNPPDPYTNGLINLTVLV 143
 QY 121 PPSNPLCSQSGTSTVGGSTALRCSSEGAPKPVYNNVRLGTPTPSPGSMWQDEVSGQLI 180
 Db 144 PPSNPLCSQSGTSTVGGSTALRCSSEGAPKPVYNNVRLGTPTPSPGSMWQDEVSGQLI 203
 QY 181 LTNLSLTSSGTYRCVATNQMSASCELTLSTVTEPSQGRVA 220

DB 204 LTNLSTSSGTYRCVATNQMGASCELTLSTVTEPSQGRVA 243

AAAY94857

RESULT 5

ID AAY94857 standard; protein; 327 AA.

XX AAY94857;

AC AAY94857;

DT 12-JUN-2000 (first entry)

DE Human protein clone HP10568.

DE

XX Human protein; hydrophobic domain; nutritional source; haematopoiesis; cytokine production; cell proliferation; cell differentiation; immune deficiency; infectious disease; autoimmune disorder; asthma; multiple sclerosis; systemic lupus erythematosus; rheumatoid arthritis; allergic reaction; osteoporosis; osteoarthritis; periodontal disease; nervous system disorder; Alzheimer's disease; Parkinson's disease; Huntington's disease; liver fibrosis; lung fibrosis; reperfusion injury; systemic cytokine damage; tissue differentiation; contraceptive; stroke; coagulation disorder; myocardial infarction; inflammatory condition; septic shock; sepsis; ischaemia; reperfusion injury; arthritis; tumour; nephritis; therapy.

XX Homo sapiens.

OS

XX WO200005367-A2.

PN

XX 03-FEB-2000.

PD

XX 22-JUL-1999; 99WO-JP003929.

PF

XX 24-JUL-1998; 98JP-00208820.

PR

XX 07-AUG-1998; 98JP-00224105.

PR

XX 25-AUG-1998; 98JP-00238116.

PR

XX 09-SEP-1998; 98JP-00234716.

PR

XX 29-SEP-1998; 98JP-00275505.

PR

XX (SAGA) SAGAMI CHEM RES CENT.

PA

PA (PROT-) PROTEGENE INC.

PI

XX Kato S, Kimura T;

XX

XX WPI; 2000-182694/16.

DR

XX

XX Novel human proteins having hydrophobic domains useful for treating osteoporosis, Alzheimer's disease, Parkinson's disease, asthma, multiple sclerosis, rheumatoid arthritis, cancer, anemia, and stroke.

PT

PT

PT

XX Claim 1; Page 183-184; 351pp; English.

PS

XX This sequence represents a human protein of the invention, which has hydrophobic domains. The DNA sequences can be used as a probe or as a genetic marker. The protein can also be used as a marker, and to identify potential genetic disorders. The DNA and protein can also be used as nutritional sources or supplements. The protein exhibits cytokine, cell proliferation, cell differentiation activities and induces production of other cytokines in certain cell populations. The protein also exhibits immune stimulating or immune suppressing activity. It can be used in the treatment of various immune deficiencies and disorders, and to treat infectious diseases caused by viral, bacterial, fungal or other infections. The protein is also used for treating autoimmune disorders such as multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. It is also useful in the treatment of allergic reactions and conditions such as asthma, and in immune suppression after organ transplantation. The protein is useful in regulation of haematopoiesis and consequently in the treatment of myeloid or lymphoid cell deficiencies. It is also used in compositions for tissue growth or regeneration. The protein is also used in the treatment of osteoporosis or osteoarthritis and in the treatment of periodontal disease and other tooth repair processes. The protein is used in the treatment of nervous system disorders such as Alzheimer's disease, Parkinson's disease, and

CC Huntington's disease. They are useful for protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage. They are also used for promoting or inhibiting tissue differentiation. They are also used as contraceptives since they exhibit activin or inhibin related activities and as a fertility inducing therapeutic. They are used for treating various coagulation disorders and in treatment and prevention of conditions resulting from coagulation activities e.g. myocardial infarction or stroke. They also acts as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. They are used to treat inflammatory conditions such as septic shock, sepsis, ischaemia reperfusion injury, arthritis, and nephritis. They can be used to prevent tumours

XX

SQ Sequence 327 AA;

Query Match 99.2%; Score 1155; DB 3; Length 327;

Best Local Similarity 100.0%; Pred. No. 1.4e-80;

Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEVKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 60

Db 24 VEVKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 83

QY 61 PTGSKSRVSLLONPPTVGATLKLTDVHPSDTCTYLQVNNPPDFYTNGLINLTLVLV 120

Db 84 PTGSKSRVSLLONPPTVGATLKLTDVHPSDTCTYLQVNNPPDFYTNGLINLTLVLV 143

QY 121 PPSNPPLCSQSQTSTVGGSTALRCSSEGAPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180

Db 144 PPSNPPLCSQSQTSTVGGSTALRCSSEGAPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 203

QY 181 LTNLSTSSGTYRCVATNQMGASCELTLSTVTEPSQGRVA 220

Db 204 LTNLSTSSGTYRCVATNQMGASCELTLSTVTEPSQGRVA 243

RESULT 6

AAAY97585

ID AAY97585 standard; protein; 327 AA.

XX

AC AAY97585;

XX

DT 05-APR-2001 (first entry)

XX

DE Human secreted protein PRO7154.

DE

XX Secreted protein; human; PRO protein; neoplastic cell growth; tumour; proliferation; leukaemia; lymphoid malignancy; inflammatory disorder; angiogenic disorder; immunologic disorder; PRO7154.

KW

KW

XX Homo sapiens.

OS

XX WO200075317-A2.

PN

XX 14-DEC-2000.

PD

XX 15-MAY-2000; 2000WO-US013358.

PF

XX 09-JUN-1999; 99US-0138385P.

PR

XX 20-JUL-1999; 99US-0144790P.

PR

XX 03-AUG-1999; 99US-0146843P.

PR

XX 10-AUG-1999; 99US-0148188P.

PR

XX 17-AUG-1999; 99US-0149320P.

PR

XX 17-AUG-1999; 99US-0149327P.

PR

XX 17-AUG-1999; 99US-0149396P.

PR

XX 20-AUG-1999; 99US-0150114P.

PR

XX 31-AUG-1999; 99US-0151700P.

PR

XX 31-AUG-1999; 99US-0151734P.

XX

XX (GETH) GENENTECH INC.

PA

PA Botstein DA, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WI;

PI

XX WPI; 2001-071075/08.
DR N-PSDB; AAA91019.
XX
XX Antibodies against PRO polypeptides, useful for diagnosing and treating
PT tumors are associated with gene amplification, neoplastic cell growth and
PT proliferation in mammals.
XX
XX Claim 61; Fig 12; 143pp; English.
XX
XX This sequence is a human PRO protein of the invention. The PRO proteins
CC are secreted proteins. Antagonists or antibodies of PRO polypeptides are
CC useful for diagnosing and treating tumors are associated with gene
CC amplification, neoplastic cell growth and proliferation in mammals, and
CC those conditions characterised by overexpression and/or activation of the
CC amplified genes. Such conditions include benign or malignant tumours
CC (e.g. renal, liver, kidney, bladder, breast, gastric, ovarian,
CC colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic
CC carcinomas, sarcomas, glioblastomas and various head and neck tumours);
CC leukaemias and lymphoid malignancies; neuronal, glial, astrocytal,
CC hypothalamic, and other glandular, macrophageal, epithelial, stromal and
CC blastocoeleic disorders; and inflammatory, angiogenic and immunologic
CC disorders. These may further be used to qualitatively or quantitatively
CC detect the expression of proteins encoded by the amplified genes, and in
CC tumour diagnostics or prognostics. The PRO polypeptide or its antagonist
CC may be used for the preparation of a medicament in the treatment of a
CC condition, which is responsive to the PRO polypeptide, its antagonist or
CC anti-PRO antibody
XX
XX Sequence 327 AA;
SQ
Query Match 99.2%; Score 1155; DB 4; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-80;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VEVKVTPEPLSTPLGKTAELCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
DB 24 VEVKVTPEPLSTPLGKTAELCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 83
QY 61 PTGSKSRVSLQNPPTVGATLKLTDVHPSTGTGLCQVNNPPDYNTGLINLTLV 120
DB 84 PTGSKSRVSLQNPPTVGATLKLTDVHPSTGTGLCQVNNPPDYNTGLINLTLV 143
QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTTSPSGMWQDEVSGQLI 180
DB 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTTSPSGMWQDEVSGQLI 203
QY 181 LTNLSLTSSGTYRCVATNMGASCELTLTSLVTEPSQGRVA 220
DB 204 LTNLSLTSSGTYRCVATNMGASCELTLTSLVTEPSQGRVA 243
RESULT 7
ABB90354
ID ABB90354 standard; protein; 327 AA.
XX
XX ABB90354;
XX
XX 24-MAY-2002 (first entry)
XX
XX Human polypeptide SEQ ID NO 2730.
XX
XX Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
KW anti-allergic; hepatotropic; antidiabetic; anti-inflammatory; antitumor;
KW vulnary; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW cardiac; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW neurological disease; infection; human; secreted protein.
XX
XX Homo sapiens.
XX
XX WO200190304-A2.
XX
XX 29-NOV-2001.

XX 18-MAY-2001; 2001WO-US016450.
XX
XX 19-MAY-2000; 2000US-0205515P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Birse CE, Rosen CA;
XX
XX WPI: 2002-122018/16.
DR N-PSDB; ABL90763.
XX
XX Novel 1405 isolated polypeptides, useful for diagnosis, treatment and
PT prevention of neural, immune system, muscular, reproductive,
PT gastrointestinal, pulmonary, cardiovascular, renal and proliferative
PT disorders.
XX
XX Claim 11; SEQ ID NO 2730; 2081pp + Sequence Listing; English.
PS
XX The invention relates to novel genes (ABL89449-ABL90853) and proteins
XX (ABB89040-ABB90444) useful for preventing, treating or ameliorating
CC medical conditions e.g. by protein or gene therapy. The genes are
CC isolated from a range of human tissues disclosed in the specification.
CC The nucleic acids, proteins, antibodies and (ant)agonists are useful in
CC the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and
CC ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,
CC breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune
CC disorders e.g. Addison's disease, allergies, autoimmune haemolytic
CC anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)
CC cardiovascular disorders such as myocardial ischaemias; (d) wound healing
CC ; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)
CC infectious diseases such as viral, bacterial, fungal and parasitic
CC infections. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 327 AA;
Query Match 99.2%; Score 1155; DB 5; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-80;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 VEVKVTPEPLSTPLGKTAELCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
DB 24 VEVKVTPEPLSTPLGKTAELCTYSTSVGDSFALEWSFVQPKPISESHPILYFTNGHLY 83
QY 61 PTGSKSRVSLQNPPTVGATLKLTDVHPSTGTGLCQVNNPPDYNTGLINLTLV 120
DB 84 PTGSKSRVSLQNPPTVGATLKLTDVHPSTGTGLCQVNNPPDYNTGLINLTLV 143
QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTTSPSGMWQDEVSGQLI 180
DB 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTTSPSGMWQDEVSGQLI 203
QY 181 LTNLSLTSSGTYRCVATNMGASCELTLTSLVTEPSQGRVA 220
DB 204 LTNLSLTSSGTYRCVATNMGASCELTLTSLVTEPSQGRVA 243
RESULT 8
AAU83709
ID AAU83709 standard; protein; 327 AA.
XX
XX AAU83709;
XX
XX 08-MAY-2002 (first entry)
XX
XX Human PRO protein, Seq ID No 236.
XX
XX Human; secreted protein; PRO; tumour; lung cancer; colon cancer;
KW breast cancer; prostate tumour; rectal tumour; liver tumour;
KW pericyte cell proliferation; chondrocyte cell proliferation;

Best Local Similarity 100.0%; Pred. No. 1.4e-80;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEVKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
DB 24 VEVKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 83

QY 61 PTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTLYLQVNNPPDPFTYNGLGLINLTVLV 120
DB 84 PTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTLYLQVNNPPDPFTYNGLGLINLTVLV 143

QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTTSPGSMVDVSGQLI 180
DB 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTTSPGSMVDVSGQLI 203

QY 181 LTNLSLTSSGTVCVATNMQGSASCELTLSTVTEPSQGRVA 220
DB 204 LTNLSLTSSGTVCVATNMQGSASCELTLSTVTEPSQGRVA 243

RESULT 10
ID AB033822 standard; protein; 327 AA.
XX AB033822;
DT 17-SEP-2003 (first entry)
XX Novel human secreted and transmembrane protein PRO7154.
DE Human; secreted and transmembrane protein; PRO; cytostatic;
KW antarthritic; osteopathic; gene therapy; TNF-Agonist-Alpha;
KW chondrocyte stimulator; pericyte stimulator; fibroblast modulator;
KW pharmacological; diagnostic; biosensor; bioreactor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; bone disorder; cartilage disorder; sports injury;
arthritis; wound.
XX Homo sapiens.
OS US2003045687-A1.
FN 06-MAR-2003.
XX 12-AUG-2002; 2002US-00218631.
XX 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
PI WPI; 2003-512315/48.
DR N-PSDB; ACD68710.
XX New genes, and its encoded secreted and transmembrane polypeptides,
PT useful for stimulating tumor Necrosis Factor alpha, or chondrocyte or
PT pericyte proliferation, especially for treating lung tumors, arthritis or
PT wounds in a mammal.
XX Claim 11; Fig 236; 314pp; English.
XX The invention describes an isolated nucleic acid molecule comprising a
CC sequence with at least 80% identity to: (a) a nucleotide encoding any of
CC 122 PRO (secreted and transmembrane) polypeptides whose sequences are
CC fully defined in the specification; or (b) any of 122 nucleotide
CC sequences having e.g. 4834, 2504 or 1759 bp fully defined in the
CC specification; or the full length coding sequence of any these 122
CC nucleotide sequences. The PRO polypeptides or polynucleotides are useful
CC as pharmaceuticals, diagnostics, biosensors or bioreactors. These are

CC particularly useful for detecting tumours (e.g. lung tumour, colon
CC tumour, breast tumour, prostate tumour, rectal tumour, or liver tumour)
CC in a mammal, for stimulating the release of TNF-alpha from human blood,
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells, for stimulating proliferation of pericyte cells, or for modulating
CC normal human fibroblast proliferation. The PRO nucleic acid or
CC polypeptide is also useful for treating tumours or various bone and/or
CC cartilage disorders (e.g. sports injuries or arthritis), or wounds. The
CC PRO polypeptides are useful in drug screening, particularly as targets
CC for therapeutic intervention in these diseases, and in the diagnostic
CC determination of the presence of these diseases. The PRO polypeptides are
CC also useful as molecular weight markers, or for chromosome
CC identification. The PRO genes are useful as hybridisation probes, or for
CC screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may
CC also be used in gene therapy, particularly for replacing a defective
CC gene. This is the amino acid sequence of a novel human secreted and
CC transmembrane PRO polypeptide
XX Sequence 327 AA;
SQ

Query Match 99.2%; Score 1155; DB 6; Length 327;
Best Local Similarity 100.0%; Pred. No. 1.4e-80;
Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEVKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 60
DB 24 VEVKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 83

QY 61 PTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTLYLQVNNPPDPFTYNGLGLINLTVLV 120
DB 84 PTGSKSRVSLQNPPTVGATLKLTDVHPSDTGTLYLQVNNPPDPFTYNGLGLINLTVLV 143

QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTTSPGSMVDVSGQLI 180
DB 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTTSPGSMVDVSGQLI 203

QY 181 LTNLSLTSSGTVCVATNMQGSASCELTLSTVTEPSQGRVA 220
DB 204 LTNLSLTSSGTVCVATNMQGSASCELTLSTVTEPSQGRVA 243

RESULT 11
ID AB082165 standard; protein; 327 AA.
XX AB082165;
XX 25-JUN-2003 (first entry)
XX Novel human secreted and transmembrane protein PRO7154.
DE Human; secreted and transmembrane protein; PRO; cardiant; cytostatic;
KW antiangiogenic; hypotensive; vulnerary; antiarteriosclerotic;
KW gene therapy; cardiovascular disorder; endothelial disorder;
KW angiocenic disorder; cardiac hypertrophy; trauma; cancer;
KW age-related macular degeneration; atherosclerosis; hypertension;
KW arterial restenosis; rheumatoid arthritis; angina; myocardial infarction;
KW thrombophlebitis; lymphangitis; tumour angiogenesis; breast carcinoma;
KW liver carcinoma; wound healing; chromosome mapping; gene mapping.
XX Homo sapiens.
OS US2003088063-A1.
FN 08-MAY-2003.
XX 12-AUG-2002; 2002US-00219003.
XX 25-JUL-2000; 2000US-0220664P.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX

PA (GETH) GENENTECH INC.
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI: 2003-393229/37.
 DR N-PSDB; ACA68614.
 XX
 PT One hundred and eighty seven nucleic acids encoding PRO polypeptides,
 PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
 PT infarction), endothelial or angiogenic disorders in a mammal.
 XX
 PS Claim 11; Fig 236; 314pp; English.
 XX
 CC The invention describes one hundred and eighty seven nucleic acids
 CC encoding novel human secreted and transmembrane (PRO) polypeptides. The
 CC PRO nucleic acids, polypeptides, agonists and antagonists are useful for
 CC treating or diagnosing a cardiovascular, endothelial or angiogenic
 CC disorder in a mammal, e.g. cardiac hypertrophy, trauma, cancer, age-
 CC related macular degeneration, atherosclerosis, hypertension, arterial
 CC restenosis, rheumatoid arthritis, angina, myocardial infarctions,
 CC thrombophlebitis, lymphangitis, tumour angiogenesis (such as breast
 CC carcinoma and liver carcinoma) and wound healing. The PRO nucleic acids
 CC have applications in molecular biology, including use as hybridisation
 CC probes, and in chromosome and gene mapping. This is the amino acid
 CC sequence of a novel human secreted and transmembrane PRO polypeptide
 XX
 SQ Sequence 327 AA;
 Query Match 99.2%; Score 1155; DB 6; Length 327;
 Best Local Similarity 100.0%; Pred. No. 1.4e-80;
 Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 VEVKVTPEPLSTPLGKTAELTCTYSTVGDSPFALEWSFVQPKPISESHPILYFTNGHLY 60
 DB 24 VEVKVTPEPLSTPLGKTAELTCTYSTVGDSPFALEWSFVQPKPISESHPILYFTNGHLY 83
 QY 61 PTGSKSRVSLQNPPTVGVAATLKTLDVHPSDTGYLCQVNNPPDFYTNGLINLTVLV 120
 DB 84 PTGSKSRVSLQNPPTVGVAATLKTLDVHPSDTGYLCQVNNPPDFYTNGLINLTVLV 143
 QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180
 DB 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 203
 QY 181 LTNLISLTSSGTYRCVATNQMGASCELTLSVTEPSQGRVA 220
 DB 204 LTNLISLTSSGTYRCVATNQMGASCELTLSVTEPSQGRVA 243
 RESULT 12
 ABJ72345
 ID ABJ72345 standard; protein; 327 AA.
 XX
 AC ABJ72345;
 XX
 DT 06-NOV-2003 (first entry)
 XX
 DE Human PRO7154 protein.
 XX
 KW PRO; proliferation; pericyte cell; TNF-alpha; blood; chondrocyte;
 KW differentiation; dermal fibroblast; tumour; gene therapy; cytostatic.
 XX
 OS Homo sapiens.
 XX
 PN US2003050448-A1.
 XX
 PD 13-MAR-2003.
 XX
 PF 28-AUG-2002; 2002US-00230414.
 XX
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR

PR 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI: 2003-521818/49.
 DR N-PSDB; ABT44343.
 XX
 PT New nucleic acid encoding for a PRO protein, useful for the manufacture
 PT of a medicament for diagnosing or treating tumors or for measuring or
 PT detecting expression of an associated gene.
 XX
 PS Claim 11; Fig 236; 315pp; English.
 XX
 CC The invention relates to a novel isolated nucleic acid encoding a fully
 CC defined PRO polypeptide. The molecules of the invention may be useful for
 CC stimulating proliferation or gene expression in pericyte cells or the
 CC release of TNF-alpha from human blood. Other possible uses include the
 CC stimulation or inhibition of chondrocyte proliferation or
 CC differentiation, the stimulation of human dermal fibroblast cell
 CC proliferation and the detection of the presence of a tumour within a
 CC mammal. Furthermore, the nucleic acid may be useful for the manufacture
 CC of a medicament for diagnosing or treating a tumour within a mammal or
 CC for measuring or detecting the expression of an associated gene, as well
 CC as during gene therapy. The current sequence is that of the human PRO
 CC protein of the invention
 XX
 SQ Sequence 327 AA;
 Query Match 99.2%; Score 1155; DB 6; Length 327;
 Best Local Similarity 100.0%; Pred. No. 1.4e-80;
 Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 VEVKVTPEPLSTPLGKTAELTCTYSTVGDSPFALEWSFVQPKPISESHPILYFTNGHLY 60
 DB 24 VEVKVTPEPLSTPLGKTAELTCTYSTVGDSPFALEWSFVQPKPISESHPILYFTNGHLY 83
 QY 61 PTGSKSRVSLQNPPTVGVAATLKTLDVHPSDTGYLCQVNNPPDFYTNGLINLTVLV 120
 DB 84 PTGSKSRVSLQNPPTVGVAATLKTLDVHPSDTGYLCQVNNPPDFYTNGLINLTVLV 143
 QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 180
 DB 144 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTFTPTSPGSMVQDEVSGQLI 203
 QY 181 LTNLISLTSSGTYRCVATNQMGASCELTLSVTEPSQGRVA 220
 DB 204 LTNLISLTSSGTYRCVATNQMGASCELTLSVTEPSQGRVA 243
 RESULT 13
 ABJ72473
 ID ABJ72473 standard; protein; 327 AA.
 XX
 AC ABJ72473;
 XX
 DT 06-NOV-2003 (first entry)
 XX
 DE Human PRO7154 protein.
 XX
 KW PRO; blood; proliferation; pericyte cell; TNF alpha; chondrocyte;
 KW tumour necrosis factor; proliferation; differentiation; gene therapy;
 KW dermal fibroblast.
 XX
 OS Homo sapiens.
 XX
 PN US2003027988-A1.
 XX
 PD 06-FEB-2003.
 XX
 PF 26-AUG-2002; 2002US-00227884.
 PF

XX 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2003-503301/47.
 DR N-PSDB; AB744626.
 XX
 PT New PRO protein encoding nucleic acid, useful for preparing PRO
 PT polypeptides and anti-PRO antibodies for detecting the presence of a
 PT tumor in a mammal.
 XX
 PS Claim 11; Fig 236; 324pp; English.
 XX
 CC The invention relates to a novel isolated PRO protein encoding nucleic
 CC acid. The nucleic acid of the invention may be useful for preparing PRO
 CC polypeptides and anti-PRO antibodies for detecting the presence of a
 CC tumor in a mammal. Furthermore, the molecules of the invention may be
 CC useful for stimulating proliferation or gene expression in pericyte
 CC cells, the release of tumour necrosis factor (TNF)-alpha from human
 CC blood, the proliferation or differentiation of chondrocyte cells and for
 CC inhibiting the proliferation of normal human dermal fibroblast cells.
 CC Finally, the molecules may be utilised during gene therapy. The current
 CC sequence is that of the human PRO protein of the invention
 XX
 SQ Sequence 327 AA;
 Query Match 99.2%; Score 1155; DB 6; Length 327;
 Best Local Similarity 100.0%; Pred. No. 1.4e-80;
 Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 VEVKPTPEPLTGLKTAELTCTYSTVGDSPALEWSFVQPKPISEHPILYFTNGHLY 60
 Db VEVKPTPEPLTGLKTAELTCTYSTVGDSPALEWSFVQPKPISEHPILYFTNGHLY 83
 QY 61 PTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYLQVNNPPDFYTNGLGLINLTIVL 120
 Db PTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYLQVNNPPDFYTNGLGLINLTIVL 143
 QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTSPGSMVQDEVSGQLI 180
 Db PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTSPGSMVQDEVSGQLI 203
 QY 181 LTNLSLTSSGTYRCVATNQMGASCELTLTSLVTEPSQGRVA 220
 Db LTNLSLTSSGTYRCVATNQMGASCELTLTSLVTEPSQGRVA 243
 RESULT 14
 ABO34368
 ID ABO34368 standard; protein; 327 AA.
 AC ABO34368;
 XX
 DT 19-SEP-2003 (first entry)
 XX
 DE Human secreted/transmembrane polypeptide PRO 7154.
 XX
 KW Human; chondrocyte stimulation; TNF-alpha stimulation; gene therapy;
 KW human dermal fibroblast stimulation; tumour; tissue typing;
 KW affinity purification.
 XX
 OS Homo sapiens.
 XX
 PN US2003044934-A1.
 XX
 PD 06-MAR-2003.
 XX

PF 28-AUG-2002; 2002US-00230338.
 XX
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2003-492274/46.
 DR N-PSDB; ACD82293.
 XX
 PT New transmembrane polypeptides and nucleic acids encoding the
 PT polypeptides, useful in gene therapy, in chromosome identification, as
 PT chromosome markers, or in generating probes.
 XX
 PS Claim 19; Fig 236; 315pp; English.
 XX
 CC The invention relates to an isolated nucleic acid encoding a PRO
 CC polypeptide. Nucleic acids that encode PRO can be used to generate either
 CC transgenic animals or knock-out animals useful in developing and
 CC screening of therapeutically useful reagents. The nucleic acids may also
 CC be used in gene therapy for replacing defective gene, in chromosome
 CC identification, as chromosome markers, or in generating probes to isolate
 CC full length PRO cDNA. The PRO polypeptides are useful for chondrocyte
 CC stimulation, TNF-alpha stimulation, human dermal fibroblasts stimulation
 CC and for detecting the presence of tumour in a mammal. The PRO
 CC polypeptides are useful as molecular markers for protein electrophoresis
 CC and the isolated nucleic acids may be used for recombinantly expressing
 CC those markers. The PRO polypeptides and nucleic acids may also be used in
 CC tissue typing. Anti-PRO antibodies are useful in diagnostic assays for
 CC PRO and in affinity purification of PRO from recombinant cell culture or
 CC natural sources. The present sequence represents the amino acid sequence
 CC of a human secreted/transmembrane PRO polypeptide
 XX
 SQ Sequence 327 AA;
 Query Match 99.2%; Score 1155; DB 6; Length 327;
 Best Local Similarity 100.0%; Pred. No. 1.4e-80;
 Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 VEVKPTPEPLTGLKTAELTCTYSTVGDSPALEWSFVQPKPISEHPILYFTNGHLY 60
 Db VEVKPTPEPLTGLKTAELTCTYSTVGDSPALEWSFVQPKPISEHPILYFTNGHLY 83
 QY 61 PTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYLQVNNPPDFYTNGLGLINLTIVL 120
 Db PTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYLQVNNPPDFYTNGLGLINLTIVL 143
 QY 121 PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTSPGSMVQDEVSGQLI 180
 Db PPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLGTPTSPGSMVQDEVSGQLI 203
 QY 181 LTNLSLTSSGTYRCVATNQMGASCELTLTSLVTEPSQGRVA 220
 Db LTNLSLTSSGTYRCVATNQMGASCELTLTSLVTEPSQGRVA 243
 RESULT 15
 ABJ72175
 ID ABJ72175 standard; protein; 327 AA.
 XX
 AC ABJ72175;
 XX
 DT 16-OCT-2003 (first entry)
 XX
 DE Human membrane bound receptor/protein PRO7154 amino acid sequence.
 XX
 KW Human; PRO; membrane bound protein; membrane bound receptor;
 KW cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;

KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.

OS Homo sapiens.

XX US2003065147-A1.

XX 03-APR-2003.

XX 29-AUG-2002; 2002US-00232224.

XX 28-JUL-1999; 99US-0146222P.

XX 24-FEB-2000; 2000WO-US005004.

XX 02-MAR-2000; 2000WO-US005841.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021065.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI: 2003-522018/49.

XX N-PSDB; ABT43999.

XX Claim 11; Fig 236; 315pp; English.

XX This invention relates to one hundred and twenty two novel nucleic acids
CC encoding human PRO membrane bound proteins or receptors. Extracellular
CC proteins play important roles in the formation, differentiation and
CC maintenance of multicellular organisms. The fate of many individual cells
CC (for example proliferation, migration or differentiation) is typically
CC governed by information received from other cells and the immediate
CC environment. The information is often transmitted by secreted
CC polypeptides (for example mitogenic factors, survival factors, cytotoxic
CC factors, differentiation factors, neuropeptides and hormones) which are
CC received and interpreted by diverse cell receptors or membrane bound
CC proteins. These membrane bound proteins and receptors may be of use as
CC pharmaceutical and diagnostic agents, such as in the blocking of receptor
CC -ligand interactions. The current invention provides the amino acid
CC sequences of novel human membrane bound receptors and proteins, along
CC with the cDNA sequences encoding them. The novel proteins of the
CC invention may have cytostatic activities through the stimulation of
CC chondrocytes. The nucleic acids of the invention may be useful for the
CC manufacture of a medicament for diagnosing or treating a tumour in a
CC mammal. In addition, they may be useful for measuring or detecting the
CC expression of a tumour associated gene. The present sequence is the amino
CC acid sequence of a human PRO protein of the invention

XX SQ Sequence 327 AA;

Query Match 99.2%; Score 1155; DB 7; Length 327;

Best Local Similarity 100.0%; Pred. No. 1.4e-80;

Matches 220; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VEVKVPTEPLSLPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 60

DB 24 VEVKVPTEPLSLPLGKTAELTCTYSTVSGDSFALEWSFVQPKPISESHPILYFTNGHLY 83

QY 61 FTGSKSKRVLLQNPTVGVATLKLTDVHPSTGYLCOVNNPPDFYTNGLINLTVLV 120

DB 84 FTGSKSKRVLLQNPTVGVATLKLTDVHPSTGYLCOVNNPPDFYTNGLINLTVLV 143

QY 121 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTPTPSPGMVDVSGQLI 180

DB 144 PPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTPTPSPGMVDVSGQLI 203

QY 181 LTNLSLTSSTSGTYRCVATNQMGASCELTLTSTPESQGRVA 220

Db 204 LTNLSLTSSTSGTYRCVATNQMGASCELTLTSTPESQGRVA 243

Search completed: August 4, 2005, 06:07:08
Job time : 68.7067 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 4, 2005, 05:53:15 ; Search time 74.7214 Seconds
(without alignments)
1268.128 Million cell updates/sec

Title: US-10-607-565-83_COPY_1_245

Perfect score: 1286
Sequence: 1 MAELPGPFLCGALLGFLCLS.....ASCELTSLVTPSQGRVABL 245

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_16Dec04:*
1: Genesecp1980s:*
2: Genesecp1990s:*
3: Genesecp2000s:*
4: Genesecp2001s:*
5: Genesecp2002s:*
6: Genesecp2003as:*
7: Genesecp2003bs:*
8: Genesecp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	1286	100.0	245	3 AAB08940	Aab08940 Human sec
2	1286	100.0	246	3 AAB08926	Aab08926 Human sec
3	1277	99.3	327	3 AAY87251	Aay87251 Human sig
4	1277	99.3	327	3 AAY94857	Aay94857 Human pro
5	1277	99.3	327	4 AAY97585	Aay97585 Human sec
6	1277	99.3	327	5 ABB90354	Abb90354 Human pol
7	1277	99.3	327	5 AAU83709	Aau83709 Human PRO
8	1277	99.3	327	6 ABU80856	Abu80856 Human PRO
9	1277	99.3	327	6 ABO33822	Ab033822 Novel hum
10	1277	99.3	327	6 ABU82165	Abu82165 Novel hum
11	1277	99.3	327	6 ABU72345	Abj72345 Human PRO
12	1277	99.3	327	6 ABJ72473	Abj72473 Human PRO
13	1277	99.3	327	6 ABO34368	Ab034368 Human sec
14	1277	99.3	327	7 ABJ72175	Abj72175 Human mem
15	1277	99.3	327	7 ADB83726	Adb83726 Novel hum
16	1277	99.3	327	7 ADB80832	Adb80832 Novel hum
17	1277	99.3	327	7 ADB73373	Adb73373 Novel hum
18	1277	99.3	327	7 ADB78455	Adb78455 Novel hum
19	1277	99.3	327	7 ADB85103	Adb85103 Human PRO
20	1277	99.3	327	7 ADB78209	Adb78209 Novel hum
21	1277	99.3	327	7 ADB87275	Adb87275 Human PRO
22	1277	99.3	327	7 ADB84857	Adb84857 Human PRO
23	1277	99.3	327	7 ADB83972	Adb83972 Novel hum
24	1277	99.3	327	7 ADB73127	Adb73127 Novel hum
25	1277	99.3	327	7 ADC36965	Adc36965 Human PRO

ALIGNMENTS

RESULT 1

AAB08940
ID AAB08940 standard; protein; 245 AA.

XX AC AAB08940;

XX 30-AUG-2000 (first entry)

XX DE Human secreted protein sequence encoded by gene 13 SEQ ID NO:97.

XX KW Human; secreted protein; cytostatic; anti-proliferative; vulnary;
XX KW immunosuppressive; antibacterial; diagnosis; immune system; chemotaxis;
XX KW hyperproliferative disorder; infectious disease; tissue regeneration;
XX KW screening; food additive; preservative; wound healing;
XX KW hyper-vascular disease; chromosome 11.

XX OS Homo sapiens.

XX PN WO200017222-A1.

XX PD 30-MAR-2000.

XX PF 22-SEP-1999; 99WO-US022012.

XX PR 23-SEP-1998; 98US-0101546P.

XX PR 02-OCT-1998; 98US-0102895P.

XX PA (HUMA-) HUMAN GENOME SCI INC.

XX PI Ruben SM, Rosen CA, Duan RD, Shi Y, Lafleur DW, Young PE, Ni J;

XX PI Komatsoulis G, Endress GA, Soppet DR;

XX DR WPI; 2000-283538/24.

XX PT Human secreted proteins and coding sequences useful in diagnostic and
therapeutic methods for disorders such as immune system or proliferative
disorders, related to the proteins.

XX PS Disclosure; Page 40; 416pp; English.

XX CC The polynucleotide sequences given in AAA39052 to AAA39088 encode the
human secreted proteins given in AAB08891 to AAB08984. The human secreted
proteins can have activities based on the tissues and cells they are
expressed in. Examples of the activities are: cytostatic; anti-
proliferative; immunosuppressive; antibacterial; and vulnary. The
secreted proteins and their related polynucleotide sequences are useful
for diagnostic and therapeutic methods useful for diagnosing and treating
disorders related to the secreted proteins. The proteins, and

CC polynucleotide sequences may be useful for treating disorders of the
CC immune system, hyperproliferative disorders, infectious disease,
CC regeneration of tissues, for chemotaxis and for screening molecules that
CC bind to the proteins. The proteins or polynucleotide sequences may be
CC used as food additives or preservatives, to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, co-factors or other nutritional components. Agonists or
CC antagonists of the proteins may be used to prevent scar tissue growth
CC during wound healing, and hyper-vascular diseases. AAA39043 to AAA39051
CC and AAB08890 are sequences used in the exemplification of the present
XX invention
SQ Sequence 245 AA;

Query Match 100.0%; Score 1286; DB 3; Length 245;
Best Local Similarity 100.0%; Pred. No. 6.1e-85;
Matches 245; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAEITCTYSTSVGDSFALEWS 60
DB 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAEITCTYSTSVGDSFALEWS 60

QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
DB 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120

QY 121 CQVNNPPDFYTNGLGLINLTVLPVPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
DB 121 CQVNNPPDFYTNGLGLINLTVLPVPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180

QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLISVTEPSQG 240
DB 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLISVTEPSQG 240

QY 241 RVAEL 245
DB 241 RVAEL 245

RESULT 2
ID AAB08926 standard; protein; 246 AA.
XX AAB08926;
XX AAB08926;
XX
DT 30-AUG-2000 (first entry)
DE Human secreted protein sequence encoded by gene 13 SEQ ID NO:83.
XX
KW Human; secreted protein; cytostatic; anti-proliferative; vulnerary;
KW immunosuppressive; antibacterial; diagnosis; immune system; chemotaxis;
KW hyperproliferative disorder; infectious disease; tissue regeneration;
KW screening; food additive; preservative; wound healing;
KW hyper-vascular disease; chromosome 11.
XX
OS Homo sapiens.
XX
PN WO200017222-A1.
XX
PD 30-MAR-2000.
XX
PF 22-SEP-1999; 99WO-US022012.
XX
PR 23-SEP-1998; 98US-0101546P.
PR 02-OCT-1998; 98US-0102895P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
XX Ruben SM, Rosen CA, Duan RD, Shi Y, Lafleur DW, Young PE, Ni J;
PI Komatsoulis G, Endress GA, Soppet DR;
XX WPI; 2000-283538/24.
DR N-PSDB; AAA39087.

XX Human secreted proteins and coding sequences useful in diagnostic and
PT therapeutic methods for disorders such as immune system or proliferative
PT disorders, related to the proteins.
XX
XX Claim 11; Page 376-377; 416pp; English.
XX
CC The polynucleotide sequences given in AAA39052 to AAA39088 encode the
CC human secreted proteins given in AAB08891 to AAB08984. The human secreted
CC proteins can have activities based on the tissues and cells they are
CC expressed in. Examples of the activities are: cytostatic; anti-
CC proliferative; immunosuppressive; antibacterial; and vulnerary. The
CC secreted proteins and their related polynucleotide sequences are useful
CC for diagnostic and therapeutic methods useful for diagnosing and treating
CC disorders related to the secreted proteins. The proteins, and
CC polynucleotide sequences may be useful for treating disorders of the
CC immune system, hyperproliferative disorders, infectious disease,
CC regeneration of tissues, for chemotaxis and for screening molecules that
CC bind to the proteins. The proteins or polynucleotide sequences may be
CC used as food additives or preservatives, to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, co-factors or other nutritional components. Agonists or
CC antagonists of the proteins may be used to prevent scar tissue growth
CC during wound healing, and hyper-vascular diseases. AAA39043 to AAA39051
CC and AAB08890 are sequences used in the exemplification of the present
XX invention
SQ Sequence 246 AA;

Query Match 100.0%; Score 1286; DB 3; Length 246;
Best Local Similarity 100.0%; Pred. No. 6.1e-85;
Matches 245; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAEITCTYSTSVGDSFALEWS 60
DB 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAEITCTYSTSVGDSFALEWS 60

QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
DB 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120

QY 121 CQVNNPPDFYTNGLGLINLTVLPVPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
DB 121 CQVNNPPDFYTNGLGLINLTVLPVPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180

QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLISVTEPSQG 240
DB 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLISVTEPSQG 240

QY 241 RVAEL 245
DB 241 RVAEL 245

RESULT 3
AAY87251
ID AAY87251 standard; protein; 327 AA.
XX AAY87251;
XX AAY87251;
XX
DT 11-MAY-2000 (first entry)
XX
DE Human signal peptide containing protein HSPF-28 SEQ ID NO:28.
XX
KW Human; signal peptide-containing protein; HSPF; diagnosis; cancer;
KW inflammation; cardiovascular disease; anticancer; anti-inflammatory;
KW antimicrobial; nontropic; neuroprotective; cardiovascular; hepatocytic;
KW antiasthmatic; gene therapy; cell proliferation; neurological disorder;
KW reproductive disorder; developmental disorder; arteriosclerosis;
KW cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;
KW asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;
KW Parkinson's disease; Huntington's disease; ovulatory defect;
KW muscular dystrophy.

XX OS Homo sapiens.
XX PN WO20000610-A2.
XX PD 06-JAN-2000.
XX PF 25-JUN-1999; 99WO-US014484.
XX PR 26-JUN-1998; 98US-0090762P.
XX PR 31-JUL-1998; 98US-0094983P.
XX PR 01-OCT-1998; 98US-0102686P.
XX PR 11-DEC-1998; 98US-0112129P.
XX PA (INCY-) INCYTE PHARM INC.
XX PI Lal P, Tang YT, Gorgone GA, Corley NC, Guegler KJ, Baughn MR;
XX PI Akerblom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL;
XX PI Bandman O;
XX DR N-PSDB; AAZ98136.
XX DR WPI; 2000-160673/14.
XX PR New human signal peptide-containing proteins useful in treatment,
XX PT prevention and diagnosis of e.g. cancer, inflammation and cardiovascular
XX PT disease.
XX PS Claim 1; Page 177-178; 327pp; English.
XX CC AAZ98109 to AAZ98242 encode AAY87224 to AAY87357 which represent the
XX CC human signal peptide-containing proteins HSP-1 to HSP-134. HSPs have
XX CC anticancer, anti-inflammatory, antimicrobial, nootropic, hepatotropic,
XX CC neuroprotective, cardiovascular and antiasthmatic activities, and can be
XX CC used in gene therapy. HSPs can be used to treat or prevent disorders
XX CC associated with decreased activity or function of HSP. Antagonists of
XX CC HSP are used to treat or prevent disorders associated with increased
XX CC activity or function of HSP. Such diseases include cell-proliferation
XX CC (including cancer), inflammation, cardiovascular, neurological,
XX CC reproductive or developmental disorders, (e.g. arteriosclerosis,
XX CC cirrhosis, psoriasis, acquired immune deficiency syndrome, anemia,
XX CC asthma, Crohn's disease, microbial or other infections, congestive or
XX CC ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's
XX CC diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSP
XX CC nucleic acids can be used for the recombinant production of HSP, for
XX CC detecting HSP in standard hybridisation and amplification assays (for
XX CC diagnosis and monitoring), in gene therapy, as antisense, triplex-forming
XX CC or ribozyme therapeutics, for detecting related sequences or genetic
XX CC variations, and for chromosomal mapping. HSP are also used to raise
XX CC specific antibodies (Ab) and to screen for agonists and antagonists
XX CC (potential therapeutic agents). Ab are used to diagnose, or monitor, HSP
XX CC -related diseases (in usual immunoassays), as therapeutic antagonists, in
XX CC competitive drug screens, and for purification of HSP from natural
XX CC sources
XX SQ Sequence 327 AA;

Query Match 99.3%; Score 1277; DB 3; Length 327;
Best Local Similarity 100.0%; Pred. No. 3.8e-84;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGFLLGALLGLFCLSLGLAVEKVPTEPLSTPLGKTAELTCYTSVSGDSFALEWS 60
DB 1 MAELPGFLLGALLGLFCLSLGLAVEKVPTEPLSTPLGKTAELTCYTSVSGDSFALEWS 60
QY 61 FVQPGPISESHPIYFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDGTGL 120
DB 61 FVQPGPISESHPIYFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDGTGL 120
QY 121 CQVNNPDDFTYNGLGLINLTIVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
DB 121 CQVNNPDDFTYNGLGLINLTIVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSSTGTYRCVATNQMGASCELTLSTVTPSQ 240

DB 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSSTGTYRCVATNQMGASCELTLSTVTPSQ 240
QY 241 RVA 243
DB 241 RVA 243
RESULT 4
AAZ94857
ID AAY94857 standard; protein; 327 AA.
XX AC
XX AC AAY94857;
XX DT 12-JUN-2000 (first entry)
XX DE Human protein clone HP10568.
XX DE
XX KW Human protein; hydrophobic domain; nutritional source; haematopoiesis;
KW cytokine production; cell proliferation; cell differentiation;
KW immune deficiency; infectious disease; autoimmune disorder; asthma;
KW multiple sclerosis; systemic lupus erythematosus; rheumatoid arthritis;
KW allergic reaction; osteoporosis; osteoarthritis; periodontal disease;
KW nervous system disease; Alzheimer's disease; Parkinson's disease;
KW Huntington's disease; liver fibrosis; lung fibrosis; reperfusion injury;
KW systemic cytokine damage; tissue differentiation; contraceptive; stroke;
KW coagulation disorder; myocardial infarction; inflammatory condition;
KW septic shock; sepsis; ischaemia; reperfusion injury; arthritis; tumour;
KW nephritis; therapy.
XX OS Homo sapiens.
XX OS WO200005367-A2.
XX PD 03-FEB-2000.
XX PF 22-JUL-1999; 99WO-JP003929.
XX PR 24-JUL-1998; 98JP-00208820.
XX PR 07-AUG-1998; 98JP-00224105.
XX PR 25-AUG-1998; 98JP-00238116.
XX PR 09-SEP-1998; 98JP-00254736.
XX PR 29-SEP-1998; 98JP-00275505.
XX PA (SAGA) SAGAMI CHEM RES CENT.
XX PA (PROT-) PROTEGENE INC.
XX PI Kato S, Kimura T;
XX WPI; 2000-182694/16.
XX PT Novel human proteins having hydrophobic domains useful for treating
XX PT osteoporosis, Alzheimer's disease, Parkinson's disease, asthma, multiple
XX PT sclerosis, rheumatoid arthritis, cancer, anemia, and stroke.
XX PS Claim 1; Page 183-184; 351pp; English.
XX CC This sequence represents a human protein of the invention, which has
XX CC hydrophobic domains. The DNA sequences can be used as a probe or as a
XX CC genetic marker. The protein can also be used as a marker, and to identify
XX CC potential genetic disorders. The DNA and protein can also be used as
XX CC nutritional sources or supplements. The protein exhibits cytokine, cell
XX CC proliferation, cell differentiation activities and induces production of
XX CC other cytokines in certain cell populations. The protein also exhibits
XX CC immune stimulating or immune suppressing activity. It can be used in the
XX CC treatment of various immune deficiencies and disorders, and to treat
XX CC infectious diseases caused by viral, bacterial, fungal or other
XX CC infections. The protein is also used for treating autoimmune disorders
XX CC such as multiple sclerosis, systemic lupus erythematosus, and rheumatoid
XX CC arthritis. It is also useful in the treatment of allergic reactions and
XX CC conditions such as asthma, and in immune suppression after organ
XX CC transplantation. The protein is useful in regulation of haematopoiesis
XX CC and consequently in the treatment of myeloid or lymphoid cell

CC deficiencies. It is also used in compositions for tissue growth or
 CC regeneration. The protein is also used in the treatment of osteoporosis
 CC or osteoarthritis and in the treatment of periodontal disease and other
 CC tooth repair processes. The protein is used in the treatment of nervous
 CC system disorders such as Alzheimer's disease, Parkinson's disease, and
 CC Huntington's disease. They are useful for protection or regeneration and
 CC treatment of lung or liver fibrosis, reperfusion injury in various
 CC tissues, and conditions resulting from systemic cytokine damage. They are
 CC also used for promoting or inhibiting tissue differentiation. They are
 CC also used as contraceptives since they exhibit activin or inhibin related
 CC activities and as a fertility inducing therapeutic. They are used for
 CC treating various coagulation disorders and in treatment and prevention of
 CC conditions resulting from coagulation activities e.g. myocardial
 CC infarction or stroke. They also acts as receptors, receptor ligands or
 CC inhibitors or agonists of receptor/ligand interactions. They are used to
 CC treat inflammatory conditions such as septic shock, sepsis, ischaemia
 CC reperfusion injury, arthritis, and nephritis. They can be used to prevent
 CC tumours
 XX

SQ Sequence 327 AA;

Query Match 99.3%; Score 1277; DB 3; Length 327;
 Best Local Similarity 100.0%; Pred. No. 3.8e-84;
 Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAEITCTYSTVSGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAEITCTYSTVSGDSFALEWS 60
 QY 61 FVQPKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTGYTL 120
 DB 61 FVQPKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTGYTL 120
 QY 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 DB 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 QY 181 RLGTPTPSPGSMQVDEVSQGLILTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQG 240
 DB 181 RLGTPTPSPGSMQVDEVSQGLILTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQG 240
 QY 241 RVA 243
 DB 241 RVA 243

RESULT 5
 AAY97585

ID AAY97585 standard; protein; 327 AA.

XX AAY97585;

AC AAY97585;

XX 05-APR-2001 (first entry)

DE Human secreted protein PRO1154.

XX Secreted protein; human; PRO protein; neoplastic cell growth; tumour;
 KW proliferation; leukaemia; lymphoid malignancy; inflammatory disorder;
 KW angiogenic disorder; immunologic disorder; PRO1154.

OS Homo sapiens.

XX WO200075317-A2.

PN 14-DEC-2000.

XX 15-MAY-2000; 2000WO-US013358.

XX 09-JUN-1999; 99US-0138385P.

PR 20-JUL-1999; 99US-0144790P.

PR 03-AUG-1999; 99US-0146843P.

PR 10-AUG-1999; 99US-0148188P.

PR 17-AUG-1999; 99US-0149320P.

PR 17-AUG-1999; 99US-0149327P.
 PR 17-AUG-1999; 99US-0149366P.
 PR 20-AUG-1999; 99US-0150114P.
 PR 31-AUG-1999; 99US-0151700P.
 PR 31-AUG-1999; 99US-0151734P.
 XX (GETH) GENEVECH INC.
 XX Botstein DA, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WI;
 PI WPI; 2001-071075/08.
 XX N-PSDB; AAA91019.
 DR Antibodies against PRO polypeptides, useful for diagnosing and treating
 XX tumors are associated with gene amplification, neoplastic cell growth and
 PT proliferation in mammals.
 XX Claim 61; Fig 12; 143pp; English.
 XX This sequence is a human PRO protein of the invention. The PRO proteins
 CC are secreted proteins. Antagonists or antibodies of PRO polypeptides are
 CC useful for diagnosing and treating tumours are associated with gene
 CC amplification, neoplastic cell growth and proliferation in mammals, and
 CC those conditions characterised by overexpression and/or activation of the
 CC amplified genes. Such conditions include benign or malignant tumours
 CC (e.g. renal, liver, kidney, bladder, breast, gastric, ovarian,
 CC colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic
 CC carcinomas, sarcomas, glioblastomas and various head and neck tumours);
 CC leukaemias and lymphoid malignancies; neuronal, glial, astrocytal,
 CC hypothalamic, and other glandular, macrophageal, epithelial, stromal and
 CC blastocoeleic disorders; and inflammatory, angiogenic and immunologic
 CC disorders. These may further be used to qualitatively or quantitatively
 CC detect the expression of proteins encoded by the amplified genes, and in
 CC tumour diagnostics or prognostics. The PRO polypeptide or its antagonist
 CC may be used for the preparation of a medicament in the treatment of a
 CC condition, which is responsive to the PRO polypeptide, its antagonist or
 CC anti-PRO antibody
 XX

SQ Sequence 327 AA;

Query Match 99.3%; Score 1277; DB 4; Length 327;
 Best Local Similarity 100.0%; Pred. No. 3.8e-84;
 Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAEITCTYSTVSGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAEITCTYSTVSGDSFALEWS 60
 QY 61 FVQPKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTGYTL 120
 DB 61 FVQPKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTGYTL 120
 QY 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 DB 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 QY 181 RLGTPTPSPGSMQVDEVSQGLILTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQG 240
 DB 181 RLGTPTPSPGSMQVDEVSQGLILTNLSLTSSGTYRCVATNMGASCELTLTSVTEPSQG 240
 QY 241 RVA 243
 DB 241 RVA 243

RESULT 6
 ABB90354

ID ABB90354 standard; protein; 327 AA.

XX ABB90354;

XX 24-MAY-2002 (first entry)

DE Human polypeptide SEQ ID NO 2730.
 XX Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
 KW antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
 KW vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;
 KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
 KW neurological disease; infection; human; secreted protein.
 XX Homo sapiens.
 OS
 XX
 XX W0200190304-A2.
 PN
 XX
 XX 29-NOV-2001.
 PD
 XX
 XX 18-MAY-2001; 2001WO-US016450.
 PF
 XX
 XX 19-MAY-2000; 2000US-0205515P.
 PR
 XX
 XX (HUMA-) HUMAN GENOME SCI INC.
 PA
 XX
 XX Birse CE, Rosen CA;
 PI
 XX
 XX WPI; 2002-122018/16.
 DR
 XX N-PSDB; ABL90763.
 DR
 XX
 XX Novel 1405 isolated polypeptides, useful for diagnosis, treatment and
 PT prevention of neural, immune system, muscular, reproductive,
 PT gastrointestinal, pulmonary, cardiovascular, renal and proliferative
 PT disorders.
 XX
 XX Claim 11; SEQ ID NO 2730; 2081pp + Sequence Listing; English.
 PS
 XX The invention relates to novel genes (ABL9449-ABL90853) and proteins
 CC (AB9040-AB90444) useful for preventing, treating or ameliorating
 CC medical conditions e.g. by protein or gene therapy. The genes are
 CC isolated from a range of human tissues disclosed in the specification.
 CC The nucleic acids, proteins, antibodies and (ant)agonists are useful in
 CC the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and
 CC ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,
 CC breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune
 CC disorders e.g. Addison's disease, allergies, autoimmune haemolytic
 CC anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
 CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)
 CC cardiovascular disorders such as myocardial ischaemias; (d) wound healing
 CC i (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)
 CC infectious diseases such as viral, bacterial, fungal and parasitic
 CC infections. Note: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 327 AA;
 SQ
 Query Match 99.3%; Score 1277; DB 5; Length 327;
 Best Local Similarity 100.0%; Pred. No. 3.8e-84;
 Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MAELPGFLCGALGFLCGLAVEVKVPTPELSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGFLCGALGFLCGLAVEVKVPTPELSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISSHPILFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGTYL 120
 DB 61 FVQPGKPISSHPILFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGTYL 120
 QY 121 CQVNNPPDFYNTGLGILNLTVPVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 DB 121 CQVNNPPDFYNTGLGILNLTVPVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 QY 181 RLCTFTPPSGSMVQDVESQQLITNLTLTSSGTTCVATNQMGASCELTLTSTPFSQ 240
 DB 181 RLCTFTPPSGSMVQDVESQQLITNLTLTSSGTTCVATNQMGASCELTLTSTPFSQ 240
 QY 241 RVA 243

Db 241 RVA 243

|||

RESULT 7

AAU83709

XX AAU83709 standard; protein; 327 AA.

XX AC

XX AAU83709;

XX DT

XX 08-MAY-2002 (first entry)

XX DE

XX Human PRO protein, Seq ID No 236.

XX KW

XX Human; secreted protein; PRO; tumour; lung cancer; colon cancer;

XX KW breast cancer; prostate tumour; rectal tumour; liver tumour;

XX KW pericyte cell proliferation; chondrocyte cell proliferation;

XX KW tumour necrosis factor-alpha.

XX OS

XX Homo sapiens.

XX PN

XX W0200208288-A2.

XX PD

XX 31-JAN-2002.

XX PF

XX 29-JUN-2001; 2001WO-US021066.

XX PR

XX 20-JUL-2000; 2000US-0219556P.

XX PR

XX 25-JUL-2000; 2000US-0220585P.

XX PR

XX 25-JUL-2000; 2000US-0220605P.

XX PR

XX 25-JUL-2000; 2000US-0220607P.

XX PR

XX 25-JUL-2000; 2000US-0220624P.

XX PR

XX 25-JUL-2000; 2000US-0220638P.

XX PR

XX 25-JUL-2000; 2000US-0220664P.

XX PR

XX 26-JUL-2000; 2000US-0220893P.

XX PR

XX 28-JUL-2000; 2000WO-US020710.

XX PR

XX 01-AUG-2000; 2000US-0222425P.

XX PR

XX 22-AUG-2000; 2000US-0227133P.

XX PR

XX 23-AUG-2000; 2000WO-US023522.

XX PR

XX 24-AUG-2000; 2000WO-US023328.

XX PR

XX 10-NOV-2000; 2000WO-US030873.

XX PR

XX 28-NOV-2000; 2000US-0253646P.

XX PR

XX 01-DEC-2000; 2000WO-US032678.

XX PR

XX 20-DEC-2000; 2000US-00747259.

XX PR

XX 28-FEB-2001; 2001WO-US004956.

XX PR

XX 01-MAR-2001; 2001WO-US005666.

XX PR

XX 22-MAR-2001; 2001US-00816744.

XX PR

XX 10-MAY-2001; 2001US-00854208.

XX PR

XX 10-MAY-2001; 2001US-00854280.

XX PR

XX 25-MAY-2001; 2001WO-US017092.

XX XX

(GETH) GENENTECH INC.

Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

WPI; 2002-172001/22.

N-PSDB; ABK33653.

One hundred and twenty two nucleic acids encoding PRO polypeptides,
 useful for treating a PRO related disorder and for diagnosing tumors such
 as lung cancer, colon cancer, breast tumor, prostate tumor, rectal tumor
 or liver tumor.

Claim 11; Fig 236; 359pp; English.

The invention relates to one hundred and twenty two nucleic acids
 encoding PRO polypeptides. The sequences of the 122 PRO polynucleotides
 encode human secreted proteins. The PRO nucleic acids, polypeptides,
 agonists and antagonists are useful for treating a PRO related disorder.
 The PRO polypeptides are useful for diagnosing tumours, especially lung

CC cancer, colon cancer, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. The PRO polypeptides are useful for stimulating the
 CC proliferation of, or gene expression, in pericyte cells, for stimulating
 CC the proliferation or differentiation of chondrocyte cells, for
 CC stimulating the release of tumour necrosis factor-alpha from human blood,
 CC for stimulating or inhibiting the proliferation of normal human dermal
 CC fibroblast cells. The PRO polypeptide may also be used as molecular
 CC weight markers and for tissue typing. The PRO nucleic acids have
 CC applications in molecular biology, including use as hybridisation probes,
 CC and in chromosome and gene mapping. AAU83592-AAU83713 represent human PRO
 CC protein sequences of the invention
 XX
 SQ Sequence 327 AA;

Query Match 99.3%; Score 1277; DB 5; Length 327;

Best Local Similarity 100.0%; Pred. No. 3.8e-84;

Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATIKLTDVHPSDTGYL 120
 DB 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATIKLTDVHPSDTGYL 120
 QY 121 CQVNNPPDFYTNGLGLINLTIVLPSPNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
 DB 121 CQVNNPPDFYTNGLGLINLTIVLPSPNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
 QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCELTLVSVPESOG 240
 DB 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCELTLVSVPESOG 240
 QY 241 RVA 243
 DB 241 RVA 243

RESULT 8

ID ABU80856

XX ABU80856 standard; protein; 327 AA.

AC ABU80856;

XX

DT 23-JUN-2003 (first entry)

XX Human PRO polypeptide #118.

DE Human; PRO polypeptide; secreted and transmembrane protein;

XX anti-PRO antibody; diagnostic assay; gene expression; tumour; cytostatic.

XX Homo sapiens.

OS US2003036635-A1.

XX 20-FEB-2003.

XX 28-AUG-2002; 2002US-00230163.

XX 25-JUL-2000; 2000US-0220638P.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2003-342045/32.

XX N-PSDB; ACA66958.

XX

PT One hundred and twenty two nucleic acids encoding PRO polypeptides,
 PT useful for the manufacture of a medicament for diagnosing or treating
 PT tumor.

XX Claim 11; Fig 236; 314pp; English.

XX The present invention relates to the isolation of novel human PRO
 CC polypeptides, and the polynucleotide sequences encoding them. The PRO
 CC polypeptides are secreted and transmembrane proteins. The PRO
 CC polypeptides and polynucleotides are useful for preparing a medicament
 CC useful in the diagnosis and treatment of tumours. Anti-PRO antibodies are
 CC useful in diagnostic assays for PRO, by detecting its expression in
 CC specific cells, tissues or serum, and for affinity purification of PRO
 CC from recombinant cell culture or natural sources. ABU80739-AAU80860
 CC represent the human PRO polypeptides of the invention. Note: The sequence
 CC data for this patent was obtained in electronic format directly from the
 CC USPTO web site at seqdata.uspto.gov/psipsDIDentry.html

SQ Sequence 327 AA;

Query Match 99.3%; Score 1277; DB 6; Length 327;

Best Local Similarity 100.0%; Pred. No. 3.8e-84;

Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATIKLTDVHPSDTGYL 120
 DB 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATIKLTDVHPSDTGYL 120
 QY 121 CQVNNPPDFYTNGLGLINLTIVLPSPNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
 DB 121 CQVNNPPDFYTNGLGLINLTIVLPSPNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNV 180
 QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCELTLVSVPESOG 240
 DB 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCELTLVSVPESOG 240
 QY 241 RVA 243
 DB 241 RVA 243

RESULT 9

ABO33822

ID ABO33822 standard; protein; 327 AA.

XX ABO33822;

XX

DT 17-SEP-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO7154.

DE Human; secreted and transmembrane protein; PRO; cytostatic;

XX antiarthritic; osteopathic; gene therapy; TNF-agonist-Alpha;

XX chondrocyte stimulator; pericyte stimulator; fibroblast modulator;

XX pharmaceutical; diagnostic; biosensor; bioreactor; tumour; lung tumour;

XX colon tumour; breast tumour; prostate tumour; rectal tumour;

XX liver tumour; bone disorder; cartilage disorder; sports injury;

XX arthritis; wound.

XX Homo sapiens.

XX US2003045687-A1.

XX 06-MAR-2003.

XX 12-AUG-2002; 2002US-00218631.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX

```

PR 09-APR-2002; 2002US-00119480.
XX (GETH ) GENENTECH INC.
PA Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-512315/48.
DR N-PSDB; ACD68710.
XX New genes, and its encoded secreted and transmembrane polypeptides,
XX useful for stimulating Tumor Necrosis Factor alpha, or chondrocyte or
XX pericyte proliferation, especially for treating lung tumors, arthritis or
XX wounds in a mammal.
XX Claim 11; Fig 236; 314pp; English.
XX
XX The invention describes an isolated nucleic acid molecule comprising a
XX sequence with at least 80% identity to: (a) a nucleotide encoding any of
XX 122 PRO (secreted and transmembrane) polypeptides whose sequences are
XX fully defined in the specification; or (b) any of 122 nucleotide
XX sequences having e.g. 4834, 2504 or 1759 bp fully defined in the
XX specification; or the full length coding sequence of any these 122
XX nucleotide sequences. The PRO polypeptides or polynucleotides are useful
XX as pharmaceuticals, diagnostics, biosensors or bioreactors. These are
XX particularly useful for detecting tumors (e.g. lung tumour, colon
XX tumour, breast tumour, prostate tumour, rectal tumour, or liver tumour)
XX in a mammal, for stimulating the release of TNF-alpha from human blood,
XX for stimulating the proliferation or differentiation of chondrocyte
XX cells, for stimulating proliferation of pericyte cells, or for modulating
XX normal human dermal fibroblast proliferation. The PRO nucleic acid or
XX polypeptide is also useful for treating tumors or various bone and/or
XX cartilage disorders (e.g. sports injuries or arthritis), or wounds. The
XX PRO polypeptides are useful in drug screening, particularly as targets
XX for therapeutic intervention in these diseases, and in the diagnostic
XX determination of the presence of these diseases. The PRO polypeptides are
XX also useful as molecular weight markers, or for chromosome
XX identification. The PRO genes are useful as hybridisation probes, or for
XX screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may
XX also be used in gene therapy, particularly for replacing a defective
XX gene. This is the amino acid sequence of a novel human secreted and
XX transmembrane PRO polypeptide
XX
XX Sequence 327 AA;
Query Match 99.3%; Score 1277; DB 6; Length 327;
Best Local Similarity 100.0%; Pred. No. 3.8e-84;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLVPTGSKSRVLLQNPPPTVGATLKLTDVHPSDGTGYL 120
Db 61 FVQPGKPISSEHPILYFTNGHLVPTGSKSRVLLQNPPPTVGATLKLTDVHPSDGTGYL 120
QY 121 CQVNNPPDPFTYNTGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNW 180
Db 121 CQVNNPPDPFTYNTGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNW 180
QY 181 RLGTFTTTPSGMVQDEVSQQLITNLSTSSQTYRCVATNQMSASCELTLTSTVPSQ 240
Db 181 RLGTFTTTPSGMVQDEVSQQLITNLSTSSQTYRCVATNQMSASCELTLTSTVPSQ 240
QY 241 RVA 243
Db 241 RVA 243

```

RESULT 10
ABU82165
ID ABU82165 standard; protein; 327 AA.

```

XX ABU82165;
XX 25-JUN-2003 (first entry)
XX Novel human secreted and transmembrane protein PRO7154.
XX
XX Human; secreted and transmembrane protein; PRO; cardiant; cytostatic;
XX antiangiogenic; hypotensive; vulnenry; antiarteriosclerotic;
XX gene therapy; cardiovascular disorder; endothelial disorder;
XX angiogenic disorder; cardiac hypertrophy; trauma; cancer;
XX age-related macular degeneration; atherosclerosis; hypertension;
XX arterial restenosis; rheumatoid arthritis; angina; myocardial infarction;
XX thrombophlebitis; lymphangitis; tumour angiogenesis; breast carcinoma;
XX liver carcinoma; wound healing; chromosome mapping; gene mapping.
XX
XX Homo sapiens.
XX
XX US2003088063-A1.
XX
XX 08-MAY-2003.
XX
XX 12-AUG-2002; 2002US-00219003.
XX
XX 25-JUL-2000; 2000US-0220664P.
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-393229/37.
XX N-PSDB; ACA68614.
XX
XX One hundred and eighty seven nucleic acids encoding PRO polypeptides,
XX useful in diagnosis and treatment of cardiovascular (e.g. myocardial
XX infarction), endothelial or angiogenic disorders in a mammal.
XX
XX Claim 11; Fig 236; 314pp; English.
XX
XX The invention describes one hundred and eighty seven nucleic acids
XX encoding novel human secreted and transmembrane (PRO) polypeptides. The
XX PRO nucleic acids, polypeptides, agonists and antagonists are useful for
XX treating or diagnosing a cardiovascular, endothelial or angiogenic
XX disorder in a mammal, e.g. cardiac hypertrophy, trauma, cancer, age-
XX related macular degeneration, atherosclerosis, hypertension, arterial
XX restenosis, rheumatoid arthritis, angina, myocardial infarctions,
XX thrombophlebitis, lymphangitis, tumour angiogenesis (such as breast
XX carcinoma and liver carcinoma) and wound healing. The PRO nucleic acids
XX have applications in molecular biology, including use as hybridisation
XX probes, and in chromosome and gene mapping. This is the amino acid
XX sequence of a novel human secreted and transmembrane PRO polypeptide
XX
XX Sequence 327 AA;
Query Match 99.3%; Score 1277; DB 6; Length 327;
Best Local Similarity 100.0%; Pred. No. 3.8e-84;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLVPTGSKSRVLLQNPPPTVGATLKLTDVHPSDGTGYL 120
Db 61 FVQPGKPISSEHPILYFTNGHLVPTGSKSRVLLQNPPPTVGATLKLTDVHPSDGTGYL 120
QY 121 CQVNNPPDPFTYNTGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNW 180
Db 121 CQVNNPPDPFTYNTGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNW 180

```

QY 181 RLGTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCELTLVSVPESQG 240
 DB 181 RLGTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCELTLVSVPESQG 240
 QY 241 RVA 243
 DB 241 RVA 243
 RESULT 11
 ID ABJ72345 standard; protein; 327 AA.
 XX AC ABJ72345;
 XX DT 06-NOV-2003 (first entry)
 XX DE Human PRO7154 protein.
 XX KW PRO; proliferation; pericyte cell; TNF-alpha; blood; chondrocyte;
 KW differentiation; dermal fibroblast; tumour; gene therapy; cytostatic.
 XX OS Homo sapiens.
 XX FN US2003050448-A1.
 XX PD 13-MAR-2003.
 XX PF 28-AUG-2002; 2002US-00230414.
 XX PR 01-JUN-2001; 2001WO-US017800.
 XX PR 29-JUN-2001; 2001WO-US021066.
 XX PR 09-APR-2002; 2002US-00119480.
 XX PA (GETH) GENENTECH INC.
 XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI: 2003-521818/49.
 XX DR N-PSDB; ABT44343.
 XX PT New nucleic acid encoding for a PRO protein, useful for the manufacture
 PT of a medicament for diagnosing or treating tumors or for measuring or
 PT detecting expression of an associated gene.
 XX PS Claim 11; Fig 236; 315pp; English.
 XX CC The invention relates to a novel isolated nucleic acid encoding a fully
 CC defined PRO polypeptide. The molecules of the invention may be useful for
 CC stimulating proliferation or gene expression in pericyte cells or the
 CC release of TNF-alpha from human blood. Other possible uses include the
 CC stimulation or inhibition of chondrocyte proliferation or
 CC differentiation, the stimulation of human dermal fibroblast cell
 CC proliferation and the detection of the presence of a tumour within a
 CC mammal. Furthermore, the nucleic acid may be useful for the manufacture
 CC of a medicament for diagnosing or treating a tumour within a mammal or
 CC for measuring or detecting the expression of an associated gene, as well
 CC as during gene therapy. The current sequence is that of the human PRO
 CC protein of the invention
 XX SQ Sequence 327 AA;
 Query Match 99.3%; Score 1277; DB 6; Length 327;
 Best Local Similarity 100.0%; Pred. No. 3.8e-84;
 Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MAELPGPFLCGALLGFLCLSGLAVERKVPTEPLSTPLGKTABLTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSGLAVERKVPTEPLSTPLGKTABLTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISHPILYFTNGHLPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTGYL 120

DB 61 FVQPGKPISHPILYFTNGHLPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTGYL 120
 QY 121 QVNNPPDFYTNGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 DB 121 QVNNPPDFYTNGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 QY 181 RLGTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCELTLVSVPESQG 240
 DB 181 RLGTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCELTLVSVPESQG 240
 QY 241 RVA 243
 DB 241 RVA 243
 RESULT 12
 ID ABJ72473 standard; protein; 327 AA.
 XX AC ABJ72473;
 XX DT 06-NOV-2003 (first entry)
 XX DE Human PRO7154 protein.
 XX KW PRO; blood; proliferation; pericyte cell; TNF alpha; chondrocyte;
 KW tumour necrosis factor; proliferation; differentiation; gene therapy;
 KW dermal fibroblast.
 XX OS Homo sapiens.
 XX FN US2003027988-A1.
 XX PD 06-FEB-2003.
 XX PF 26-AUG-2002; 2002US-00227884.
 XX PR 01-JUN-2001; 2001WO-US017800.
 XX PR 29-JUN-2001; 2001WO-US021066.
 XX PR 09-APR-2002; 2002US-00119480.
 XX PA (GETH) GENENTECH INC.
 XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI: 2003-503301/47.
 XX DR N-PSDB; ABT44626.
 XX PT New PRO protein encoding nucleic acid, useful for preparing PRO
 PT polypeptides and anti-PRO antibodies for detecting the presence of a
 PT tumor in a mammal.
 XX PS Claim 11; Fig 236; 324pp; English.
 XX CC The invention relates to a novel isolated PRO protein encoding nucleic
 CC acid. The nucleic acid of the invention may be useful for preparing PRO
 CC polypeptides and anti-PRO antibodies for detecting the presence of a
 CC tumour in a mammal. Furthermore, the molecules of the invention may be
 CC useful for stimulating proliferation or gene expression in pericyte
 CC cells, the release of tumour necrosis factor (TNF)-alpha from human
 CC blood, the proliferation or differentiation of chondrocyte cells and for
 CC inhibiting the proliferation of normal human dermal fibroblast cells.
 CC Finally, the molecules may be utilised during gene therapy. The current
 CC sequence is that of the human PRO protein of the invention
 XX SQ Sequence 327 AA;
 Query Match 99.3%; Score 1277; DB 6; Length 327;
 Best Local Similarity 100.0%; Pred. No. 3.8e-84;
 Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTYSTVSGDSFALEWS 60
 Db |||||
 QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTYSTVSGDSFALEWS 60
 Db |||||
 QY 61 FVQPKPISESHPILYFTNGHLPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTCGYL 120
 Db |||||
 QY 61 FVQPKPISESHPILYFTNGHLPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTCGYL 120
 Db |||||
 QY 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSESGAPKPVNVW 180
 Db |||||
 QY 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSESGAPKPVNVW 180
 Db |||||
 QY 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPSQ 240
 Db |||||
 QY 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPSQ 240
 Db |||||
 QY 241 RVA 243
 Db |||||
 QY 241 RVA 243
 Db |||||
 RESULT 13
 ABO34368
 ID ABO34368 standard; protein; 327 AA.
 AC
 AC ABO34368;
 DT 19-SEP-2003 (first entry)
 DE Human secreted/transmembrane polypeptide PRO 7154.
 DE
 DE Human; chondrocyte stimulation; TNF-alpha stimulation; gene therapy;
 KW human dermal fibroblast stimulation; tumour; tissue typing;
 KW affinity purification.
 XX
 OS Homo sapiens.
 XX
 XX US2003044934-A1.
 XX
 XX 06-MAR-2003.
 XX
 XX 28-AUG-2002; 2002US-00230338.
 XX
 XX 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.
 PA
 PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX
 XX WPI; 2003-492274/46.
 DR N-PSDB; ACD82293.
 XX
 XX New transmembrane polypeptides and nucleic acids encoding the
 PT polypeptides, useful in gene therapy, in chromosome identification, as
 PT chromosome markers, or in generating probes.
 XX
 XX Claim 19; Fig 236; 315pp; English.
 PS
 XX The invention relates to an isolated nucleic acid encoding a PRO
 CC polypeptide. Nucleic acids that encode PRO can be used to generate either
 CC transgenic animals or knock-out animals useful in developing and
 CC screening of therapeutically useful reagents. The nucleic acids may also
 CC be used in gene therapy for replacing defective gene, in chromosome
 CC identification, as chromosome markers, or in generating probes to isolate
 CC full length PRO cDNA. The PRO polypeptides are useful for chondrocyte
 CC stimulation, TNF-alpha stimulation, human dermal fibroblasts stimulation
 CC and for detecting the presence of tumour in an animal. The PRO
 CC polypeptides are useful as molecular markers for protein electrophoresis
 CC and the isolated nucleic acids may be used for recombinantly expressing
 CC those markers. The PRO polypeptides and nucleic acids may also be used in

CC tissue typing. Anti-PRO antibodies are useful in diagnostic assays for
 CC PRO and in affinity purification of PRO from recombinant cell culture or
 CC natural sources. The present sequence represents the amino acid sequence
 CC of a human secreted/transmembrane PRO polypeptide
 XX
 SQ Sequence 327 AA;
 Query Match 99.3%; Score 1277; DB 6; Length 327;
 Best Local Similarity 100.0%; Pred. No. 3.8e-84;
 Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTYSTVSGDSFALEWS 60
 Db |||||
 QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTYSTVSGDSFALEWS 60
 Db |||||
 QY 61 FVQPKPISESHPILYFTNGHLPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTCGYL 120
 Db |||||
 QY 61 FVQPKPISESHPILYFTNGHLPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTCGYL 120
 Db |||||
 QY 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSESGAPKPVNVW 180
 Db |||||
 QY 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSESGAPKPVNVW 180
 Db |||||
 QY 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPSQ 240
 Db |||||
 QY 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPSQ 240
 Db |||||
 QY 241 RVA 243
 Db |||||
 QY 241 RVA 243
 Db |||||
 RESULT 14
 ABO72175
 ID ABO72175 standard; protein; 327 AA.
 AC
 AC ABO72175;
 XX
 XX 16-OCT-2003 (first entry)
 XX
 XX Human membrane bound receptor/protein PRO7154 amino acid sequence.
 DE
 DE Human; PRO; membrane bound protein; membrane bound receptor;
 KW cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;
 KW differentiation factor; neurotrophin; hormone; cell receptor;
 KW receptor-ligand interaction; cytoskeletal; chondrocyte; tumour.
 XX
 OS Homo sapiens.
 XX
 XX US2003065147-A1.
 PN
 PD 03-APR-2003.
 XX
 XX 29-AUG-2002; 2002US-00232224.
 XX
 XX 28-JUL-1999; 99US-0146222P.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.
 PA
 PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX
 XX WPI; 2003-522018/49.
 DR N-PSDB; ABO743999.
 XX
 XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
 PT useful for the manufacture of a medicament for diagnosing or treating

PT tumor.
XX Claim 11; Fig 236; 315pp; English.
XX
CC This invention relates to one hundred and twenty two novel nucleic acids
CC encoding human PRO membrane bound proteins or receptors. Extracellular
CC proteins play important roles in the formation, differentiation and
CC maintenance of multicellular organisms. The fate of many individual cells
CC (for example proliferation, migration or differentiation) is typically
CC governed by information received from other cells and the immediate
CC environment. The information is often transmitted by secreted
CC polypeptides (for example mitogenic factors, survival factors, cytotoxic
CC factors, differentiation factors, neuropeptides and hormones) which are
CC received and interpreted by diverse cell receptors or membrane bound
CC proteins. These membrane bound proteins and receptors may be of use as
CC pharmaceutical and diagnostic agents, such as in the blocking of receptor
CC -ligand interactions. The current invention provides the amino acid
CC sequences of novel human membrane bound receptors and proteins, along
CC with the cDNA sequences encoding them. The novel proteins of the
CC invention may have cytosolic activities through the stimulation of
CC chondrocytes. The nucleic acids of the invention may be useful for the
CC manufacture of a medicament for diagnosing or treating a tumour in a
CC mammal. In addition, they may be useful for measuring or detecting the
CC expression of a tumour associated gene. The present sequence is the amino
CC acid sequence of a human PRO protein of the invention
XX
SQ Sequence 327 AA;
Query Match 99.3%; Score 1277; DB 7; Length 327;
Best Local Similarity 100.0%; Pred. No. 3.8e-84;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVGDSFALEWS 60
QY 61 FVQPGKPISEHPILYFTNGHLPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYL 120
Db 61 FVQPGKPISEHPILYFTNGHLPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYL 120
QY 121 CQVNNPPDYTYTGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPYNVV 180
Db 121 CQVNNPPDYTYTGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPYNVV 180
QY 181 RLGTFTPTSPGSMQVDEVSQILITNLSTSTGYRCVATNQMGASCELTLTVTEPSQG 240
Db 181 RLGTFTPTSPGSMQVDEVSQILITNLSTSTGYRCVATNQMGASCELTLTVTEPSQG 240
QY 241 RVA 243
Db 241 RVA 243
RESULT 15
ADB83726
ID ADB83726 standard; protein; 327 AA.
AC ADB83726;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO7154.
XX
KW human; secreted and transmembrane protein; PRO; cytostatic; vulnery;
KW antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX

OS Homo sapiens.
XX US2003073814-A1.
XX PD 17-APR-2003.
XX
XX 12-AUG-2002; 2002US-00218849.
XX
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-644806/61.
XX N-PSDB; ADB83725.
XX
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
XX in gene therapy, chromosome identification, tissue typing, or as
XX hybridization probes in chromosome and gene mapping.
XX
XX Claim 11; Fig 236; 315pp; English.
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF) -
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO1341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO572, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO1774, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptide of
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This is the amino acid sequence of a human secreted and
CC transmembrane PRO polypeptide.
XX
XX Sequence 327 AA;
Query Match 99.3%; Score 1277; DB 7; Length 327;
Best Local Similarity 100.0%; Pred. No. 3.8e-84;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVGDSFALEWS 60
QY 61 FVQPGKPISEHPILYFTNGHLPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGYL 120

Db	61	FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLIQNPPTVGAVATLKLTVDHPSDGTGYL	120
Qy	121	QVANNPPDFYTNGLGLINLTVLVPPSPNPLCSQSGQTSVGGSTALRCSSEGAKPQVYNNV	180
Db	121	QVANNPPDFYTNGLGLINLTVLVPPSPNPLCSQSGQTSVGGSTALRCSSEGAKPQVYNNV	180
Qy	181	RLGTFPPSPGSMQVDEVSGOLILTNLSLTSSGTYRCVATNQMGASCELTLSVTEPSQG	240
Db	181	RLGTFPPSPGSMQVDEVSGOLILTNLSLTSSGTYRCVATNQMGASCELTLSVTEPSQG	240
Qy	241	RVA	243
Db	241	RVA	243

Search completed: August 4, 2005, 06:07:07
Job time : 74.7214 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 4, 2005, 06:13:42 ; Search time 66.3695 Seconds
(without alignments)
1447.018 Million cell updates/sec

Title: US-10-607-565-83

Perfect score: 1287

Sequence: 1 MAELPGPFLCGALLGLFCLLS.....SCELTSLVTEPSQGRVAELX 246

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1752860 seqs, 390397842 residues

Total number of hits satisfying chosen parameters: 1752860

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications_AA:*
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US10E_PUBCOMB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
19: /cgn2_6/ptodata/1/pubpaa/US11A_PUBCOMB.pep.*
20: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
21: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
22: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1286	99.9	245	9	US-09-820-893-98
2	1286	99.9	245	15	US-10-607-565-98
3	1286	99.9	246	9	US-09-820-893-83
4	1286	99.9	246	15	US-10-607-565-83
5	1277	99.2	327	14	US-10-227-884-236
6	1277	99.2	327	14	US-10-230-163-236
7	1277	99.2	327	14	US-10-230-338-236
8	1277	99.2	327	14	US-10-218-631-236
9	1277	99.2	327	14	US-10-230-414-236
10	1277	99.2	327	14	US-10-232-224-236
11	1277	99.2	327	14	US-10-216-159A-236

12	1277	99.2	327	14	US-10-218-849-236	Sequence 236, App
13	1277	99.2	327	14	US-10-227-873-236	Sequence 236, App
14	1277	99.2	327	14	US-10-227-883-236	Sequence 236, App
15	1277	99.2	327	14	US-10-219-078-236	Sequence 236, App
16	1277	99.2	327	14	US-10-230-434-236	Sequence 236, App
17	1277	99.2	327	14	US-10-219-003-236	Sequence 236, App
18	1277	99.2	327	14	US-10-219-075-236	Sequence 236, App
19	1277	99.2	327	14	US-10-219-464-236	Sequence 236, App
20	1277	99.2	327	14	US-10-219-466-236	Sequence 236, App
21	1277	99.2	327	14	US-10-219-479-236	Sequence 236, App
22	1277	99.2	327	14	US-10-219-481-236	Sequence 236, App
23	1277	99.2	327	14	US-10-230-260-236	Sequence 236, App
24	1277	99.2	327	14	US-10-232-231-236	Sequence 236, App
25	1277	99.2	327	14	US-10-232-233-236	Sequence 236, App
26	1277	99.2	327	14	US-10-216-165-236	Sequence 236, App
27	1277	99.2	327	14	US-10-218-956-236	Sequence 236, App
28	1277	99.2	327	14	US-10-219-468-236	Sequence 236, App
29	1277	99.2	327	14	US-10-219-478-236	Sequence 236, App
30	1277	99.2	327	14	US-10-219-536-236	Sequence 236, App
31	1277	99.2	327	14	US-10-233-205-236	Sequence 236, App
32	1277	99.2	327	14	US-10-219-072-236	Sequence 236, App
33	1277	99.2	327	14	US-10-219-470-236	Sequence 236, App
34	1277	99.2	327	14	US-10-219-474-236	Sequence 236, App
35	1277	99.2	327	14	US-10-219-528-236	Sequence 236, App
36	1277	99.2	327	14	US-10-219-528-236	Sequence 236, App
37	1277	99.2	327	14	US-10-227-880-236	Sequence 236, App
38	1277	99.2	327	14	US-10-227-881-236	Sequence 236, App
39	1277	99.2	327	14	US-10-227-882-236	Sequence 236, App
40	1277	99.2	327	14	US-10-230-436-236	Sequence 236, App
41	1277	99.2	327	14	US-10-232-223-236	Sequence 236, App
42	1277	99.2	327	14	US-10-232-225-236	Sequence 236, App
43	1277	99.2	327	14	US-10-232-225-236	Sequence 236, App
44	1277	99.2	327	14	US-10-232-229-236	Sequence 236, App
45	1277	99.2	327	14	US-10-232-234-236	Sequence 236, App

ALIGNMENTS

RESULT 1
US-09-820-893-98
; Sequence 98, Application US/09820893
; Patent No. US20020076705A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human Secreted Proteins
; FILE REFERENCE: PZ033P1
; CURRENT APPLICATION NUMBER: US/09/820,893
; CURRENT FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 09/531,119
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: 60/102,895
; PRIOR FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 98
; LENGTH: 245
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-820-893-98

Query Match 99.9%; Score 1286; DB 9; Length 245;
Best Local Similarity 100.0%; Pred. No. 1.1e-96;
Matches 245; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MAELPGPFLCGALLGLFCLLSGLAVEVKVTEPLSLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGLFCLLSGLAVEVKVTEPLSLGKTAELTCTYSTSVGDSFALEWS 60
Qy 61 FVQPGKPISESHPILYFTNGHLPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
Db 61 FVQPGKPISESHPILYFTNGHLPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120

Db 1 MAELPGFLCAGLFLCSGLAVEVVKVTEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
QY 61 FVQPKPISHSHPILYFTNGHLVPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTCYIL 120
Db 61 FVQPKPISHSHPILYFTNGHLVPTGSKSRVSLQNPPTVGVATLKLTDVHPSDTCYIL 120
QY 121 CQVNNPDFYFTNGLGLINLTVLPVPSNPLCSQSQTSVGGSTALRCSSEGAPKPVYNNV 180
Db 121 CQVNNPDFYFTNGLGLINLTVLPVPSNPLCSQSQTSVGGSTALRCSSEGAPKPVYNNV 180
QY 181 RLGTFTPPSGVMQDVSVSQILITNLSTSSGTYRCVATNOMGSASCELTLSVTEPSQ 240
Db 181 RLGTFTPPSGVMQDVSVSQILITNLSTSSGTYRCVATNOMGSASCELTLSVTEPSQ 240
QY 241 RVAEL 245
Db 241 RVAEL 245

RESULT 5
US-10-227-884-236
; Sequence 236, Application US/10227884
; Publication No. US20030027988A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C79
; CURRENT APPLICATION NUMBER: US/10/227,884
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15

; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464

;
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
;
;
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/115558
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115565
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115733
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/119549
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/123618
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/125259
; PRIOR FILING DATE: 1999-03-19
; PRIOR APPLICATION NUMBER: 60/125775
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 60/126773
; PRIOR FILING DATE: 1999-03-29
; PRIOR APPLICATION NUMBER: 60/127887
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 60/130232
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: 60/131022
; PRIOR FILING DATE: 1999-04-26
; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14
; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/144758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638

```
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match          99.2%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 MAELPGPFICGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db      1 MAELPGPFICGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY      61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPPTVGATLKLTDVHPSDTGTYL 120
Db      61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPPTVGATLKLTDVHPSDTGTYL 120
QY      121 CQVNNPPDYTYNGLGINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYVW 180
Db      121 CQVNNPPDYTYNGLGINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYVW 180
QY      181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNOMGSASCELTLISVTEPSOG 240
Db      181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNOMGSASCELTLISVTEPSOG 240
QY      241 RVA 243
Db      241 RVA 243

RESULT 7
US-10-230-338-236
; Sequence 236, Application US/10230338
; Publication No. US2003004934A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P35301C92
; CURRENT FILING DATE: 2002-08-28
; PRIOR FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20

; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/079728
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-230-338-236

Query Match          99.2%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 MAELPGPFICGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db      1 MAELPGPFICGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY      61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPPTVGATLKLTDVHPSDTGTYL 120
Db      61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPPTVGATLKLTDVHPSDTGTYL 120
QY      121 CQVNNPPDYTYNGLGINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYVW 180
Db      121 CQVNNPPDYTYNGLGINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYVW 180
QY      181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNOMGSASCELTLISVTEPSOG 240
Db      181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNOMGSASCELTLISVTEPSOG 240
QY      241 RVA 243
Db      241 RVA 243

RESULT 8
US-10-218-631-236
; Sequence 236, Application US/10218631
; Publication No. US20030045687A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P35301C14
; CURRENT FILING DATE: 2002-08-12
; PRIOR FILING DATE: 2002-08-12
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
```


; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-631-236

Query Match 99.2%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGFLCGALLGFLCGLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGFLCGALLGFLCGLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGTYL 120
Db 61 FVQPGKPISSEHPILYFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGTYL 120
QY 121 CQVNNPPDFYTNGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSESSEGAKPVYNNV 180
Db 121 CQVNNPPDFYTNGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSESSEGAKPVYNNV 180
QY 181 RLCTFTPPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSASCELTLSVTPESQ 240
Db 181 RLCTFTPPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSASCELTLSVTPESQ 240
QY 241 RVA 243
Db 241 RVA 243

RESULT 9
US-10-230-414-236
; Sequence 236, Application US/10230414
; Publication No. US20030050448A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C98
; CURRENT APPLICATION NUMBER: US/10/230,414
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17

; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-230-414-236

Query Match 99.2%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGFLCGALLGFLCGLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGFLCGALLGFLCGLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGTYL 120
Db 61 FVQPGKPISSEHPILYFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGTYL 120
QY 121 CQVNNPPDFYTNGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSESSEGAKPVYNNV 180
Db 121 CQVNNPPDFYTNGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSESSEGAKPVYNNV 180
QY 181 RLCTFTPPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSASCELTLSVTPESQ 240
Db 181 RLCTFTPPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSASCELTLSVTPESQ 240
QY 241 RVA 243
Db 241 RVA 243

RESULT 10
US-10-232-224-236
; Sequence 236, Application US/10232224
; Publication No. US20030065147A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C111
; CURRENT APPLICATION NUMBER: US/10/232,224
; CURRENT FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873

Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	MAELPGFLCAGLGLCLSLGLAVEVVKVTEPLSTPLGKTAELTCTYSTVSGDSFALEWS	60
Db	1	MAELPGFLCAGLGLCLSLGLAVEVVKVTEPLSTPLGKTAELTCTYSTVSGDSFALEWS	60
Qy	61	FVQPKPISSEHPILYFTNGHLVPTGSKSKRVSLIQNPPTVGVATLKLTDVHPSDTCTYL	120
Db	61	FVQPKPISSEHPILYFTNGHLVPTGSKSKRVSLIQNPPTVGVATLKLTDVHPSDTCTYL	120
Qy	121	QVNNPPDFTYNGGLINLTVLVPPSNPLCSQSQTSTVGGSTALRCSSESGAPKPVNVW	180
Db	121	QVNNPPDFTYNGGLINLTVLVPPSNPLCSQSQTSTVGGSTALRCSSESGAPKPVNVW	180
Qy	181	RLGTFPTPSGSMQDVSQGLIILTNLSLTSSGTYRCVATNQMSGASCELTLSTVTPSQ	240
Db	181	RLGTFPTPSGSMQDVSQGLIILTNLSLTSSGTYRCVATNQMSGASCELTLSTVTPSQ	240
Qy	241	RVA 243	
Db	241	RVA 243	

RESULT 13

US-10-227-873-236
; Sequence 236, Application US/10227873
; Publication No. US20030073816A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: F3530P1C72
; CURRENT APPLICATION NUMBER: US/10/227,873
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06

; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178

; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/115558
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115565
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115733
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/119549
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/123618
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/125259
; PRIOR FILING DATE: 1999-03-19
; PRIOR APPLICATION NUMBER: 60/125775
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 60/126773
; PRIOR FILING DATE: 1999-03-29
; PRIOR APPLICATION NUMBER: 60/127887
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 60/130232
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: 60/131022
; PRIOR FILING DATE: 1999-04-26
; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14
; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/144758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09

; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.2%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLGSLGLAVEVKVPTPELSTPLGKTAELTCTYSTSVGDSFALEWS 60
DB 1 MAELPGPFLCGALLGFLGSLGLAVEVKVPTPELSTPLGKTAELTCTYSTSVGDSFALEWS 60

QY 61 FVQPGKPISEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGTYL 120
DB 61 FVQPGKPISEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTDVHPSDTGTYL 120

QY 121 QVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSSEGAPKPYNVW 180
DB 121 QVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSSEGAPKPYNVW 180

QY 181 RLGTPTTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNOMGASCELTLSTVTEPSOG 240
DB 181 RLGTPTTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNOMGASCELTLSTVTEPSOG 240

QY 241 RVA 243
DB 241 RVA 243

RESULT 14
US-10-227-883-236
; Sequence 236, Application US/10227883
; Publication No. US20030073817A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC78
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525
---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.2%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQLNPPPTGVATLKLTDVHPSDTGYL 120
Db 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQLNPPPTGVATLKLTDVHPSDTGYL 120
QY 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPYNNV 180
Db 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPYNNV 180
QY 181 RLGTFTPPSGMWQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLISVTEPSOG 240
Db 181 RLGTFTPPSGMWQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLISVTEPSOG 240
QY 241 RVA 243
Db 241 RVA 243

RESULT 15
US-10-219-076-236
; Sequence 236, Application US/10219076
; Publication No. US20030078379A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530PIC62
; CURRENT APPLICATION NUMBER: US/10/219, 076
; CURRENT FILING DATE: 2002-08-14
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31

; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-219-076-236

Query Match 99.2%; Score 1277; DB 14; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.7e-96;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQLNPPPTGVATLKLTDVHPSDTGYL 120
Db 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQLNPPPTGVATLKLTDVHPSDTGYL 120
QY 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPYNNV 180
Db 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPYNNV 180
QY 181 RLGTFTPPSGMWQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLISVTEPSOG 240
Db 181 RLGTFTPPSGMWQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLISVTEPSOG 240
QY 241 RVA 243
Db 241 RVA 243

Search completed: August 4, 2005, 06:47:28
Job time : 67.3695 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 4, 2005, 05:53:15 ; Search time 75.0264 Seconds
(without alignments)
1268.128 Million cell updates/sec

Title: US-10-607-565-83

Perfect score: 1287

Sequence: 1 MABLPGFLCGALLGFLCLS.....SCEILTSVTFPSQGRVAELX 246

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A Geneseq_16Dec04:*

- 1: Geneseqp1980s:*
- 2: Geneseqp1990s:*
- 3: Geneseqp2000s:*
- 4: Geneseqp2001s:*
- 5: Geneseqp2002s:*
- 6: Geneseqp2003as:*
- 7: Geneseqp2003bs:*
- 8: Geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1286	99.9	245	3 AAB08940	Aab08940 Human sec
2	1286	99.9	246	3 AAB08926	Aab08926 Human sec
3	1277	99.2	327	3 AAY87251	Aay87251 Human sig
4	1277	99.2	327	3 AAY94857	Aay94857 Human pro
5	1277	99.2	327	4 AAY97585	Aay97585 Human sec
6	1277	99.2	327	5 ABB90354	Abb90354 Human pol
7	1277	99.2	327	5 AAU83709	Aau83709 Human PRO
8	1277	99.2	327	6 ABU80856	Abu80856 Human PRO
9	1277	99.2	327	6 ABO33822	Abo33822 Novel hum
10	1277	99.2	327	6 ABU82165	Abu82165 Novel hum
11	1277	99.2	327	6 ABJ72345	Abj72345 Human PRO
12	1277	99.2	327	6 ABJ72473	Abj72473 Human PRO
13	1277	99.2	327	6 ABO34368	Abo34368 Human sec
14	1277	99.2	327	7 ABJ72175	Abj72175 Human mem
15	1277	99.2	327	7 ADB83726	Adb83726 Novel hum
16	1277	99.2	327	7 ADB80832	Adb80832 Novel hum
17	1277	99.2	327	7 ADB73373	Adb73373 Novel hum
18	1277	99.2	327	7 ADB78455	Adb78455 Novel hum
19	1277	99.2	327	7 ADB85103	Adb85103 Human PRO
20	1277	99.2	327	7 ADB78209	Adb78209 Novel hum
21	1277	99.2	327	7 ADB87275	Adb87275 Human PRO
22	1277	99.2	327	7 ADB84857	Adb84857 Human PRO
23	1277	99.2	327	7 ADB83972	Adb83972 Novel hum
24	1277	99.2	327	7 ADB73127	Adb73127 Novel hum
25	1277	99.2	327	7 ADC36965	Adc36965 Human PRO

ALIGNMENTS

RESULT 1

AAB08940
ID AAB08940 standard; protein; 245 AA.

XX AC AAB08940;

XX AC (first entry)

DT 30-AUG-2000 (first entry)

DE Human secreted protein sequence encoded by gene 13 SEQ ID NO:97.

XX Human; secreted protein; cytostatic; anti-proliferative; vulnery;
KW immunosuppressive; antibacterial; diagnosis; immune system; chemotaxis;
KW hyperproliferative disorder; infectious disease; tissue regeneration;
KW screening; food additive; preservative; wound healing;
KW hyper-vascular disease; chromosome 11.

XX Homo sapiens.

XX WO200017222-A1.

XX 30-MAR-2000.

XX 22-SEP-1999; 99WO-US022012.

XX 23-SEP-1998; 98US-0101546P.

XX 02-OCT-1998; 98US-0102895P.

XX (HUMA-) HUMAN GENOME SCI INC.

PI Ruben SM, Rosen CA, Duan RD, Shi Y, Lafleur DW, Young PE, Ni J;

PI Komatsoulis G, Endress GA, Soppet DR;

XX WPI; 2000-283538/24.

XX Human secreted proteins and coding sequences useful in diagnostic and
PT therapeutic methods for disorders such as immune system or proliferative
PT disorders, related to the proteins.

PS Disclosure; Page 40; 416pp; English.

CC The polynucleotide sequences given in AAA39052 to AAA39088 encode the
CC human secreted proteins given in AAB08991 to AAB08984. The human secreted
CC proteins can have activities based on the tissues and cells they are
CC expressed in. Examples of the activities are: cytostatic; anti-
CC proliferative; immunosuppressive; antibacterial; and vulnery. The
CC secreted proteins and their related polynucleotide sequences are useful
CC for diagnostic and therapeutic methods useful for diagnosing and treating
CC disorders related to the secreted proteins. The proteins, and

CC polynucleotide sequences may be useful for treating disorders of the
CC immune system, hyperproliferative disorders, infectious disease,
CC regeneration of tissues, for chemotaxis and for screening molecules that
CC bind to the proteins. The proteins or polynucleotide sequences may be
CC used as food additives or preservatives, to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, co-factors or other nutritional components. Agonists or
CC antagonists of the proteins may be used to prevent scar tissue growth
CC during wound healing, and hyper-vascular diseases. AAA39043 to AAA39051
CC and AAB08890 are sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 245 AA;
Query Match: 99.9%; Score 1286; DB 3; Length 245;
Best Local Similarity 100.0%; Pred. No. 6.1e-85;
Matches 245; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGPFLLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
DB 1 MAELPGPFLLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDGTGYL 120
DB 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDGTGYL 120
QY 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
DB 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
QY 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSAECLTSLVTPSPQ 240
DB 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSAECLTSLVTPSPQ 240
QY 241 RVAEL 245
DB 241 RVAEL 245
RESULT 2
AAB08926
ID AAB08926 standard; protein; 246 AA.
XX
AC AAB08926;
XX
XX 30-AUG-2000 (first entry)
DE Human secreted protein sequence encoded by gene 13 SEQ ID NO:83.
XX
KW Human; secreted protein; cytostatic; anti-proliferative; vulnery;
KW immunosuppressive; antibacterial; diagnosis; immune system; chemotaxis;
KW hyperproliferative disorder; infectious disease; tissue regeneration;
KW screening; food additive; preservative; wound healing;
KW hyper-vascular disease; chromosome 11.
XX
OS Homo sapiens.
XX
XX WO200017222-A1.
XX
XX 30-MAR-2000.
XX
XX 22-SEP-1999; 99WO-US022012.
XX
XX 23-SEP-1998; 98US-0101546P.
XX 02-OCT-1998; 98US-0102895P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Ruben SM, Rosen CA, Duan RD, Shi Y, Lafleur DW, Young PE, Ni J;
XX Komatsoulis G, Endress GA, Soppet DR;
XX WPI; 2000-283538/24.
XX
XX N-PSDB; AAA39087.

XX Human secreted proteins and coding sequences useful in diagnostic and
PT therapeutic methods for disorders such as immune system or proliferative
PT disorders, related to the proteins.
XX
PS Claim 11; Page 376-377; 416pp; English.
XX
CC The polynucleotide sequences given in AAA39052 to AAA39088 encode the
CC human secreted proteins given in AAB08891 to AAB08984. The human secreted
CC proteins can have activities based on the tissues and cells they are
CC expressed in. Examples of the activities are: cytostatic; anti-
CC proliferative; immunosuppressive; antibacterial; and vulnery. The
CC secreted proteins and their related polynucleotide sequences are useful
CC for diagnostic and therapeutic methods useful for diagnosing and treating
CC disorders related to the secreted proteins. The proteins, and
CC polynucleotide sequences may be useful for treating disorders of the
CC immune system, hyperproliferative disorders, infectious disease,
CC regeneration of tissues, for chemotaxis and for screening molecules that
CC bind to the proteins. The proteins or polynucleotide sequences may be
CC used as food additives or preservatives, to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, co-factors or other nutritional components. Agonists or
CC antagonists of the proteins may be used to prevent scar tissue growth
CC during wound healing, and hyper-vascular diseases. AAA39043 to AAA39051
CC and AAB08890 are sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 246 AA;
Query Match: 99.9%; Score 1286; DB 3; Length 246;
Best Local Similarity 100.0%; Pred. No. 6.1e-85;
Matches 245; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGPFLLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
DB 1 MAELPGPFLLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDGTGYL 120
DB 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDGTGYL 120
QY 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
DB 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
QY 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSAECLTSLVTPSPQ 240
DB 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSAECLTSLVTPSPQ 240
QY 241 RVAEL 245
DB 241 RVAEL 245
RESULT 3
AAB087251
ID AAB087251 standard; protein; 327 AA.
XX
AC AAB087251;
XX
XX 11-MAY-2000 (first entry)
XX
XX Human signal peptide containing protein HSPP-28 SEQ ID NO:28.
XX
XX Human; signal peptide-containing protein; HSPP; diagnosis; cancer;
XX inflammation; cardiovascular disease; anticancer; anti-inflammatory;
XX antimicrobial; nootropic; neuroprotective; cardiovascular; hepatotropic;
XX antiasthmatic; gene therapy; cell proliferation; neurological disorder;
XX reproductive disorder; developmental disorder; arteriosclerosis;
XX cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;
XX asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;
XX Parkinson's disease; Huntington's diseases; ovulatory defect;
XX muscular dystrophy.

XX OS Homo sapiens.
 XX PN WO20000610-A2.
 XX PD 06-JAN-2000.
 XX PF 25-JUN-1999; 99WO-US014484.
 XX PR 26-JUN-1998; 98US-0090762P.
 XX PR 31-JUL-1998; 98US-0094983P.
 XX PR 01-OCT-1998; 98US-0102686P.
 XX PR 11-DEC-1998; 98US-0112129P.
 XX PA (INCY-) INCYTE PHARM INC.
 XX PI Lal P, Tang YT, Gorgone GA, Corley NC, Guegler KJ, Baughn MR;
 XX PI Akerblom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL;
 XX PI Bandman O;
 XX DR WPI; 2000-160673/14.
 XX DR N-PSDB; AAZ98136.
 XX PT New human signal peptide-containing proteins useful in treatment,
 XX PT prevention and diagnosis of e.g. cancer, inflammation and cardiovascular
 XX PT disease.
 XX PS Claim 1; Page 177-178; 327pp; English.
 XX CC AAZ98109 to AAZ98242 encode AAY87224 to AAY87357 which represent the
 CC human signal peptide-containing proteins HSP-1 to HSP-134. HSPs have
 CC anticancer, anti-inflammatory, antimicrobial, nontropic, hepatotropic,
 CC neuroprotective, cardiovascular and antiasthmatic activities, and can be
 CC used in gene therapy. HSPs can be used to treat or prevent disorders
 CC associated with decreased activity or function of HSP. Antagonists of
 CC HSP are used to treat or prevent disorders associated with increased
 CC activity or function of HSP. Such diseases include cell proliferation
 CC (including cancer), inflammation, cardiovascular, neurological,
 CC reproductive or developmental disorders, (e.g. arteriosclerosis,
 CC cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia,
 CC asthma, Crohn's disease, microbial or other infections, congestive or
 CC ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's
 CC diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSP
 CC nucleic acids can be used for the recombinant production of HSP, for
 CC detecting HSP in standard hybridisation and amplification assays (for
 CC diagnosis and monitoring), in gene therapy, as antisense, triplex-forming
 CC or ribozyme therapeutics, for detecting related sequences or genetic
 CC variations, and for chromosomal mapping. HSP are also used to raise
 CC specific antibodies (Ab) and to screen for agonists and antagonists
 CC (potential therapeutic agents). Ab are used to diagnose, or monitor, HSP
 CC -related diseases (in usual immunoassays), as therapeutic antagonists, in
 CC competitive drug screens, and for purification of HSP from natural
 CC sources
 XX SQ Sequence 327 AA;

Query Match 99.2%; Score 1277; DB 3; Length 327;
 Best Local Similarity 100.0%; Pred. No. 3.8e-84;
 Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGFLCAGLGFCLSGLAIVEVKVPTPLTGLKTAELTCTYSTVSGDFALEWS 60
 DB 1 MAELPGFLCAGLGFCLSGLAIVEVKVPTPLTGLKTAELTCTYSTVSGDFALEWS 60

QY 61 FVQPKPISSEPHLYFTNGHLYPTGSKSRVSLQLQNPPTGVATLKLTDVHSDTCTYL 120
 DB 61 FVQPKPISSEPHLYFTNGHLYPTGSKSRVSLQLQNPPTGVATLKLTDVHSDTCTYL 120

QY 121 QVNNPPDFYFTNGHLYFTNGHLYPTGSKSRVSLQLQNPPTGVATLKLTDVHSDTCTYL 180
 DB 121 QVNNPPDFYFTNGHLYFTNGHLYPTGSKSRVSLQLQNPPTGVATLKLTDVHSDTCTYL 180

QY 181 RLGTFTFPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSTVPSQ 240

DB 181 RLGTFTFPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSTVPSQ 240
 QY 241 RVA 243
 DB 241 RVA 243

RESULT 4
 AAY94857
 ID AAY94857 standard; protein; 327 AA.
 XX AC AAY94857;
 XX DT 12-JUN-2000 (first entry)
 XX DE Human protein clone HP10568.
 XX KW Human protein; hydrophobic domain; nutritional source; haematopoiesis;
 KW cytokine production; cell proliferation; cell differentiation;
 KW immune deficiency; infectious disease; autoimmune disorder; asthma;
 KW multiple sclerosis; systemic lupus erythematosus; rheumatoid arthritis;
 KW allergic reaction; osteoporosis; osteoarthritis; periodontal disease;
 KW nervous system disorder; Alzheimer's disease; Parkinson's disease;
 KW Huntington's disease; liver fibrosis; lung fibrosis; reperfusion injury;
 KW systemic cytokine damage; tissue differentiation; contraceptive; stroke;
 KW coagulation disorder; myocardial infarction; inflammatory condition;
 KW septic shock; sepsis; ischaemia; reperfusion injury; arthritis; tumour;
 KW nephritis; therapy.
 XX OS Homo sapiens.
 XX PN WO200005367-A2.
 XX PD 03-FEB-2000.
 XX PF 22-JUL-1999; 99WO-JP003929.
 XX PR 24-JUL-1998; 98JP-00208820.
 XX PR 07-AUG-1998; 98JP-00224105.
 XX PR 25-AUG-1998; 98JP-00238116.
 XX PR 09-SEP-1998; 98JP-00254736.
 XX PR 29-SEP-1998; 98JP-00275505.
 XX PA (SAGA) SAGAMI CHEM RES CENT.
 XX PI (PROT-) PROTEGENE INC.
 XX PI Kato S, Kimura T;
 XX WPI; 2000-182694/16.
 XX PT Novel human proteins having hydrophobic domains useful for treating
 PT osteoporosis, Alzheimer's disease, Parkinson's disease, asthma, multiple
 PT sclerosis, rheumatoid arthritis, cancer, anemia, and stroke.
 XX PS Claim 1; Page 183-184; 351pp; English.
 XX CC This sequence represents a human protein of the invention, which has
 CC hydrophobic domains. The DNA sequences can be used as a probe or as a
 CC genetic marker. The protein can also be used as a marker, and to identify
 CC potential genetic disorders. The DNA and protein can also be used as
 CC nutritional sources or supplements. The protein exhibits cytokine, cell
 CC proliferation, cell differentiation activities and induces production of
 CC other cytokines in certain cell populations. The protein also exhibits
 CC immune stimulating or immune suppressing activity. It can be used in the
 CC treatment of various immune deficiencies and disorders, and to treat
 CC infectious diseases caused by viral, bacterial, fungal or other
 CC infections. The protein is also used for treating autoimmune disorders
 CC such as multiple sclerosis, systemic lupus erythematosus, and rheumatoid
 CC arthritis. It is also useful in the treatment of allergic reactions and
 CC conditions such as asthma, and in immune suppression after organ
 CC transplantation. The protein is useful in regulation of haematopoiesis
 CC and consequently in the treatment of myeloid or lymphoid cell

CC deficiencies. It is also used in compositions for tissue growth or
 CC regeneration. The protein is also used in the treatment of osteoporosis
 CC or osteoarthritis and in the treatment of periodontal disease and other
 CC tooth repair processes. The protein is used in the treatment of nervous
 CC system disorders such as Alzheimer's disease, Parkinson's disease, and
 CC Huntington's disease. They are useful for protection or regeneration and
 CC treatment of lung or liver fibrosis, reperfusion injury in various
 CC tissues, and conditions resulting from systemic cytokine damage. They are
 CC also used for promoting or inhibiting tissue differentiation. They are
 CC also used as contraceptives since they exhibit activin or inhibin related
 CC activities and as a fertility inducing therapeutic. They are used for
 CC treating various coagulation disorders and in treatment and prevention of
 CC conditions resulting from coagulation activities e.g. myocardial
 CC infarction or stroke. They also acts as receptors, receptor ligands or
 CC inhibitors or agonists of receptor/ligand interactions. They are used to
 CC treat inflammatory conditions such as septic shock, sepsis, ischaemia
 CC reperfusion injury, arthritis, and nephritis. They can be used to prevent
 CC tumours
 XX
 SQ Sequence 327 AA;

Query Match 99.2%; Score 1277; DB 3; Length 327;
 Best Local Similarity 100.0%; Pred. No. 3.8e-84;
 Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGFPCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGFPCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISEHPILYFTNGHLIYPTGSKSRVLLQNPPTVGVATILKLTVDHPSDTGYL 120
 DB 61 FVQPGKPISEHPILYFTNGHLIYPTGSKSRVLLQNPPTVGVATILKLTVDHPSDTGYL 120
 QY 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNW 180
 DB 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNW 180
 QY 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTTCVATNMGSGASCELTLSTVTPSQ 240
 DB 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTTCVATNMGSGASCELTLSTVTPSQ 240
 QY 241 RVA 243
 DB 241 RVA 243

RESULT 5
 AAY97585
 ID AAY97585 standard; protein; 327 AA.
 XX
 AC AAY97585;
 XX
 DT 05-APR-2001 (first entry)
 DE Human secreted protein PRO71154.
 XX
 KW Secreted protein; human; PRO protein; neoplastic cell growth; tumour;
 KW proliferation; leukaemia; lymphoid malignancy; inflammatory disorder;
 KW angiogenic disorder; immunologic disorder; PRO71154.
 XX
 OS Homo sapiens.
 XX
 PN WO200075317-A2.
 XX
 PD 14-DEC-2000.
 XX
 PF 15-MAY-2000; 2000WO-US013358.
 XX
 PR 09-JUN-1999; 99US-0138385P.
 PR 20-JUL-1999; 99US-0144790P.
 PR 03-AUG-1999; 99US-0146843P.
 PR 10-AUG-1999; 99US-0148188P.
 PR 17-AUG-1999; 99US-0149320P.

PR 17-AUG-1999; 99US-0149327P.
 PR 17-AUG-1999; 99US-0149396P.
 PR 20-AUG-1999; 99US-0150114P.
 PR 31-AUG-1999; 99US-0151700P.
 PR 31-AUG-1999; 99US-0151734P.
 XX (GETH) GENENTECH INC.
 PA Botstein DA, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WI;
 XX WPI: 2001-071075/08.
 PI N-PSDB; AAY91019.
 XX
 DR Antibodies against PRO polypeptides, useful for diagnosing and treating
 PT tumors are associated with gene amplification, neoplastic cell growth and
 PT proliferation in mammals.
 XX
 PS Claim 61; Fig 12; 143pp; English.
 XX
 CC This sequence is a human PRO protein of the invention. The PRO proteins
 CC are secreted proteins. Antagonists or antibodies of PRO polypeptides are
 CC useful for diagnosing and treating tumours are associated with gene
 CC amplification, neoplastic cell growth and proliferation in mammals, and
 CC those conditions characterised by overexpression and/or activation of the
 CC amplified genes. Such conditions include benign or malignant tumours
 CC (e.g. renal, liver, kidney, bladder, breast, gastric, ovarian,
 CC colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic
 CC carcinomas, sarcomas, glioblastomas and various head and neck tumours);
 CC leukaemias and lymphoid malignancies; neuronal, glial, astrocytal,
 CC hypothalamic, and other glandular, macrophageal, epithelial, stromal and
 CC blastocoeleic disorders; and inflammatory, angiogenic and immunologic
 CC disorders. These may further be used to qualitatively or quantitatively
 CC detect the expression of proteins encoded by the amplified genes, and in
 CC tumour diagnostics or prognostics. The PRO polypeptide or its antagonist
 CC may be used for the preparation of a medicament in the treatment of a
 CC condition, which is responsive to the PRO polypeptide, its antagonist or
 CC anti-PRO antibody
 XX
 SQ Sequence 327 AA;

Query Match 99.2%; Score 1277; DB 4; Length 327;
 Best Local Similarity 100.0%; Pred. No. 3.8e-84;
 Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGFPCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGFPCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISEHPILYFTNGHLIYPTGSKSRVLLQNPPTVGVATILKLTVDHPSDTGYL 120
 DB 61 FVQPGKPISEHPILYFTNGHLIYPTGSKSRVLLQNPPTVGVATILKLTVDHPSDTGYL 120
 QY 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNW 180
 DB 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNW 180
 QY 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTTCVATNMGSGASCELTLSTVTPSQ 240
 DB 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTTCVATNMGSGASCELTLSTVTPSQ 240
 QY 241 RVA 243
 DB 241 RVA 243

RESULT 6
 ABB90354
 ID ABB90354 standard; protein; 327 AA.
 XX
 AC ABB90354;
 XX
 DT 24-MAY-2002 (first entry)
 XX

DE Human polypeptide SEQ ID NO 2730.
XX Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
KW anti-allergic; hepatotropic; antidiabetic; anti-inflammatory; antitumor;
KW vulnary; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW neurological disease; infection; human; secreted protein.
XX
OS Homo sapiens.
XX WO200190304-A2.
XX
XX 29-NOV-2001.
XX
XX 18-MAY-2001; 2001WO-US016450.
XX
XX 19-MAY-2000; 2000US-0205515P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Birse CE, Rosen CA;
XX WPI; 2002-122018/16.
XX N-PSDB; ABL90763.
XX
XX Novel 1405 isolated polypeptides, useful for diagnosis, treatment and
PT prevention of neural, immune system, muscular, reproductive,
PT gastrointestinal, pulmonary, cardiovascular, renal and proliferative
PT disorders.
XX
XX Claim 11; SEQ ID NO 2730; 2081pp + Sequence Listing; English.
XX
XX The invention relates to novel genes (ABL89449-ABL90853) and proteins
CC (ABB89040-ABB90444) useful for preventing, treating or ameliorating
CC medical conditions e.g. by protein or gene therapy. The genes are
CC isolated from a range of human tissues disclosed in the specification.
CC The nucleic acids, proteins, antibodies and (ant)agonists are useful in
CC the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and
CC ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,
CC breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune
CC disorders e.g. Addison's disease, allergies, autoimmune haemolytic
CC anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)
CC cardiovascular disorders such as myocardial ischaemia; (d) wound healing
CC ; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)
CC infectious diseases such as viral, bacterial, fungal and parasitic
CC infections. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 327 AA;
XX
XX Query Match 99.2%; Score 1277; DB 5; Length 327;
XX Best Local Similarity 100.0%; Pred. No. 3.8e-84;
XX Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 MAELPGFLCALGFLCLSLAVEVVKVPTPELTPGLKTAELTCTYSTVSGDSFALEWS 60
XX
XX 1 MAELPGFLCALGFLCLSLAVEVVKVPTPELTPGLKTAELTCTYSTVSGDSFALEWS 60
XX
XX 61 FVQPGKPISESHPILYFTNGHLIYPTGSKSRVSLQLNPPTVGVATLKLTDVHPSDTGYL 120
XX
XX 61 FVQPGKPISESHPILYFTNGHLIYPTGSKSRVSLQLNPPTVGVATLKLTDVHPSDTGYL 120
XX
XX 121 CQVNNPPDFYFTNGHLINLTVLPVPSNPLCSQSQSTVSGGSTALRCSSEGAPKPVYVNW 180
XX
XX 121 CQVNNPPDFYFTNGHLINLTVLPVPSNPLCSQSQSTVSGGSTALRCSSEGAPKPVYVNW 180
XX
XX 181 RLGTFTPTSPGSMQVDSVSGQLILTNLSLTSSGTYRCVATNQMSASCELTLSVTEPSQ 240
XX
XX 181 RLGTFTPTSPGSMQVDSVSGQLILTNLSLTSSGTYRCVATNQMSASCELTLSVTEPSQ 240
XX
XX 241 RVA 243

Db 241 RVA 243

RESULT 7
AAU83709

ID AAU83709 standard; protein; 327 AA.

XX AC AAU83709;

XX 08-MAY-2002 (first entry)

XX Human PRO protein, Seq ID No 236.

XX Human; secreted protein; PRO; tumour; lung cancer; colon cancer;
KW breast cancer; prostate tumour; rectal tumour; liver tumour;
KW pericyte cell proliferation; chondrocyte cell proliferation;
KW tumour necrosis factor-alpha.

XX OS Homo sapiens.

XX WO200208288-A2.

XX 31-JAN-2002.

XX 29-JUN-2001; 2001WO-US021066.

XX 20-JUL-2000; 2000US-0219556P.

XX 25-JUL-2000; 2000US-0220585P.

XX 25-JUL-2000; 2000US-0220605P.

XX 25-JUL-2000; 2000US-0220607P.

XX 25-JUL-2000; 2000US-0220624P.

XX 25-JUL-2000; 2000US-0220638P.

XX 25-JUL-2000; 2000US-0220664P.

XX 25-JUL-2000; 2000US-0220666P.

XX 26-JUL-2000; 2000US-0220893P.

XX 01-AUG-2000; 2000US-0220710.

XX 22-AUG-2000; 2000US-0227133P.

XX 23-AUG-2000; 2000WO-US023522.

XX 24-AUG-2000; 2000WO-US023328.

XX 10-NOV-2000; 2000WO-US030873.

XX 01-DEC-2000; 2000US-0253646P.

XX 20-DEC-2000; 2000US-00747259.

XX 20-DEC-2000; 2000WO-US034956.

XX 28-FEB-2001; 2001WO-US006520.

XX 01-MAR-2001; 2001US-00816744.

XX 10-MAY-2001; 2001US-00854208.

XX 25-MAY-2001; 2001WO-US017092.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski RJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2002-172001/22.

XX N-PSDB; ABK33653.

XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful for treating a PRO related disorder and for diagnosing tumors such
PT as lung cancer, colon cancer, breast tumor, prostate tumor, rectal tumor
PT or liver tumor.

XX Claim 11; Fig 236; 359pp; English.

XX The invention relates to one hundred and twenty two nucleic acids
CC encoding PRO polypeptides. The sequences of the 122 PRO polynucleotides
CC encode human secreted proteins. The PRO nucleic acids, polypeptides,
CC agonists and antagonists are useful for treating a PRO related disorder.
CC The PRO polypeptides are useful for diagnosing tumors, especially lung

CC cancer, colon cancer, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. The PRO polypeptides are useful for stimulating the
 CC proliferation of, or gene expression, in pericyte cells, for stimulating
 CC the proliferation or differentiation of chondrocyte cells, for
 CC stimulating the release of tumour necrosis factor-alpha from human blood,
 CC for stimulating or inhibiting the proliferation of normal human dermal
 CC fibroblast cells. The PRO polypeptide may also be used as molecular
 CC weight markers and for tissue typing. The PRO nucleic acids have
 CC applications in molecular biology, including use as hybridisation probes,
 CC and in chromosome and gene mapping. AAU83592-AAU83713 represent human PRO
 CC protein sequences of the invention
 XX
 SQ Sequence 327 AA;

Query Match 99.2%; Score 1277; DB 5; Length 327;
 Best Local Similarity 100.0%; Pred. No. 3.8e-84;
 Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSGLAIVEKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSGLAIVEKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
 QY 61 FVQPGKPISSEHPILYFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGTYL 120
 DB 61 FVQPGKPISSEHPILYFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGTYL 120
 QY 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 DB 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 QY 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLTSVTPSQ 240
 DB 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLTSVTPSQ 240
 QY 241 RVA 243
 DB 241 RVA 243

RESULT 8
 ABU80856
 ID ABU80856 standard; protein; 327 AA.
 XX
 AC ABU80856;
 XX
 DT 23-JUN-2003 (first entry)
 XX
 DE Human PRO polypeptide #118.
 XX
 KW Human; PRO polypeptide; secreted and transmembrane protein;
 KW anti-PRO antibody; diagnostic assay; gene expression; tumour; cytostatic.
 XX
 OS Homo sapiens.
 XX
 PN US2003036635-A1.
 XX
 PD 20-FEB-2003.
 XX
 PF 28-AUG-2002; 2002US-00230163.
 XX
 PR 25-JUL-2000; 2000US-0220638P.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX
 XX WPI; 2003-342045/32.
 DR
 DR N-PSDB; ACA66958.
 XX

PT One hundred and twenty two nucleic acids encoding PRO polypeptides,
 PT useful for the manufacture of a medicament for diagnosing or treating
 PT tumor.
 XX
 PS Claim 11; Fig 236; 314pp; English.
 XX
 CC The present invention relates to the isolation of novel human PRO
 CC polypeptides, and the polynucleotide sequences encoding them. The PRO
 CC polypeptides are secreted and transmembrane proteins. The PRO
 CC polypeptides and polynucleotides are useful for preparing a medicament
 CC useful in the diagnosis and treatment of tumours. Anti-PRO antibodies are
 CC useful in diagnostic assays for PRO, by detecting its expression in
 CC specific cells, tissues or serum, and for affinity purification of PRO
 CC from recombinant cell culture or natural sources. ABU80739-ABU80860
 CC represent the human PRO polypeptides of the invention. Note: The sequence
 CC data for this patent was obtained in electronic format directly from the
 CC USPTO web site at seqdata.uspto.gov/psip9dIDEntry.html
 XX

SQ Sequence 327 AA;

Query Match 99.2%; Score 1277; DB 6; Length 327;
 Best Local Similarity 100.0%; Pred. No. 3.8e-84;
 Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSGLAIVEKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSGLAIVEKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
 QY 61 FVQPGKPISSEHPILYFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGTYL 120
 DB 61 FVQPGKPISSEHPILYFTNGHLPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGTYL 120
 QY 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 DB 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 QY 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLTSVTPSQ 240
 DB 181 RLGTFTPPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLTSVTPSQ 240
 QY 241 RVA 243
 DB 241 RVA 243

RESULT 9
 ABO33822
 ID ABO33822 standard; protein; 327 AA.
 XX
 AC ABO33822;
 XX
 DT 17-SEP-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO7154.
 XX
 KW Human; secreted and transmembrane protein; PRO; cytostatic;
 KW antiarthritic; osteopathic; gene therapy; TNF-Agonist-Alpha;
 KW chondrocyte stimulator; pericyte stimulator; fibroblast modulator;
 KW pharmaceutical; diagnostic; biosensor; bioreactor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; bone disorder; cartilage disorder; sports injury;
 KW arthritis; wound.
 XX
 OS Homo sapiens.
 XX
 PN US2003045687-A1.
 XX
 PD 06-MAR-2003.
 XX
 PF 12-AUG-2002; 2002US-00218631.
 XX
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR

PR 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski RJ,
 XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2003-512315/48.
 XX N-PSDB; ACD68710.
 XX New genes, and its encoded secreted and transmembrane polypeptides,
 XX useful for stimulating tumor Necrosis factor alpha, or chondrocyte or
 XX pericyte proliferation, especially for treating lung tumors, arthritis or
 XX wounds in a mammal.
 XX Claim 11; Fig 236; 314pp; English.
 XX The invention describes an isolated nucleic acid molecule comprising a
 XX sequence with at least 80% identity to: (a) a nucleotide encoding any of
 XX 122 PRO (secreted and transmembrane) polypeptides whose sequences are
 XX fully defined in the specification; or (b) any of 122 nucleotide
 XX sequences having e.g. 4834, 2504 or 1759 bp fully defined in the
 XX specification; or the full length coding sequence of any these 122
 XX nucleotide sequences. The PRO polypeptides or polynucleotides are useful
 XX as pharmaceuticals, diagnostics, biosensors or bioreactors. These are
 XX particularly useful for detecting tumours (e.g. lung tumour, colon
 XX tumour, breast tumour, prostate tumour, rectal tumour, or liver tumour)
 XX in a mammal, for stimulating the release of TNF-alpha from human blood,
 XX for stimulating the proliferation or differentiation of chondrocyte
 XX cells, for stimulating proliferation of pericyte cells, or for modulating
 XX normal human dermal fibroblast proliferation. The PRO nucleic acid or
 XX polypeptide is also useful for treating tumours or various bone and/or
 XX cartilage disorders (e.g. sports injuries or arthritis), or wounds. The
 XX PRO polypeptides are useful in drug screening, particularly as targets
 XX for therapeutic intervention in these diseases, and in the diagnostic
 XX determination of the presence of these diseases. The PRO polypeptides are
 XX also useful as molecular weight markers, or for chromosome
 XX identification. The PRO genes are useful as hybridisation probes, or for
 XX screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may
 XX also be used in gene therapy, particularly for replacing a defective
 XX gene. This is the amino acid sequence of a novel human secreted and
 XX transmembrane PRO polypeptide

XX Sequence 327 AA;

Query Match 99.2%; Score 1277; DB 6; Length 327;
 Best Local Similarity 100.0%; Pred. No. 3.8e-84;
 Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MAELPGPFLCGALLGFLCLSGLAIVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSGLAIVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
 QY 61 FVOPGKPISESHPILYFTNGHLVPTGSKSRVLLQNPPTVGVAATKLTDVHPSDTGYL 120
 DB 61 FVOPGKPISESHPILYFTNGHLVPTGSKSRVLLQNPPTVGVAATKLTDVHPSDTGYL 120
 QY 121 CQVNNPPDFYTNGLINLTNLVPPSNPLCSQSGQTSVGGSTALRCSSESSEGAPKPVYVNW 180
 DB 121 CQVNNPPDFYTNGLINLTNLVPPSNPLCSQSGQTSVGGSTALRCSSESSEGAPKPVYVNW 180
 QY 181 RLGTFFPTPSGSMVQDVSQGLITNLSSSTGYRCVATNMGASCELTLSVTSPSQ 240
 DB 181 RLGTFFPTPSGSMVQDVSQGLITNLSSSTGYRCVATNMGASCELTLSVTSPSQ 240
 QY 241 RVA 243
 DB 241 RVA 243

RESULT 10
 ABU82165
 ID ABU82165 standard; protein; 327 AA.

XX AC ABU82165;
 XX XX 25-JUN-2003 (first entry)
 XX DE Novel human secreted and transmembrane protein PRO7154.
 XX XX Human; secreted and transmembrane protein; PRO; cardiant; cytostatic;
 XX KW antiangiogenic; hypotensive; vulnenry; antiarteriosclerotic;
 XX KW gene therapy; cardiovascular disorder; endothelial disorder;
 XX KW angiogenic disorder; cardiac hypertrophy; trauma; cancer;
 XX KW age-related macular degeneration; atherosclerosis; hypertension;
 XX KW arterial restenosis; rheumatoid arthritis; angina; myocardial infarction;
 XX KW thrombophlebitis; lymphangitis; tumour angiogenesis; breast carcinoma;
 XX KW liver carcinoma; wound healing; chromosome mapping; gene mapping.
 XX OS Homo sapiens.
 XX XX US2003088063-A1.
 XX XX 08-MAY-2003.
 XX XX 12-AUG-2002; 2002US-00219003.
 XX XX 25-JUL-2000; 2000US-0220664P.
 XX PR 01-JUN-2001; 2001WO-US017800.
 XX PR 29-JUN-2001; 2001WO-US021066.
 XX PR 09-APR-2002; 2002US-00119480.
 XX XX (GETH) GENENTECH INC.
 XX XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski RJ;
 XX XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX XX WPI; 2003-393229/37.
 XX XX N-PSDB; ACA68614.
 XX XX One hundred and eighty seven nucleic acids encoding PRO polypeptides,
 XX useful in diagnosis and treatment of cardiovascular (e.g. myocardial
 XX infarction), endothelial or angiogenic disorders in a mammal.
 XX XX Claim 11; Fig 236; 314pp; English.
 XX XX The invention describes one hundred and eighty seven nucleic acids
 XX encoding novel human secreted and transmembrane (PRO) polypeptides. The
 XX PRO nucleic acids, polypeptides, agonists and antagonists are useful for
 XX treating or diagnosing a cardiovascular, endothelial or angiogenic
 XX disorder in a mammal, e.g. cardiac hypertrophy, trauma, cancer, age-
 XX related macular degeneration, atherosclerosis, hypertension, arterial
 XX restenosis, rheumatoid arthritis, angina, myocardial infarctions,
 XX thrombophlebitis, lymphangitis, tumour angiogenesis (such as breast
 XX carcinoma and liver carcinoma) and wound healing. The PRO nucleic acids
 XX have applications in molecular biology, including use as hybridisation
 XX probes, and in chromosome and gene mapping. This is the amino acid
 XX sequence of a novel human secreted and transmembrane PRO polypeptide
 XX Sequence 327 AA;
 XX
 XX Query Match 99.2%; Score 1277; DB 6; Length 327;
 XX Best Local Similarity 100.0%; Pred. No. 3.8e-84;
 XX Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MAELPGPFLCGALLGFLCLSGLAIVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSGLAIVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
 QY 61 FVOPGKPISESHPILYFTNGHLVPTGSKSRVLLQNPPTVGVAATKLTDVHPSDTGYL 120
 DB 61 FVOPGKPISESHPILYFTNGHLVPTGSKSRVLLQNPPTVGVAATKLTDVHPSDTGYL 120
 QY 121 CQVNNPPDFYTNGLINLTNLVPPSNPLCSQSGQTSVGGSTALRCSSESSEGAPKPVYVNW 180
 DB 121 CQVNNPPDFYTNGLINLTNLVPPSNPLCSQSGQTSVGGSTALRCSSESSEGAPKPVYVNW 180

Qy 1 MAELPGPFLCGALLGFLCLSGLAIVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAIVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Qy 61 FVQPGKPISESHPILYFTNGHLYPTGSKSKRVSLQLQNPPTVGVATLKLTDVHPDSDTGTYL 120
Db 61 FVQPGKPISESHPILYFTNGHLYPTGSKSKRVSLQLQNPPTVGVATLKLTDVHPDSDTGTYL 120
Qy 121 CQVNNPPDFYTNGLGLINLTVLPPSNPLCSQSQGTSVGGSTALRCSSEGAPKPVNVW 180
Db 121 CQVNNPPDFYTNGLGLINLTVLPPSNPLCSQSQGTSVGGSTALRCSSEGAPKPVNVW 180
Qy 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCCELLTSLVTPESQ 240
Db 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCCELLTSLVTPESQ 240
Qy 241 RVA 243
Db 241 RVA 243

RESULT 13
ABO34368
ID ABO34368 standard; protein; 327 AA.
XX
AC ABO34368;
XX
DT 19-SEP-2003 (first entry)
XX
DE Human secreted/transmembrane polypeptide PRO 7154.
XX

XX Human; chondrocyte stimulation; TNF-alpha stimulation; gene therapy;
KW human dermal fibroblast stimulation; tumour; tissue typing;
KW affinity purification.
XX
OS Homo sapiens.
XX

PN US2003044934-A1.
XX
PD 06-MAR-2003.
XX
PF 28-AUG-2002; 2002US-00230338.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH) GENENTECH INC.
XX

PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-492274/46.
DR N-PSDB; ACD82293.
XX

XX New transmembrane polypeptides and nucleic acids encoding the
PT polypeptides, useful in gene therapy, in chromosome identification, as
PT chromosome markers, or in generating probes.
XX
PS Claim 19; Fig 236; 315pp; English.
XX

XX The invention relates to an isolated nucleic acid encoding a PRO
CC polypeptide. Nucleic acids that encode PRO can be used to generate either
CC transgenic animals or knock-out animals useful in developing and
CC screening of therapeutically useful reagents. The nucleic acids may also
CC be used in gene therapy for replacing defective gene, in chromosome
CC identification, as chromosome markers, or in generating probes to isolate
CC full length PRO cDNA. The PRO polypeptides are useful for chondrocyte
CC stimulation, TNF-alpha stimulation, human dermal fibroblasts stimulation
CC and for detecting the presence of tumour in a mammal. The PRO
CC polypeptides are useful as molecular markers for protein electrophoresis
CC and the isolated nucleic acids may be used for recombinantly expressing
CC those markers. The PRO polypeptides and nucleic acids may also be used in

CC tissue typing. Anti-PRO antibodies are useful in diagnostic assays for
CC PRO and in affinity purification of PRO from recombinant cell culture or
CC natural sources. The present sequence represents the amino acid sequence
CC of a human secreted/transmembrane PRO polypeptide
XX
SQ Sequence 327 AA;

Query Match 99.2%; Score 1277; DB 6; Length 327;
Best Local Similarity 100.0%; Pred. No. 3.8e-84;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAELPGPFLCGALLGFLCLSGLAIVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAIVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Qy 61 FVQPGKPISESHPILYFTNGHLYPTGSKSKRVSLQLQNPPTVGVATLKLTDVHPDSDTGTYL 120
Db 61 FVQPGKPISESHPILYFTNGHLYPTGSKSKRVSLQLQNPPTVGVATLKLTDVHPDSDTGTYL 120
Qy 121 CQVNNPPDFYTNGLGLINLTVLPPSNPLCSQSQGTSVGGSTALRCSSEGAPKPVNVW 180
Db 121 CQVNNPPDFYTNGLGLINLTVLPPSNPLCSQSQGTSVGGSTALRCSSEGAPKPVNVW 180
Qy 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCCELLTSLVTPESQ 240
Db 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCCELLTSLVTPESQ 240
Qy 241 RVA 243
Db 241 RVA 243

RESULT 14
ABJ72175
ID ABJ72175 standard; protein; 327 AA.
XX
AC ABJ72175;
XX
DT 16-OCT-2003 (first entry)
XX
DE Human membrane bound receptor/protein PRO7154 amino acid sequence.
XX

XX Human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neurotrophic factor; hormone; cell receptor;
KW receptor-ligand interaction; cytoskeletal; chondrocyte; tumour.
XX

OS Homo sapiens.
XX
XX US2003065147-A1.
XX
XX 03-APR-2003.
XX
XX 29-AUG-2002; 2002US-00232224.
XX
XX 28-JUL-1999; 99US-0146222P.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-522018/49.
DR N-PSDB; AB743999.
XX

XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful for the manufacture of a medicament for diagnosing or treating

PT tumor.
XX Claim 11; Fig 236; 315pp; English.
XX
XX This invention relates to one hundred and twenty two novel nucleic acids
CC encoding human PRO membrane bound proteins or receptors. Extracellular
CC proteins play important roles in the formation, differentiation and
CC maintenance of multicellular organisms. The fate of many individual cells
CC (for example proliferation, migration or differentiation) is typically
CC governed by information received from other cells and the immediate
CC environment. The information is often transmitted by secreted
CC polypeptides (for example mitogenic factors, survival factors, cytotoxic
CC factors, differentiation factors, neuropeptides and hormones) which are
CC received and interpreted by diverse cell receptors or membrane bound
CC proteins. These membrane bound proteins and receptors may be of use as
CC pharmaceutical and diagnostic agents, such as in the blocking of receptor
CC -ligand interactions. The current invention provides the amino acid
CC sequences of novel human membrane bound receptors and proteins, along
CC with the cDNA sequences encoding them. The novel proteins of the
CC invention may have cytostatic activities through the stimulation of
CC chondrocytes. The nucleic acids of the invention may be useful for the
CC manufacture of a medicament for diagnosing or treating a tumour in a
CC mammal. In addition, they may be useful for measuring or detecting the
CC expression of a tumour associated gene. The present sequence is the amino
CC acid sequence of a human PRO protein of the invention
XX
SQ

Query Match 99.2%; Score 1277; DB 7; Length 327;
Best Local Similarity 100.0%; Pred. No. 3.8e-84;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGFFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGFFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISESHPILYFTNGHLVPTGSKSRVSLQLQNPPTVGATVATKLTIDVHPSDTGYL 120
Db 61 FVQPGKPISESHPILYFTNGHLVPTGSKSRVSLQLQNPPTVGATVATKLTIDVHPSDTGYL 120
QY 121 CQVNNPDEFYTNGLGILNLTVPNPNLCSQSGQTSVGGSTALRCSSEGAKPKVYNNV 180
Db 121 CQVNNPDEFYTNGLGILNLTVPNPNLCSQSGQTSVGGSTALRCSSEGAKPKVYNNV 180
QY 181 RLCTFTPTSPGSMVQDEVSGQLITLNLSTSSGTYRCVATNQMSASCELTLTSVTFPSQ 240
Db 181 RLCTFTPTSPGSMVQDEVSGQLITLNLSTSSGTYRCVATNQMSASCELTLTSVTFPSQ 240
QY 241 RVA 243
Db 241 RVA 243

RESULT 15
ADB83726
ID ADB83726 standard; protein; 327 AA.
XX
AC ADB83726;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO7154.
XX
KW human; secreted and transmembrane protein; PRO; cytostatic; vulnery;
KW antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX

OS Homo sapiens.
XX US2003073814-A1.
PN
XX 17-APR-2003.
PD
XX 12-AUG-2002; 2002US-00218849.
PF
XX 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
PR
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Guerny AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
PI
XX WPI; 2003-644806/61.
DR N-PSDB; ADB83725.
DR
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
XX in gene therapy, chromosome identification, tissue typing, or as
XX hybridization probes in chromosome and gene mapping.
XX
XX Claim 11; Fig 236; 315pp; English.
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF) -
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080.
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567,
CC PRO1887, PRO1928, PRO1341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This is the amino acid sequence of a human secreted and
CC transmembrane PRO polypeptide.
XX
SQ

Sequence 327 AA;
Query Match 99.2%; Score 1277; DB 7; Length 327;
Best Local Similarity 100.0%; Pred. No. 3.8e-84;
Matches 243; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAELPGFFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGFFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISESHPILYFTNGHLVPTGSKSRVSLQLQNPPTVGATVATKLTIDVHPSDTGYL 120

[illegible]

Search completed: August 4, 2005, 06:07:07
Job time : 76.0264 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 4, 2005, 05:56:06 ; Search time 89.5513 Seconds
(without alignments)
1852.722 Million cell updates/sec

Title: US-10-607-565-60_COPY_4_327

Perfect score: 1685

Sequence: 1 LPGPFLCGALLGLCLSLA.....ERPSSASTVTTTKSLPMV 324

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : UniProt_03.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1677	99.5	327	2	Q96107
2	1632	96.9	325	2	Q95791
3	1462	86.8	284	2	Q9N442
4	1309	77.7	328	2	Q92109
5	1305	77.4	304	2	Q9CV44
6	988	58.6	248	2	Q9D0T4
7	408.5	24.2	387	2	Q86XK7
8	408.5	24.2	412	2	Q6MZS4
9	399	23.7	259	2	Q7Z2Q1
10	392	23.3	430	2	Q8N4F1
11	389.5	23.1	407	2	Q8D2J4
12	359	21.3	432	2	Q6DD57
13	358.5	21.3	318	2	Q91664
14	355	21.1	335	2	Q9PWR4
15	352	20.9	335	2	Q9YGH1
16	347	20.6	335	2	Q9YGV5
17	343	20.4	372	2	Q90V50
18	338	20.1	323	2	Q8ND02
19	334.5	19.9	319	2	Q9TU80
20	331.5	19.7	352	2	Q91W66
21	331.5	19.7	365	1	CKAR MOUSE
22	331.5	19.7	365	2	Q9DBJ8
23	328.5	19.5	390	2	Q95K13
24	324.5	19.3	394	2	Q95K13
25	322	19.1	365	2	Q8WMV3
26	319.5	19.0	300	2	Q9D9J0
27	319.5	19.0	319	2	Q9TU79
28	319.5	19.0	344	2	Q9R067
29	319.5	19.0	358	2	Q9R066
30	318.5	18.9	390	2	Q96AP7
31	318.5	18.9	390	2	Q96T50

RESULT 1
Q961Q7 Q961Q7 PRELIMINARY; PRT; 327 AA.
AC Q961Q7;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE V-set and immunoglobulin domain containing 2 (CTH Variant).
GN Name=VSIQ2; ORFName=UNQ2770;
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Theria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Colon;
RX MEDLINE=42386257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Scapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.B.,
RA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahney J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smalusz D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Colon;
RL Director MGC Project;
RL Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=22887296; PubMed=12975309; DOI=10.1101/gr.1293003;
RA Clark H.F., Gurney A.L., Abaya E., Baker K., Balgwin D., Brush J.,
RA Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA Eaton D., Foster J., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA Lewis L., Liao D., Mark M., Robbie E., Sanchez C., Schoenfeld J.,
RA Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA Vandlen R., Watanabe C., Wieand D., Woods K., Xie M.H., Yansura D.,
RA Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A., Wood W.I.,
RA Godowski P.;

ALIGNMENTS

32 317 18.8 394 2 Q6AYD4
33 316.5 18.8 300 2 Q9DA22
34 316 18.8 406 2 Q8N7T8
35 312.5 18.5 344 2 Q9UKV4
36 312.5 18.5 365 1 CXAR_HUMAN
37 307 18.2 298 2 Q804R4
38 307 18.2 319 1 A33_HUMAN
39 306.5 18.2 373 2 Q9H6B4
40 302.5 18.0 372 2 Q8K1G0
41 300.5 17.8 373 2 Q8R373
42 300 17.8 319 1 A33_MOUSE
43 298 17.7 442 2 Q6N888
44 296.5 17.6 373 2 Q920S5
45 294 17.4 332 2 Q640U3

Q6ayd4 rattus norv
Q9da22 mus musculu
Q8n7t8 homo sapien
Q9ukv4 homo sapien
P78310 homo sapien
Q804r4 brachydanio
Q99795 homo sapien
Q9h6b4 homo sapien
Q8k1g0 rattus norv
Q8r373 mus musculu
Q9jka5 mus musculu
Q6n888 brachydanio
Q920s5 mus musculu
Q640u3 xenopus tro

RT "The secreted protein discovery initiative (SPDI), a large-scale
 RT effort to identify novel human secreted and transmembrane proteins: a
 RT bioinformatics assessment.";
 RL Genome Res. 13:2265-2270(2003).
 DR ENBL; BC007313; AA070313.1; -.
 DR ENBL; AV358897; AA089256.1; -.
 DR HSP; O88792; I197.
 DR GO; GO:0004872; F:receptor activity; IEA.
 DR InterPro; IPR007110; Ig-like.
 DR Pfam; PF00047; Ig; 1.
 DR PROSITE; PS50835; IG_LIKE; 2.
 SQ SEQUENCE 327 AA; 34348 MW; CF395AC7EF951AC1 CRC64;

Query Match 99.5%; Score 1677; DB 2; Length 327;
 Best Local Similarity 99.7%; Pred. No. 1.9e-109;
 Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 LPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
 DB 4 LPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
 QY 61 PGKPISSEHPILYFTNGHLYPTGSKSRVLLQNPPPTVGATLKLTDVHPSDGTGYLCQV 120
 DB 64 PGKPISSEHPILYFTNGHLYPTGSKSRVLLQNPPPTVGATLKLTDVHPSDGTGYLCQV 123
 QY 121 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRLG 180
 DB 124 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRLG 183
 QY 181 TPTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLTSTVTEPPQGRVA 240
 DB 184 TPTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLTSTVTEPPQGRVA 243
 QY 241 GALIGVLLGVLLLSVAACLVRFQKRGKKPKETYGGSDLRDAIAPGISEHTCMRADSS 300
 DB 244 GALIGVLLGVLLLSVAACLVRFQKRGKKPKETYGGSDLRDAIAPGISEHTCMRADSS 303
 QY 301 KGFLERPSSASTVTTTKSKLPMVV 324
 DB 304 KGFLERPSSASTVTTTKSKLPMVV 327

RESULT 2

O95791 PRELIMINARY; PRT; 325 AA.
 AC O95791;
 DT 01-MAY-1999 (TrEMBLrel. 10, Created)
 DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE CTH.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=99077161; PubMed=9862345;
 RX DOI=10.1002/(SICI)1521-4141(199812)28:12<4094::AID-IMMU4094>3.3.CO;2-U;
 RA Chretien I., Marcuz A., Courtet M., Katevuo K., Vainio O., Heath J.K.,
 RA White S.J., Du Pasquier L.;
 RT "CTX, a Xenopus thymocyte receptor, defines a molecular family
 RT conserved throughout vertebrates.";
 RL Eur. J. Immunol. 28:4094-4104(1998).
 DR ENBL; AF061022; AAD17522.1; -.
 DR HSP; O88792; I197.
 DR GO; GO:0005887; C:integral to plasma membrane; TAS.
 DR GO; GO:0005624; C:membrane fraction; TAS.
 DR InterPro; IPR007110; Ig-like.
 DR Pfam; PF00047; Ig; 1.
 DR SMART; SM00408; IGC2; 1.
 DR PROSITE; PS50835; IG_LIKE; 2.
 SQ SEQUENCE 325 AA; 34239 MW; B7B5B664CBCEFF4BB CRC64;

Query Match 96.9%; Score 1632; DB 2; Length 325;
 Best Local Similarity 97.8%; Pred. No. 2.7e-106;
 Matches 317; Conservative 2; Mismatches 3; Indels 2; Gaps 2;
 QY 1 LPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
 DB 4 LPGPFLCGALLGFLCLX-LAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDTFALEWSFVQ 62
 QY 61 PGKPISSEHPILYFTNGHLYPTGSKSRVLLQNPPPTVGATLKLTDVHPSDGTGYLCQV 120
 DB 63 PGKPISSEHPILYFTNGHLYPTGSKSRVLLQNPPPTVGATLKLTDVHPSDGTGYLCQV 122
 QY 121 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRLG 180
 DB 123 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRLG 182
 QY 181 TPTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLTSTVTEPPQGRVA 240
 DB 183 TPTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASCELTLTSTVTEPPQGRVT 242
 QY 241 GALIGVLLGVLLLSVAACLVRFQKRGKKPKETYGGSDLRDAIAPGISEHTCMRADSS 300
 DB 243 GALIGVLLGVLLLSVAACLVRFQKRGKKPKETYGGSDLRDAIAPGISEHTCMRADSS 302
 QY 301 KGFLERPSSASTVTTTKSKLPMVV 324
 DB 303 KGFLERP-SASTVTTTKSKLPMVV 325

RESULT 3

O9NX42 PRELIMINARY; PRT; 284 AA.
 ID O9NX42
 AC O9NX42;
 DT 01-OCT-2000 (TrEMBLrel. 15, Created)
 DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Hypothetical protein FLJ20453.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Watanabe K., Kumagai A., Itakura S., Yamazaki M., Tashiro H., Ota T.,
 RA Suzuki Y., Obayashi M., Nishi T., Shibahara T., Tanaka T.,
 RA Nakamura Y., Isogai T., Sugano S.;
 RL Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.
 DR ENBL; AK000460; BA91179.1; -.
 DR HSP; O88792; I197.
 DR InterPro; IPR007110; Ig-like.
 DR InterPro; IPR003598; Ig_c2.
 DR Pfam; PF00047; Ig; 1.
 DR SMART; SM00408; IGC2; 1.
 DR PROSITE; PS50835; IG_LIKE; 2.
 SQ SEQUENCE 284 AA; 29829 MW; 1F9E09C60856B9A9 CRC64;

Query Match 86.8%; Score 1462; DB 2; Length 284;
 Best Local Similarity 99.6%; Pred. No. 1.8e-94;
 Matches 280; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 LPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
 DB 4 LPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
 QY 61 PGKPISSEHPILYFTNGHLYPTGSKSRVLLQNPPPTVGATLKLTDVHPSDGTGYLCQV 120
 DB 64 PGKPISSEHPILYFTNGHLYPTGSKSRVLLQNPPPTVGATLKLTDVHPSDGTGYLCQV 123
 QY 121 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRLG 180
 DB 124 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRLG 183

```
Qy 181 TPTPTSPGSMVQDVEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPPQGRVA 240
Db 184 TPTPTSPGSMVQDVEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPPQGRVA 243
Qy 241 GALIGVLLGVLLSVAACLVRFKRGKPKETVGGSDLR 281
Db 244 GALIGVLLGVLLSVAACLVRFKRGKPKETVGGSDLR 284

RESULT 4
Q92109 PRELIMINARY; PRT; 328 AA.
AC Q92109;
DT 01-MAY-1999 (TrEMBLrel. 10, Created)
DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE CTM.
GN Name=2210413P10Rik;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=99077161; PubMed=9862345;
RX DOI=10.1002/(SICI)1521-4141(199812)28:12<4094::AID-IMMU4094>3.3.CO;2-U;
RA Chretien I., Marcuz A., Courtet M., Katevuo K., Vainio O., Heath J.K.,
RA White S.J., Du Pasquier L.;
RT "CTX, a Xenopus thymocyte receptor, defines a molecular family
RT conserved throughout vertebrates.";
RL Eur. J. Immunol. 28:4094-4104 (1998).
DR HSP; O88792.1F97.
DR MGD; MGI:1928009; 2210413P10Rik.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_V.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IgV; 1.
DR PROSITE; PS00835; IG LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 1.
SQ SEQUENCE 328 AA; 34258 MW; 0DA4C7BP7E221255 CRC64;

Query Match 77.7%; Score 1309; DB 2; Length 328;
Best Local Similarity 79.0%; Pred. No. 1.1e-83;
Matches 256; Conservative 19; Mismatches 49; Indels 0; Gaps 0;

Qy 1 LPGAFLCALGFLCLSGLAVEVKVPTPELSTPIGKTAELTCTYSTVSGDSFALEWSFVQ 60
Db 5 LVGAFLCGHLGFLGFLCLSGLAVEVTPTEPLSVPRGKTAELSCSYKTSVGNFALEWSFVQ 64
Qy 61 PGKPISESHPILYFTNGHLYPTGSKRVSLQNPPTVGATLKLTDVHPSDTGYLCOV 120
Db 65 PGKPIASVPLVLYFTNGHLYPTGSKADRALLLHDPPTGGATLKLTLDRSDTGYLCNV 124
Qy 121 NNPDFFTYNGLGLINLTVLPSPNPLCSQSGOTSVGGSTALRCSSSGAPKPVNVNRLG 180
Db 125 NNPDFFTYNGLGLINLTVLPSPNPLCSQSGOTLVGSSAALGCRSSGAPKPVNVNRLC 184
Qy 181 TPTPTSPGSMVQDVEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLSTVTEPPQGRVA 240
Db 185 SSPTPTSPGSMVQDVEVSGQLILTNLSLTSSGTYRCVASHQMGASCELNLSTVSDSGRVA 244
Qy 241 GALIGVLLGVLLSVAACLVRFKRGKPKETVGGSDLRDIAFGISEHTCMRADSS 300
Db 245 GTLIGVLLGVLLSVAACLVRFKRGKPKETVGGSDLRDIAFGISEHTCMRADSS 304
Qy 301 KGLERPSASTVTTTKSKLPMVV 324
Db 305 KELLEKSPCASMTPTKSLSMVV 328

RESULT 5
```

```
Q9CVA4 PRELIMINARY; PRT; 304 AA.
AC Q9CVA4;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Mus musculus adult male stomach cDNA, RIKEN full-length enriched
DE library, clone:2210413P10 product:CTM homolog (Fragment).
GN Name=2210413P10Rik;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN=C57BL/6J; TISSUE=Stomach;
RX MEDLINE=99279253; PubMed=10349636; DOI=10.1016/S0076-6879(99)03004-9;
RX Carninci P., Hayashizaki Y.;
RX "High-efficiency full-length cDNA cloning.";
RX Meth. Enzymol. 303:19-44 (1999).
RN [2]
RP SEQUENCE FROM N.A.
RX STRAIN=C57BL/6J; TISSUE=Stomach;
RX MEDLINE=21085660; PubMed=11217851; DOI=10.1038/35055500;
RX RIKEN FANTOM Consortium;
RX "Functional annotation of a full-length mouse cDNA collection.";
RX Nature 409:685-690 (2001).
RN [3]
RP SEQUENCE FROM N.A.
RX STRAIN=C57BL/6J; TISSUE=Stomach;
RX MEDLINE=20499374; PubMed=11042159; DOI=10.1101/gr.145100;
RX Carninci P., Shibata Y., Hayatsu N., Sugahara Y., Shibata K., Itoh M.,
RX Konno H., Okazaki Y., Muramatsu M., Hayashizaki Y.;
RX "Normalization and subtraction of cap-trapper-selected cDNAs to
RX prepare full-length cDNA libraries for rapid discovery of new genes.";
RX Genome Res. 10:1617-1630 (2000).
RN [5]
RP SEQUENCE FROM N.A.
RX STRAIN=C57BL/6J; TISSUE=Stomach;
RX MEDLINE=20530913; PubMed=11076861; DOI=10.1101/gr.152600;
RX Shibata K., Itoh M., Aizawa K., Nagao K., Kitaunai T., Tashiro H., Itoh M.,
RX Konno H., Akiyama J., Nishi K., Hazama M., Nishine T., Harada A.,
RX Sumi N., Ishii Y., Nakamura S., Sakaguchi S., Ikegami T., Kashiwagi K.,
RX Yamamoto R., Matsumoto H., Togawa Y., Izawa M., Ohara E., Wataniki M.,
RX Yoneda Y., Ishikawa T., Ozawa K., Tanaka T., Matsuura S., Kawai J.,
RX Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;
RX "RIKEN integrated sequence analysis (RISA) system-384-format
RX sequencing pipeline with 384 multicapillary sequencer.";
RX Genome Res. 10:1757-1771 (2000).
RN [6]
RP SEQUENCE FROM N.A.
RX STRAIN=C57BL/6J; TISSUE=Stomach;
RX Adachi J., Aizawa K., Akahira S., Akimura T., Arai A., Aono H.,
RX Arakawa T., Bono H., Carninci P., Fukuda S., Fukunishi Y., Furuno M.,
RX Hanagaki T., Hara A., Hayatsu N., Hiramoto K., Hiraoka T., Horii F.,
RX Inotani K., Ishii Y., Itoh M., Izawa M., Kasukawa T., Kato H.,
RX Kawai J., Kojima Y., Konno H., Kouda M., Koya S., Kurihara C.,
RX Matsuyama T., Miyazaki A., Nishi K., Nomura K., Numazaki R., Ohno M.,
RX Okazaki Y., Okido T., Owa C., Saito H., Saito R., Sakai C., Sakai K.,
RX Sano H., Sasaki D., Shibata K., Shibata Y., Shinagawa A., Shiraki T.,
RX Sogabe Y., Suzuki T., Tagami M., Tanaka T., Takahashi F., Tanaka T.,
RX Tejima Y., Toya T., Yamamura T., Yasunishi A., Yoshida K., Yoshino M.,
RX Muramatsu M., Hayashizaki Y.;
RX Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.
```

```
DR EMBL; AK008920; BAB25968.1; -.
DR HSSP; O88792; 1F97.
DR MGD; MGI:1928009; 2210413P10Rik.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF00047; ig; 1.
DR SMART; SM00406; IG; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
FT NON TER 304
SQ SEQUENCE 304 AA; 31919 MW; 522BA38898AD7A9F CRC64;

Query Match 77.4%; Score 1305; DB 2; Length 304;
Best Local Similarity 83.3%; Pred. No. 1.9e-83;
Matches 250; Conservative 17; Mismatches 33; Indels 0; Gaps 0;

QY 1 LQPFPLCGALLGFLCLSGLAVEVKVPTPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 60
Db 5 LVGAFLCGHLHGFVCLSGLAVEVTPTPLSVPGKTAELSCYKTSVGDNFALEWSFVQ 64

QY 61 PGKPISSEHPILYFTNGHLYPTGSKSRVSLQLQNPPTVGATLKLTVDHPSDTGTYLCOV 120
Db 65 PGKPISASVPVLYFTNGHLYPTGSKADRAILLHDPTTGGTLATLKLTDLRPSDTGTLYCNV 124

QY 121 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGTSTALRCSSEGAPKPYNNWRVLG 180
Db 125 NNPPDFYTNGLGLINLTVLVPPSHPLCSQSGTSTVSGSAALGCRSSEGAPKPYNNWERLG 184

QY 181 TPPTSPGSMVQDEVSGQLILTNLSLTSSGTGYRCVATNMGSAALGCRSSEGAPKPYNNWRVLG 240
Db 185 SSPTPPGSMVQDEVSGQLILTNLSLTSSGTGYRCVATNMGSAALGCRSSEGAPKPYNNWRVLG 244

QY 241 GALIGVLLGVLLSVAACFLVRPQKRGKKPKETYGSGDLREDALAPGISEHTCMRADSS 300
Db 245 GTLIGVLLGVLLSVAACFLVRPQKRGKKPKETYGSGDLREDATAPGVFEQASMRADHS 304

RESULT 6
Q9D0T4 PRELIMINARY; PRT; 248 AA.
AC Q9D0T4;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Mus musculus 18-day embryo whole body cDNA, RIKEN full-length enriched
DE library, clone:1190004B15 product:CTM homolog.
GN Name=2210413P10Rik;
OS Mus musculus (Mouse);
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Whole body;
RX MEDLINE=927253; PubMed=10349636; DOI=10.1016/S0076-6879(99)03004-9;
RA Carninci P., Hayashizaki Y.;
RT "High-efficiency full-length cDNA cloning.";
RL Meth. Enzymol. 303:19-44 (1999).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Whole body;
RX MEDLINE=21085660; PubMed=11217851; DOI=10.1038/35055500;
RA RIKEN FANTOM Consortium;
RT "Functional annotation of a full-length mouse cDNA collection.";
RL Nature 409:685-690 (2001).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Whole body;
RA The FANTOM Consortium;
RA the RIKEN Genome Exploration Research Group Phase I & II Team;
RT "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs.";
RL Nature 420:563-573 (2002).
RN [4]
```

```
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Whole body;
RX MEDLINE=20499374; PubMed=11042159; DOI=10.1101/gr.145100;
RA Carninci P., Shibata Y., Hayatsu N., Sugahara Y., Shibata K., Itoh M.,
RA Konno H., Okazaki Y., Muramatsu M., Hayashizaki Y.;
RT "Normalization and subtraction of cap-trapper-selected cDNAs to
RT prepare full-length cDNA libraries for rapid discovery of new genes.";
RL Genome Res. 10:1617-1630 (2000).
RN [5]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Whole body;
RX MEDLINE=20530913; PubMed=11076861; DOI=10.1101/gr.152600;
RA Shibata K., Itoh M., Aizawa K., Nagaoka S., Sasaki N., Carninci P.,
RA Konno H., Akiyama J., Nishi K., Kitsuai T., Tashiro H., Itoh M.,
RA Sumi N., Ishii Y., Nakamura S., Hazama M., Nishine T., Harada A.,
RA Yamamoto R., Matsumoto H., Sakaguchi S., Ikegami T., Kashiwagi K.,
RA Fujiwaka S., Inoue K., Togawa Y., Izawa M., Ohara E., Watahiki M.,
RA Oneda Y., Ishikawa T., Ozawa K., Tanaka T., Matsuura S., Kawai J.,
RA Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;
RT "RIKEN integrated sequence analysis (RISA) system-384-format
RT sequencing pipeline with 384 multicapillary sequencer.";
RL Genome Res. 10:1757-1771 (2000).
RN [6]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Whole body;
RA Adachi J., Aizawa K., Akahira S., Akimura T., Arai A., Aono H.,
RA Arakawa T., Bono H., Carninci P., Fukuda S., Fukunishi Y., Furuno M.,
RA Hanagaki T., Hara A., Hayatsu N., Hiramoto K., Hiraoka T., Hori F.,
RA Imotani K., Ishii Y., Itoh M., Izawa M., Kasukawa T., Kato H.,
RA Kawai J., Kojima Y., Komori H., Kouda M., Koya S., Kurihara C.,
RA Matsuura T., Miyazaki A., Nishi K., Nomura K., Numazaki R., Ohno M.,
RA Okazaki Y., Okido T., Owa C., Saito H., Saito R., Sakai C., Sakai K.,
RA Sano H., Sasaki D., Shibata K., Shibata Y., Shinagawa A., Shiraki T.,
RA Sogabe Y., Suzuki H., Tagami M., Tagawa A., Takahashi F., Tanaka T.,
RA Tejima Y., Toyota T., Yamamura T., Yasunishi A., Yoshida K., Yoshino M.,
RA Muramatsu M., Hayashizaki Y.;
RL Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK004478; BAB23323.1; -.
DR HSSP; O88792; 1F97.
DR MGD; MGI:1928009; 2210413P10Rik.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003598; IG_c2.
DR Pfam; PF00047; ig; 1.
DR SMART; SM00408; IGC2; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
SQ SEQUENCE 248 AA; 26061 MW; 3146D8F85BD3BD81 CRC64;

Query Match 58.6%; Score 988; DB 2; Length 248;
Best Local Similarity 62.3%; Pred. No. 2.3e-61;
Matches 202; Conservative 14; Mismatches 28; Indels 80; Gaps 1;

QY 1 LQPFPLCGALLGFLCLSGLAVEVKVPTPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 60
Db 5 LVGAFLCGHLHGFVCLSG- 22

QY 61 PGKPISSEHPILYFTNGHLYPTGSKSRVSLQLQNPPTVGATLKLTVDHPSDTGTYLCOV 120
Db 23 - 44

QY 121 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGTSTALRCSSEGAPKPYNNWRVLG 180
Db 45 NNPPDFYTNGLGLINLTVLVPPSHPLCSQSGTSTVSGSAALGCRSSEGAPKPYNNWERLG 104

QY 181 TPPTSPGSMVQDEVSGQLILTNLSLTSSGTGYRCVATNMGSAALGCRSSEGAPKPYNNWRVLG 240
Db 105 SSPTPPGSMVQDEVSGQLILTNLSLTSSGTGYRCVATNMGSAALGCRSSEGAPKPYNNWRVLG 164

QY 241 GALIGVLLGVLLSVAACFLVRPQKRGKKPKETYGSGDLREDALAPGISEHTCMRADSS 300
Db 165 GTLIGVLLGVLLSVAACFLVRPQKRGKKPKETYGSGDLREDATAPGVFEQASMRADHS 224

QY 301 KGFLERPSSASVTVTTKSKLPVWV 324
```

QY 13 FLCISGLA-----VEKVPTEPLSTPLGKTAELICTYSTSVG--DSFALEWSFVQPGKPI 65

```
Db 207 IVPKRNFP--NPTTGLVIGLNTNFQGYQCTAINRLGNSCEIDLTSSHPVEVGIIGA 264
QY 243 LIGVLGLVLLSVAAPCLVRFO-----KERGKK 270
Db 265 LIGSLVGAII-ISVVCFARNKAKAKERNK 296

RESULT 9
ID Q722Q1 PRELIMINARY; PRT; 259 AA.
AC Q722Q1;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE DJ889N15.1 (Novel protein similar to X. laevis Cortical Thymocyte
DE Marker CTX) (Fragment).
GN Name=dJ889N15.1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Graham D.;
RL Submitted (JUN-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AL031177; CAA20116.1; -.
DR HSSP; O88792; 1P97.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003598; Ig_c2.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00408; Igc2; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
FT NON_TER 1
FT NON_TER 259
SQ SEQUENCE 259 AA; 27813 MW; 66B729303B9A6B18 CRC64;

Query Match 23.7%; Score 399; DB 2; Length 259;
Best Local Similarity 34.2%; Pred. No. 4e-20;
Matches 89; Conservative 54; Mismatches 97; Indels 20; Gaps 9;

QY 21 VEKVTPELSTPLGKTAELTCTYSTSVG--DSFALEWSFVQPKPISSHPI-LYPT-N 76
Db 5 VQVTIPDGFVNVVGSNVTLICITYTTTASREQLSIQWSPFHK----KEMEPISYFSQ 60
QY 77 GHLYPTGSKSKVSLQLQNPPTGVATLKLTDVHPSTGTGLCOVNNPPDFTYNGLGILN 136
Db 61 GQAVAGQFQKDRITGNDP---GNASITSHMQPADSGIYICDVNNPPDFLGQNGILNV 117
QY 137 TVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRL-GTFPTSPGSMVQDEV 195
Db 118 SVLVKPSKPLCSVQGRPETGHTISLCLSLALGTSPVYVHKLGRDIVPVKENF--NPT 175
QY 196 SGQILTLNLSLTSSGYRCVATNMQSGASCELTLSTVTEPPQGRVAGALIGVLGLVLSV 255
Db 176 TGILVIGLNTNFQGYQCTAINRLGNSCEIDLTSSHPVEVGIIVGALISLVGAII-I 234
QY 256 AAFCLVRFO-----KERGKK 270
Db 235 SVVCFARNKAKAKERNK 254

RESULT 10
Q8N4F1 PRELIMINARY; PRT; 430 AA.
ID Q8N4F1
AC Q8N4F1;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Brain and testis-specific immunoglobulin superfamily protein.
GN Name=IGSF11;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```

```
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Strausberg R.L.;
RC TISSUE=Brain;
RX MEDLINE=22386257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.P., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RA Strausberg R.;
RC TISSUE=Brain;
RX Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC034411; AAH34411.1; -.
DR HSSP; P78310; 1EAJ.
DR Genew; HGNC:16669; IGSF11.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003598; Ig_c2.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00408; Igc2; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
SQ SEQUENCE 430 AA; 46245 MW; E53FC71BC10D049D CRC64;

Query Match 23.3%; Score 392; DB 2; Length 430;
Best Local Similarity 32.6%; Pred. No. 2.2e-19;
Matches 105; Conservative 57; Mismatches 132; Indels 28; Gaps 13;

QY 10 LLGFCLLS--GLAVEVKVPTPEP--LSTPLGKTAELTCTYSTSVG--DSFALEWSFVQPKP 64
Db 7 LLWNCFSTRGTVAASLEVSSESGSQVARGQTAVLECTTTSNALINLVIV-MVTPLSN 65
QY 65 ISSEHPILYFTNGHLYPTGSK-SKRVSLQLQNPPTGVATLKLTDVHPSTGTGLCOVNNP 123
Db 66 ANQPEQVILYQGGQMPDGPAPRFGHGVGTGTPATNV-SIFINNTQLSDTGTQCLVNNL 124
QY 124 PPFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFP 183
Db 125 PDIGGRNIGVTGLTVLPSPAPHCQIQGSQDQIGSDVILLCSSSEGIPTPTLWEKLDN-T 183
QY 184 TSPSGSMVQDEVSGQILTLNLSLTSSGYRCVATNMQSGASCELTLSTVTEP-PQ--GRVA 240
Db 184 LKLPPTATQDQVQGTVTIRNISALSSGLYQCVASNAIGTSTCLLDLOVISPQPNIGLIA 243
QY 241 GALIG----VLGLVLLSVAAPCLVRFOKRGKPKETYGSGDLRDEDAIAPGISEHTCMR 296
Db 244 GA-IGTGAVIIIFCIALILGAF--YMRSKNKEEEEEIPNEIREDDLPP-----K 291
QY 297 ADSKGFLEPSPASIVTTTKS 318
Db 292 CSSAKAFHTEISSDNDNTLTSS 313

RESULT 11
Q9D2J4 PRELIMINARY; PRT; 407 AA.
ID Q9D2J4
```



```
DR PROSITE; PS50835; IG_LIKE; 2.
KW Signal.
FT SIGNAL 1 21 Potential.
FT CHAIN 22 335 Cht1 thymocyte antigen.
SQ SEQUENCE 335 AA; 36509 MW; AA6159598079B438 CRC64;

Query Match 21.1%; Score 355; DB 2; Length 335;
Best Local Similarity 32.1%; Pred. No. 6.4e-17;
Matches 86; Conservative 52; Mismatches 116; Indels 14; Gaps 6;

QY 13 FLCISGLA-----VEVKVPTPEPLSTPLGKTAELTCTYSTS--VGDSFALEWSFVQPKPI 65
DB 9 FPIATLAGHVGVVTVPEKTVNKGATLLCTYTSSQPLG-NFFIQWSFYSAKE-- 65

QY 66 SESHPILYFTNGHLIPTGSKSRVSLQNPPTGVGATLKLTDVHPSDTGTLYLCQVNNPPD 125
DB 66 SOLHTIYYSEGQSYSGEFGKDRITAATSP---GNASITISNMQPSDTGSGTCEVFSPOD 122

QY 126 FYTNGGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTP 185
DB 123 DAGOSQKSVIVNVLVPSKPKFKIEGTPKGHLYLLCKCDQGLPHPTIRYWKVDE-NTL 181

QY 186 SPGSMVQDEVSGQLILNLSTSSGTYRCVATNMGASCELTLTSTVTEPPQGRVAGALIG 245
DB 182 TPVTEYFNPDGTGILYIGNLTFTFETGHYRCIASNMGNSCTCELDLTSMHSDGNI VAGALIG 241

QY 246 VLGVLVLLSVAAFCLVRFQKRGKKPK 273
DB 242 AILAAVLIICAVVWLTKKAKKKSSSNE 269

RESULT 15
QYVGH1 ID QYVGH1 PRELIMINARY; PRT; 335 AA.
AC QYVGH1;
DT 01-MAY-1999 (TrEMBLrel. 10, Created)
DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Cht1 thymocyte antigen precursor.
GN Name=Cht1;
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=RPRL line 0; TISSUE=Thymus;
RA Katevuo K.H., Boyd R., Gobel T.T., Bean A., Dunon D., Imhof B.A.,
RA Vainio O.;
RL Submitted (JUN-1997) to the EMBL/GenBank/DBJ databases.
DR EMBL; Y14063; CAA74390.1; -.
DR HSSP; P78310; IKAC.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF00047; Ig; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
KW Signal.
FT SIGNAL 1 21 Potential.
FT CHAIN 22 335 Cht1 thymocyte antigen.
SQ SEQUENCE 335 AA; 36553 MW; AA640C5CD02CB16D CRC64;

Query Match 20.9%; Score 352; DB 2; Length 335;
Best Local Similarity 32.1%; Pred. No. 1e-16;
Matches 86; Conservative 52; Mismatches 116; Indels 14; Gaps 6;

QY 13 FLCISGLA-----VEVKVPTPEPLSTPLGKTAELTCTYSTS--VGDSFALEWSFVQPKPI 65
DB 9 FPIATLAGHVGVVTVPEKTVNKGATLLCTYTSSQPLG-NFFIQWSFYSAKE-- 65

QY 66 SESHPILYFTNGHLIPTGSKSRVSLQNPPTGVGATLKLTDVHPSDTGTLYLCQVNNPPD 125
DB 66 SOLHTIYYSEGQSYSGEFGKDRITAATSP---GNASITISNMQPSDTGSGTCEVFSPOD 122
```

```
Db 66 SOLHTIYYSEGQSYSGEFGKDRITAATSP---GNASITISNMQPSDTGSGTCEVFSPOD 122
QY 126 FYTNGGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNNVRLGTFPTP 185
DB 123 DAGOSQKSVIVNVLVPSKPKFKIEGTPKGHLYLLCKCDQGLPHPTIRYWKVDE-NTL 181
QY 186 SPGSMVQDEVSGQLILNLSTSSGTYRCVATNMGASCELTLTSTVTEPPQGRVAGALIG 245
DB 182 TPVTEYFNPDGTGILYIGNLTFTFETGHYRCIASNMGNSCTCELDLTSMHSDGNI VAGALIG 241
QY 246 VLGVLVLLSVAAFCLVRFQKRGKKPK 273
DB 242 AILAAVLIICAVVWLTKKAKKKSSSNE 269
```

Search completed: August 4, 2005, 06:13:28
Job time : 90.5513 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 4, 2005, 05:53:15 ; Search time 99.7302 Seconds
(without alignments)
1268.128 Million cell updates/sec

Title: US-10-607-565-60
Perfect score: 1699
Sequence: 1 MASELPGLCGALLGFLCLS.....ERPSSASTVTTTKSLPMV 327

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_16Dec04:.*
1: Geneseqp1980s:.*
2: Geneseqp1990s:.*
3: Geneseqp2000s:.*
4: Geneseqp2001s:.*
5: Geneseqp2002s:.*
6: Geneseqp2003as:.*
7: Geneseqp2003bs:.*
8: Geneseqp2004s:.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1692	99.6	327	3 AAB08903	Aab08903 Human sec
2	1691	99.5	327	3 AAY87251	Aay87251 Human sig
3	1691	99.5	327	3 AAY94857	Aay94857 Human pro
4	1691	99.5	327	4 AAY97585	Aay97585 Human sec
5	1691	99.5	327	5 ABB90354	Aab90354 Human pol
6	1691	99.5	327	5 AAU83709	Aau83709 Human PRO
7	1691	99.5	327	6 ABU80856	Abu80856 Human PRO
8	1691	99.5	327	6 ABO33822	Abo33822 Novel hum
9	1691	99.5	327	6 ABU82165	Abu82165 Novel hum
10	1691	99.5	327	6 ABJ72345	Abj72345 Human PRO
11	1691	99.5	327	6 ABJ72473	Abj72473 Human PRO
12	1691	99.5	327	6 ABO34368	Abo34368 Human sec
13	1691	99.5	327	7 ABJ72175	Abj72175 Human mem
14	1691	99.5	327	7 ADB83726	Adb83726 Novel hum
15	1691	99.5	327	7 ADB80832	Adb80832 Novel hum
16	1691	99.5	327	7 ADB73373	Adb73373 Novel hum
17	1691	99.5	327	7 ADB78455	Adb78455 Novel hum
18	1691	99.5	327	7 ADB85103	Adb85103 Human PRO
19	1691	99.5	327	7 ADB78209	Adb78209 Novel hum
20	1691	99.5	327	7 ADB87275	Adb87275 Human PRO
21	1691	99.5	327	7 ADB84857	Adb84857 Human PRO
22	1691	99.5	327	7 ADB83972	Adb83972 Novel hum
23	1691	99.5	327	7 ADB73127	Adb73127 Novel hum
24	1691	99.5	327	7 ADC36965	Adc36965 Human PRO
25	1691	99.5	327	7 ADC21955	Adc21955 Human PRO

26	1691	99.5	327	7 ADC49986	Adc49986 Novel hum
27	1691	99.5	327	7 ADC49185	Adc49185 Novel hum
28	1691	99.5	327	7 ADC49702	Adc49702 Novel hum
29	1691	99.5	327	7 ADC47563	Adc47563 Novel hum
30	1691	99.5	327	7 ADC47308	Adc47308 Novel hum
31	1691	99.5	327	7 ADC78183	Adc78183 Novel hum
32	1691	99.5	327	7 ADD06418	Add06418 Novel hum
33	1691	99.5	327	7 ADC77937	Adc77937 Novel hum
34	1691	99.5	327	7 ADD50900	Add50900 Novel hum
35	1691	99.5	327	7 ADD51146	Add51146 Novel hum
36	1691	99.5	327	7 ADD50627	Add50627 Human PRO
37	1691	99.5	327	7 ADD50381	Add50381 Human PRO
38	1691	99.5	327	7 ADD51392	Add51392 Novel hum
39	1691	99.5	327	8 ADC48939	Adc48939 Novel hum
40	1691	99.5	327	8 ADE21110	Ade21110 Novel hum
41	1691	99.5	327	8 ADE05954	Ade05954 Human PRO
42	1691	99.5	327	8 ADD75183	Add75183 Human PRO
43	1691	99.5	327	8 ADD75929	Add75929 Novel hum
44	1691	99.5	327	8 ADD85161	Add85161 Novel hum
45	1691	99.5	327	8 ADD86987	Add86987 Novel hum

ALIGNMENTS

RESULT 1

AAB08903
ID AAB08903 standard; protein; 327 AA.

AC AAB08903;

XX
XX 30-AUG-2000 (first entry)

XX Human secreted protein sequence encoded by gene 13 SEQ ID NO:60.

XX Human; secreted protein; cytostatic; anti-proliferative; vulnerary;
KW immunosuppressive; antibacterial; diagnosis; immune system; chemotaxis;
KW hyperproliferative disorder; infectious disease; tissue regeneration;
KW screening; food additive; preservative; wound healing;
KW hyper-vascular disease; chromosome 11.

XX Homo sapiens.

XX WO200017222-A1.

XX 30-MAR-2000.

XX 22-SEP-1999; 99WO-US022012.

XX 23-SEP-1998; 98US-0101546P.

XX 02-OCT-1998; 98US-0102895P.

XX (HUMA-) HUMAN GENOME SCI INC.

XX Ruben SM, Rosen CA, Duan RD, Shi Y, Lafleur DW, Young PE, Ni J;

XX Komatsoulis G, Endress GA, Soppet DR;

XX WPI; 2000-283538/24.

XX N-PSDB; AAA39064.

XX Human secreted proteins and coding sequences useful in diagnostic and therapeutic methods for disorders such as immune system or proliferative disorders, related to the proteins.

XX Claim 11; Page 359-360; 416pp; English.

XX The polynucleotide sequences given in AAA39052 to AAA39088 encode the human secreted proteins given in AAB08991 to AAB08984. The human secreted proteins can have activities based on the tissues and cells they are expressed in. Examples of the activities are: cytostatic; anti-proliferative; immunosuppressive; antibacterial; and vulnerary. The secreted proteins and their related polynucleotide sequences are useful for diagnostic and therapeutic methods useful for diagnosing and treating

CC disorders related to the secreted proteins. The proteins, and
 CC polynucleotide sequences may be useful for treating disorders of the
 CC immune system, hyperproliferative disorders, infectious disease,
 CC regeneration of tissues, for chemotaxis and for screening molecules that
 CC bind to the proteins. The proteins or polynucleotide sequences may be
 CC used as food additives or preservatives, to increase or decrease storage
 CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
 CC minerals, co-factors or other nutritional components. Agonists or
 CC antagonists of the proteins may be used to prevent scar tissue growth
 CC during wound healing, and hyper-vascular diseases. AAA39043 to AAA39051
 CC and AAB08890 are sequences used in the exemplification of the present
 CC invention

XX Sequence 327 AA;

Query Match 99.6%; Score 1692; DB 3; Length 327;
 Best Local Similarity 99.7%; Pred. No. 7.4e-114;
 Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGPFLLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFLLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60

QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDGTLYL 120
 DB 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDGTLYL 120

QY 121 CQVNNPPDFYTNGLGILNLTLPVPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
 DB 121 CQVNNPPDFYTNGLGILNLTLPVPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180

QY 181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTTCVATNQMGSAECLTLTSTVTPPQ 240
 DB 181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTTCVATNQMGSAECLTLTSTVTPPQ 240

QY 241 RVAGALIGVLLGVLLSVAACFLVRQKRGKPKETYGSGDLREDAIAPGISEHTCMRA 300
 DB 241 RVAGALIGVLLGVLLSVAACFLVRQKRGKPKETYGSGDLREDAIAPGISEHTCMRA 300

QY 301 DSSKGFLEPSSASTVTTTKSKLPMVV 327
 DB 301 DSSKGFLEPSSASTVTTTKSKLPMVV 327

RESULT 2

ID AAY87251 standard; protein; 327 AA.

XX AAY87251;

AC AAY87251;

XX 11-MAY-2000 (first entry)

XX Human signal peptide containing protein HSPP-28 SEQ ID NO:28.

XX Human; signal peptide-containing protein; HSPP; diagnosis; cancer;
 KW inflammation; cardiovascular disease; anticancer; anti-inflammatory;
 KW antimicrobial; neuroprotective; cardiovascular; hepatotropic;
 KW antiasthmatic; gene therapy; cell proliferation; neurological disorder;
 KW reproductive disorder; developmental disorder; arteriosclerosis;
 KW cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;
 KW asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;
 KW Parkinson's disease; Huntington's disease; ovulatory defect;
 KW muscular dystrophy.

OS Homo sapiens.

XX W0200000610-A2.

XX 06-JAN-2000.

XX 25-JUN-1999; 99WO-US014484.

XX 26-JUN-1998; 98US-0090762P.

PR 31-JUL-1998; 98US-0094983P.
 PR 01-OCT-1998; 98US-0102686P.
 PR 11-DEC-1998; 98US-0112129P.
 XX (INCY-) INCYTE PHARM INC.
 XX Lal P, Tang YT, Gorgone GA, Corley NC, Guegler KJ, Baughn MR;
 PI Akerblom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL;
 PI Bandman O;
 XX WPI: 2000-160673/14.
 DR N-PSDB; ANZ98136.
 XX New human signal peptide-containing proteins useful in treatment,
 PT prevention and diagnosis of e.g. cancer, inflammation and cardiovascular
 PT disease.
 XX Claim 1; Page 177-178; 327pp; English.

CC AAZ98109 to AAZ98242 encode AAY87224 to AAY87357 which represent the
 CC human signal peptide-containing proteins HSPP-1 to HSPP-134. HSPPs have
 CC anticancer, anti-inflammatory, antimicrobial, nootropic, hepatotropic,
 CC neuroprotective, cardiovascular and antiasthmatic activities, and can be
 CC used in gene therapy. HSPPs can be used to treat or prevent disorders
 CC associated with decreased activity or function of HSPP. Antagonists of
 CC HSPP are used to treat or prevent disorders associated with increased
 CC activity or function of HSPP. Such diseases include cell proliferation
 CC (including cancer), inflammation, cardiovascular, neurological,
 CC reproductive or developmental disorders, (e.g. arteriosclerosis,
 CC cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia,
 CC asthma, Crohn's disease, microbial or other infections, congestive or
 CC ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's, HSPP
 CC diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSPP
 CC nucleic acids can be used for the recombinant production of HSPP, for
 CC detecting HSPP in standard hybridisation and amplification assays (for
 CC diagnosis and monitoring), in gene therapy, as antisense, triplex-forming
 CC or ribozyme therapeutics, for detecting related sequences or genetic
 CC variations, and for chromosomal mapping. HSPP are also used to raise
 CC specific antibodies (Ab) and to screen for agonists and antagonists
 CC (potential therapeutic agents). Ab are used to diagnose, or monitor, HSPP
 CC -related diseases (in usual immunoassays), as therapeutic antagonists, in
 CC competitive drug screens, and for purification of HSPP from natural
 CC sources

XX SQ Sequence 327 AA;

Query Match 99.5%; Score 1691; DB 3; Length 327;
 Best Local Similarity 99.7%; Pred. No. 8.8e-114;
 Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGPFLLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFLLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60

QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDGTLYL 120
 DB 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDGTLYL 120

QY 121 CQVNNPPDFYTNGLGILNLTLPVPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
 DB 121 CQVNNPPDFYTNGLGILNLTLPVPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180

QY 181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTTCVATNQMGSAECLTLTSTVTPPQ 240
 DB 181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTTCVATNQMGSAECLTLTSTVTPPQ 240

QY 241 RVAGALIGVLLGVLLSVAACFLVRQKRGKPKETYGSGDLREDAIAPGISEHTCMRA 300
 DB 241 RVAGALIGVLLGVLLSVAACFLVRQKRGKPKETYGSGDLREDAIAPGISEHTCMRA 300

QY 301 DSSKGFLEPSSASTVTTTKSKLPMVV 327
 DB 301 DSSKGFLEPSSASTVTTTKSKLPMVV 327

RESULT 3
 ID AAY94857 standard; protein; 327 AA.
 XX
 AC AAY94857;
 DT 12-JUN-2000 (first entry)
 XX
 DE Human protein clone HP10568.
 XX
 KW Human protein; hydrophobic domain; nutritional source; haematopoiesis;
 KW cytokine production; cell proliferation; cell differentiation;
 KW immune deficiency; infectious disease; autoimmune disorder; asthma;
 KW multiple sclerosis; systemic lupus erythematosus; rheumatoid arthritis;
 KW allergic reaction; osteoporosis; osteoarthritis; periodontal disease;
 KW nervous system disorder; Alzheimer's disease; Parkinson's disease;
 KW Huntington's disease; liver fibrosis; lung fibrosis; reperfusion injury;
 KW systemic cytokine damage; tissue differentiation; contraceptive; stroke;
 KW coagulation disorder; myocardial infarction; inflammatory condition;
 KW septic shock; sepsis; ischaemia; reperfusion injury; arthritis; tumour;
 KW nephritis; therapy.
 XX
 OS Homo sapiens.
 XX
 PN WO200005367-A2.
 XX
 PD 03-FEB-2000.
 XX
 PF 22-JUL-1999; 99WO-JP003929.
 XX
 PR 24-JUL-1998; 98JP-00208820.
 PR 07-AUG-1998; 98JP-00224105.
 PR 25-AUG-1998; 98JP-00238116.
 PR 03-SEP-1998; 98JP-00254736.
 PR 29-SEP-1998; 98JP-00275505.
 XX
 PA (SAGA) SAGAMI CHEM RES CENT.
 PA (PROT-) PROTEGENE INC.
 XX
 PI Kato S, Kimura T;
 XX
 WP1; 2000-182694/16.
 XX
 PT Novel human proteins having hydrophobic domains useful for treating
 PT osteoporosis, Alzheimer's disease, Parkinson's disease, asthma, multiple
 PT sclerosis, rheumatoid arthritis, cancer, anemia, and stroke.
 XX
 PS Claim 1; Page 183-184; 351pp; English.
 XX
 CC This sequence represents a human protein of the invention, which has
 CC hydrophobic domains. The DNA sequences can be used as a probe or as a
 CC genetic marker. The protein can also be used as a marker, and to identify
 CC potential genetic disorders. The DNA and protein can also be used as
 CC nutritional sources or supplements. The protein exhibits cytokine, cell
 CC proliferation, cell differentiation activities and induces production of
 CC other cytokines in certain cell populations. The protein also exhibits
 CC immune stimulating or immune suppressing activity. It can be used in the
 CC treatment of various immune deficiencies and disorders, and to treat
 CC infectious diseases caused by viral, bacterial, fungal or other
 CC infections. The protein is also used for treating autoimmune disorders
 CC such as multiple sclerosis, systemic lupus erythematosus, and rheumatoid
 CC arthritis. It is also useful in the treatment of allergic reactions and
 CC conditions such as asthma, and in immune suppression after organ
 CC transplantation. The protein is useful in regulation of haematopoiesis
 CC and consequently in the treatment of myeloid or lymphoid cell
 CC deficiencies. It is also used in compositions for tissue growth or
 CC regeneration. The protein is also used in the treatment of osteoporosis
 CC or osteoarthritis and in the treatment of periodontal disease and other
 CC tooth repair processes. The protein is used in the treatment of nervous
 CC system disorders such as Alzheimer's disease, Parkinson's disease, and
 CC Huntington's disease. They are useful for protection or regeneration and

CC treatment of lung or liver fibrosis, reperfusion injury in various
 CC tissues, and conditions resulting from systemic cytokine damage. They are
 CC also used for promoting or inhibiting tissue differentiation. They are
 CC also used as contraceptives since they exhibit activin or inhibin related
 CC activities and as a fertility inducing therapeutic. They are used for
 CC treating various coagulation disorders and in treatment and prevention of
 CC conditions resulting from coagulation activities e.g. myocardial
 CC infarction or stroke. They also acts as receptors, receptor ligands or
 CC inhibitors or agonists of receptor/ligand interactions. They are used to
 CC treat inflammatory conditions such as septic shock, sepsis, ischaemia
 CC reperfusion injury, arthritis, and nephritis. They can be used to prevent
 CC tumours
 XX
 SQ Sequence 327 AA;
 Query Match 99.5%; Score 1691; DB 3; Length 327;
 Best Local Similarity 99.7%; Pred. No. 8.8e-114;
 Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPEPLSTPLGKTAEPLTCTYSTVSGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSGLAWEVKVPTPEPLSTPLGKTAEPLTCTYSTVSGDSFALEWS 60
 QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGYL 120
 DB 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVLLQNPPTVGATLKLTDVHPSDTGYL 120
 QY 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSQSTVSGSSEALRCSSEGAPKPVNVW 180
 DB 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSQSTVSGSSEALRCSSEGAPKPVNVW 180
 QY 181 RLGTFTPTSPGSMVQDEVSGQLITNLSTSSGTYRCVATNMGASCELTLSTVTEPQG 240
 DB 181 RLGTFTPTSPGSMVQDEVSGQLITNLSTSSGTYRCVATNMGASCELTLSTVTEPQG 240
 QY 241 RVAGALIGVLLGVLLSVAACLVRFQKRGKPKETYGSGDLREDIAFGISEHTCWA 300
 DB 241 RVAGALIGVLLGVLLSVAACLVRFQKRGKPKETYGSGDLREDIAFGISEHTCWA 300
 QY 301 DSSKGFLEPSSASTVTTTTSKLPVW 327
 DB 301 DSSKGFLEPSSASTVTTTTSKLPVW 327
 RESULT 4
 AAY97585
 ID AAY97585 standard; protein; 327 AA.
 XX
 AC AAY97585;
 XX
 DT 05-APR-2001 (first entry)
 XX
 DE Human secreted protein PRO7154.
 XX
 KW Secreted protein; human; PRO protein; neoplastic cell growth; tumour;
 KW proliferation; leukaemia; lymphoid malignancy; inflammatory disorder;
 KW angiogenic disorder; immunologic disorder; PRO7154.
 XX
 OS Homo sapiens.
 XX
 PN WO200075317-A2.
 XX
 PD 14-DEC-2000.
 XX
 PF 15-MAY-2000; 2000WO-US013358.
 PR 09-JUN-1999; 99US-0138385P.
 PR 20-JUL-1999; 99US-0144790P.
 PR 03-AUG-1999; 99US-0146843P.
 PR 10-AUG-1999; 99US-0148188P.
 PR 17-AUG-1999; 99US-0149320P.
 PR 17-AUG-1999; 99US-0149327P.
 PR 17-AUG-1999; 99US-0149396P.

PR 20-AUG-1999; 99US-0150114P.
 PR 31-AUG-1999; 99US-0151700P.
 PR 31-AUG-1999; 99US-0151734P.
 XX (GETH) GENENTECH INC.
 PA Botstein DA, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WI;
 PI WPI; 2001-071075/08.
 XX N-PSDB; AAA91019.
 XX Antibodies against PRO polypeptides, useful for diagnosing and treating
 PT tumors are associated with gene amplification, neoplastic cell growth and
 PT proliferation in mammals.
 XX
 XX Claim 61; Fig 12; 143pp; English.
 XX This sequence is a human PRO protein of the invention. The PRO proteins
 CC are secreted proteins. Antagonists or antibodies of PRO polypeptides are
 CC useful for diagnosing and treating tumors are associated with gene
 CC amplification, neoplastic cell growth and proliferation in mammals, and
 CC those conditions characterised by overexpression and/or activation of the
 CC amplified genes. Such conditions include benign or malignant tumours
 CC (e.g. renal, liver, kidney, bladder, breast, gastric, ovarian,
 CC colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic
 CC carcinomas, sarcomas, glioblastomas and various head and neck tumours);
 CC leukaemias and lymphoid malignancies; neuronal, glial, astrocytal,
 CC hypochalamic, and other glandular, macrophageal, epithelial, stromal and
 CC blastocoeleic disorders; and inflammatory, angiogenic and immunologic
 CC disorders. These may further be used to qualitatively or quantitatively
 CC detect the expression of proteins encoded by the amplified genes, and in
 CC tumour diagnostics or prognostics. The PRO polypeptide or its antagonist
 CC may be used for the preparation of a medicament in the treatment of a
 CC condition, which is responsive to the PRO polypeptide, its antagonist or
 CC anti-PRO antibody
 XX
 XX Sequence 327 AA;
 SQ
 Query Match 99.5%; Score 1691; DB 4; Length 327;
 Best Local Similarity 99.7%; Pred. No. 8.8e-114;
 Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 MAELPGPFCGALLGFLCGLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFCGALLGFLCGLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVLLQNPPVGVATLKLTDVHPSDGTGTYL 120
 DB 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVLLQNPPVGVATLKLTDVHPSDGTGTYL 120
 QY 121 CQVNNPPDFYTNGLGLINLTVLPVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 DB 121 CQVNNPPDFYTNGLGLINLTVLPVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 QY 181 RLGTFPTPSGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSASCELTLSTVTEPPQG 240
 DB 181 RLGTFPTPSGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSASCELTLSTVTEPPQG 240
 QY 241 RVAGALIGVLGVLILLSVAACFLVRFOKRGKKPKETYGGSDLDREDAIAPGISEHTCMRA 300
 DB 241 RVAGALIGVLGVLILLSVAACFLVRFOKRGKKPKETYGGSDLDREDAIAPGISEHTCMRA 300
 QY 301 DSSKGFLERPSSASTVTTTKSKLPMVV 327
 DB 301 DSSKGFLERPSSASTVTTTKSKLPMVV 327
 RESULT 5
 ID ABB90354
 XX ABB90354 standard; protein; 327 AA.
 AC ABB90354;
 XX

DT 24-MAY-2002 (first entry)
 XX Human polypeptide SEQ ID NO 2730.
 XX
 KW Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
 KW anti-allergic; hepatotropic; antidiabetic; anti-inflammatory; anti-ulcer;
 KW vulnary; anticonvulsant; antibacterial; antifungal; antiparasitic;
 KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
 KW neurological disease; infection; human; secreted protein.
 XX
 OS Homo sapiens.
 XX
 XX WO200190304-A2.
 XX
 XX 29-NOV-2001.
 XX
 XX 18-MAY-2001; 2001WO-US016450.
 XX
 XX 19-MAY-2000; 2000US-0205515P.
 XX
 XX (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Birse CE, Rosen CA;
 XX
 XX WPI; 2002-122018/16.
 XX N-PSDB; ABL90763.
 DR
 XX Novel 1405 isolated polypeptides, useful for diagnosis, treatment and
 PT prevention of neural, immune system, muscular, reproductive,
 PT gastrointestinal, pulmonary, cardiovascular, renal and proliferative
 PT disorders.
 XX
 XX Claim 11; SEQ ID NO 2730; 2081pp + Sequence Listing; English.
 XX
 XX The invention relates to novel genes (ABL89449-ABL90853) and proteins
 CC (ABB89040-ABB90444) useful for preventing, treating or ameliorating
 CC medical conditions e.g. by protein or gene therapy. The genes are
 CC isolated from a range of human tissues disclosed in the specification.
 CC The nucleic acids, proteins, antibodies and (ant)agonists are useful in
 CC the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and
 CC ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,
 CC breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune
 CC disorders e.g. Addison's disease, allergies, autoimmune haemolytic
 CC anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
 CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)
 CC cardiovascular disorders such as myocardial ischaemia; (d) wound healing
 CC ; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)
 CC infectious diseases such as viral, bacterial, fungal and parasitic
 CC infections. Note: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 327 AA;
 SQ
 Query Match 99.5%; Score 1691; DB 5; Length 327;
 Best Local Similarity 99.7%; Pred. No. 8.8e-114;
 Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 MAELPGPFCGALLGFLCGLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFCGALLGFLCGLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVLLQNPPVGVATLKLTDVHPSDGTGTYL 120
 DB 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVLLQNPPVGVATLKLTDVHPSDGTGTYL 120
 QY 121 CQVNNPPDFYTNGLGLINLTVLPVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 DB 121 CQVNNPPDFYTNGLGLINLTVLPVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV 180
 QY 181 RLGTFPTPSGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSASCELTLSTVTEPPQG 240
 DB 181 RLGTFPTPSGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSASCELTLSTVTEPPQG 240

Qy	241	RVAGALIGVLLGVLLLSVAACFLVFQKRGKKPKETYGGSDRLREDAIAFGISEHTCMRA	300
Db <td>241 <td>RVAGALIGVLLGVLLLSVAACFLVFQKRGKKPKETYGGSDRLREDAIAFGISEHTCMRA <td>300</td> </td></td>	241 <td>RVAGALIGVLLGVLLLSVAACFLVFQKRGKKPKETYGGSDRLREDAIAFGISEHTCMRA <td>300</td> </td>	RVAGALIGVLLGVLLLSVAACFLVFQKRGKKPKETYGGSDRLREDAIAFGISEHTCMRA <td>300</td>	300
Qy <td>301 <td>DSSKGFLEPSPSASTVTTTTSKLPVV</td> <td>327</td> </td>	301 <td>DSSKGFLEPSPSASTVTTTTSKLPVV</td> <td>327</td>	DSSKGFLEPSPSASTVTTTTSKLPVV	327
Db <td>301 <td>DSSKGFLEPSPSASTVTTTTSKLPVV</td> <td>327</td> </td>	301 <td>DSSKGFLEPSPSASTVTTTTSKLPVV</td> <td>327</td>	DSSKGFLEPSPSASTVTTTTSKLPVV	327

XX	The invention relates to one hundred and twenty two nucleic acids				
CC	encoding PRO polypeptides. The sequences of the 122 PRO polynucleotides				
CC	encode human secreted proteins. The PRO nucleic acids, polypeptides,				
CC	agonists and antagonists are useful for treating a PRO related disorder.				
CC	The PRO polypeptides are useful for diagnosing tumours, especially lung				
CC	cancer, colon cancer, breast tumour, prostate tumour, rectal tumour or				
CC	liver tumour. The PRO polypeptides are useful for stimulating the				
CC	proliferation of, or gene expression, in pericyte cells, for stimulating				
CC	the proliferation or differentiation of chondrocyte cells, for				
CC	stimulating the release of tumour necrosis factor-alpha from human blood,				
CC	for stimulating or inhibiting the proliferation of normal human dermal				
CC	fibroblast cells. The PRO polypeptide may also be used as molecular				
CC	weight markers and for tissue typing. The PRO nucleic acids have				
CC	applications in molecular biology, including use as hybridisation probes,				
CC	and in chromosome and gene mapping. AAU83592-AAU83713 represent human PRO				
CC	protein sequences of the invention				
XX					
SQ	Sequence 327 AA;				
	Query Match	99.5%;	Score 1691;	DB 5;	Length 327;
	Best Local Similarity	99.7%;	Pred. No. 8.8e-114;		
	Matches 326;	Conservative 0;	Mismatches 1;	Indels 0;	Gaps 0;
Qy	1	MAELPGFLCGALLGFLCLSGLA	VEVKVPTPEPLSTPLGKTAELTCTYSTV	SGDSFAL	EW 60
Db	1	MAELPGFLCGALLGFLCLSGLA	VEVKVPTPEPLSTPLGKTAELTCTYSTV	SGDSFAL	EW 60
Qy	61	FVQPGKPISSHPILYFTNGHL	YPTGSKSRVSLQNPPTVGVATLKLTDV	HPSDTG	YL 120
Db	61	FVQPGKPISSHPILYFTNGHL	YPTGSKSRVSLQNPPTVGVATLKLTDV	HPSDTG	YL 120
Qy	121	QVNNPPDFYTNGLGLINLTV	LPSPNPLCSQSQSTVSGGSTALRCS	SSGAPKPV	YNW 180
Db	121	QVNNPPDFYTNGLGLINLTV	LPSPNPLCSQSQSTVSGGSTALRCS	SSGAPKPV	YNW 180
Qy	181	RLGFTFPSPGSMQDVBVSG	QLILTNLSLTSSGGTYRCVATNQMG	SASCELTL	SVTEPPQ 240
Db	181	RLGFTFPSPGSMQDVBVSG	QLILTNLSLTSSGGTYRCVATNQMG	SASCELTL	SVTEPPQ 240
Qy	241	RVAGALIGVLGVLILLSVA	APCLVRFOKERGKKPKETYGGSDLR	EDATAPG	ISEHTCM 300
Db	241	RVAGALIGVLGVLILLSVA	APCLVRFOKERGKKPKETYGGSDLR	EDATAPG	ISEHTCM 300
Qy	301	DSKGFLERPSSASTVTTT	SKLPMVV 327		
Db	301	DSKGFLERPSSASTVTTT	SKLPMVV 327		
RESULT 7					
ID	ABU80856				
XX	ABU80856 standard; protein; 327 AA.				
AC	ABU80856;				
XX					
DT	23-JUN-2003 (first entry)				
XX					
DE	Human PRO polypeptide #119.				
XX					
KW	Human; PRO polypeptide; secreted and transmembrane protein;				
KX	anti-PRO antibody; diagnostic assay; gene expression; tumour; cytostatic.				
OS	Homo sapiens.				
XX					
FN	US2003036635-A1.				
XX					
PD	20-FEB-2003.				
XX					
PF	28-AUG-2002; 2002US-00230163.				
XX					
PR	25-JUL-2000; 2000US-0220638P.				
PR	01-JUN-2001; 2001WO-US017800.				
PR	29-JUN-2001; 2001WO-US021066.				

PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-342045/32.
DR N-PSDB; ACA66958.
XX
XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful for the manufacture of a medicament for diagnosing or treating
PT tumor.
XX
XX Claim 11; Fig 236; 314pp; English.
XX
XX The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides and polynucleotides are useful for preparing a medicament
CC useful in the diagnosis and treatment of tumours. Anti-PRO antibodies are
CC useful in diagnostic assays for PRO, by detecting its expression in
CC specific cells, tissues or serum, and for affinity purification of PRO
CC from recombinant cell culture or natural sources. ABU80739-ABU80860
CC represent the human PRO polypeptides of the invention. Note: The sequence
CC data for this patent was obtained in electronic format directly from the
CC USPTO web site at seqdata.uspto.gov/psipeDIDEntry.html
XX
XX Sequence 327 AA;

Query Match 99.5%; Score 1691; DB 6; Length 327;
Best Local Similarity 99.7%; Pred. No. 8.8e-114;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAEITCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAEITCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISHPILYFTNGHLPTGSKSRVSLQNPPPTVGATLKLTDVHPSDTGTYL 120
Db 61 FVQPGKPISHPILYFTNGHLPTGSKSRVSLQNPPPTVGATLKLTDVHPSDTGTYL 120
QY 121 CQVNNPPDYNTGLGILNLTVPSPNPLCSQSGQTSVCGSTALRCSSEGAPKPYNNV 180
Db 121 CQVNNPPDYNTGLGILNLTVPSPNPLCSQSGQTSVCGSTALRCSSEGAPKPYNNV 180
QY 181 RLGTFTFPSPGSMVQDEVSGQLILTNLSTSSGTTCVATNQMSASCELTLSVTEPPQ3 240
Db 181 RLGTFTFPSPGSMVQDEVSGQLILTNLSTSSGTTCVATNQMSASCELTLSVTEPPQ3 240
QY 241 RVAGALIGVLLGVLVLLSVAACFLVRQKRGKKPKETYGSGDLREDAIAPGISEHTCMRA 300
Db 241 RVAGALIGVLLGVLVLLSVAACFLVRQKRGKKPKETYGSGDLREDAIAPGISEHTCMRA 300
QY 301 DSSKGFLERPSSASTVTTTKSKLPMVV 327
Db 301 DSSKGFLERPSSASTVTTTKSKLPMVV 327

RESULT 8
ABO33822
ID ABO33822 standard; protein; 327 AA.
XX
XX ABO33822;
DT 17-SEP-2003 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO7154.
DE
XX Human; secreted and transmembrane protein; PRO; cytostatic;
KW antiarthritic; osteopathic; gene therapy; TNF-Agonist-Alpha;
KW chondrocyte stimulator; pericyte stimulator; fibroblast modulator;
KW pharmaceutical; diagnostic; biosensor; bioreactor; tumour; lung tumour;

KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; bone disorder; cartilage disorder; sports injury;
XX arthritis; wound.
XX Homo sapiens.
XX US2003045687-A1.
XX 06-MAR-2003.
XX
XX 12-AUG-2002; 2002US-00218631.
XX
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-512315/48.
DR N-PSDB; ACD68710.
XX
XX New genes, and its encoded secreted and transmembrane polypeptides,
PT useful for stimulating Tumor Necrosis Factor alpha, or chondrocyte or
PT pericyte proliferation, especially for treating lung tumors, arthritis or
PT wounds in a mammal.
XX
XX Claim 11; Fig 236; 314pp; English.

The invention describes an isolated nucleic acid molecule comprising a
sequence with at least 80% identity to: (a) a nucleotide encoding any of
122 PRO (secreted and transmembrane) polypeptides whose sequences are
fully defined in the specification; or (b) any of 122 nucleotide
sequences having e.g. 4834, 2504 or 1759 bp fully defined in the
specification; or the full length coding sequence of any these 122
nucleotide sequences. The PRO polypeptides or polynucleotides are useful
as pharmaceuticals, diagnostics, biosensors or bioreactors. These are
particularly useful for detecting tumours (e.g. lung tumour, colon
tumour, breast tumour, prostate tumour, rectal tumour, or liver tumour)
in a mammal, for stimulating the release of TNF-alpha from human blood,
for stimulating the proliferation or differentiation of chondrocyte
cells, for stimulating proliferation of pericyte cells, or for modulating
normal human dermal fibroblast proliferation. The PRO nucleic acid or
polypeptide is also useful for treating tumours or various bone and/or
cartilage disorders (e.g. sports injuries or arthritis), or wounds. The
PRO polypeptides are useful in drug screening, particularly as targets
for therapeutic intervention in these diseases, and in the diagnostic
determination of the presence of these diseases. The PRO polypeptides are
also useful as molecular weight markers, or for chromosome
identification. The PRO genes are useful as hybridisation probes, or for
screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may
also be used in gene therapy, particularly for replacing a defective
gene. This is the amino acid sequence of a novel human secreted and
transmembrane PRO polypeptide

Sequence 327 AA;

Query Match 99.5%; Score 1691; DB 6; Length 327;
Best Local Similarity 99.7%; Pred. No. 8.8e-114;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAEITCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAEITCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISHPILYFTNGHLPTGSKSRVSLQNPPPTVGATLKLTDVHPSDTGTYL 120
Db 61 FVQPGKPISHPILYFTNGHLPTGSKSRVSLQNPPPTVGATLKLTDVHPSDTGTYL 120
QY 121 CQVNNPPDYNTGLGILNLTVPSPNPLCSQSGQTSVCGSTALRCSSEGAPKPYNNV 180
XX
XX Sequence 327 AA;

Db 121 CQNNPPDYFTNGGLINLTVLPSPNPLCSQSQTSGSTALRCSSEGAPKPVNVW 180
Qy 181 RLGTFTPPSPGSMQVDEVSQGLILTNLSLTSSGYRCVATNQMGSAACELTSLVTEPPQG 240
Db 181 RLGTFTPPSPGSMQVDEVSQGLILTNLSLTSSGYRCVATNQMGSAACELTSLVTEPPQG 240
Qy 241 RVAGALIGVLLGVLLSVAACLVRFQKRGKPKETVGGSDLRDAIAPGISHTCMRA 300
Db 241 RVAGALIGVLLGVLLSVAACLVRFQKRGKPKETVGGSDLRDAIAPGISHTCMRA 300
Qy 301 DSSKGFLEPSSASTVTTTKSKLPMVV 327
Db 301 DSSKGFLEPSSASTVTTTKSKLPMVV 327
RESULT 9
ABU82165
ID ABU82165 standard; protein; 327 AA.
XX AC ABU82165;
XX DT 25-JUN-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO7154.
XX KW Human; secreted and transmembrane protein; PRO; cardiac; cytostatic;
KW antiangiogenic; hypotensive; vulnery; antiarteriosclerotic;
KW gene therapy; cardiovascular disorder; endothelial disorder;
KW angiogenic disorder; cardiac hypertrophy; trauma; cancer;
KW age-related macular degeneration; atherosclerosis; hypertension;
KW arterial restenosis; rheumatoid arthritis; angina; myocardial infarction;
KW thrombophlebitis; lymphangitis; tumour angiogenesis; breast carcinoma;
KW liver carcinoma; wound healing; chromosome mapping; gene mapping.
XX OS Homo sapiens.
XX PN US2003088063-A1.
XX PD 08-MAY-2003.
XX PF 12-AUG-2002; 2002US-00219003.
XX PR 25-JUL-2000; 2000US-0220664P.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX PA (GETH) GENENTECH INC.
XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PU;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-393229/37.
XX DR N-PSDB; ACA68614.
XX PT One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT infarction), endothelial or angiogenic disorders in a mammal.
XX PS Claim 11; Fig 236; 314pp; English.
XX CC The invention describes one hundred and eighty seven nucleic acids
CC encoding novel human secreted and transmembrane (PRO) polypeptides. The
CC PRO nucleic acids, polypeptides, agonists and antagonists are useful for
CC treating or diagnosing a cardiovascular, endothelial or angiogenic
CC disorder in a mammal, e.g. cardiac hypertrophy, trauma, cancer, age-
CC related macular degeneration, atherosclerosis, hypertension, arterial
CC restenosis, rheumatoid arthritis, angina, myocardial infarctions,
CC thrombophlebitis, lymphangitis, tumour angiogenesis (such as breast
CC carcinoma and liver carcinoma) and wound healing. The PRO nucleic acids
CC have applications in molecular biology, including use as hybridisation
CC probes, and in chromosome and gene mapping. This is the amino acid
CC sequence of a novel human secreted and transmembrane PRO polypeptide

XX SQ Sequence 327 AA;
Query Match 99.5%; Score 1691; DB 6; Length 327;
Best Local Similarity 99.7%; Pred. No. 8.8e-114;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 MAELPGFPLCGALIGFLCLSGLAVEVVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
Db 1 MAELPGFPLCGALIGFLCLSGLAVEVVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
Qy 61 FVQPKDISRHPILYFTNGHLVPTGSKSRVSLLONPPTVGVATLKLTDVHPSDTGYL 120
Db 61 FVQPKDISRHPILYFTNGHLVPTGSKSRVSLLONPPTVGVATLKLTDVHPSDTGYL 120
Qy 121 CQNNPPDYFTNGGLINLTVLPSPNPLCSQSQTSGSTALRCSSEGAPKPVNVW 180
Db 121 CQNNPPDYFTNGGLINLTVLPSPNPLCSQSQTSGSTALRCSSEGAPKPVNVW 180
Qy 181 RLGTFTPPSPGSMQVDEVSQGLILTNLSLTSSGYRCVATNQMGSAACELTSLVTEPPQG 240
Db 181 RLGTFTPPSPGSMQVDEVSQGLILTNLSLTSSGYRCVATNQMGSAACELTSLVTEPPQG 240
Qy 241 RVAGALIGVLLGVLLSVAACLVRFQKRGKPKETVGGSDLRDAIAPGISHTCMRA 300
Db 241 RVAGALIGVLLGVLLSVAACLVRFQKRGKPKETVGGSDLRDAIAPGISHTCMRA 300
Qy 301 DSSKGFLEPSSASTVTTTKSKLPMVV 327
Db 301 DSSKGFLEPSSASTVTTTKSKLPMVV 327
RESULT 10
ABJ72345
ID ABJ72345 standard; protein; 327 AA.
XX AC ABJ72345;
XX DT 06-NOV-2003 (first entry)
XX DE Human PRO7154 protein.
XX KW PRO; proliferation; pericyte cell; TNF-alpha; blood; chondrocyte;
KW differentiation; dermal fibroblast; tumour; gene therapy; cytostatic.
XX OS Homo sapiens.
XX PN US2003050448-A1.
XX PD 13-MAR-2003.
XX PF 28-AUG-2002; 2002US-00230414.
XX PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX PA (GETH) GENENTECH INC.
XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PU;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-521818/49.
XX DR N-PSDB; ABT44343.
XX PT New nucleic acid encoding for a PRO protein, useful for the manufacture
PT of a medicament for diagnosing or treating tumors or for measuring or
PT detecting expression of an associated gene.
XX PS Claim 11; Fig 236; 315pp; English.
XX CC The invention relates to a novel isolated nucleic acid encoding a fully
CC defined PRO polypeptide. The molecules of the invention may be useful for

CC stimulating proliferation or gene expression in pericyte cells or the
 CC release of TNF-alpha from human blood. Other possible uses include the
 CC stimulation or inhibition of chondrocyte proliferation or
 CC differentiation, the stimulation of human dermal fibroblast cell
 CC proliferation and the detection of the presence of a tumour within a
 CC mammal. Furthermore, the nucleic acid may be useful for the manufacture
 CC of a medicament for diagnosing or treating a tumour within a mammal or
 CC for measuring or detecting the expression of an associated gene, as well
 CC as during gene therapy. The current sequence is that of the human PRO
 CC protein of the invention
 XX
 SQ Sequence 327 AA;

Query Match 99.5%; Score 1691; DB 6; Length 327;
 Best Local Similarity 99.7%; Pred. No. 8.8e-114;
 Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISSEHPILYFTNGHLIPTGSKSRVSLQNPPPTVGATLKLTDVHPSDTGTYL 120
 DB 61 FVQPGKPISSEHPILYFTNGHLIPTGSKSRVSLQNPPPTVGATLKLTDVHPSDTGTYL 120
 QY 121 CQVNNPPDFYNTGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNW 180
 DB 121 CQVNNPPDFYNTGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNW 180
 QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCELTLTSVTEPPQG 240
 DB 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCELTLTSVTEPPQG 240
 QY 241 RVAGALIGVLLGVLLLSVAAFCLVRFOKRGKKPKETYGGSDLRDAIAPGISEHTCMRA 300
 DB 241 RVAGALIGVLLGVLLLSVAAFCLVRFOKRGKKPKETYGGSDLRDAIAPGISEHTCMRA 300
 QY 301 DSSKGFLERPSSASTVTTTTSKLPMMV 327
 DB 301 DSSKGFLERPSSASTVTTTTSKLPMMV 327

RESULT 11
 ABJ72473
 ID ABJ72473 standard; protein; 327 AA.

XX AC ABJ72473;
 XX DT 06-NOV-2003 (first entry)
 XX DE Human PRO7154 protein.
 XX KW PRO; blood; proliferation; pericyte cell; TNF alpha; chondrocyte;
 XX KW tumour necrosis factor; proliferation; differentiation; gene therapy;
 XX KW dermal fibroblast.

XX OS Homo sapiens.
 XX PN US2003027988-A1.
 XX PD 06-FEB-2003.
 XX XX 26-AUG-2002; 2002US-00227884.
 XX PR 01-JUN-2001; 2001WO-US017800.
 XX PR 29-JUN-2001; 2001WO-US021066.
 XX PR 03-APR-2002; 2002US-00119480.

XX PA (GETH) GENENTECH INC.
 XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

DR WPI; 2003-503301/47.
 DR N-PSDB; ABT44626.
 XX
 PT New PRO protein encoding nucleic acid, useful for preparing PRO
 PT polypeptides and anti-PRO antibodies for detecting the presence of a
 PT tumor in a mammal.

XX Claim 11; Fig 236; 324pp; English.

CC The invention relates to a novel isolated PRO protein encoding nucleic
 CC acid. The nucleic acid of the invention may be useful for preparing PRO
 CC polypeptides and anti-PRO antibodies for detecting the presence of a
 CC tumour in a mammal. Furthermore, the molecules of the invention may be
 CC useful for stimulating proliferation or gene expression in pericyte
 CC cells, the release of tumour necrosis factor (TNF)-alpha from human
 CC blood, the proliferation or differentiation of chondrocyte cells and for
 CC inhibiting the proliferation of normal human dermal fibroblast cells.
 CC Finally, the molecules may be utilised during gene therapy. The current
 CC sequence is that of the human PRO protein of the invention
 XX
 SQ Sequence 327 AA;

Query Match 99.5%; Score 1691; DB 6; Length 327;
 Best Local Similarity 99.7%; Pred. No. 8.8e-114;
 Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 DB 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISSEHPILYFTNGHLIPTGSKSRVSLQNPPPTVGATLKLTDVHPSDTGTYL 120
 DB 61 FVQPGKPISSEHPILYFTNGHLIPTGSKSRVSLQNPPPTVGATLKLTDVHPSDTGTYL 120
 QY 121 CQVNNPPDFYNTGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNW 180
 DB 121 CQVNNPPDFYNTGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNW 180
 QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCELTLTSVTEPPQG 240
 DB 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMQSGASCELTLTSVTEPPQG 240
 QY 241 RVAGALIGVLLGVLLLSVAAFCLVRFOKRGKKPKETYGGSDLRDAIAPGISEHTCMRA 300
 DB 241 RVAGALIGVLLGVLLLSVAAFCLVRFOKRGKKPKETYGGSDLRDAIAPGISEHTCMRA 300
 QY 301 DSSKGFLERPSSASTVTTTTSKLPMMV 327
 DB 301 DSSKGFLERPSSASTVTTTTSKLPMMV 327

RESULT 12
 ABO34368
 ID ABO34368 standard; protein; 327 AA.

XX AC ABO34368;
 XX DT 19-SEP-2003 (first entry)
 XX DE Human secreted/transmembrane polypeptide PRO 7154.
 XX KW Human; chondrocyte stimulation; TNF-alpha stimulation; gene therapy;
 XX KW human dermal fibroblast stimulation; tumour; tissue typing;
 XX KW affinity purification.

XX OS Homo sapiens.
 XX PN US2003044934-A1.
 XX PD 06-MAR-2003.
 XX XX 28-AUG-2002; 2002US-00230338.

PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 DR WPI; 2003-492274/46.
 DR N-PSDB; ACD82293.
 XX
 XX New transmembrane polypeptides and nucleic acids encoding the
 PT polypeptides, useful in gene therapy, in chromosome identification, as
 PT chromosome markers, or in generating probes.
 XX
 XX Claim 19; Fig 236; 315pp; English.
 XX
 CC The invention relates to an isolated nucleic acid encoding a PRO
 CC polypeptide. Nucleic acids that encode PRO can be used to generate either
 CC transgenic animals or knock-out animals useful in developing and
 CC screening of therapeutically useful reagents. The nucleic acids may also
 CC be used in gene therapy for replacing defective gene, in chromosome
 CC identification, as chromosome markers, or in generating probes to isolate
 CC full length PRO cDNA. The PRO polypeptides are useful for chondrocyte
 CC stimulation, TNF-alpha stimulation, human dermal fibroblasts stimulation
 CC and for detecting the presence of tumour in an animal. The PRO
 CC polypeptides are useful as molecular markers for protein electrophoresis
 CC and the isolated nucleic acids may be used for recombinantly expressing
 CC those markers. The PRO polypeptides and nucleic acids may also be used in
 CC tissue typing. Anti-PRO antibodies are useful in diagnostic assays for
 CC PRO and in affinity purification of PRO from recombinant cell culture or
 CC natural sources. The present sequence represents the amino acid sequence
 CC of a human secreted/transmembrane PRO polypeptide
 XX
 SQ Sequence 327 AA;

Query Match 99.5%; Score 1691; DB 6; Length 327;
 Best Local Similarity 99.7%; Pred. No. 8.8e-114;
 Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 MAELPGFLCGALLGFLCGLSLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 Db 1 MAELPGFLCGALLGFLCGLSLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
 Db 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
 QY 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSSEGAKPVTNVV 180
 Db 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSSEGAKPVTNVV 180
 QY 181 RLGTFTPPSGMVQDEVSQQLITNLISLTSSGTYRCVATNQMSASCELTLSVTPPQG 240
 Db 181 RLGTFTPPSGMVQDEVSQQLITNLISLTSSGTYRCVATNQMSASCELTLSVTPPQG 240
 QY 241 RVAGALIGVLLGVLLISVAFCVLRQKRGKPKETYGSGDSLREDAIAPGISEHTCMRA 300
 Db 241 RVAGALIGVLLGVLLISVAFCVLRQKRGKPKETYGSGDSLREDAIAPGISEHTCMRA 300
 QY 301 DSSKGFLEPSSASTVTTTKSKLPMVV 327
 Db 301 DSSKGFLEPSSASTVTTTKSKLPMVV 327

RESULT 13
 ID ABJ72175 standard; protein; 327 AA.
 XX
 AC ABJ72175;
 XX
 DT 16-OCT-2003 (first entry)

XX Human membrane bound receptor/protein PRO7154 amino acid sequence.
 DE
 XX Human; PRO; membrane bound protein; membrane bound receptor;
 XX cell proliferation; cell migration; cell differentiation;
 XX mitogenic factor; survival factor; cytotoxic factor;
 XX differentiation factor; neuroepithelial; hormone; cell receptor;
 XX receptor-ligand interaction; cytostatic; chondrocyte; tumour.
 OS Homo sapiens.
 XX
 XX US2003065147-A1.
 XX
 XX 03-APR-2003.
 XX
 XX 29-AUG-2002; 2002US-00232224.
 XX
 XX 28-JUL-1999; 99US-0146222P.
 XX 24-FEB-2000; 2000WO-US005004.
 XX 02-MAR-2000; 2000WO-US005841.
 XX 01-JUN-2001; 2001WO-US017800.
 XX 29-JUN-2001; 2001WO-US021066.
 XX 03-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 WPI; 2003-522018/49.
 N-PSDB; ABT43999.
 One hundred and twenty two nucleic acids encoding PRO polypeptides,
 useful for the manufacture of a medicament for diagnosing or treating
 tumor.
 XX
 Claim 11; Fig 236; 315pp; English.
 XX
 CC This invention relates to one hundred and twenty two novel nucleic acids
 CC encoding human PRO membrane bound proteins or receptors. Extracellular
 CC proteins play important roles in the formation, differentiation and
 CC maintenance of multicellular organisms. The fate of many individual cells
 CC (for example proliferation, migration or differentiation) is typically
 CC governed by information received from other cells and the immediate
 CC environment. The information is often transmitted by secreted
 CC polypeptides (for example mitogenic factors, survival factors, cytotoxic
 CC factors, differentiation factors, neuroepithelial and hormones) which are
 CC received and interpreted by diverse cell receptors or membrane bound
 CC proteins. These membrane bound proteins and receptors may be of use as
 CC pharmaceutical and diagnostic agents, such as in the blocking of receptor
 CC -ligand interactions. The current invention provides the amino acid
 CC sequences of novel human membrane bound receptors and proteins, along
 CC with the cDNA sequences encoding them. The novel proteins of the
 CC invention may have cytostatic activities through the stimulation of
 CC chondrocytes. The nucleic acids of the invention may be useful for the
 CC manufacture of a medicament for diagnosing or treating a tumour in a
 CC mammal. In addition, they may be useful for measuring or detecting the
 CC expression of a tumour associated gene. The present sequence is the amino
 CC acid sequence of a human PRO protein of the invention
 XX
 SQ Sequence 327 AA;

Query Match 99.5%; Score 1691; DB 7; Length 327;
 Best Local Similarity 99.7%; Pred. No. 8.8e-114;
 Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 MAELPGFLCGALLGFLCGLSLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 Db 1 MAELPGFLCGALLGFLCGLSLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120
 Db 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVSLQNPPTVGATLKLTDVHPSDTGYL 120

QY 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYVNV 180
 Db 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYVNV 180
 QY 181 RLGTFTPTSPGSMVQDEVSGQLLTLNLSLTSSGTYRCVATNMGSAACELTILSVTEPPQG 240
 Db 181 RLGTFTPTSPGSMVQDEVSGQLLTLNLSLTSSGTYRCVATNMGSAACELTILSVTEPPSQ 240
 QY 241 RVAGALIGVLLGVLNLSVAAFCLVRFQKRGKKPKETYGSDLRDAIAFGISEHTCMRA 300
 Db 241 RVAGALIGVLLGVLNLSVAAFCLVRFQKRGKKPKETYGSDLRDAIAFGISEHTCMRA 300
 QY 301 DSSKGFLEPSSASTVTTTKSKLPMV 327
 Db 301 DSSKGFLEPSSASTVTTTKSKLPMV 327
 RESULT 14
 ADB83726
 ID ADB83726 standard; protein; 327 AA.
 AC ADB83726;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO7154.
 XX
 KW human; secreted and transmembrane protein; PRO; cytostatic; vulnerary;
 KW antiarthritic; pericyte cell proliferation; chondrocyte cell proliferation;
 KW pericyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX
 OS Homo sapiens.
 XX US2003073814-A1.
 XX
 PD 17-APR-2003.
 XX
 PF 12-AUG-2002; 2002US-00218849.
 XX
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2003-644806/61.
 DR N-PSDB; ADB83725.
 XX
 PT New PRO polypeptides and nucleic acids encoding the polypeptides, useful
 PT in gene therapy, chromosome identification, tissue typing, or as
 PT hybridization probes in chromosome and gene mapping.
 XX
 XX Claim 11; Fig 236; 315pp; English.
 XX
 CC The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF) -
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO1083, PRO840, PRO1080,

CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO1801, PRO1801, PRO3433, PRO3543, PRO3444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This is the amino acid sequence of a human secreted and
 CC transmembrane PRO polypeptide.
 XX
 SQ Sequence 327 AA;
 Query Match 99.5%; Score 1691; DB 7; Length 327;
 Best Local Similarity 99.7%; Pred. No. 8.8e-114;
 Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 MAELPGPFLCGALLGFLCLSLGLAVEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 Db 1 MAELPGPFLCGALLGFLCLSLGLAVEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
 QY 61 FVQPKPISESHPILYFTNGHLYPTGSKSKRVSLQNPPVGVATLKLTDVHPSDGTGTYL 120
 Db 61 FVQPKPISESHPILYFTNGHLYPTGSKSKRVSLQNPPVGVATLKLTDVHPSDGTGTYL 120
 QY 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYVNV 180
 Db 121 CQVNNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYVNV 180
 QY 181 RLGTFTPTSPGSMVQDEVSGQLLTLNLSLTSSGTYRCVATNMGSAACELTILSVTEPPQG 240
 Db 181 RLGTFTPTSPGSMVQDEVSGQLLTLNLSLTSSGTYRCVATNMGSAACELTILSVTEPPSQ 240
 QY 241 RVAGALIGVLLGVLNLSVAAFCLVRFQKRGKKPKETYGSDLRDAIAFGISEHTCMRA 300
 Db 241 RVAGALIGVLLGVLNLSVAAFCLVRFQKRGKKPKETYGSDLRDAIAFGISEHTCMRA 300
 QY 301 DSSKGFLEPSSASTVTTTKSKLPMV 327
 Db 301 DSSKGFLEPSSASTVTTTKSKLPMV 327
 RESULT 15
 ADB80832
 ID ADB80832 standard; protein; 327 AA.
 XX
 AC ADB80832;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO7154.
 XX
 KW Human; secreted and transmembrane protein; PRO; cytostatic; vulnerary;
 KW antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;

KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
XX Homo sapiens.
XX
XX US200308068-A1.
XX
XX 08-MAY-2003.
XX
XX 13-AUG-2002; 2002US-00219481.
XX
XX 01-JUN-2001; 2001WO-US017800.
XX
XX 29-JUN-2001; 2001WO-US021066.
XX
XX 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PU;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WT;
XX
XX WPI: 2003-657982/62.
XX
XX N-PSDB; ADB80831.
XX
XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
XX useful in gene therapy, chromosome identification, tissue typing, or as
XX hybridization probes in chromosome and gene mapping.
XX
XX Claim 11; Fig 236; 305pp; English.
XX

The invention describes an isolated PRO (secreted and transmembrane) polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are useful for stimulating the proliferation of or gene expression in pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful for stimulating the proliferation or differentiation of chondrocyte cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide are useful for stimulating the release of tumour necrosis factor (TNF)-alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214, PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080, PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309, PRO1025, PRO1181, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412, PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338, PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567, PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322, PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for stimulating the proliferation of normal human dermal fibroblasts cells. PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408, PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for inhibiting the proliferation of normal human dermal fibroblast cells. PRO polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc., are useful for detecting the presence of tumour in a mammal which involves comparing the level of expression of the above PRO polypeptides in a test sample of cells taken from the mammal, and a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptides in the test sample as compared to the control sample is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for chromosome and gene mapping or gene therapy. (II) is useful for generating transgenic animals or knock-out animals which are useful screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide is useful for treating bone and/or cartilage disorders (e.g., arthritis, sport injuries). This is the amino acid sequence of a human secreted and transmembrane PRO polypeptide.

SQ Sequence 327 AA;
Query Match 99.5%; Score 1691; DB 7; Length 327;
Best Local Similarity 99.7%; Pred. No. 8.8e-114;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy	1	MAELPGFLCGALIGFLCSGLAVEVVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS	60
Db	1	MAELPGFLCGALIGFLCSGLAVEVVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS	60
Qy	61	FVQPGKDISSEHPILYFTNGHLYPTGSKSRVSLLONPPTVGATLKLTDVHPSDTGTYL	120
Db	61	FVQPGKDISSEHPILYFTNGHLYPTGSKSRVSLLONPPTVGATLKLTDVHPSDTGTYL	120
Qy	121	QVNNPPDFVTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV	180
Db	121	QVNNPPDFVTNGLGLINLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV	180
Qy	181	RLGFTPTPPSGMVQDEVSGQLITNLSTSSGTYRCVATNQMGSAACELTSLSVTEPPQG	240
Db	181	RLGFTPTPPSGMVQDEVSGQLITNLSTSSGTYRCVATNQMGSAACELTSLSVTEPSQG	240
Qy	241	RVAGALIGVLLGVLLLSVAAFCVRFQKRGKPKPKETYGGSDLRDADAIAFGISEHTCMRA	300
Db	241	RVAGALIGVLLGVLLLSVAAFCVRFQKRGKPKPKETYGGSDLRDADAIAFGISEHTCMRA	300
Qy	301	DSSKGFLERPSSASTVTTTTSKSLPMVV	327
Db	301	DSSKGFLERPSSASTVTTTTSKSLPMVV	327

Search completed: August 4, 2005, 06:07:05
Job time : 103.73 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.
OM protein - protein search, using sw model
Run on: August 4, 2005, 06:13:42 ; Search time 87.4135 Seconds
(without alignments)
1447.018 Million cell updates/sec

Title: US-10-607-565-60_COPY_4_327
Perfect score: 1685
Sequence: 1 LFGPFLCGALLGFLCLSLGSLA.....ERPSSASTVTTTKSKLPMV 324

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1752860 seqs, 390397842 residues
Total number of hits satisfying chosen parameters: 1752860

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA: *
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep: *
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep: *
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep: *
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep: *
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep: *
6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep: *
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep: *
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep: *
9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep: *
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep: *
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep: *
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep: *
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep: *
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep: *
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep: *
16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep: *
17: /cgn2_6/ptodata/1/pubpaa/US10E_PUBCOMB.pep: *
18: /cgn2_6/ptodata/1/pubpaa/US10F_PUBCOMB.pep: *
19: /cgn2_6/ptodata/1/pubpaa/US11A_PUBCOMB.pep: *
20: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep: *
21: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep: *
22: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1685	100.0	327	9	US-09-820-893-60
2	1685	100.0	327	15	US-10-607-565-60
3	1677	99.5	327	14	US-10-227-884-236
4	1677	99.5	327	14	US-10-230-163-236
5	1677	99.5	327	14	US-10-230-338-236
6	1677	99.5	327	14	US-10-218-631-236
7	1677	99.5	327	14	US-10-230-414-236
8	1677	99.5	327	14	US-10-232-224-236
9	1677	99.5	327	14	US-10-216-159A-236
10	1677	99.5	327	14	US-10-218-849-236
11	1677	99.5	327	14	US-10-227-873-236

12	1677	99.5	327	14	US-10-227-883-236	Sequence 236, App
13	1677	99.5	327	14	US-10-219-076-236	Sequence 236, App
14	1677	99.5	327	14	US-10-230-434-236	Sequence 236, App
15	1677	99.5	327	14	US-10-219-003-236	Sequence 236, App
16	1677	99.5	327	14	US-10-219-075-236	Sequence 236, App
17	1677	99.5	327	14	US-10-219-464-236	Sequence 236, App
18	1677	99.5	327	14	US-10-219-466-236	Sequence 236, App
19	1677	99.5	327	14	US-10-219-479-236	Sequence 236, App
20	1677	99.5	327	14	US-10-219-481-236	Sequence 236, App
21	1677	99.5	327	14	US-10-230-260-236	Sequence 236, App
22	1677	99.5	327	14	US-10-232-231-236	Sequence 236, App
23	1677	99.5	327	14	US-10-232-233-236	Sequence 236, App
24	1677	99.5	327	14	US-10-216-165-236	Sequence 236, App
25	1677	99.5	327	14	US-10-218-956-236	Sequence 236, App
26	1677	99.5	327	14	US-10-219-468-236	Sequence 236, App
27	1677	99.5	327	14	US-10-219-478-236	Sequence 236, App
28	1677	99.5	327	14	US-10-219-536-236	Sequence 236, App
29	1677	99.5	327	14	US-10-233-205-236	Sequence 236, App
30	1677	99.5	327	14	US-10-219-072-236	Sequence 236, App
31	1677	99.5	327	14	US-10-219-474-236	Sequence 236, App
32	1677	99.5	327	14	US-10-219-474-236	Sequence 236, App
33	1677	99.5	327	14	US-10-219-524-236	Sequence 236, App
34	1677	99.5	327	14	US-10-219-528-236	Sequence 236, App
35	1677	99.5	327	14	US-10-227-881-236	Sequence 236, App
36	1677	99.5	327	14	US-10-227-882-236	Sequence 236, App
37	1677	99.5	327	14	US-10-230-436-236	Sequence 236, App
38	1677	99.5	327	14	US-10-227-881-236	Sequence 236, App
39	1677	99.5	327	14	US-10-232-223-236	Sequence 236, App
40	1677	99.5	327	14	US-10-232-225-236	Sequence 236, App
41	1677	99.5	327	14	US-10-232-227-236	Sequence 236, App
42	1677	99.5	327	14	US-10-232-229-236	Sequence 236, App
43	1677	99.5	327	14	US-10-232-234-236	Sequence 236, App
44	1677	99.5	327	14	US-10-219-060-236	Sequence 236, App
45	1677	99.5	327	14	US-10-216-160-236	Sequence 236, App

ALIGNMENTS

RESULT 1
US-09-820-893-60
; Sequence 60, Application US/09820893
; Patent No. US20020076705A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human Secreted Proteins
; FILE REFERENCE: P2033PI
; CURRENT APPLICATION NUMBER: US/09/820,893
; CURRENT FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 09/531,119
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: 60/102,895
; PRIOR FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 60
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-820-893-60

Query Match 100.0%; Score 1685; DB 9; Length 327;
Best Local Similarity 100.0%; Pred No. 7.8e-120;
Matches 324; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 LFGPFLCGALLGFLCLSLGSLAVEKVPTEPLSTPLGKTABLTCTYSTSVGDSFALEWSFVQ 60
Db 4 LFGPFLCGALLGFLCLSLGSLAVEKVPTEPLSTPLGKTABLTCTYSTSVGDSFALEWSFVQ 63
QY 61 PGKPTSESHPIFYFTNGHLYPTGSKSKRVSLLONPPTGVATLKLTDVHPDSTGYLCQV 120
Db 64 PGKPTSESHPIFYFTNGHLYPTGSKSKRVSLLONPPTGVATLKLTDVHPDSTGYLCQV 123

;
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/115558
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115565
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115733
; PRIOR FILING DATE: 1999-01-12

;
; PRIOR APPLICATION NUMBER: 60/119549
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/123618
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/125259
; PRIOR FILING DATE: 1999-03-19
; PRIOR APPLICATION NUMBER: 60/125775
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 60/126773
; PRIOR FILING DATE: 1999-03-29
; PRIOR APPLICATION NUMBER: 60/127887
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 60/130232
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: 60/131022
; PRIOR FILING DATE: 1999-04-26
; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14
; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/144758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.5%; Score 1677; DB 14; Length 327;

Best Local Similarity 99.7%; Pred. No. 3.2e-119;

Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LRGPFLLCGALLGFLCLSLGLAVEVVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60

Db 4 LRGPFLLCGALLGFLCLSLGLAVEVVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63

QY 61 PGKPISESHPILYFTNGHLYPTGSKSKRVSLLONPVTGVATLKLTDVHPSDTGTLYCQV 120

Db 64 PGKPISESHPILYFTNGHLYPTGSKSKRVSLLONPVTGVATLKLTDVHPSDTGTLYCQV 123

QY 121 NNPPDPFYTNGLGLINLTVLVPPSNPLCSQSGQTSVCGSTALRCSSEGAPKPYNNWVRLG 180

Db 124 NNPPDPFYTNGLGLINLTVLVPPSNPLCSQSGQTSVCGSTALRCSSEGAPKPYNNWVRLG 183

QY 181 TPTTPSPGSMVQDEVSGQILNLNLSTSSGTVCRCVATNQMGASCBELTSLVTPPPQGRVA 240

Db 184 TPTTPSPGSMVQDEVSGQILNLNLSTSSGTVCRCVATNQMGASCBELTSLVTPPPQGRVA 244

OY 241 GALIGVLLGVLLLSVAACFLVRFOKRGKKPKETTYGGSDLRDADATAPGISEHTCMRADSS 300
Db |||||
244 GALIGVLLGVLLLSVAACFLVRFOKRGKKPKETTYGGSDLRDADATAPGISEHTCMRADSS 303
OY 301 KGFLERPSSASTVTTTTSKSLPMVV 324
Db ||||| 304 KGFLERPSSASTVTTTTSKSLPMVV 327

RESULT 4

US-10-230-163-236
; Sequence 236, Application US/10230163
; Publication No. US20030036635A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC96
; CURRENT APPLICATION NUMBER: US/10/230,163
; PRIOR FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24

; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422

PRIOR FILING DATE: 1998-12-15
PRIOR APPLICATION NUMBER: 60/113296
PRIOR FILING DATE: 1998-12-22
PRIOR APPLICATION NUMBER: 60/113605
PRIOR FILING DATE: 1998-12-23
PRIOR APPLICATION NUMBER: 60/113621
PRIOR FILING DATE: 1998-12-23
PRIOR APPLICATION NUMBER: 60/115558
PRIOR FILING DATE: 1999-01-12
PRIOR APPLICATION NUMBER: 60/115565
PRIOR FILING DATE: 1999-01-12
PRIOR APPLICATION NUMBER: 60/115733
PRIOR FILING DATE: 1999-01-12
PRIOR APPLICATION NUMBER: 60/119549
PRIOR FILING DATE: 1999-02-10
PRIOR APPLICATION NUMBER: 60/123618
PRIOR FILING DATE: 1999-03-10
PRIOR APPLICATION NUMBER: 60/125259
PRIOR FILING DATE: 1999-03-19
PRIOR APPLICATION NUMBER: 60/125775
PRIOR FILING DATE: 1999-03-23
PRIOR APPLICATION NUMBER: 60/126773
PRIOR FILING DATE: 1999-03-29
PRIOR APPLICATION NUMBER: 60/127887
PRIOR FILING DATE: 1999-04-05
PRIOR APPLICATION NUMBER: 60/130232
PRIOR FILING DATE: 1999-04-21
PRIOR APPLICATION NUMBER: 60/131022
PRIOR FILING DATE: 1999-04-26
PRIOR APPLICATION NUMBER: 60/131270
PRIOR FILING DATE: 1999-04-27
PRIOR APPLICATION NUMBER: 60/131291
PRIOR FILING DATE: 1999-04-27
PRIOR APPLICATION NUMBER: 60/131445
PRIOR FILING DATE: 1999-04-28
PRIOR APPLICATION NUMBER: 60/134287
PRIOR FILING DATE: 1999-05-14
PRIOR APPLICATION NUMBER: 60/140650
PRIOR FILING DATE: 1999-06-22
PRIOR APPLICATION NUMBER: 60/140723
PRIOR FILING DATE: 1999-06-22
PRIOR APPLICATION NUMBER: 60/141037
PRIOR FILING DATE: 1999-06-23
PRIOR APPLICATION NUMBER: 60/144758
PRIOR FILING DATE: 1999-07-20
PRIOR APPLICATION NUMBER: 60/145698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: 60/146222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: 60/146963
PRIOR FILING DATE: 1999-08-03
PRIOR APPLICATION NUMBER: 60/149320
PRIOR FILING DATE: 1999-08-17
PRIOR APPLICATION NUMBER: 60/149638
PRIOR FILING DATE: 1999-08-17
PRIOR APPLICATION NUMBER: 60/151733
PRIOR FILING DATE: 1999-08-31
PRIOR APPLICATION NUMBER: 60/164418
PRIOR FILING DATE: 1999-11-09
PRIOR APPLICATION NUMBER: 60/166361
PRIOR FILING DATE: 1999-11-16
PRIOR APPLICATION NUMBER: 60/169445
PRIOR FILING DATE: 1999-12-07
PRIOR APPLICATION NUMBER: 60/169495
PRIOR FILING DATE: 1999-12-07
PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.5%; Score 1677; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.2e-119;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
1 LPGPFLCGALLGFLCLSLGLAVEKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 60
|||||

Db 4 LPGPFLCGALLGFLCLSLGLAVEKVPTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 63
Qy 61 PGKPISESHPILYFTNGHLYPTGSKRVSLLQNPPVGVATLKLTDVHPSDTGYLCQV 120
Db 64 PGKPISESHPILYFTNGHLYPTGSKRVSLLQNPPVGVATLKLTDVHPSDTGYLCQV 123
Qy 121 NNPPDFYTNGLGLINLTIVLPSPNPLCSQSGQTSVGSSTALRCSSEGAPKPYNNWVRLG 180
Db 124 NNPPDFYTNGLGLINLTIVLPSPNPLCSQSGQTSVGSSTALRCSSEGAPKPYNNWVRLG 183
Qy 181 TPPTSPGSMQVDEVSQGLILTNLSLTSSGTYRCVATNQMSASCBLTILSVTPPQGRVA 240
Db 184 TPPTSPGSMQVDEVSQGLILTNLSLTSSGTYRCVATNQMSASCBLTILSVTPPQGRVA 243
Qy 241 GALIGVLLGVLILLSVAACFCLVRPQKRGKKPKETYCGSLRDIAIAPGISEHTCMRADSS 300
Db 244 GALIGVLLGVLILLSVAACFCLVRPQKRGKKPKETYCGSLRDIAIAPGISEHTCMRADSS 303
Qy 301 KGFLERPSSASTVTTTKSKLPMVV 324
Db 304 KGFLERPSSASTVTTTKSKLPMVV 327

RESULT 5
US-10-230-338-236
; Sequence 236, Application US/10230338
; Publication No. US2003004934A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530PIC92
; CURRENT APPLICATION NUMBER: US/10/230,338
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-230-338-236
Query Match 99.5%; Score 1677; DB 14; Length 327;

Best Local Similarity 99.7%; Pred. No. 3.2e-119; Mismatches 0; Gaps 0; Indels 0; Length 327;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LFGPFLCGALLGFLCLSGLAIVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
Db 4 LFGPFLCGALLGFLCLSGLAIVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63

QY 61 PKPITSESHPILYFTNGHLYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYLCOV 120
Db 64 PKPITSESHPILYFTNGHLYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYLCOV 123

QY 121 NNPPDFYNTGLGLNLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLG 180
Db 124 NNPPDFYNTGLGLNLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLG 183

QY 181 TPTTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSCASCELTLSTVTEPPQGRVA 240
Db 184 TPTTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSCASCELTLSTVTEPPQGRVA 243

QY 241 GALIGVLLGVLLSVAAFCVRFQKRGKKPKETTYGGSDLRDAIAPGISEHTCMRADSS 300
Db 244 GALIGVLLGVLLSVAAFCVRFQKRGKKPKETTYGGSDLRDAIAPGISEHTCMRADSS 303

QY 301 KGFLERPSSASTVTTTTSKLPWV 324
Db 304 KGFLERPSSASTVTTTTSKLPWV 327

RESULT 6

US-10-218-631-236
; Sequence 236, Application US/10218631
; Publication No. US20030045687A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C14
; CURRENT APPLICATION NUMBER: US/10/218,631
; PRIOR FILING DATE: 2002-08-12
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327

; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-631-236

Query Match 99.5%; Score 1677; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.2e-119;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LFGPFLCGALLGFLCLSGLAIVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
Db 4 LFGPFLCGALLGFLCLSGLAIVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63

QY 61 PKPITSESHPILYFTNGHLYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYLCOV 120
Db 64 PKPITSESHPILYFTNGHLYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYLCOV 123

QY 121 NNPPDFYNTGLGLNLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLG 180
Db 124 NNPPDFYNTGLGLNLTVLPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNVRLG 183

QY 181 TPTTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSCASCELTLSTVTEPPQGRVA 240
Db 184 TPTTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSCASCELTLSTVTEPPQGRVA 243

QY 241 GALIGVLLGVLLSVAAFCVRFQKRGKKPKETTYGGSDLRDAIAPGISEHTCMRADSS 300
Db 244 GALIGVLLGVLLSVAAFCVRFQKRGKKPKETTYGGSDLRDAIAPGISEHTCMRADSS 303

QY 301 KGFLERPSSASTVTTTTSKLPWV 324
Db 304 KGFLERPSSASTVTTTTSKLPWV 327

RESULT 7

US-10-230-414-236
; Sequence 236, Application US/10230414
; Publication No. US20030050448A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C98
; CURRENT APPLICATION NUMBER: US/10/230,414
; PRIOR FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728

1 PRIOR APPLICATION NUMBER: 60/079294
 2
 3 PRIOR FILING DATE: 1998-03-25
 4
 5 PRIOR APPLICATION NUMBER: 60/079656
 6
 7 PRIOR FILING DATE: 1998-03-26
 8
 9 PRIOR APPLICATION NUMBER: 60/079728
 10
 11 PRIOR FILING DATE: 1998-03-27
 12
 13 Remaining Prior Application data removed - See File Wrapper or PALM
 14 NUMBER OF SEQ IN PGS: 245
 15

```

; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-232-224-236

Query Match          99.5%; Score 1677; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.2e-119;
Matches 32; Conservative 0; Mismatches 1; Indels 0; Gaps 0

QY      1  LPGPFLCGALLGFLCGLAVEVKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
      |||
Db       4  LPGPFLCGALLGFLCGLAVEVKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63

QY      61  PGKPISBSHPILYFTNGHLVPTGSKSRVSLQNPPVTGVATLKLTDVHPSDTGTLYLCOV 120
      |||
Db       64  PGKPISBSHPILYFTNGHLVPTGSKSRVSLQNPPVTGVATLKLTDVHPSDTGTLYLCOV 123

QY      121  NNPPDPFYTNGLGLINLTLYVPPNPLCSQSGQTSVGGSTALRCSSSEGAKPKVYNWVRLG 180
      |||
Db       124  NNPPDPFYTNGLGLINLTLYVPPNPLCSQSGQTSVGGSTALRCSSSEGAKPKVYNWVRLG 183

QY      181  TFTPSPGSMVDEVSGQLILTNLSSTSGTYRCVATNQMSASCELTLSVTEPPQGRVA 240
      |||
Db       184  TFTPSPGSMVDEVSGQLILTNLSSTSGTYRCVATNQMSASCELTLSVTEPPQGRVA 243

QY      241  GALLIGVLLGLVLLSVAACFLVRFOKRGKKPKETYGGSDLRDIAIPGISBHTCWADRSS 300
      |||

```

RESULT 9
US-10-216-159A-236
; Sequence 236, Application US/10216159A
; Publication No. US20030069397A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe P.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530PIC6
; CURRENT APPLICATION NUMBER: US/10/216,159A
; CURRENT FILING DATE: 2002-08-09
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103

```
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-216-159A-236

Query Match          99.5%; Score 1677; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.2e-119;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LPPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 60
Db 4 LPPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 63

QY 61 PGKPISSEHPILYFTNGHLYPTGSKSRVLSLQNPPTVGVAATLKLTVDHPSDTGYLCOV 120
Db 64 PGKPISSEHPILYFTNGHLYPTGSKSRVLSLQNPPTVGVAATLKLTVDHPSDTGYLCOV 123

QY 121 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRLG 180
Db 124 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRLG 183

QY 181 TPTTSPGSMQVDEVSQGLILTNLSLTSSGTVCVATNOMGSASCELTLSTVTEPPQGRVA 240
Db 184 TPTTSPGSMQVDEVSQGLILTNLSLTSSGTVCVATNOMGSASCELTLSTVTEPPQGRVA 243

QY 241 GALIGVLLGVLLSVAAPCLVRFQKRGKKPKETYGGSGLRDLREDAIAPGISHTCMRADSS 300
Db 244 GALIGVLLGVLLSVAAPCLVRFQKRGKKPKETYGGSGLRDLREDAIAPGISHTCMRADSS 303

QY 301 KGFLERPSSASTVTTTTSKLPWV 324
Db 304 KGFLERPSSASTVTTTTSKLPWV 327

RESULT 10
US-10-218-849-236
; Sequence 236, Application US/10218849
; Publication No. US20030073814A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC11
; CURRENT APPLICATION NUMBER: US/10/218,849
; CURRENT FILING DATE: 2002-08-12
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
```

```
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-849-236

Query Match          99.5%; Score 1677; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.2e-119;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LPPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 60
Db 4 LPPFLCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 63

QY 61 PGKPISSEHPILYFTNGHLYPTGSKSRVLSLQNPPTVGVAATLKLTVDHPSDTGYLCOV 120
Db 64 PGKPISSEHPILYFTNGHLYPTGSKSRVLSLQNPPTVGVAATLKLTVDHPSDTGYLCOV 123

QY 121 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRLG 180
Db 124 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRLG 183

QY 181 TPTTSPGSMQVDEVSQGLILTNLSLTSSGTVCVATNOMGSASCELTLSTVTEPPQGRVA 240
Db 184 TPTTSPGSMQVDEVSQGLILTNLSLTSSGTVCVATNOMGSASCELTLSTVTEPPQGRVA 243

QY 241 GALIGVLLGVLLSVAAPCLVRFQKRGKKPKETYGGSGLRDLREDAIAPGISHTCMRADSS 300
Db 244 GALIGVLLGVLLSVAAPCLVRFQKRGKKPKETYGGSGLRDLREDAIAPGISHTCMRADSS 303

QY 301 KGFLERPSSASTVTTTTSKLPWV 324
Db 304 KGFLERPSSASTVTTTTSKLPWV 327

RESULT 11
US-10-227-873-236
; Sequence 236, Application US/10227873
; Publication No. US20030073816A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC72
; CURRENT APPLICATION NUMBER: US/10/227,873
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
```


;	PRIOR FILING DATE:	1998-03-27	;
;	PRIOR APPLICATION NUMBER:	60/081819	;
;	PRIOR FILING DATE:	1998-04-15	;
;	PRIOR APPLICATION NUMBER:	60/081955	;
;	PRIOR FILING DATE:	1998-04-15	;
;	PRIOR APPLICATION NUMBER:	60/082804	;
;	PRIOR FILING DATE:	1998-04-22	;
;	PRIOR APPLICATION NUMBER:	60/084441	;
;	PRIOR FILING DATE:	1998-05-06	;
;	PRIOR APPLICATION NUMBER:	60/085323	;
;	PRIOR FILING DATE:	1998-05-13	;
;	PRIOR APPLICATION NUMBER:	60/085579	;
;	PRIOR FILING DATE:	1998-05-15	;
;	PRIOR APPLICATION NUMBER:	60/086392	;
;	PRIOR FILING DATE:	1998-05-22	;
;	PRIOR APPLICATION NUMBER:	60/089532	;
;	PRIOR FILING DATE:	1998-06-17	;
;	PRIOR APPLICATION NUMBER:	60/089538	;
;	PRIOR FILING DATE:	1998-06-17	;
;	PRIOR APPLICATION NUMBER:	60/089905	;
;	PRIOR FILING DATE:	1998-06-18	;
;	PRIOR APPLICATION NUMBER:	60/090472	;
;	PRIOR FILING DATE:	1998-06-24	;
;	PRIOR APPLICATION NUMBER:	60/090557	;
;	PRIOR FILING DATE:	1998-06-24	;
;	PRIOR APPLICATION NUMBER:	60/090691	;
;	PRIOR FILING DATE:	1998-06-25	;
;	PRIOR APPLICATION NUMBER:	60/090695	;
;	PRIOR FILING DATE:	1998-06-25	;
;	PRIOR APPLICATION NUMBER:	60/091982	;
;	PRIOR FILING DATE:	1998-07-07	;
;	PRIOR APPLICATION NUMBER:	60/095302	;
;	PRIOR FILING DATE:	1998-08-04	;
;	PRIOR APPLICATION NUMBER:	60/095318	;
;	PRIOR FILING DATE:	1998-08-04	;
;	PRIOR APPLICATION NUMBER:	60/095916	;
;	PRIOR FILING DATE:	1998-08-10	;
;	PRIOR APPLICATION NUMBER:	60/096146	;
;	PRIOR FILING DATE:	1998-08-11	;
;	PRIOR APPLICATION NUMBER:	60/096791	;
;	PRIOR FILING DATE:	1998-08-17	;
;	PRIOR APPLICATION NUMBER:	60/097986	;
;	PRIOR FILING DATE:	1998-08-26	;
;	PRIOR APPLICATION NUMBER:	60/098544	;
;	PRIOR FILING DATE:	1998-08-31	;
;	PRIOR APPLICATION NUMBER:	60/099596	;
;	PRIOR FILING DATE:	1998-09-09	;
;	PRIOR APPLICATION NUMBER:	60/099598	;
;	PRIOR FILING DATE:	1998-09-09	;
;	PRIOR APPLICATION NUMBER:	60/099803	;
;	PRIOR FILING DATE:	1998-09-10	;
;	PRIOR APPLICATION NUMBER:	60/099811	;
;	PRIOR FILING DATE:	1998-09-10	;
;	PRIOR APPLICATION NUMBER:	60/100038	;
;	PRIOR FILING DATE:	1998-09-11	;
;	PRIOR APPLICATION NUMBER:	60/100385	;
;	PRIOR FILING DATE:	1998-09-15	;
;	PRIOR APPLICATION NUMBER:	60/100390	;
;	PRIOR FILING DATE:	1998-09-15	;
;	PRIOR APPLICATION NUMBER:	60/100627	;
;	PRIOR FILING DATE:	1998-09-16	;
;	PRIOR APPLICATION NUMBER:	60/100848	;
;	PRIOR FILING DATE:	1998-09-18	;
;	PRIOR APPLICATION NUMBER:	60/100919	;
;	PRIOR FILING DATE:	1998-09-17	;
;	PRIOR APPLICATION NUMBER:	60/101477	;
;	PRIOR FILING DATE:	1998-09-23	;
;	PRIOR APPLICATION NUMBER:	60/101738	;
;	PRIOR FILING DATE:	1998-09-24	;

1	1	PRIOR APPLICATION NUMBER: 60/101744	1
2	2	PRIOR FILING DATE: 1998-09-24	2
3	3	PRIOR APPLICATION NUMBER: 60/101786	3
4	4	PRIOR FILING DATE: 1998-09-25	4
5	5	PRIOR APPLICATION NUMBER: 60/101916	5
6	6	PRIOR FILING DATE: 1998-09-24	6
7	7	PRIOR APPLICATION NUMBER: 60/101922	7
8	8	PRIOR FILING DATE: 1998-09-24	8
9	9	PRIOR APPLICATION NUMBER: 60/106178	9
10	10	PRIOR FILING DATE: 1998-10-28	10
11	11	PRIOR APPLICATION NUMBER: 60/106248	11
12	12	PRIOR FILING DATE: 1998-10-29	12
13	13	PRIOR APPLICATION NUMBER: 60/106464	13
14	14	PRIOR FILING DATE: 1998-10-30	14
15	15	PRIOR APPLICATION NUMBER: 60/106905	15
16	16	PRIOR FILING DATE: 1998-11-03	16
17	17	PRIOR APPLICATION NUMBER: 60/108787	17
18	18	PRIOR FILING DATE: 1998-11-17	18
19	19	PRIOR APPLICATION NUMBER: 60/108800	19
20	20	PRIOR FILING DATE: 1998-11-17	20
21	21	PRIOR APPLICATION NUMBER: 60/108849	21
22	22	PRIOR FILING DATE: 1998-11-18	22
23	23	PRIOR APPLICATION NUMBER: 60/112422	23
24	24	PRIOR FILING DATE: 1998-12-15	24
25	25	PRIOR APPLICATION NUMBER: 60/113296	25
26	26	PRIOR FILING DATE: 1998-12-22	26
27	27	PRIOR APPLICATION NUMBER: 60/113605	27
28	28	PRIOR FILING DATE: 1998-12-23	28
29	29	PRIOR APPLICATION NUMBER: 60/113621	29
30	30	PRIOR FILING DATE: 1998-12-23	30
31	31	PRIOR APPLICATION NUMBER: 60/115558	31
32	32	PRIOR FILING DATE: 1999-01-12	32
33	33	PRIOR APPLICATION NUMBER: 60/115565	33
34	34	PRIOR FILING DATE: 1999-01-12	34
35	35	PRIOR APPLICATION NUMBER: 60/115733	35
36	36	PRIOR FILING DATE: 1999-01-12	36
37	37	PRIOR APPLICATION NUMBER: 60/119549	37
38	38	PRIOR FILING DATE: 1999-02-10	38
39	39	PRIOR APPLICATION NUMBER: 60/123618	39
40	40	PRIOR FILING DATE: 1999-03-10	40
41	41	PRIOR APPLICATION NUMBER: 60/125259	41
42	42	PRIOR FILING DATE: 1999-03-19	42
43	43	PRIOR APPLICATION NUMBER: 60/125775	43
44	44	PRIOR FILING DATE: 1999-03-23	44
45	45	PRIOR APPLICATION NUMBER: 60/126773	45
46	46	PRIOR FILING DATE: 1999-03-29	46
47	47	PRIOR APPLICATION NUMBER: 60/127887	47
48	48	PRIOR FILING DATE: 1999-04-05	48
49	49	PRIOR APPLICATION NUMBER: 60/130232	49
50	50	PRIOR FILING DATE: 1999-04-21	50
51	51	PRIOR APPLICATION NUMBER: 60/131022	51
52	52	PRIOR FILING DATE: 1999-04-26	52
53	53	PRIOR APPLICATION NUMBER: 60/131270	53
54	54	PRIOR FILING DATE: 1999-04-27	54
55	55	PRIOR APPLICATION NUMBER: 60/131291	55
56	56	PRIOR FILING DATE: 1999-04-27	56
57	57	PRIOR APPLICATION NUMBER: 60/131445	57
58	58	PRIOR FILING DATE: 1999-04-28	58
59	59	PRIOR APPLICATION NUMBER: 60/134287	59
60	60	PRIOR FILING DATE: 1999-05-14	60
61	61	PRIOR APPLICATION NUMBER: 60/140650	61
62	62	PRIOR FILING DATE: 1999-06-22	62
63	63	PRIOR APPLICATION NUMBER: 60/140723	63
64	64	PRIOR FILING DATE: 1999-06-22	64
65	65	PRIOR APPLICATION NUMBER: 60/141037	65
66	66	PRIOR FILING DATE: 1999-06-23	66
67	67	PRIOR APPLICATION NUMBER: 60/144758	67
68	68	PRIOR FILING DATE: 1999-07-20	68
69	69	PRIOR APPLICATION NUMBER: 60/145698	69
70	70	PRIOR FILING DATE: 1999-07-26	70
71	71	PRIOR APPLICATION NUMBER: 60/146222	71
72	72	PRIOR FILING DATE: 1999-07-28	72
73	73	PRIOR APPLICATION NUMBER: 60/146963	73

```
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
```

```
Query Match          99.5%; Score 1677; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.2e-119;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LRGPFLLCGALLGFLCLSLGLAVEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
    |||||
Db 4 LRGPFLLCGALLGFLCLSLGLAVEKVPTEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
    |||||

QY 61 PKPTISEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYLQGV 120
    |||||
Db 64 PKPTISEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGVATLKLTDVHPSDTGYLQGV 123
    |||||

QY 121 NNPPDYFTNGGLINLTVLVPSPNPLCSOGSTVGGSTALRCSSEGAPKPVYNWVRIG 180
    |||||
Db 124 NNPPDYFTNGGLINLTVLVPSPNPLCSOGSTVGGSTALRCSSEGAPKPVYNWVRIG 183
    |||||

QY 181 TPTFTSPGSMVDVSGQLILNLSLTSSGTYRCVATNQMSASCELTLTSVTEPPQGRVA 240
    |||||
Db 184 TPTFTSPGSMVDVSGQLILNLSLTSSGTYRCVATNQMSASCELTLTSVTEPPQGRVA 243
    |||||

QY 241 GALIGVLLGVLLSVAAPCLVRFQERKKPKETTYGGSDLRDADAIPGISEHTCMRADSS 300
    |||||
Db 244 GALIGVLLGVLLSVAAPCLVRFQERKKPKETTYGGSDLRDADAIPGISEHTCMRADSS 303
    |||||

QY 301 KGFLEPSSASTVTTKSKLPMWV 324
    |||||
Db 304 KGFLEPSSASTVTTKSKLPMWV 327
    |||||

RESULT 12
US-10-227-883-236
; Sequence 236, Application US/10227883
; Publication No. US20030073817A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC78
; CURRENT APPLICATION NUMBER: US/10/227,883
; PRIOR FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
```

; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/115558
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115565
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115733
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/119549
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/123618
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/125259
; PRIOR FILING DATE: 1999-03-19
; PRIOR APPLICATION NUMBER: 60/125775
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 60/126773
; PRIOR FILING DATE: 1999-03-29
; PRIOR APPLICATION NUMBER: 60/127887
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 60/130232
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: 60/131022
; PRIOR FILING DATE: 1999-04-26
; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14

; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/144758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.5%; Score 1677; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.2e-119;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LPGPFLLGALLGFLCLSLGLAVEVVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
DB 4 LPGPFLLGALLGFLCLSLGLAVEVVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63

QY 61 PGKPISESHPILYFTNGHLYPTGSKRSVLLQNPPTVGATLKLTDVHPSDTGTLYLCQV 120
DB 64 PGKPISESHPILYFTNGHLYPTGSKRSVLLQNPPTVGATLKLTDVHPSDTGTLYLCQV 123

QY 121 NNPPDFYTNGLGLINLTVLPPSNPLCSQSGQTSVGSSTALRCSSEGAPKPVYNNWVRLG 180
DB 124 NNPPDFYTNGLGLINLTVLPPSNPLCSQSGQTSVGSSTALRCSSEGAPKPVYNNWVRLG 183

QY 181 TPTSPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLTSVTEPPQGRVA 240
DB 184 TPTSPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGASCELTLTSVTEPPQGRVA 243

QY 241 GALIGVLLGVLLLSVAACFLVRFOKRGKKPKETYGSDLRDAIAPGISEHTCMRADSS 300
DB 244 GALIGVLLGVLLLSVAACFLVRFOKRGKKPKETYGSDLRDAIAPGISEHTCMRADSS 303

QY 301 KGFLERPSSASTVTTTKSKLPWV 324
DB 304 KGFLERPSSASTVTTTKSKLPWV 327

RESULT 13
US-10-219-076-236
; Sequence 236, Application US/10219076
; Publication No. US20030078379A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.

```
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530P1C62
; CURRENT APPLICATION NUMBER: US/10/219,076
; CURRENT FILING DATE: 2002-08-14
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986

; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe P.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530P1C82
; CURRENT APPLICATION NUMBER: US/10/230,434
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986

Query Match 99.5%; Score 1677; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.2e-119;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LFGPFLCGALLGFLCGLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTVSGDSPALEWSFVQ 60
Db 4 LFGPFLCGALLGFLCGLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTVSGDSPALEWSFVQ 63
QY 61 PKGPISHPILYFTNGHLIYPTGSKSKRVSLQNPPTVGAVATLKLDVHPSPDTGYLCOV 120
Db 64 PKGPISHPILYFTNGHLIYPTGSKSKRVSLQNPPTVGAVATLKLDVHPSPDTGYLCOV 123
QY 121 NNPPDPYNTGLGINLTVLPSPNPLCSOGQTSVGGSTALRCSSSEGAPKPVYNWVRIG 180
Db 124 NNPPDPYNTGLGINLTVLPSPNPLCSOGQTSVGGSTALRCSSSEGAPKPVYNWVRIG 183
QY 181 TPTTSPGSMQDEVSGQILNLNLSITSSGTYRCVATNQMGASCELTLSTVTEPPQGRVA 240
Db 184 TPTTSPGSMQDEVSGQILNLNLSITSSGTYRCVATNQMGASCELTLSTVTEPPQGRVA 243
QY 241 GALIGVLLGVLLSVAACFLVRFQERKKPKETVGGSDLRDAIAPGISEHTCMRADSS 300
Db 244 GALIGVLLGVLLSVAACFLVRFQERKKPKETVGGSDLRDAIAPGISEHTCMRADSS 303
QY 301 KGFLERPSSASTVTTTKSLPMVV 324
Db 304 KGFLERPSSASTVTTTKSLPMVV 327

RESULT 14
US-10-230-434-236
; Sequence 236, Application US/10230434
; Publication No. US20030078380A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
```

;; PRIOR FILING DATE: 1998-08-26
;; PRIOR APPLICATION NUMBER: 60/098544
;; PRIOR FILING DATE: 1998-08-31
;; PRIOR APPLICATION NUMBER: 60/099596
;; PRIOR FILING DATE: 1998-09-09
;; PRIOR APPLICATION NUMBER: 60/099598
;; PRIOR FILING DATE: 1998-09-09
;; PRIOR APPLICATION NUMBER: 60/099803
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/099811
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/099812
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/099816
;; PRIOR FILING DATE: 1998-09-10
;; PRIOR APPLICATION NUMBER: 60/100038
;; PRIOR FILING DATE: 1998-09-11
;; PRIOR APPLICATION NUMBER: 60/100385
;; PRIOR FILING DATE: 1998-09-15
;; PRIOR APPLICATION NUMBER: 60/100390
;; PRIOR FILING DATE: 1998-09-15
;; PRIOR APPLICATION NUMBER: 60/100627
;; PRIOR FILING DATE: 1998-09-16
;; PRIOR APPLICATION NUMBER: 60/100848
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/100919
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/101477
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101738
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101741
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101786
;; PRIOR FILING DATE: 1998-09-25
;; PRIOR APPLICATION NUMBER: 60/101916
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101922
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/106178
;; PRIOR FILING DATE: 1998-10-28
;; PRIOR APPLICATION NUMBER: 60/106248
;; PRIOR FILING DATE: 1998-10-29
;; PRIOR APPLICATION NUMBER: 60/106464
;; PRIOR FILING DATE: 1998-10-30
;; PRIOR APPLICATION NUMBER: 60/106905
;; PRIOR FILING DATE: 1998-11-03
;; PRIOR APPLICATION NUMBER: 60/108787
;; PRIOR FILING DATE: 1998-11-17
;; PRIOR APPLICATION NUMBER: 60/108801
;; PRIOR FILING DATE: 1998-11-17
;; PRIOR APPLICATION NUMBER: 60/108849
;; PRIOR FILING DATE: 1998-11-18
;; PRIOR APPLICATION NUMBER: 60/112422
;; PRIOR FILING DATE: 1998-12-15
;; PRIOR APPLICATION NUMBER: 60/113296
;; PRIOR FILING DATE: 1998-12-22
;; PRIOR APPLICATION NUMBER: 60/113605
;; PRIOR FILING DATE: 1998-12-23
;; PRIOR APPLICATION NUMBER: 60/113621
;; PRIOR FILING DATE: 1998-12-23
;; PRIOR APPLICATION NUMBER: 60/115558
;; PRIOR FILING DATE: 1999-01-12
;; PRIOR APPLICATION NUMBER: 60/115565
;; PRIOR FILING DATE: 1999-01-12
;; PRIOR APPLICATION NUMBER: 60/115733
;; PRIOR FILING DATE: 1999-01-12
;; PRIOR APPLICATION NUMBER: 60/119549
;; PRIOR FILING DATE: 1999-02-10
;; PRIOR APPLICATION NUMBER: 60/123618
;; PRIOR FILING DATE: 1999-03-10
;; PRIOR APPLICATION NUMBER: 60/125259
;; PRIOR FILING DATE: 1999-03-19

;; PRIOR APPLICATION NUMBER: 60/125775
;; PRIOR FILING DATE: 1999-03-23
;; PRIOR APPLICATION NUMBER: 60/126773
;; PRIOR FILING DATE: 1999-03-29
;; PRIOR APPLICATION NUMBER: 60/127887
;; PRIOR FILING DATE: 1999-04-05
;; PRIOR APPLICATION NUMBER: 60/130232
;; PRIOR FILING DATE: 1999-04-21
;; PRIOR APPLICATION NUMBER: 60/131022
;; PRIOR FILING DATE: 1999-04-26
;; PRIOR APPLICATION NUMBER: 60/131270
;; PRIOR FILING DATE: 1999-04-27
;; PRIOR APPLICATION NUMBER: 60/131291
;; PRIOR FILING DATE: 1999-04-27
;; PRIOR APPLICATION NUMBER: 60/131445
;; PRIOR FILING DATE: 1999-04-28
;; PRIOR APPLICATION NUMBER: 60/134287
;; PRIOR FILING DATE: 1999-05-14
;; PRIOR APPLICATION NUMBER: 60/140650
;; PRIOR FILING DATE: 1999-06-22
;; PRIOR APPLICATION NUMBER: 60/140723
;; PRIOR FILING DATE: 1999-06-22
;; PRIOR APPLICATION NUMBER: 60/141037
;; PRIOR FILING DATE: 1999-06-23
;; PRIOR APPLICATION NUMBER: 60/144758
;; PRIOR FILING DATE: 1999-07-20
;; PRIOR APPLICATION NUMBER: 60/145698
;; PRIOR FILING DATE: 1999-07-26
;; PRIOR APPLICATION NUMBER: 60/146222
;; PRIOR FILING DATE: 1999-07-28
;; PRIOR APPLICATION NUMBER: 60/149663
;; PRIOR FILING DATE: 1999-08-03
;; PRIOR APPLICATION NUMBER: 60/149320
;; PRIOR FILING DATE: 1999-08-17
;; PRIOR APPLICATION NUMBER: 60/149638
;; PRIOR FILING DATE: 1999-08-17
;; PRIOR APPLICATION NUMBER: 60/151733
;; PRIOR FILING DATE: 1999-08-31
;; PRIOR APPLICATION NUMBER: 60/164418
;; PRIOR FILING DATE: 1999-11-09
;; PRIOR APPLICATION NUMBER: 60/166361
;; PRIOR FILING DATE: 1999-11-16
;; PRIOR APPLICATION NUMBER: 60/169445
;; PRIOR FILING DATE: 1999-12-07
;; PRIOR APPLICATION NUMBER: 60/169495
;; PRIOR FILING DATE: 1999-12-07
;; PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.5%; Score 1677; DB 14; Length 327;

Best Local Similarity 99.7%; Pred. No. 3.2e-119;

Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LPGPFLCGALLGFLCISGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60

|||||
Db 4 LPGPFLCGALLGFLCISGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63

|||||
QY 61 PGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPTVCVATLKLTDVHPSDGTLYLCOV 120

|||||
Db 64 PGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPTVCVATLKLTDVHPSDGTLYLCOV 123

|||||
QY 121 NNPPDFYTNGLGLINLTVLPSPNPLCSQSGOTSVGGSTALRCSSEGAPKPVYNNVRLG 180

|||||
Db 124 NNPPDFYTNGLGLINLTVLPSPNPLCSQSGOTSVGGSTALRCSSEGAPKPVYNNVRLG 183

|||||
QY 181 TPPTSPGSMVQDEVSGQLILTNLSLTSSGTVCVATNMQGSASCELTLSVTEPPQGRVA 240

|||||
Db 184 TPPTSPGSMVQDEVSGQLILTNLSLTSSGTVCVATNMQGSASCELTLSVTEPPQGRVA 243

|||||
QY 241 GALIGVLLGVLALLSVAACFLVRFQERKKPKETYGGSGLREDATAIPGISEHTCMRADSS 300

|||||
Db 244 GALIGVLLGVLALLSVAACFLVRFQERKKPKETYGGSGLREDATAIPGISEHTCMRADSS 303

QY 301 KGFLERPSSASTVTTTTSKSLPMWV 324

102 PRIOR FILING DATE: 1998-12-23
103 PRIOR APPLICATION NUMBER: 60/115558
104 PRIOR FILING DATE: 1999-01-12
105 PRIOR APPLICATION NUMBER: 60/115565
106 PRIOR FILING DATE: 1999-01-12
107 PRIOR APPLICATION NUMBER: 60/115733
108 PRIOR FILING DATE: 1999-01-12
109 PRIOR APPLICATION NUMBER: 60/119549
110 PRIOR FILING DATE: 1999-02-10
111 PRIOR APPLICATION NUMBER: 60/123618
112 PRIOR FILING DATE: 1999-03-10
113 PRIOR APPLICATION NUMBER: 60/125259
114 PRIOR FILING DATE: 1999-03-19
115 PRIOR APPLICATION NUMBER: 60/125775
116 PRIOR FILING DATE: 1999-03-23
117 PRIOR APPLICATION NUMBER: 60/126773
118 PRIOR FILING DATE: 1999-03-29
119 PRIOR APPLICATION NUMBER: 60/127887
120 PRIOR FILING DATE: 1999-04-05
121 PRIOR APPLICATION NUMBER: 60/130232
122 PRIOR FILING DATE: 1999-04-21
123 PRIOR APPLICATION NUMBER: 60/131022
124 PRIOR FILING DATE: 1999-04-26
125 PRIOR APPLICATION NUMBER: 60/131270
126 PRIOR FILING DATE: 1999-04-27
127 PRIOR APPLICATION NUMBER: 60/131291
128 PRIOR FILING DATE: 1999-04-27
129 PRIOR APPLICATION NUMBER: 60/131445
130 PRIOR FILING DATE: 1999-04-28
131 PRIOR APPLICATION NUMBER: 60/134287
132 PRIOR FILING DATE: 1999-05-14
133 PRIOR APPLICATION NUMBER: 60/140650
134 PRIOR FILING DATE: 1999-06-22
135 PRIOR APPLICATION NUMBER: 60/140723
136 PRIOR FILING DATE: 1999-06-22
137 PRIOR APPLICATION NUMBER: 60/141037
138 PRIOR FILING DATE: 1999-06-23
139 PRIOR APPLICATION NUMBER: 60/144758
140 PRIOR FILING DATE: 1999-07-20
141 PRIOR APPLICATION NUMBER: 60/145698
142 PRIOR FILING DATE: 1999-07-26
143 PRIOR APPLICATION NUMBER: 60/146222
144 PRIOR FILING DATE: 1999-07-28
145 PRIOR APPLICATION NUMBER: 60/146963
146 PRIOR FILING DATE: 1999-08-03
147 PRIOR APPLICATION NUMBER: 60/149320
148 PRIOR FILING DATE: 1999-08-17
149 PRIOR APPLICATION NUMBER: 60/149638
150 PRIOR FILING DATE: 1999-08-17
151 PRIOR APPLICATION NUMBER: 60/151733
152 PRIOR FILING DATE: 1999-08-31
153 PRIOR APPLICATION NUMBER: 60/164418
154 PRIOR FILING DATE: 1999-11-09
155 PRIOR APPLICATION NUMBER: 60/166361
156 PRIOR FILING DATE: 1999-11-16
157 PRIOR APPLICATION NUMBER: 60/169445
158 PRIOR FILING DATE: 1999-12-07
159 PRIOR APPLICATION NUMBER: 60/169495
160 PRIOR FILING DATE: 1999-12-07
161 PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.5%; Score 1677; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.2e-119;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 LPGPFLCGALLGFLCGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
DB 4 LPGPFLCGALLGFLCGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
QY 61 PGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPTVGATVATKLTVDVHPSDTGTLYCQV 120
DB 64 PGKPISSEHPILYFTNGHLYPTGSKSRVSLQNPPTVGATVATKLTVDVHPSDTGTLYCQV 123

QY 121 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSOGQTSVGGSTALRCSSEGAPKPVYNWVRLG 180
DB 124 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSOGQTSVGGSTALRCSSEGAPKPVYNWVRLG 183
QY 181 TPTTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASASCELTLSTVTEPPQGRVA 240
DB 184 TPTTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNMGASASCELTLSTVTEPPQGRVA 243
QY 241 GALIGVLLGVLLLSVAAFCLVRFQKRGKKPKETYGSGDLREDAIAPGISEHTCMRADSS 300
DB 244 GALIGVLLGVLLLSVAAFCLVRFQKRGKKPKETYGSGDLREDAIAPGISEHTCMRADSS 303
QY 301 KGFLERPSSASTVTTTTSKSLPMVV 324
DB 304 KGFLERPSSASTVTTTTSKSLPMVV 327

Search completed: August 4, 2005, 06:47:27
Job time : 88.4135 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 4, 2005, 06:13:42 ; Search time 88.2229 Seconds
(without alignments)
1447.018 Million cell updates/sec

Title: US-10-607-565-60

Perfect score: 1699

Sequence: 1 MAELPGFLLCGALLGLFCLLS.....ERPSSASTVTTTKSLPMV 327

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1752860 seqs, 390397842 residues

Total number of hits satisfying chosen parameters: 1752860

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:*

1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US10E_PUBCOMB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
19: /cgn2_6/ptodata/1/pubpaa/US11A_PUBCOMB.pep.*
20: /cgn2_6/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
21: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
22: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1699	100.0	327	9	US-09-820-893-60
2	1699	100.0	327	15	US-10-607-565-60
3	1691	99.5	327	14	US-10-227-884-236
4	1691	99.5	327	14	US-10-230-163-236
5	1691	99.5	327	14	US-10-230-338-236
6	1691	99.5	327	14	US-10-218-631-236
7	1691	99.5	327	14	US-10-230-414-236
8	1691	99.5	327	14	US-10-232-224-236
9	1691	99.5	327	14	US-10-216-159A-236
10	1691	99.5	327	14	US-10-218-849-236
11	1691	99.5	327	14	US-10-227-873-236

12	1691	99.5	327	14	US-10-227-883-236	Sequence 236, App
13	1691	99.5	327	14	US-10-219-076-236	Sequence 236, App
14	1691	99.5	327	14	US-10-230-434-236	Sequence 236, App
15	1691	99.5	327	14	US-10-219-003-236	Sequence 236, App
16	1691	99.5	327	14	US-10-219-075-236	Sequence 236, App
17	1691	99.5	327	14	US-10-219-464-236	Sequence 236, App
18	1691	99.5	327	14	US-10-219-466-236	Sequence 236, App
19	1691	99.5	327	14	US-10-219-479-236	Sequence 236, App
20	1691	99.5	327	14	US-10-219-481-236	Sequence 236, App
21	1691	99.5	327	14	US-10-230-260-236	Sequence 236, App
22	1691	99.5	327	14	US-10-232-231-236	Sequence 236, App
23	1691	99.5	327	14	US-10-232-233-236	Sequence 236, App
24	1691	99.5	327	14	US-10-216-165-236	Sequence 236, App
25	1691	99.5	327	14	US-10-218-956-236	Sequence 236, App
26	1691	99.5	327	14	US-10-219-468-236	Sequence 236, App
27	1691	99.5	327	14	US-10-219-478-236	Sequence 236, App
28	1691	99.5	327	14	US-10-219-536-236	Sequence 236, App
29	1691	99.5	327	14	US-10-233-205-236	Sequence 236, App
30	1691	99.5	327	14	US-10-219-072-236	Sequence 236, App
31	1691	99.5	327	14	US-10-219-470-236	Sequence 236, App
32	1691	99.5	327	14	US-10-219-474-236	Sequence 236, App
33	1691	99.5	327	14	US-10-219-524-236	Sequence 236, App
34	1691	99.5	327	14	US-10-219-528-236	Sequence 236, App
35	1691	99.5	327	14	US-10-227-881-236	Sequence 236, App
36	1691	99.5	327	14	US-10-227-880-236	Sequence 236, App
37	1691	99.5	327	14	US-10-227-882-236	Sequence 236, App
38	1691	99.5	327	14	US-10-230-436-236	Sequence 236, App
39	1691	99.5	327	14	US-10-232-223-236	Sequence 236, App
40	1691	99.5	327	14	US-10-232-225-236	Sequence 236, App
41	1691	99.5	327	14	US-10-232-227-236	Sequence 236, App
42	1691	99.5	327	14	US-10-232-229-236	Sequence 236, App
43	1691	99.5	327	14	US-10-232-234-236	Sequence 236, App
44	1691	99.5	327	14	US-10-219-060-236	Sequence 236, App
45	1691	99.5	327	14	US-10-216-160-236	Sequence 236, App

ALIGNMENTS

RESULT 1
US-09-820-893-60
; Sequence 60, Application US/09820893
; Patent No. US20020076705A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 31 Human Secreted Proteins
; FILE REFERENCE: P2033PI
; CURRENT APPLICATION NUMBER: US/09/820,893
; CURRENT FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 09/531,119
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: 60/102,895
; PRIOR FILING DATE: 1998-10-02
; NUMBER OF SEQ ID NOS: 140
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 60
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-820-893-60

Query Match 100.0%; Score 1699; DB 9; Length 327;
Best Local Similarity 100.0%; Pred. No. 8.3e-121;
Matches 327; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MAELPGFLLCGALLGLFCLLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
Db 1 MAELPGFLLCGALLGLFCLLSGLAVEVKVPTPEPLSTPLGKTAELTCTYSTVSGDSFALEWS 60
Qy 61 FVOPGKPISESHPIILFTNGHLPTGSKSKRVSLLONPPTVGATLKLTDVHPSDGTYL 120
Db 61 FVOPGKPISESHPIILFTNGHLPTGSKSKRVSLLONPPTVGATLKLTDVHPSDGTYL 120

Qy	121	QCVANNPDPFYTNGLGLINLTVLVPPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV	180
Db	121	QCVANNPDPFYTNGLGLINLTVLVPPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV	180
Qy	181	RLGTFPPSPGSMQVDEVSQGLILNLNLSITSSGTYRCVATNQMGASCELTLISVTEPPQG	240
Db	181	RLGTFPPSPGSMQVDEVSQGLILNLNLSITSSGTYRCVATNQMGASCELTLISVTEPPQG	240
Qy	241	RVAGALIGVLGLVLLSVAAFCLVRFOKERGKKPKETYGGSDLRDEAIPGISEHTCMRA	300
Db	241	RVAGALIGVLGLVLLSVAAFCLVRFOKERGKKPKETYGGSDLRDEAIPGISEHTCMRA	300
Qy	301	DSSKGFLERPSSASTVTTTTSKLPMMV	327
Db	301	DSSKGFLERPSSASTVTTTTSKLPMMV	327
RESULT 2			
US-10-607-565-60			
; Sequence 60, Application US/10607565			
; Publication No. US20040048294A1			
; GENERAL INFORMATION:			
; APPLICANT: Rosen et al.			
; TITLE OF INVENTION: 31 Human Secreted Proteins			

Query Match	100.0%;	Score 1699;	DB 15;	Length 327;
Best Local Similarity	100.0%;	Pred. No. 8.3e-121;		
Matches 327;	Conservative	0;	Mismatches 0;	Indels 0;
Gaps	0;			

```

; Publication No. US20030027988A1
;
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Guney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
;
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; ACIDS ENCODING THE SAME
;
; FILE REFERENCE: P3530P1C79
;
; CURRENT APPLICATION NUMBER: US/10/227,884
;
; CURRENT FILING DATE: 2002-08-26
;
; PRIOR APPLICATION NUMBER: 10/119,480
;
; PRIOR FILING DATE: 2002-04-09
;
; PRIOR APPLICATION NUMBER: 60/059113
;
; PRIOR FILING DATE: 1997-09-17
;
; PRIOR APPLICATION NUMBER: 60/062287
;
; PRIOR FILING DATE: 1997-10-17
;
; PRIOR APPLICATION NUMBER: 60/063549
;
; PRIOR FILING DATE: 1997-10-28
;
; PRIOR APPLICATION NUMBER: 60/064103
;
; PRIOR FILING DATE: 1997-10-31
;
; PRIOR APPLICATION NUMBER: 60/069873
;
; PRIOR FILING DATE: 1997-12-17
;
; PRIOR APPLICATION NUMBER: 60/078910
;
; PRIOR FILING DATE: 1998-03-20
;
; PRIOR APPLICATION NUMBER: 60/079294
;
; PRIOR FILING DATE: 1998-03-25
;
; PRIOR APPLICATION NUMBER: 60/079656
;
; PRIOR FILING DATE: 1998-03-26
;
; PRIOR APPLICATION NUMBER: 60/079728
;
; PRIOR FILING DATE: 1998-03-27
;
; PRIOR APPLICATION NUMBER: 60/081819
;
; PRIOR FILING DATE: 1998-04-15
;
; PRIOR APPLICATION NUMBER: 60/081955
;
; PRIOR FILING DATE: 1998-04-15
;
; PRIOR APPLICATION NUMBER: 60/082804
;
; PRIOR FILING DATE: 1998-04-22
;
; PRIOR APPLICATION NUMBER: 60/084441
;
; PRIOR FILING DATE: 1998-05-06
;
; PRIOR APPLICATION NUMBER: 60/085323
;
; PRIOR FILING DATE: 1998-05-13
;
; PRIOR APPLICATION NUMBER: 60/085579
;
; PRIOR FILING DATE: 1998-05-15
;
; PRIOR APPLICATION NUMBER: 60/086392
;
; PRIOR FILING DATE: 1998-05-22
;
; PRIOR APPLICATION NUMBER: 60/089532
;
; PRIOR FILING DATE: 1998-06-17
;
; PRIOR APPLICATION NUMBER: 60/089538
;
; PRIOR FILING DATE: 1998-06-17
;
; PRIOR APPLICATION NUMBER: 60/090557
;
; PRIOR FILING DATE: 1998-06-24
;
; PRIOR APPLICATION NUMBER: 60/090691
;
; PRIOR FILING DATE: 1998-06-25
;
; PRIOR APPLICATION NUMBER: 60/090695
;
; PRIOR FILING DATE: 1998-06-25
;
; PRIOR APPLICATION NUMBER: 60/091982
;
; PRIOR FILING DATE: 1998-07-07
;
; PRIOR APPLICATION NUMBER: 60/095302
;
; PRIOR FILING DATE: 1998-08-04
;
; PRIOR APPLICATION NUMBER: 60/095318
;
; PRIOR FILING DATE: 1998-08-04
;
; PRIOR APPLICATION NUMBER: 60/095916

```

; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/115558
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115565
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115733
; PRIOR FILING DATE: 1999-01-12

; PRIOR APPLICATION NUMBER: 60/119549
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/123618
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/125259
; PRIOR FILING DATE: 1999-03-19
; PRIOR APPLICATION NUMBER: 60/125775
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 60/126773
; PRIOR FILING DATE: 1999-03-29
; PRIOR APPLICATION NUMBER: 60/127887
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 60/130232
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: 60/131022
; PRIOR FILING DATE: 1999-04-26
; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14
; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/144758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.5%; Score 1691; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.4e-120;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 MAELPGFPCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTABLTCTYTSVSGDSFALEWS 60
Db 1 MAELPGFPCGALLGFLCLSGLAVEVKVPTPEPLSTPLGKTABLTCTYTSVSGDSFALEWS 60
Qy 61 FVOPGKPISEHPILYFTNGHLYPTGSKSRVLLQNPPTVGATLKLTDVHPSDTCYTL 120
Db 61 FVOPGKPISEHPILYFTNGHLYPTGSKSRVLLQNPPTVGATLKLTDVHPSDTCYTL 120
Qy 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSQSQTSVGGSTALRCSSSGGAKPKPVYVNW 180
Db 121 CQVNNPPDFYTNGLGLINLTVLPSPNPLCSQSQSQTSVGGSTALRCSSSGGAKPKPVYVNW 180
Qy 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSASCELTLSTVTEPPQG 240
Db 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSASCELTLSTVTEPPSQG 240

1 MABLPGPFLCGALLGFLCISGLAVEVKVPTPLGKTAELTCTYSTVSGDSFALEWS 60
PRIOR FILING DATE: 1998-12-15
PRIOR APPLICATION NUMBER: 60/113296
PRIOR FILING DATE: 1998-12-22
PRIOR APPLICATION NUMBER: 60/113605
PRIOR FILING DATE: 1998-12-23
PRIOR APPLICATION NUMBER: 60/113621
PRIOR FILING DATE: 1998-12-23
PRIOR APPLICATION NUMBER: 60/115558
PRIOR FILING DATE: 1999-01-12
PRIOR APPLICATION NUMBER: 60/115565
PRIOR FILING DATE: 1999-01-12
PRIOR APPLICATION NUMBER: 60/115733
PRIOR FILING DATE: 1999-01-12
PRIOR APPLICATION NUMBER: 60/119549
PRIOR FILING DATE: 1999-02-10
PRIOR APPLICATION NUMBER: 60/123618
PRIOR FILING DATE: 1999-03-10
PRIOR APPLICATION NUMBER: 60/125259
PRIOR FILING DATE: 1999-03-19
PRIOR APPLICATION NUMBER: 60/125775
PRIOR FILING DATE: 1999-03-23
PRIOR APPLICATION NUMBER: 60/126773
PRIOR FILING DATE: 1999-03-29
PRIOR APPLICATION NUMBER: 60/127887
PRIOR FILING DATE: 1999-04-05
PRIOR APPLICATION NUMBER: 60/130232
PRIOR FILING DATE: 1999-04-21
PRIOR APPLICATION NUMBER: 60/131022
PRIOR FILING DATE: 1999-04-26
PRIOR APPLICATION NUMBER: 60/131270
PRIOR FILING DATE: 1999-04-27
PRIOR APPLICATION NUMBER: 60/131291
PRIOR FILING DATE: 1999-04-27
PRIOR APPLICATION NUMBER: 60/131445
PRIOR FILING DATE: 1999-04-28
PRIOR APPLICATION NUMBER: 60/134287
PRIOR FILING DATE: 1999-05-14
PRIOR APPLICATION NUMBER: 60/140650
PRIOR FILING DATE: 1999-06-22
PRIOR APPLICATION NUMBER: 60/140723
PRIOR FILING DATE: 1999-06-22
PRIOR APPLICATION NUMBER: 60/141037
PRIOR FILING DATE: 1999-06-23
PRIOR APPLICATION NUMBER: 60/144758
PRIOR FILING DATE: 1999-07-20
PRIOR APPLICATION NUMBER: 60/145698
PRIOR FILING DATE: 1999-07-26
PRIOR APPLICATION NUMBER: 60/146222
PRIOR FILING DATE: 1999-07-28
PRIOR APPLICATION NUMBER: 60/146963
PRIOR FILING DATE: 1999-08-03
PRIOR APPLICATION NUMBER: 60/149320
PRIOR FILING DATE: 1999-08-17
PRIOR APPLICATION NUMBER: 60/149638
PRIOR FILING DATE: 1999-08-17
PRIOR APPLICATION NUMBER: 60/151733
PRIOR FILING DATE: 1999-08-31
PRIOR APPLICATION NUMBER: 60/164418
PRIOR FILING DATE: 1999-11-09
PRIOR APPLICATION NUMBER: 60/166361
PRIOR FILING DATE: 1999-11-16
PRIOR APPLICATION NUMBER: 60/169445
PRIOR FILING DATE: 1999-12-07
PRIOR APPLICATION NUMBER: 60/169495
PRIOR FILING DATE: 1999-12-07
PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.5%; Score 1691; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.4e-120;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
1 MABLPGPFLCGALLGFLCISGLAVEVKVPTPLGKTAELTCTYSTVSGDSFALEWS 60
|||||

Db 1 MABLPGPFLCGALLGFLCISGLAVEVKVPTPLGKTAELTCTYSTVSGDSFALEWS 60
QY 61 FVOPGPISSEHPILYFTNGHLYPTGSKSRVSLHQNPPTVGVATLKLTDVHPSDCTYL 120
Db 61 FVOPGPISSEHPILYFTNGHLYPTGSKSRVSLHQNPPTVGVATLKLTDVHPSDCTYL 120
QY 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSSGAPKPVNWW 180
Db 121 CQVNNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSSGAPKPVNWW 180
QY 181 RLCTFTPTSPGSMQVDEVSQGLILTNLSLTSSGTGYRCVATNOMGSASCELTLSVTEPPQG 240
Db 181 RLCTFTPTSPGSMQVDEVSQGLILTNLSLTSSGTGYRCVATNOMGSASCELTLSVTEPSQG 240
QY 241 RVAGALIGVLLGVLLLSVAAFCLVRFQKRGKKPKETYGGSDLRREDIAIPGISHTCMRA 300
Db 241 RVAGALIGVLLGVLLLSVAAFCLVRFQKRGKKPKETYGGSDLRREDIAIPGISHTCMRA 300
QY 301 DSSKGFLEPSSASTVTTTTSKLPMMVV 327
Db 301 DSSKGFLEPSSASTVTTTTSKLPMMVV 327

RESULT 5

US-10-230-338-236
; Sequence 236, Application US/10230338
; Publication No. US20030044934A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC92
; CURRENT APPLICATION NUMBER: US/10/230,338
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-230-338-236

Query Match 99.5%; Score 1691; DB 14; Length 327;

```
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-631-236

Query Match          99.5%; Score 1691; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.4e-120;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSLGLAVEKVPTEPLSTPLGKTABLTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSLGLAVEKVPTEPLSTPLGKTABLTCTYSTSVGDSFALEWS 60

QY 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQLQNPPVGVATLKLTDVHPSDTGTYL 120
Db 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQLQNPPVGVATLKLTDVHPSDTGTYL 120

QY 121 CQVNNPPDPFYTNGLGINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
Db 121 CQVNNPPDPFYTNGLGINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180

QY 181 RLGTPTPSPGSMVQDEVSGQLILTNLSLTSSGTVCVATNMGSAACELTSLVTEPPQG 240
Db 181 RLGTPTPSPGSMVQDEVSGQLILTNLSLTSSGTVCVATNMGSAACELTSLVTEPPQG 240

QY 241 RVAGALIGVLLGVLLSVAAFCVLRFOKRGKKPKETYGGSDLRDAIAPGISEHTCMRA 300
Db 241 RVAGALIGVLLGVLLSVAAFCVLRFOKRGKKPKETYGGSDLRDAIAPGISEHTCMRA 300

QY 301 DSSKGFLERPSSASTVTTTTSKLPWV 327
Db 301 DSSKGFLERPSSASTVTTTTSKLPWV 327
```

```
RESULT 6
US-10-218-631-236
; Sequence 236, Application US/10218631
; Publication No. US20030045687A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC14
; CURRENT APPLICATION NUMBER: US/10/218,631
; PRIOR FILING DATE: 2002-08-12
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
```

```
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-631-236

Query Match          99.5%; Score 1691; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.4e-120;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSLGLAVEKVPTEPLSTPLGKTABLTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSLGLAVEKVPTEPLSTPLGKTABLTCTYSTSVGDSFALEWS 60

QY 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQLQNPPVGVATLKLTDVHPSDTGTYL 120
Db 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQLQNPPVGVATLKLTDVHPSDTGTYL 120

QY 121 CQVNNPPDPFYTNGLGINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
Db 121 CQVNNPPDPFYTNGLGINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180

QY 181 RLGTPTPSPGSMVQDEVSGQLILTNLSLTSSGTVCVATNMGSAACELTSLVTEPPQG 240
Db 181 RLGTPTPSPGSMVQDEVSGQLILTNLSLTSSGTVCVATNMGSAACELTSLVTEPPQG 240

QY 241 RVAGALIGVLLGVLLSVAAFCVLRFOKRGKKPKETYGGSDLRDAIAPGISEHTCMRA 300
Db 241 RVAGALIGVLLGVLLSVAAFCVLRFOKRGKKPKETYGGSDLRDAIAPGISEHTCMRA 300

QY 301 DSSKGFLERPSSASTVTTTTSKLPWV 327
Db 301 DSSKGFLERPSSASTVTTTTSKLPWV 327
```

```
RESULT 7
US-10-230-414-236
; Sequence 236, Application US/10230414
; Publication No. US20030050448A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC98
; CURRENT APPLICATION NUMBER: US/10/230,414
; PRIOR FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
```



```
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-216-159A-236

Query Match          99.5%; Score 1691; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.4e-120;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPPTGVATILKLTDVHPSDTGTYL 120
Db 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPPTGVATILKLTDVHPSDTGTYL 120
QY 121 CQVNNPPDFYTNGLGLINLTIVLPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
Db 121 CQVNNPPDFYTNGLGLINLTIVLPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
QY 181 RLGTFTPTSPGSMQVDEVSQGLILTNLSLTSSGTVCVATNQMGSASCELTLSTVTEPPQG 240
Db 181 RLGTFTPTSPGSMQVDEVSQGLILTNLSLTSSGTVCVATNQMGSASCELTLSTVTEPPQG 240
QY 241 RVAGALIGVLLGVLLSVAAFLVRFQKRGKKPKETVGGSDLRDAIAPGISEHTCMRA 300
Db 241 RVAGALIGVLLGVLLSVAAFLVRFQKRGKKPKETVGGSDLRDAIAPGISEHTCMRA 300
QY 301 DSSKGFLEPSSASTVTTTTSKLPMMV 327
Db 301 DSSKGFLEPSSASTVTTTTSKLPMMV 327

RESULT 10
US-10-218-849-236
; Sequence 236, Application US/10218849
; Publication No. US20030073814A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: F3530PIC11
; CURRENT APPLICATION NUMBER: US/10/218,849
; PRIOR FILING DATE: 2002-08-12
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 236
; LENGTH: 327
```

```
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-218-849-236

Query Match          99.5%; Score 1691; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.4e-120;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
Db 1 MAELPGPFLCGALLGFLCLSGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPPTGVATILKLTDVHPSDTGTYL 120
Db 61 FVQPGKPISSEHPILYFTNGHLYPTGSKSKRVSLQNPPPTGVATILKLTDVHPSDTGTYL 120
QY 121 CQVNNPPDFYTNGLGLINLTIVLPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
Db 121 CQVNNPPDFYTNGLGLINLTIVLPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
QY 181 RLGTFTPTSPGSMQVDEVSQGLILTNLSLTSSGTVCVATNQMGSASCELTLSTVTEPPQG 240
Db 181 RLGTFTPTSPGSMQVDEVSQGLILTNLSLTSSGTVCVATNQMGSASCELTLSTVTEPPQG 240
QY 241 RVAGALIGVLLGVLLSVAAFLVRFQKRGKKPKETVGGSDLRDAIAPGISEHTCMRA 300
Db 241 RVAGALIGVLLGVLLSVAAFLVRFQKRGKKPKETVGGSDLRDAIAPGISEHTCMRA 300
QY 301 DSSKGFLEPSSASTVTTTTSKLPMMV 327
Db 301 DSSKGFLEPSSASTVTTTTSKLPMMV 327

RESULT 11
US-10-227-873-236
; Sequence 236, Application US/10227873
; Publication No. US20030073816A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530PIC72
; CURRENT APPLICATION NUMBER: US/10/227,873
; PRIOR FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
```


1	1	PRIOR APPLICATION NUMBER:	60/101741	1
2	2	PRIOR FILING DATE:	1998-09-24	2
3	3	PRIOR APPLICATION NUMBER:	60/101786	3
4	4	PRIOR FILING DATE:	1998-09-25	4
5	5	PRIOR APPLICATION NUMBER:	60/101916	5
6	6	PRIOR FILING DATE:	1998-09-24	6
7	7	PRIOR APPLICATION NUMBER:	60/101922	7
8	8	PRIOR FILING DATE:	1998-09-24	8
9	9	PRIOR APPLICATION NUMBER:	60/106178	9
10	10	PRIOR FILING DATE:	1998-10-28	10
11	11	PRIOR APPLICATION NUMBER:	60/106248	11
12	12	PRIOR FILING DATE:	1998-10-29	12
13	13	PRIOR APPLICATION NUMBER:	60/106464	13
14	14	PRIOR FILING DATE:	1998-10-30	14
15	15	PRIOR APPLICATION NUMBER:	60/106905	15
16	16	PRIOR FILING DATE:	1998-11-03	16
17	17	PRIOR APPLICATION NUMBER:	60/108787	17
18	18	PRIOR FILING DATE:	1998-11-17	18
19	19	PRIOR APPLICATION NUMBER:	60/108801	19
20	20	PRIOR FILING DATE:	1998-11-17	20
21	21	PRIOR APPLICATION NUMBER:	60/108849	21
22	22	PRIOR FILING DATE:	1998-11-18	22
23	23	PRIOR APPLICATION NUMBER:	60/112422	23
24	24	PRIOR FILING DATE:	1998-12-15	24
25	25	PRIOR APPLICATION NUMBER:	60/113296	25
26	26	PRIOR FILING DATE:	1998-12-22	26
27	27	PRIOR APPLICATION NUMBER:	60/113605	27
28	28	PRIOR FILING DATE:	1998-12-23	28
29	29	PRIOR APPLICATION NUMBER:	60/113621	29
30	30	PRIOR FILING DATE:	1998-12-23	30
31	31	PRIOR APPLICATION NUMBER:	60/115558	31
32	32	PRIOR FILING DATE:	1999-01-12	32
33	33	PRIOR APPLICATION NUMBER:	60/115565	33
34	34	PRIOR FILING DATE:	1999-01-12	34
35	35	PRIOR APPLICATION NUMBER:	60/115733	35
36	36	PRIOR FILING DATE:	1999-01-12	36
37	37	PRIOR APPLICATION NUMBER:	60/119549	37
38	38	PRIOR FILING DATE:	1999-02-10	38
39	39	PRIOR APPLICATION NUMBER:	60/123618	39
40	40	PRIOR FILING DATE:	1999-03-10	40
41	41	PRIOR APPLICATION NUMBER:	60/125259	41
42	42	PRIOR FILING DATE:	1999-03-19	42
43	43	PRIOR APPLICATION NUMBER:	60/125775	43
44	44	PRIOR FILING DATE:	1999-03-23	44
45	45	PRIOR APPLICATION NUMBER:	60/126773	45
46	46	PRIOR FILING DATE:	1999-03-29	46
47	47	PRIOR APPLICATION NUMBER:	60/127887	47
48	48	PRIOR FILING DATE:	1999-04-05	48
49	49	PRIOR APPLICATION NUMBER:	60/130232	49
50	50	PRIOR FILING DATE:	1999-04-21	50
51	51	PRIOR APPLICATION NUMBER:	60/131022	51
52	52	PRIOR FILING DATE:	1999-04-26	52
53	53	PRIOR APPLICATION NUMBER:	60/131270	53
54	54	PRIOR FILING DATE:	1999-04-27	54
55	55	PRIOR APPLICATION NUMBER:	60/131291	55
56	56	PRIOR FILING DATE:	1999-04-27	56
57	57	PRIOR APPLICATION NUMBER:	60/131445	57
58	58	PRIOR FILING DATE:	1999-04-28	58
59	59	PRIOR APPLICATION NUMBER:	60/134287	59
60	60	PRIOR FILING DATE:	1999-05-14	60
61	61	PRIOR APPLICATION NUMBER:	60/140650	61
62	62	PRIOR FILING DATE:	1999-06-22	62
63	63	PRIOR APPLICATION NUMBER:	60/140723	63
64	64	PRIOR FILING DATE:	1999-06-22	64
65	65	PRIOR APPLICATION NUMBER:	60/141037	65
66	66	PRIOR FILING DATE:	1999-06-23	66
67	67	PRIOR APPLICATION NUMBER:	60/14758	67
68	68	PRIOR FILING DATE:	1999-07-20	68
69	69	PRIOR APPLICATION NUMBER:	60/145698	69
70	70	PRIOR FILING DATE:	1999-07-26	70
71	71	PRIOR APPLICATION NUMBER:	60/146222	71
72	72	PRIOR FILING DATE:	1999-07-28	72
73	73	PRIOR APPLICATION NUMBER:	60/146963	73

```
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match          99.5%; Score 1691; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.4e-120;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGFPCGALLGFLCGLSLAVEVKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
   |||||
Db 1 MAELPGFPCGALLGFLCGLSLAVEVKVTEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60

QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKRVSLLQNPPVTGVATLKLTDVHPSDTGTYL 120
   |||||
Db 61 FVQPGKPISESHPILYFTNGHLYPTGSKRVSLLQNPPVTGVATLKLTDVHPSDTGTYL 120

QY 121 CQVNNPPDYNTGLGILNITLVLPSPNPLCSQGSQTSVGGSTALRCSSEGAPKPYNNV 180
   |||||
Db 121 CQVNNPPDYNTGLGILNITLVLPSPNPLCSQGSQTSVGGSTALRCSSEGAPKPYNNV 180

QY 181 RLCTFTPPSGMVQDEVSGQLITLNLSTSSGTYRCVATNOMGSASCELTLSVTEPPQG 240
   |||||
Db 181 RLCTFTPPSGMVQDEVSGQLITLNLSTSSGTYRCVATNOMGSASCELTLSVTEPPSQ 240

QY 241 RVAGALIGVLLGVLLLSVAACFLVRFOKRGKPKETYGSGDLREDIAIPGISEHTCMRA 300
   |||||
Db 241 RVAGALIGVLLGVLLLSVAACFLVRFOKRGKPKETYGSGDLREDIAIPGISEHTCMRA 300

QY 301 DSKGFLERPSSASTVTTTKSLPMVV 327
   |||||
Db 301 DSKGFLERPSSASTVTTTKSLPMVV 327

RESULT 12
US-10-227-883-236
; Sequence 236, Application US/10227883
; Publication No. US20030073817A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Guney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530P1C78
; CURRENT APPLICATION NUMBER: US/10/227,883
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
```

1	PRIOR FILING DATE: 1998-09-15	60/100390
2	PRIOR APPLICATION NUMBER: 60/100390	
3	PRIOR FILING DATE: 1998-09-15	60/100390
4	PRIOR APPLICATION NUMBER: 60/100390	
5	PRIOR FILING DATE: 1998-09-15	60/100627
6	PRIOR APPLICATION NUMBER: 60/100627	
7	PRIOR FILING DATE: 1998-09-16	60/100848
8	PRIOR APPLICATION NUMBER: 60/100848	
9	PRIOR FILING DATE: 1998-09-18	60/100919
10	PRIOR APPLICATION NUMBER: 60/100919	
11	PRIOR FILING DATE: 1998-09-17	60/101477
12	PRIOR APPLICATION NUMBER: 60/101477	
13	PRIOR FILING DATE: 1998-09-23	60/101738
14	PRIOR APPLICATION NUMBER: 60/101738	
15	PRIOR FILING DATE: 1998-09-24	60/101741
16	PRIOR APPLICATION NUMBER: 60/101741	
17	PRIOR FILING DATE: 1998-09-24	60/101786
18	PRIOR APPLICATION NUMBER: 60/101786	
19	PRIOR FILING DATE: 1998-09-25	60/101916
20	PRIOR APPLICATION NUMBER: 60/101916	
21	PRIOR FILING DATE: 1998-09-24	60/101922
22	PRIOR APPLICATION NUMBER: 60/101922	
23	PRIOR FILING DATE: 1998-09-24	60/106178
24	PRIOR APPLICATION NUMBER: 60/106178	
25	PRIOR FILING DATE: 1998-10-28	60/106248
26	PRIOR APPLICATION NUMBER: 60/106248	
27	PRIOR FILING DATE: 1998-10-29	60/106464
28	PRIOR APPLICATION NUMBER: 60/106464	
29	PRIOR FILING DATE: 1998-10-30	60/106905
30	PRIOR APPLICATION NUMBER: 60/106905	
31	PRIOR FILING DATE: 1998-11-03	60/108787
32	PRIOR APPLICATION NUMBER: 60/108787	
33	PRIOR FILING DATE: 1998-11-17	60/108801
34	PRIOR APPLICATION NUMBER: 60/108801	
35	PRIOR FILING DATE: 1998-11-17	60/113296
36	PRIOR APPLICATION NUMBER: 60/113296	
37	PRIOR FILING DATE: 1998-12-22	60/108849
38	PRIOR APPLICATION NUMBER: 60/108849	
39	PRIOR FILING DATE: 1998-11-18	60/113605
40	PRIOR APPLICATION NUMBER: 60/113605	
41	PRIOR FILING DATE: 1998-12-23	60/113621
42	PRIOR APPLICATION NUMBER: 60/113621	
43	PRIOR FILING DATE: 1998-12-23	60/115558
44	PRIOR APPLICATION NUMBER: 60/115558	
45	PRIOR FILING DATE: 1999-01-12	60/115565
46	PRIOR APPLICATION NUMBER: 60/115565	
47	PRIOR FILING DATE: 1999-01-12	60/115733
48	PRIOR APPLICATION NUMBER: 60/115733	
49	PRIOR FILING DATE: 1999-01-12	60/119549
50	PRIOR APPLICATION NUMBER: 60/119549	
51	PRIOR FILING DATE: 1999-02-10	60/123618
52	PRIOR APPLICATION NUMBER: 60/123618	
53	PRIOR FILING DATE: 1999-03-10	60/125259
54	PRIOR APPLICATION NUMBER: 60/125259	
55	PRIOR FILING DATE: 1999-03-19	60/125775
56	PRIOR APPLICATION NUMBER: 60/125775	
57	PRIOR FILING DATE: 1999-03-23	60/126773
58	PRIOR APPLICATION NUMBER: 60/126773	
59	PRIOR FILING DATE: 1999-03-29	60/127887
60	PRIOR APPLICATION NUMBER: 60/127887	
61	PRIOR FILING DATE: 1999-04-05	60/130232
62	PRIOR APPLICATION NUMBER: 60/130232	
63	PRIOR FILING DATE: 1999-04-21	60/131022
64	PRIOR APPLICATION NUMBER: 60/131022	
65	PRIOR FILING DATE: 1999-04-26	60/131270
66	PRIOR APPLICATION NUMBER: 60/131270	
67	PRIOR FILING DATE: 1999-04-27	60/131291
68	PRIOR APPLICATION NUMBER: 60/131291	
69	PRIOR FILING DATE: 1999-04-27	60/131445
70	PRIOR APPLICATION NUMBER: 60/131445	
71	PRIOR FILING DATE: 1999-04-28	60/134287
72	PRIOR APPLICATION NUMBER: 60/134287	
73	PRIOR FILING DATE: 1999-05-14	60/134287
74	PRIOR APPLICATION NUMBER: 60/134287	

;	PRIOR APPLICATION NUMBER:	60/140650
;	PRIOR FILING DATE:	1999-06-22
;	PRIOR APPLICATION NUMBER:	60/140723
;	PRIOR FILING DATE:	1999-06-22
;	PRIOR APPLICATION NUMBER:	60/141037
;	PRIOR FILING DATE:	1999-06-23
;	PRIOR APPLICATION NUMBER:	60/144758
;	PRIOR FILING DATE:	1999-07-20
;	PRIOR APPLICATION NUMBER:	60/145698
;	PRIOR FILING DATE:	1999-07-26
;	PRIOR APPLICATION NUMBER:	60/146222
;	PRIOR FILING DATE:	1999-07-28
;	PRIOR APPLICATION NUMBER:	60/146963
;	PRIOR FILING DATE:	1999-08-03
;	PRIOR APPLICATION NUMBER:	60/149320
;	PRIOR FILING DATE:	1999-08-17
;	PRIOR APPLICATION NUMBER:	60/149638
;	PRIOR FILING DATE:	1999-08-17
;	PRIOR APPLICATION NUMBER:	60/151733
;	PRIOR FILING DATE:	1999-08-31
;	PRIOR APPLICATION NUMBER:	60/164418
;	PRIOR FILING DATE:	1999-11-09
;	PRIOR APPLICATION NUMBER:	60/166361
;	PRIOR FILING DATE:	1999-11-16
;	PRIOR APPLICATION NUMBER:	60/169445
;	PRIOR FILING DATE:	1999-12-07
;	PRIOR APPLICATION NUMBER:	60/169495
;	PRIOR FILING DATE:	1999-12-07
;	PRIOR APPLICATION NUMBER:	60/169835

Query Match 99.5%; Score 1691; DB 14; Length 327;
 Best Local Similarity 99.7%; Pred.No.3.4e-120;
 Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0

Qy	1	MAELPGPLCGALGFLCLSLGLAVEVKVPTPLSTPDKTAEKTAELTCTYSTSVGDSFALEWS	60
Dd	1	MAELPGPLCGALGFLCLSLGLAVEVKVPTPLSTPDKTAEKTAELTCTYSTSVGDSFALEWS	60
Qy	61	FVQPKGISSHPILYFTNGHLIYPTGSKSRKVSLLQPPTVGVAATLKLTDVHPSDTGYL	120
Dd	61	FVQPKGISSHPILYFTNGHLIYPTGSKSRKVSLLQPPTVGVAATLKLTDVHPSDTGYL	120
Qy	121	CQVNPPDFYFNYGLNLINLVLPSPNPLCSQSQTSTVGGSTALRCSSEGAPKPVYNW	180
Dd	121	CQVNPPDFYFNYGLNLINLVLPSPNPLCSQSQTSTVGGSTALRCSSEGAPKPVYNW	180
Qy	181	RLGTFFTPSGSMVDVSGQLITNLISLTSSGTYRCRVATNQMSASCELTLSTEPPQG	240
Dd	181	RLGTFFTPSGSMVDVSGQLITNLISLTSSGTYRCRVATNQMSASCELTLSTEPPSQG	240
Qy	241	RVAGALLGVLLGVLLSVAACLVRFQKERKKPKETYGGSDDLREDAIAPGISHTCMRA	300
Dd	241	RVAGALLGVLLGVLLSVAACLVRFQKERKKPKETYGGSDDLREDAIAPGISHTCMRA	300
Qy	301	DSSKGFLERPSSASTVTTTTKSLPMVV	327
Dd	301	DSSKGFLERPSSASTVTTTTKSLPMVV	327

RESULT 13
 US-10-219-076-236
 ; Sequence 236, Application US/10219076
 ; Publication No. US20030078379A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Gerritsen, Mary
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, J. Christopher
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stephan, Jean-Philippe F.

```
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530PIC62
; CURRENT APPLICATION NUMBER: US/10/219,076
; CURRENT FILING DATE: 2002-08-14
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986

; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3530PIC82
; CURRENT APPLICATION NUMBER: US/10/230,434
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986

Query Match 99.5%; Score 1691; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.4e-120;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGPFICGALLGFLCISGLAVEVKVPTPEPLSTPLGTAELTCTYSTVSGDSFALEWS 60
Db 1 MAELPGPFICGALLGFLCISGLAVEVKVPTPEPLSTPLGTAELTCTYSTVSGDSFALEWS 60
QY 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVLLQNPPTVGVAATLKLTDVHPSDTGYL 120
Db 61 FVQPGKPISESHPILYFTNGHLYPTGSKSRVLLQNPPTVGVAATLKLTDVHPSDTGYL 120
QY 121 CQVNNPPDFYTNGLGLINLTVPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
Db 121 CQVNNPPDFYTNGLGLINLTVPSPNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNV 180
QY 181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNMGSAACELTSLVTPPOG 240
Db 181 RLGTFTPPSGMVQDEVSGQLILTNLSLTSSGTYRCVATNMGSAACELTSLVTPPOG 240
QY 241 RVAGALIGVLLGVLISVAACFLVRPQKRGKPKETYGGSGLREDIAIPGISEHTCMRA 300
Db 241 RVAGALIGVLLGVLISVAACFLVRPQKRGKPKETYGGSGLREDIAIPGISEHTCMRA 300
QY 301 DSSKGFLEPSSASTVTTTTSKLPMMV 327
Db 301 DSSKGFLEPSSASTVTTTTSKLPMMV 327

RESULT 14
US-10-230-434-236
; Sequence 236, Application US/10230434
; Publication No. US20030078380A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Deenoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
```

; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/115558
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115565
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/115733
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/119549
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/123618
; PRIOR FILING DATE: 1999-03-10
; PRIOR APPLICATION NUMBER: 60/125259
; PRIOR FILING DATE: 1999-03-19

; PRIOR APPLICATION NUMBER: 60/125775
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 60/126773
; PRIOR FILING DATE: 1999-03-29
; PRIOR APPLICATION NUMBER: 60/127887
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 60/130232
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: 60/131022
; PRIOR FILING DATE: 1999-04-26
; PRIOR APPLICATION NUMBER: 60/131270
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/131445
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 60/134287
; PRIOR FILING DATE: 1999-05-14
; PRIOR APPLICATION NUMBER: 60/140650
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/140723
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 60/141037
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/144758
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/145698
; PRIOR FILING DATE: 1999-07-26
; PRIOR APPLICATION NUMBER: 60/146222
; PRIOR FILING DATE: 1999-07-28
; PRIOR APPLICATION NUMBER: 60/146963
; PRIOR FILING DATE: 1999-08-03
; PRIOR APPLICATION NUMBER: 60/149320
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/149638
; PRIOR FILING DATE: 1999-08-17
; PRIOR APPLICATION NUMBER: 60/151733
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 60/164418
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/166361
; PRIOR FILING DATE: 1999-11-16
; PRIOR APPLICATION NUMBER: 60/169445
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/169835

Query Match 99.5%; Score 1691; DB 14; Length 327;
Best Local Similarity 99.7%; Pred. No. 3.4e-120;
Matches 326; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MAELPGPFLLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
DB 1 MAELPGPFLLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWS 60
QY 61 FVOPGKPISESHPILYFTNGHLYPTGSKSRVSLLOPPPTVGATLKLTDVHPSDGTLYL 120
DB 61 FVOPGKPISESHPILYFTNGHLYPTGSKSRVSLLOPPPTVGATLKLTDVHPSDGTLYL 120
QY 121 CQVNNPDPFYTNGLGLINLTIVLPSPNPLCSQSGQTSVGGSTALRCSSSSGGAKPVVNVV 180
DB 121 CQVNNPDPFYTNGLGLINLTIVLPSPNPLCSQSGQTSVGGSTALRCSSSSGGAKPVVNVV 180
QY 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSGASCELTLSVTEPPQG 240
DB 181 RLGTFTPTSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMSGASCELTLSVTEPPQG 240
QY 241 RVAGALIGVLLGVLLLSVAACFLVRQKRGKPKETYGSGDLREDAIAPGISEHTCMRA 300
DB 241 RVAGALIGVLLGVLLLSVAACFLVRQKRGKPKETYGSGDLREDAIAPGISEHTCMRA 300
QY 301 DSSKGFLEPSSASTVTTTKSKLPMVV 327

```
Db          301 DSSKGLRPSASTVTTTKSLPMVV 327
RESULT 15
US-10-219-003-236
; Sequence 236, Application US/10219003
; Publication No. US200308063A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C12
; CURRENT APPLICATION NUMBER: US/10/219,003
; CURRENT FILING DATE: 2002-08-12
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/081819
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081955
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082804
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/084441
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086392
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089905
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090691
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/095302
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095318
; PRIOR FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: 60/095916
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096146
; PRIOR FILING DATE: 1998-08-11
; PRIOR APPLICATION NUMBER: 60/096791
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/097986
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098544
; PRIOR FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099803
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099811
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100038
; PRIOR FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101786
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101922
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/106178
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106248
; PRIOR FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106905
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108787
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108801
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/108849
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/113296
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113605
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
```

;	PRIOR	FILING	DATE:	1998-12-23	
;	PRIOR	APPLICATION	NUMBER:	60/115558	
;	PRIOR	FILING	DATE:	1999-01-12	
;	PRIOR	APPLICATION	NUMBER:	60/115565	
;	PRIOR	FILING	DATE:	1999-01-12	
;	PRIOR	APPLICATION	NUMBER:	60/115733	
;	PRIOR	FILING	DATE:	1999-01-12	
;	PRIOR	APPLICATION	NUMBER:	60/119549	
;	PRIOR	FILING	DATE:	1999-02-10	
;	PRIOR	APPLICATION	NUMBER:	60/123618	
;	PRIOR	FILING	DATE:	1999-03-10	
;	PRIOR	APPLICATION	NUMBER:	60/125259	
;	PRIOR	FILING	DATE:	1999-03-19	
;	PRIOR	APPLICATION	NUMBER:	60/125775	
;	PRIOR	FILING	DATE:	1999-03-23	
;	PRIOR	APPLICATION	NUMBER:	60/126773	
;	PRIOR	FILING	DATE:	1999-03-29	
;	PRIOR	APPLICATION	NUMBER:	60/127987	
;	PRIOR	FILING	DATE:	1999-04-05	
;	PRIOR	APPLICATION	NUMBER:	60/130232	
;	PRIOR	FILING	DATE:	1999-04-21	
;	PRIOR	APPLICATION	NUMBER:	60/131022	
;	PRIOR	FILING	DATE:	1999-04-26	
;	PRIOR	APPLICATION	NUMBER:	60/131270	
;	PRIOR	FILING	DATE:	1999-04-27	
;	PRIOR	APPLICATION	NUMBER:	60/131291	
;	PRIOR	FILING	DATE:	1999-04-27	
;	PRIOR	APPLICATION	NUMBER:	60/131445	
;	PRIOR	FILING	DATE:	1999-04-28	
;	PRIOR	APPLICATION	NUMBER:	60/134287	
;	PRIOR	FILING	DATE:	1999-05-14	
;	PRIOR	APPLICATION	NUMBER:	60/140650	
;	PRIOR	FILING	DATE:	1999-06-22	
;	PRIOR	APPLICATION	NUMBER:	60/140723	
;	PRIOR	FILING	DATE:	1999-06-22	
;	PRIOR	APPLICATION	NUMBER:	60/141037	
;	PRIOR	FILING	DATE:	1999-06-23	
;	PRIOR	APPLICATION	NUMBER:	60/144758	
;	PRIOR	FILING	DATE:	1999-07-20	
;	PRIOR	APPLICATION	NUMBER:	60/145698	
;	PRIOR	FILING	DATE:	1999-07-26	
;	PRIOR	APPLICATION	NUMBER:	60/146222	
;	PRIOR	FILING	DATE:	1999-07-28	
;	PRIOR	APPLICATION	NUMBER:	60/146963	
;	PRIOR	FILING	DATE:	1999-08-03	
;	PRIOR	APPLICATION	NUMBER:	60/149320	
;	PRIOR	FILING	DATE:	1999-08-17	
;	PRIOR	APPLICATION	NUMBER:	60/149638	
;	PRIOR	FILING	DATE:	1999-08-17	
;	PRIOR	APPLICATION	NUMBER:	60/151733	
;	PRIOR	FILING	DATE:	1999-08-31	
;	PRIOR	APPLICATION	NUMBER:	60/164418	
;	PRIOR	FILING	DATE:	1999-11-09	
;	PRIOR	APPLICATION	NUMBER:	60/166361	
;	PRIOR	FILING	DATE:	1999-11-16	
;	PRIOR	APPLICATION	NUMBER:	60/169445	
;	PRIOR	FILING	DATE:	1999-12-07	
;	PRIOR	APPLICATION	NUMBER:	60/169495	
;	PRIOR	FILING	DATE:	1999-12-07	
;	PRIOR	APPLICATION	NUMBER:	60/169835	

	Query Match	99.5%; Score 1691; DB 14; Length 327;
	Best Local Similarity	99.7%; Pred. No. 3,4e-120;
	Matches 326; Conservative	0; Mismatches 1; Indels 0; Gaps 0
Qy	1 MAELPGPFLCAGLIGFLCSGLAVEVVKPTPEPLSTPLGKTAAELTCTYTSVGDSFALEWS	60
Db	1 MAELPGPFLCAGLIGFLCSGLAVEVVKPTPEPLSTPLGKTAAELTCTYTSVGDSFALEWS	60
Qy	61 FVQPKPISESHPILYFTNGHLYTGSKSRVSLLONPPTVGATILKLTDVHPSDGTGYL	120
Db	61 FVQPKPISESHPILYFTNGHLYTGSKSRVSLLONPPTVGATILKLTDVHPSDGTGYL	120

Qy	121	QVNNPDPFYNTGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV	180
Db	121	QVNNPDPFYNTGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNNV	180
Qy	181	RLGTFPTSPGSMQVDEVSGQLIITNLISLTSSGTYRCVATNQMGASCELLTILSVTEPPQG	240
Db	181	RLGTFPTSPGSMQVDEVSGQLIITNLISLTSSGTYRCVATNQMGASCELLTILSVTEPPSQG	240
Qy	241	RVGALLGVLLGVLLLSVAAPCLVRFQKERGKKPKETYGGSDRLREDATAPGISEHTCMRA	300
Db	241	RVGALLGVLLGVLLLSVAAPCLVRFQKERGKKPKETYGGSDRLREDATAPGISEHTCMRA	300
Qy	301	DSSKGFLERPSSASTVTTTTSKLPVV	327
Db	301	DSSKGFLERPSSASTVTTTTSKLPVV	327

Search completed: August 4, 2005, 06:47:26
Job time : 90.2229 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 4, 2005, 05:53:15 ; Search time 98.8153 Seconds
(without alignments)
1268.128 Million cell updates/sec

Title: US-10-607-565-60_COPY_4_327
Perfect score: 1685
Sequence: 1 LPPFFCIGALLGLCLSLA.....ERPSSASTVTTTKSLPMV 324

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2105692 segs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A Geneseq_16Dec04:.*
1: Geneseqp1980s:.*
2: Geneseqp1990s:.*
3: Geneseqp2000s:.*
4: Geneseqp2001s:.*
5: Geneseqp2002s:.*
6: Geneseqp2003as:.*
7: Geneseqp2003bs:.*
8: Geneseqp2004s:.*

pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1678	99.6	327	3	AAB08903 Human sec
2	1677	99.5	327	3	AAY87251 Human sig
3	1677	99.5	327	3	AAY94857 Human pro
4	1677	99.5	327	4	AAY97585 Human sec
5	1677	99.5	327	5	ABB90354 Human pol
6	1677	99.5	327	5	AAB83709 Human pro
7	1677	99.5	327	6	ABU80856 Human PRO
8	1677	99.5	327	6	ABO33822 Novel hum
9	1677	99.5	327	6	ABU82165 Novel hum
10	1677	99.5	327	6	ABJ72345 Human PRO
11	1677	99.5	327	6	ABJ72473 Human PRO
12	1677	99.5	327	6	ABO34368 Human sec
13	1677	99.5	327	7	ABJ72175 Human mem
14	1677	99.5	327	7	ADB83726 Novel hum
15	1677	99.5	327	7	ADB80832 Novel hum
16	1677	99.5	327	7	ADB73373 Novel hum
17	1677	99.5	327	7	ADB78455 Novel hum
18	1677	99.5	327	7	ADB85103 Human PRO
19	1677	99.5	327	7	ADB78209 Novel hum
20	1677	99.5	327	7	ADB87275 Human PRO
21	1677	99.5	327	7	ADB84857 Human PRO
22	1677	99.5	327	7	ADB83972 Novel hum
23	1677	99.5	327	7	ADB73127 Novel hum
24	1677	99.5	327	7	ADC36965 Human PRO
25	1677	99.5	327	7	ADC21955 Human PRO

ALIGNMENTS

RESULT 1

AAB08903					
ID	AAB08903	standard; protein;	327	AA.	
XX	AC	AAB08903;			
XX	AC				
DT	30-AUG-2000	(first entry)			
XX	XX				
DE	Human secreted protein sequence encoded by gene 13	SEQ ID NO:60.			
XX	XX				
KW	Human; secreted protein; cytostatic; anti-proliferative; vulnary;				
KW	immunosuppressive; antibacterial; diagnosis; immune system; chemotaxis;				
KW	hyperproliferative disorder; infectious disease; tissue regeneration;				
KW	screening; food additive; preservative; wound healing;				
KW	hyper-vascular disease; chromosome 11.				
XX	Homo sapiens.				
OS					
XX	XX				
PN	WO200017222-A1.				
XX	XX				
PD	30-MAR-2000.				
XX	XX				
PF	22-SEP-1999;	99WO-US022012.			
XX	XX				
PR	23-SEP-1998;	98US-0101546P.			
PR	02-OCT-1998;	98US-0102895P.			
XX	XX				
PA	(HUMA-) HUMAN GENOME SCI INC.				
PI	Ruben SM, Rosen CA, Duan RD, Shi Y, Lafleur DW, Young PE, Ni J;				
PI	Komatsoulis G, Endress GA, Soppet DR;				
DR	WPI; 2000-283538/24.				
DR	N-PSDB; AAA39064.				
XX	XX				
PT	Human secreted proteins and coding sequences useful in diagnostic and				
PT	therapeutic methods for disorders such as immune system or proliferative				
PT	disorders, related to the proteins.				
XX	XX				
PS	Claim 11; Page 359-360; 416pp; English.				
CC	The polynucleotide sequences given in AAA39052 to AAA39088 encode the				
CC	human secreted proteins given in AAB08891 to AAB08984. The human secreted				
CC	proteins can have activities based on the tissues and cells they are				
CC	expressed in. Examples of the activities are: cytostatic; anti-				
CC	proliferative; immunosuppressive; antibacterial; and vulnary. The				
CC	secreted proteins and their related polynucleotide sequences are useful				
CC	for diagnostic and therapeutic methods useful for diagnosing and treating				

26	1677	99.5	327	7	ADC49986	Novel hum
27	1677	99.5	327	7	ADC49185	Novel hum
28	1677	99.5	327	7	ADC49702	Novel hum
29	1677	99.5	327	7	ADC47563	Novel hum
30	1677	99.5	327	7	ADC47308	Novel hum
31	1677	99.5	327	7	ADC78183	Novel hum
32	1677	99.5	327	7	ADC77937	Novel hum
33	1677	99.5	327	7	ADC77937	Novel hum
34	1677	99.5	327	7	ADD50900	Novel hum
35	1677	99.5	327	7	ADD51146	Novel hum
36	1677	99.5	327	7	ADD50627	Human PRO
37	1677	99.5	327	7	ADD50381	Human PRO
38	1677	99.5	327	7	ADD51392	Novel hum
39	1677	99.5	327	8	ADC48939	Novel hum
40	1677	99.5	327	8	ADE21110	Novel hum
41	1677	99.5	327	8	ADE05954	Human PRO
42	1677	99.5	327	8	ADD75183	Human PRO
43	1677	99.5	327	8	ADD75929	Novel hum
44	1677	99.5	327	8	ADD85161	Novel hum
45	1677	99.5	327	8	ADD86987	Novel hum

CC disorders related to the secreted proteins. The proteins, and
CC polynucleotide sequences may be useful for treating disorders of the
CC immune system, hyperproliferative disorders, infectious disease,
CC regeneration of tissues, for chemotaxis and for screening molecules that
CC bind to the proteins. The proteins or polynucleotide sequences may be
CC used as food additives or preservatives, to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, co-factors or other nutritional components. Agonists or
CC antagonists of the proteins may be used to prevent scar tissue growth
CC during wound healing, and hyper-vascular diseases. AAA39043 to AAA39051
CC and AA808890 are sequences used in the exemplification of the present
CC invention

XX SQ Sequence 327 AA;

Query Match 99.6%; Score 1678; DB 3; Length 327;
Best Local Similarity 99.7%; Pred. No. 5.7e-113;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 LFGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
DB 4 LFGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
QY 61 PKGPTSESHPILYFTNGHLIYPTGSKSKRVSLIQNPPTVGVATLKLTDVHPSDTGYLCQV 120
DB 64 PKGPTSESHPILYFTNGHLIYPTGSKSKRVSLIQNPPTVGVATLKLTDVHPSDTGYLCQV 123
QY 121 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGTSGVGTALRCSSSEGAPKPYNNVRLG 180
DB 124 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGTSGVGTALRCSSSEGAPKPYNNVRLG 183
QY 181 TPTPTSPGSMVQDEVSQGLILTNLSLTSSGTYRCVATNQMGASCELTLSVTEPPQGRVA 240
DB 184 TPTPTSPGSMVQDEVSQGLILTNLSLTSSGTYRCVATNQMGASCELTLSVTEPPQGRVA 243
QY 241 GALIGVLLGVLLSVAAAFCLVRFQKRGKKPKETGYGSDLRDAIAPGISEHTCMRADSS 300
DB 244 GALIGVLLGVLLSVAAAFCLVRFQKRGKKPKETGYGSDLRDAIAPGISEHTCMRADSS 303
QY 301 KGFLERPSSASTVTTTTSKLPWV 324
DB 304 KGFLERPSSASTVTTTTSKLPWV 327

RESULT 2

AA87251

ID AAY87251 standard; protein; 327 AA.

XX AC AAY87251;

XX DT 11-MAY-2000 (first entry)

XX DE Human signal peptide containing protein HSP-28 SEQ ID NO:28.

XX KW Human; signal peptide-containing protein; HSP; diagnosis; cancer;
KW inflammation; cardiovascular disease; anticancer; anti-inflammatory;
KW antimicrobial; nontropic; neuroprotective; cardiovascular; hepatotropic;
KW antasthmatic; gene therapy; cell proliferation; neurological disorder;
KW reproductive disorder; developmental disorder; arteriosclerosis;
KW cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;
KW Parkinson's disease; infection; Alzheimer's disease; schizophrenia;
KW muscular dystrophy.

OS Homo sapiens.

XX PN WO20000610-A2.

XX PD 06-JAN-2000.

XX PF 25-JUN-1999; 99WO-US014484.

XX PR 26-JUN-1998; 98US-0090762P.

PR 31-JUL-1998; 98US-0094983P.
PR 01-OCT-1998; 98US-0102686P.
PR 11-DEC-1998; 98US-0112129P.
XX (INCY-) INCYTE PHARM INC.
XX PI Lal P, Tang YT, Gorgone GA, Corley NC, Guegler KJ, Baughn MR;
PI Akerblom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL;
PI Bandman O;
XX WPI: 2000-160673/14.
DR N-PSDB; AA298136.
XX New human signal peptide-containing proteins useful in treatment,
PT prevention and diagnosis of e.g. cancer, inflammation and cardiovascular
PT disease.
XX Claim 1; Page 177-178; 327pp; English.

CC AA298109 to AA298242 encode AAY87224 to AAY87357 which represent the
CC human signal peptide-containing proteins HSP-1 to HSP-134. HSPs have
CC anticancer, anti-inflammatory, antimicrobial, nontropic, hepatotropic,
CC neuroprotective, cardiovascular and antiasthmatic activities, and can be
CC used in gene therapy. HSPs can be used to treat or prevent disorders
CC associated with decreased activity or function of HSP. Antagonists of
CC HSP are used to treat or prevent disorders associated with increased
CC activity or function of HSP. Such diseases include cell proliferation
CC (including cancer), inflammation, cardiovascular, neurological,
CC reproductive or developmental disorders, (e.g. arteriosclerosis,
CC cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia,
CC asthma, Crohn's disease, microbial or other infections, congestive or
CC ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's
CC diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSP
CC nucleic acids can be used for the recombinant production of HSP, for
CC detecting HSP in standard hybridisation and amplification assays (for
CC diagnosis and monitoring), in gene therapy, as antisense, triplex-forming
CC or ribozyme therapeutics, for detecting related sequences or genetic
CC variations, and for chromosomal mapping. HSP are also used to raise
CC specific antibodies (Ab) and to screen for agonists and antagonists
CC (potential therapeutic agents). Ab are used to diagnose, or monitor, HSP
CC -related diseases (in usual immunoassays), as therapeutic antagonists, in
CC competitive drug screens, and for purification of HSP from natural
CC sources

XX SQ Sequence 327 AA;

Query Match 99.5%; Score 1677; DB 3; Length 327;
Best Local Similarity 99.7%; Pred. No. 6.8e-113;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LFGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
DB 4 LFGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
QY 61 PKGPTSESHPILYFTNGHLIYPTGSKSKRVSLIQNPPTVGVATLKLTDVHPSDTGYLCQV 120
DB 64 PKGPTSESHPILYFTNGHLIYPTGSKSKRVSLIQNPPTVGVATLKLTDVHPSDTGYLCQV 123
QY 121 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGTSGVGTALRCSSSEGAPKPYNNVRLG 180
DB 124 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGTSGVGTALRCSSSEGAPKPYNNVRLG 183
QY 181 TPTPTSPGSMVQDEVSQGLILTNLSLTSSGTYRCVATNQMGASCELTLSVTEPPQGRVA 240
DB 184 TPTPTSPGSMVQDEVSQGLILTNLSLTSSGTYRCVATNQMGASCELTLSVTEPPQGRVA 243
QY 241 GALIGVLLGVLLSVAAAFCLVRFQKRGKKPKETGYGSDLRDAIAPGISEHTCMRADSS 300
DB 244 GALIGVLLGVLLSVAAAFCLVRFQKRGKKPKETGYGSDLRDAIAPGISEHTCMRADSS 303
QY 301 KGFLERPSSASTVTTTTSKLPWV 324
DB 304 KGFLERPSSASTVTTTTSKLPWV 327

RESULT 3

AA94857
 ID AAY94857 standard; protein; 327 AA.
 XX
 AC AAY94857;
 XX
 DT 12-JUN-2000 (first entry)
 XX
 DE Human protein clone HP10568.
 XX
 KW Human protein; hydrophobic domain; nutritional source; haematopoiesis;
 KW cytokine production; cell proliferation; cell differentiation;
 KW immune deficiency; infectious disease; autoimmune disorder; asthma;
 KW multiple sclerosis; systemic lupus erythematosus; rheumatoid arthritis;
 KW allergic reaction; osteoporosis; osteoarthritis; periodontal disease;
 KW nervous system disorder; Alzheimer's disease; Parkinson's disease;
 KW Huntington's disease; liver fibrosis; lung fibrosis; reperfusion injury;
 KW systemic cytokine damage; tissue differentiation; contraceptive; stroke;
 KW coagulation disorder; myocardial infarction; inflammatory condition;
 KW septic shock; sepsis; ischaemia; reperfusion injury; arthritis; tumour;
 KW nephritis; therapy.
 XX
 OS Homo sapiens.
 XX
 PN WO200005367-A2.
 XX
 PD 03-FEB-2000.
 XX
 PF 22-JUL-1999; 99WO-JP003929.
 XX
 PR 24-JUL-1998; 98JP-00208820.
 PR 07-AUG-1998; 98JP-00224105.
 PR 25-AUG-1998; 98JP-00238116.
 PR 09-SEP-1998; 98JP-00254736.
 PR 29-SEP-1998; 98JP-00275505.
 XX
 (SAGA) SAGAMI CHEM RES CENT.
 PA (PROT-) PROTEGENE INC.
 PA
 PI Kato S, Kimura T;
 XX
 WPI; 2000-182694/16.
 XX
 Novel human proteins having hydrophobic domains useful for treating
 PT osteoporosis, Alzheimer's disease, Parkinson's disease, asthma, multiple
 PT sclerosis, rheumatoid arthritis, cancer, anemia, and stroke.
 XX
 Claim 1; Page 183-184; 351pp; English.
 XX
 This sequence represents a human protein of the invention, which has
 CC hydrophobic domains. The DNA sequences can be used as a probe or as a
 CC genetic marker. The protein can also be used as a marker, and to identify
 CC potential genetic disorders. The DNA and protein can also be used as
 CC nutritional sources or supplements. The protein exhibits cytokine, cell
 CC proliferation, cell differentiation activities and induces production of
 CC other cytokines in certain cell populations. The protein also exhibits
 CC immune stimulating or immune suppressing activity. It can be used in the
 CC treatment of various immune deficiencies and disorders, and to treat
 CC infectious diseases caused by viral, bacterial, fungal or other
 CC infections. The protein is also used for treating autoimmune disorders
 CC such as multiple sclerosis, systemic lupus erythematosus, and rheumatoid
 CC arthritis. It is also useful in the treatment of allergic reactions and
 CC conditions such as asthma, and in immune suppression after organ
 CC transplantation. The protein is useful in regulation of haematopoiesis
 CC and consequently in the treatment of myeloid or lymphoid cell
 CC deficiencies. It is also used in compositions for tissue growth or
 CC regeneration. The protein is also used in the treatment of osteoporosis
 CC or osteoarthritis and in the treatment of periodontal disease and other
 CC tooth repair processes. The protein is used in the treatment of nervous
 CC system disorders such as Alzheimer's disease, Parkinson's disease, and
 CC Huntington's disease. They are useful for protection or regeneration and

CC treatment of lung or liver fibrosis, reperfusion injury in various
 CC tissues, and conditions resulting from systemic cytokine damage. They are
 CC also used for promoting or inhibiting tissue differentiation. They are
 CC also used as contraceptives since they exhibit activin or inhibin related
 CC activities and as a fertility inducing therapeutic. They are used for
 CC treating various coagulation disorders and in treatment and prevention of
 CC conditions resulting from coagulation activities e.g. myocardial
 CC infarction or stroke. They also act as receptors, receptor ligands or
 CC inhibitors or agonists of receptor/ligand interactions. They are used to
 CC treat inflammatory conditions such as septic shock, sepsis, ischaemia
 CC reperfusion injury, arthritis, and nephritis. They can be used to prevent
 CC tumours
 XX

SQ Sequence 327 AA;

Query Match 99.5%; Score 1677; DB 3; Length 327;
 Best Local Similarity 99.7%; Pred. No. 6.8e-113;
 Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 L P G P F L C G A L L G F L C L S G L A V E V K V P T E P L S T P L G K T A E L T C T Y S T S V G D S F A L E W S F V Q 60
 D B 4 L P G P F L C G A L L G F L C L S G L A V E V K V P T E P L S T P L G K T A E L T C T Y S T S V G D S F A L E W S F V Q 63
 QY 61 P G K P I S E S H P I L Y F T N G H L Y P T G S K R V S L L Q N P P T V G V A T L K L T D V H P S D T G T Y L C Q V 120
 D B 64 P G K P I S E S H P I L Y F T N G H L Y P T G S K R V S L L Q N P P T V G V A T L K L T D V H P S D T G T Y L C Q V 123
 QY 121 N N P P D F Y T N G L G L I N L T V L P P S N P L C S Q G T S V G S T A L R C S S E G A P K P Y N N W R L G 180
 D B 124 N N P P D F Y T N G L G L I N L T V L P P S N P L C S Q G T S V G S T A L R C S S E G A P K P Y N N W R L G 183
 QY 181 T P T P S P G S M V Q D E V S G Q L I L T N L S L T S S G T Y R C V A T N Q M G S A C E L T L S V T P P Q G R V A 240
 D B 184 T P T P S P G S M V Q D E V S G Q L I L T N L S L T S S G T Y R C V A T N Q M G S A C E L T L S V T P P Q G R V A 243
 QY 241 G A L I G V L L G V L L S V A A F C L V R F Q K E R G K K P K E T Y G G S D L R E D A I A P G I S E H T C M R A D S S 300
 D B 244 G A L I G V L L G V L L S V A A F C L V R F Q K E R G K K P K E T Y G G S D L R E D A I A P G I S E H T C M R A D S S 303
 QY 301 K G F L E R P S S A S T V T T T K S K L P M V V 324
 D B 304 K G F L E R P S S A S T V T T T K S K L P M V V 327

RESULT 4

AA97585
 ID AAY97585 standard; protein; 327 AA.
 XX
 AC AAY97585;
 XX
 DT 05-APR-2001 (first entry)
 XX
 DE Human secreted protein PRO7154.
 XX
 KW Secreted protein; human; PRO protein; neoplastic cell growth; tumour;
 KW proliferation; leukaemia; lymphoid malignancy; inflammatory disorder;
 KW angiogenic disorder; immunologic disorder; PRO7154.
 XX
 OS Homo sapiens.
 XX
 PN WO200075317-A2.
 XX
 PD 14-DEC-2000.
 XX
 PF 15-MAY-2000; 2000WO-US013358.
 XX
 PR 09-JUN-1999; 99US-0138385P.
 PR 20-JUL-1999; 99US-0144790P.
 PR 03-AUG-1999; 99US-0146843P.
 PR 10-AUG-1999; 99US-0148188P.
 PR 17-AUG-1999; 99US-0149320P.
 PR 17-AUG-1999; 99US-0149327P.
 PR 17-AUG-1999; 99US-0149396P.

PR 20-AUG-1999; 99US-0150114P.
 PR 31-AUG-1999; 99US-0151700P.
 PR 31-AUG-1999; 99US-0151734P.
 XX
 XX (GETH) GENENTECH INC.
 PA
 PA Botstein DA, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WI;
 PI WPI; 2001-071075/08.
 XX WPI; 2001-071075/08.
 DR N-PSDB; AAA91019.
 XX
 XX Antibodies against PRO polypeptides, useful for diagnosing and treating
 PT tumors are associated with gene amplification, neoplastic cell growth and
 PT proliferation in mammals.
 XX
 XX Claim 61; Fig 12; 143pp; English.
 PS
 PS This sequence is a human PRO protein of the invention. The PRO proteins
 CC are secreted proteins. Antagonists or antibodies of PRO polypeptides are
 CC useful for diagnosing and treating tumors are associated with gene
 CC amplification, neoplastic cell growth and proliferation in mammals, and
 CC those conditions characterised by overexpression and/or activation of the
 CC amplified genes. Such conditions include benign or malignant tumours
 CC (e.g. renal, liver, kidney, bladder, breast, gastric, ovarian,
 CC colorectal, prostate, pancreas, lung, vulva, thyroid, hepatic
 CC carcinomas, sarcomas, glioblastomas and various head and neck tumours);
 CC leukaemias and lymphoid malignancies; neuronal, glial, astrocytic,
 CC hypothalamic, and other glandular, macrophageal, epithelial, stromal and
 CC blastocoele disorders; and inflammatory, angiogenic and immunologic
 CC disorders. These may further be used to qualitatively or quantitatively
 CC detect the expression of proteins encoded by the amplified genes, and in
 CC tumour diagnostics or prognostics. The PRO polypeptide or its antagonist
 CC may be used for the preparation of a medicament in the treatment of a
 CC condition, which is responsive to the PRO polypeptide, its antagonist or
 CC anti-PRO antibody
 XX
 XX Sequence 327 AA;
 SQ
 Query Match 99.5%; Score 1677; DB 4; Length 327;
 Best Local Similarity 99.7%; Pred. No. 6.8e-113;
 Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 LPGPFLCGALLGFLCLSGLAWEVKVTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 60
 DB 4 LPGPFLCGALLGFLCLSGLAWEVKVTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 63
 QY 61 PGKPISEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTVDHPSDTGYLCOV 120
 DB 64 PGKPISEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTVDHPSDTGYLCOV 123
 QY 121 NNPPDFYTNGLINLTIVLPSPNPLCSQSGTSGVGGTALRCSSSEGAPKPVYNNVRLG 180
 DB 124 NNPPDFYTNGLINLTIVLPSPNPLCSQSGTSGVGGTALRCSSSEGAPKPVYNNVRLG 183
 QY 181 TPPTSPGSMQDEVSQGLILTNLSLTSSGTGYRCVATNQMGASCELTLSTVTEPQGRVA 240
 DB 184 TPPTSPGSMQDEVSQGLILTNLSLTSSGTGYRCVATNQMGASCELTLSTVTEPQGRVA 243
 QY 241 GALIGVLLGVLLLSVAFCVLRFOKRGKKPKETYGGSDLRDAPAGISEHTCMRADSS 300
 DB 244 GALIGVLLGVLLLSVAFCVLRFOKRGKKPKETYGGSDLRDAPAGISEHTCMRADSS 303
 QY 301 KGFLERPSSASTVTTTKSKLPMVV 324
 DB 304 KGFLERPSSASTVTTTKSKLPMVV 327
 RESULT 5
 ABB90354
 ID ABB90354 standard; protein; 327 AA.
 XX
 AC ABB90354;
 XX

DT 24-MAY-2002 (first entry)
 XX Human polypeptide SEQ ID NO 2730.
 XX
 KW Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
 KW antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
 KW vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;
 KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
 KW neurological disease; infection; human; secreted protein.
 XX
 OS Homo sapiens.
 XX
 PN WO200190304-A2.
 XX
 PD 29-NOV-2001.
 XX
 XX 18-MAY-2001; 2001WO-US016450.
 PF
 XX 19-MAY-2000; 2000US-0205515P.
 PR
 XX (HUMA-) HUMAN GENOME SCI INC.
 XX
 PI Birse CE, Rosen CA;
 XX
 XX WPI; 2002-122018/16.
 DR N-PSDB; ABL90763.
 XX
 XX Novel 1405 isolated polypeptides, useful for diagnosis, treatment and
 PT prevention of neural, immune system, muscular, reproductive,
 PT gastrointestinal, pulmonary, cardiovascular, renal and proliferative
 PT disorders.
 XX
 PS Claim 11; SEQ ID NO 2730; 2081pp + Sequence Listing; English.
 XX
 CC The invention relates to novel genes (ABL9449-ABL90853) and proteins
 CC (ABB9040-ABB90444) useful for preventing, treating or ameliorating
 CC medical conditions e.g. by protein or gene therapy. The genes are
 CC isolated from a range of human tissues disclosed in the specification.
 CC The nucleic acids, proteins, antibodies and (ant)agonists are useful in
 CC the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and
 CC ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,
 CC breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune
 CC disorders e.g. Addison's disease, allergies, autoimmune haemolytic
 CC anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
 CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)
 CC cardiovascular disorders such as myocardial ischaemias; (d) wound healing
 CC ; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)
 CC infectious diseases such as viral, bacterial, fungal and parasitic
 CC infections. Note: The sequence data for this patent did not form part of
 CC the printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 327 AA;
 Query Match 99.5%; Score 1677; DB 5; Length 327;
 Best Local Similarity 99.7%; Pred. No. 6.8e-113;
 Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 LPGPFLCGALLGFLCLSGLAWEVKVTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 60
 DB 4 LPGPFLCGALLGFLCLSGLAWEVKVTEPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 63
 QY 61 PGKPISEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTVDHPSDTGYLCOV 120
 DB 64 PGKPISEHPILYFTNGHLYPTGSKSKRVSLQNPPTVGATLKLTVDHPSDTGYLCOV 123
 QY 121 NNPPDFYTNGLINLTIVLPSPNPLCSQSGTSGVGGTALRCSSSEGAPKPVYNNVRLG 180
 DB 124 NNPPDFYTNGLINLTIVLPSPNPLCSQSGTSGVGGTALRCSSSEGAPKPVYNNVRLG 183
 QY 181 TPPTSPGSMQDEVSQGLILTNLSLTSSGTGYRCVATNQMGASCELTLSTVTEPQGRVA 240
 DB 184 TPPTSPGSMQDEVSQGLILTNLSLTSSGTGYRCVATNQMGASCELTLSTVTEPQGRVA 243

QY 241 GALIGVLLGVLISVAACFLVRFOKRGKKPKETGGSDLRDAIAPGISEHTCMRADSS 300
 |||||
 Db 244 GALIGVLLGVLISVAACFLVRFOKRGKKPKETGGSDLRDAIAPGISEHTCMRADSS 303
 |||||
 QY 301 KGFLERPSSASTVTTTKSKLPMVV 324
 |||||
 Db 304 KGFLERPSSASTVTTTKSKLPMVV 327
 |||||

RESULT 6

AAU83709
 ID AAU83709 standard; protein; 327 AA.

XX AC AAU83709;

XX DT 08-MAY-2002 (first entry)

XX DE Human PRO protein, Seq ID No 236.

XX KW Human; secreted protein; PRO; tumour; lung cancer; colon cancer;

XX KW breast cancer; prostate tumour; rectal tumour; liver tumour;

XX KW priocyte cell proliferation; chondrocyte cell proliferation;

XX KW tumour necrosis factor-alpha.

XX OS Homo sapiens.

XX PN WC200208288-A2.

XX PD 31-JAN-2002.

XX PF 29-JUN-2001; 2001WO-US021066.

XX PR 20-JUL-2000; 2000US-0219556P.

XX PR 25-JUL-2000; 2000US-0220385P.

XX PR 25-JUL-2000; 2000US-0220605P.

XX PR 25-JUL-2000; 2000US-0220607P.

XX PR 25-JUL-2000; 2000US-0220624P.

XX PR 25-JUL-2000; 2000US-0220638P.

XX PR 25-JUL-2000; 2000US-0220664P.

XX PR 25-JUL-2000; 2000US-0220666P.

XX PR 26-JUL-2000; 2000US-0220893P.

XX PR 28-JUL-2000; 2000WO-US020710.

XX PR 01-AUG-2000; 2000US-0222425P.

XX PR 22-AUG-2000; 2000US-0227133P.

XX PR 23-AUG-2000; 2000WO-US021352.

XX PR 24-AUG-2000; 2000WO-US023328.

XX PR 10-NOV-2000; 2000WO-US030873.

XX PR 28-NOV-2000; 2000US-0253646P.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 20-DEC-2000; 2000US-00747259.

XX PR 20-DEC-2000; 2000WO-US034956.

XX PR 28-FEB-2001; 2001WO-US006520.

XX PR 01-MAR-2001; 2001WO-US006666.

XX PR 22-MAR-2001; 2001US-00816744.

XX PR 10-MAY-2001; 2001US-00854208.

XX PR 10-MAY-2001; 2001US-00854280.

XX PR 25-MAY-2001; 2001WO-US017092.

XX (GETH) GENENTECH INC.

XX PA Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX XX N-PSDB; ABK33653.

XX DR WPI; 2002-172001/22.

XX DR N-PSDB; ABK33653.

XX PT One hundred and twenty two nucleic acids encoding PRO polypeptides,

XX PT useful for treating a PRO related disorder and for diagnosing tumors such

XX PT as lung cancer, colon cancer, breast tumor, prostate tumor, rectal tumor

XX PT or liver tumor.

XX PS Claim 11; Fig 236; 359pp; English.

XX The invention relates to one hundred and twenty two nucleic acids
 CC encoding PRO polypeptides. The sequences of the 122 PRO polynucleotides
 CC encode human secreted proteins. The PRO nucleic acids, polypeptides,
 CC agonists and antagonists are useful for treating a PRO related disorder.
 CC The PRO polypeptides are useful for diagnosing tumours, especially lung
 CC cancer, colon cancer, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. The PRO polypeptides are useful for stimulating the
 CC proliferation of, or gene expression, in pericyte cells, for stimulating
 CC the proliferation or differentiation of chondrocyte cells, for
 CC stimulating the release of tumour necrosis factor-alpha from human blood,
 CC for stimulating or inhibiting the proliferation of normal human dermal
 CC fibroblast cells. The PRO polypeptide may also be used as molecular
 CC weight markers and for tissue typing. The PRO nucleic acids have
 CC applications in molecular biology, including use as hybridisation probes,
 CC and in chromosome and gene mapping. AAU83592-AAU83713 represent human PRO
 CC protein sequences of the invention
 XX
 SQ Sequence 327 AA;

Query Match 99.5%; Score 1677; DB 5; Length 327;
 Best Local Similarity 99.7%; Pred. No. 6.8e-113;
 Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 LPGFFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
 |||||
 Db 4 LPGFFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
 |||||
 QY 61 PGKPISEHPILYFTNGHLYPTGSKSRVLLQNPPTVGATVATLKTVDHPSDTGTYLQV 120
 |||||
 Db 64 PGKPISEHPILYFTNGHLYPTGSKSRVLLQNPPTVGATVATLKTVDHPSDTGTYLQV 123
 |||||
 QY 121 NNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGSSTALRCSSEGAPKPVNWWRLG 180
 |||||
 Db 124 NNPPDFYTNGLGLINLTVLPSPNPLCSQSGQTSVGSSTALRCSSEGAPKPVNWWRLG 183
 |||||
 QY 181 TFPTSPGSMVQDEVSGQLILTNLSLTSGTYRCVATNQMGSA SCELTL SVTPPPQGRVA 240
 |||||
 Db 184 TFPTSPGSMVQDEVSGQLILTNLSLTSGTYRCVATNQMGSA SCELTL SVTPPPQGRVA 243
 |||||
 QY 241 GALIGVLLGVLISVAACFLVRFOKRGKKPKETGGSDLRDAIAPGISEHTCMRADSS 300
 |||||
 Db 244 GALIGVLLGVLISVAACFLVRFOKRGKKPKETGGSDLRDAIAPGISEHTCMRADSS 303
 |||||
 QY 301 KGFLERPSSASTVTTTKSKLPMVV 324
 |||||
 Db 304 KGFLERPSSASTVTTTKSKLPMVV 327
 |||||

RESULT 7

ABU80856

ID ABU80856 standard; protein; 327 AA.

XX AC ABU80856;

XX DT 23-JUN-2003 (first entry)

XX DE Human PRO polypeptide #118.

XX KW Human; PRO polypeptide; secreted and transmembrane protein;

XX KW anti-PRO antibody; diagnostic assay; gene expression; tumour; cytostatic.

XX OS Homo sapiens.

XX PN US2003036635-A1.

XX PD 20-FEB-2003.

XX PF 28-AUG-2002; 2002US-00230163.

XX PR 25-JUL-2000; 2000US-0220638P.

XX PR 01-JUN-2001; 2001WO-US017800.

XX PR 29-JUN-2001; 2001WO-US021066.

PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-342045/32.
DR N-PSDB; ACA66958.
XX
XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful for the manufacture of a medicament for diagnosing or treating
PT tumor.
XX
XX Claim 11; Fig 236; 314pp; English.
PS
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides and polynucleotides are useful for preparing a medicament
CC useful in the diagnosis and treatment of tumours. Anti-PRO antibodies are
CC useful in diagnostic assays for PRO, by detecting its expression in
CC specific cells, tissues or serum, and for affinity purification of PRO
CC from recombinant cell culture or natural sources. ABU80739-ABU80860
CC represent the human PRO polypeptides of the invention. Note: The sequence
CC data for this patent was obtained in electronic format directly from the
CC USPTO web site at seqdata.uspto.gov/psipsdIDEntry.html
XX
SQ Sequence 327 AA;

Query Match 99.5%; Score 1677; DB 6; Length 327;
Best Local Similarity 99.7%; Pred. No. 6.8e-113;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LFGPFLCGALLGFLCLSGLAIVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
Db 4 LFGPFLCGALLGFLCLSGLAIVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63

QY 61 PKGPISSEHPILYFTNGHLYPTGSKSKRVSLQLQNPPTVGVATLKLTDVHPSDTGTYLCOV 120
Db 64 PKGPISSEHPILYFTNGHLYPTGSKSKRVSLQLQNPPTVGVATLKLTDVHPSDTGTYLCOV 123

QY 121 NNPPDPFTYNGLGLINLTVLPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNVRLG 180
Db 124 NNPPDPFTYNGLGLINLTVLPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNVRLG 183

QY 181 TPTPTSPGSMVQDEVSGQILNLTLTSSGTYRCVATNMGASCBELTSLVTEPPQGRVA 240
Db 184 TPTPTSPGSMVQDEVSGQILNLTLTSSGTYRCVATNMGASCBELTSLVTEPPQGRVA 243

QY 241 GALIGVLLGVLILLSVAAPCLVRFQERKKPKETYGGSLREDIAIAPGISSEHTCMRADSS 300
Db 244 GALIGVLLGVLILLSVAAPCLVRFQERKKPKETYGGSLREDIAIAPGISSEHTCMRADSS 303

QY 301 KGFLERPSSASTVTTTKSLPMWV 324
Db 304 KGFLERPSSASTVTTTKSLPMWV 327

RESULT 8
ABO33822
ID ABO33822 standard; protein; 327 AA.
XX
AC ABO33822;
XX
DT 17-SEP-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO7154.
XX
XX Human; secreted and transmembrane protein; PRO; cytostatic;
KW antarthritic; osteopathic; gene therapy; TNF-Agonist-Alpha;
KW chondrocyte stimulator; pericyte stimulator; fibroblast modulator;
KW pharmaceutical; diagnostic; biosensor; bioreactor; tumour; lung tumour;

KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; bone disorder; cartilage disorder; sports injury;
XX arthritis; wound.
XX Homo sapiens.
XX OS
XX PN US2003045687-A1.
XX XX
XX PD 06-MAR-2003.
XX
XX PF 12-AUG-2002; 2002US-00218631.
XX
XX XX 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021086.
PR 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
XX WPI; 2003-512315/48.
DR N-PSDB; ACD68710.
XX
XX New genes, and its encoded secreted and transmembrane polypeptides,
PT useful for stimulating Tumor Necrosis Factor alpha, or chondrocyte or
PT pericyte proliferation, especially for treating lung tumors, arthritis or
PT wounds in a mammal.
XX
XX Claim 11; Fig 236; 314pp; English.
XX
CC The invention describes an isolated nucleic acid molecule comprising a
CC sequence with at least 80% identity to: (a) a nucleotide encoding any of
CC 122 PRO (secreted and transmembrane) polypeptides whose sequences are
CC fully defined in the specification; or (b) any of 122 nucleotide
CC sequences having e.g. 4834, 2504 or 1759 bp fully defined in the
CC specification; or the full length coding sequence of any these 122
CC nucleotide sequences. The PRO polypeptides or polynucleotides are useful
CC as pharmaceuticals, diagnostics, biosensors or bioreactors. These are
CC particularly useful for detecting tumors (e.g. lung tumour, colon
CC tumour, breast tumour, prostate tumour, rectal tumour, or liver tumour)
CC in a mammal, for stimulating the release of TNF-alpha from human blood,
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells, for stimulating proliferation of pericyte cells, or for modulating
CC normal human dermal fibroblast proliferation. The PRO nucleic acid or
CC polypeptide is also useful for treating tumors or various bone and/or
CC cartilage disorders (e.g. sports injuries or arthritis), or wounds. The
CC PRO polypeptides are useful in drug screening, particularly as targets
CC for therapeutic intervention in these diseases, and in the diagnostic
CC determination of the presence of these diseases. The PRO polypeptides are
CC also useful as molecular weight markers, or for chromosome
CC identification. The PRO genes are useful as hybridisation probes, or for
CC screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may
CC also be used in gene therapy, particularly for replacing a defective
CC gene. This is the amino acid sequence of a novel human secreted and
CC transmembrane PRO polypeptide
XX
SQ Sequence 327 AA;

Query Match 99.5%; Score 1677; DB 6; Length 327;
Best Local Similarity 99.7%; Pred. No. 6.8e-113;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LFGPFLCGALLGFLCLSGLAIVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
Db 4 LFGPFLCGALLGFLCLSGLAIVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63

QY 61 PKGPISSEHPILYFTNGHLYPTGSKSKRVSLQLQNPPTVGVATLKLTDVHPSDTGTYLCOV 120
Db 64 PKGPISSEHPILYFTNGHLYPTGSKSKRVSLQLQNPPTVGVATLKLTDVHPSDTGTYLCOV 123

QY 121 NNPPDPFTYNGLGLINLTVLPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNVRLG 180
XX

Db 124 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRLG 183
QY 181 TFTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSAACELTSLVTEPPQGRVA 240
Db 184 TFTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSAACELTSLVTEPPQGRVA 243
QY 241 GALIGVLLGVLLSVAAFCVLRQKRGKKPKETYGGSDLREDIAIAPGISEHTCMRADSS 300
Db 244 GALIGVLLGVLLSVAAFCVLRQKRGKKPKETYGGSDLREDIAIAPGISEHTCMRADSS 303
QY 301 KGFLERPSSASTVTTTTSKLPWV 324
Db 304 KGFLERPSSASTVTTTTSKLPWV 327
RESULT 9
ABU82165
ID ABU82165 standard; protein; 327 AA.
XX
AC ABU82165;
XX
DT 25-JUN-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO7154.
XX
KW Human; secreted and transmembrane protein; PRO; cardiac; cytostatic;
KW antiangiogenic; hypotensive; vulnery; antiarteriosclerotic;
KW gene therapy; cardiovascular disorder; endothelial disorder;
KW angiogenic disorder; cardiac hypertrophy; trauma; cancer;
KW age-related macular degeneration; atherosclerosis; hypertension;
KW arterial restenosis; rheumatoid arthritis; angina; myocardial infarction;
KW thrombophlebitis; lymphangitis; tumour angiogenesis; breast carcinoma;
KW liver carcinoma; wound healing; chromosome mapping; gene mapping.
XX
OS Homo sapiens.
XX
PN US2003088063-A1.
XX
PD 08-MAY-2003.
XX
PF 12-AUG-2002; 2002US-00219003.
XX
PR 25-JUL-2000; 2000US-0220664P.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
DR WPI; 2003-393229/37.
DR N-PSDB; ACA68614.
XX
PT One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT infarction), endothelial or angiogenic disorders in a mammal.
XX
PS Claim 11; Fig 236; 314pp; English.
XX
CC The invention describes one hundred and eighty seven nucleic acids
CC encoding novel human secreted and transmembrane (PRO) polypeptides. The
CC PRO nucleic acids, polypeptides, agonists and antagonists are useful for
CC treating or diagnosing a cardiovascular, endothelial or angiogenic
CC disorder in a mammal, e.g. cardiac hypertrophy, trauma, cancer, age-
CC related macular degeneration, atherosclerosis, hypertension, arterial
CC restenosis, rheumatoid arthritis, angina, myocardial infarctions,
CC thrombophlebitis, lymphangitis, tumour angiogenesis (such as breast
CC carcinoma and liver carcinoma) and wound healing. The PRO nucleic acids
CC have applications in molecular biology, including use as hybridisation
CC probes, and in chromosome and gene mapping. This is the amino acid
CC sequence of a novel human secreted and transmembrane PRO polypeptide

XX SQ Sequence 327 AA;
Query Match 99.5%; Score 1677; DB 6; Length 327;
Best Local Similarity 99.7%; Pred. No. 6.8e-113; Indels 0; Gaps 0;
Matches 323; Conservative 0; Mismatches 1;
QY 1 LPGPFLCGALLGFLCLSLGLAVEVKVTEPLSTPLGKTAEITCTYSTSVGDSFALEWFSVQ 60
Db 4 LPGPFLCGALLGFLCLSLGLAVEVKVTEPLSTPLGKTAEITCTYSTSVGDSFALEWFSVQ 63
QY 61 PGKPISESHPILYFTNGHLYPTGSKSRVSLQLQNPPTVGVATLKLTDVHPSDTGTLYLCOV 120
Db 64 PGKPISESHPILYFTNGHLYPTGSKSRVSLQLQNPPTVGVATLKLTDVHPSDTGTLYLCOV 123
QY 121 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRLG 180
Db 124 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNWVRLG 183
QY 181 TFTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSAACELTSLVTEPPQGRVA 240
Db 184 TFTPSPGSMVQDEVSGQLILTNLSLTSSGTYRCVATNQMGSAACELTSLVTEPPQGRVA 243
QY 241 GALIGVLLGVLLSVAAFCVLRQKRGKKPKETYGGSDLREDIAIAPGISEHTCMRADSS 300
Db 244 GALIGVLLGVLLSVAAFCVLRQKRGKKPKETYGGSDLREDIAIAPGISEHTCMRADSS 303
QY 301 KGFLERPSSASTVTTTTSKLPWV 324
Db 304 KGFLERPSSASTVTTTTSKLPWV 327
RESULT 10
ABJ72345
ID ABJ72345 standard; protein; 327 AA.
XX
AC ABJ72345;
XX
DT 06-NOV-2003 (first entry)
XX
DE Human PRO7154 protein.
XX
KW PRO; proliferation; pericyte cell; TNF-alpha; blood; chondrocyte;
KW differentiation; dermal fibroblast; tumour; gene therapy; cytostatic.
XX
OS Homo sapiens.
XX
PN US2003050448-A1.
XX
PD 13-MAR-2003.
XX
PF 28-AUG-2002; 2002US-00230414.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
DR WPI; 2003-521818/49.
DR N-PSDB; ABT44343.
XX
PT New nucleic acid encoding for a PRO protein, useful for the manufacture
PT of a medicament for diagnosing or treating tumors or for measuring or
PT detecting expression of an associated gene.
XX
PS Claim 11; Fig 236; 315pp; English.
XX
CC The invention relates to a novel isolated nucleic acid encoding a fully
CC defined PRO polypeptide. The molecules of the invention may be useful for

CC stimulating proliferation or gene expression in pericyte cells or the
CC release of TNF-alpha from human blood. Other possible uses include the
CC stimulation or inhibition of chondrocyte proliferation or
CC differentiation, the stimulation of human dermal fibroblast cell
CC proliferation and the detection of the presence of a tumour within a
CC mammal. Furthermore, the nucleic acid may be useful for the manufacture
CC of a medicament for diagnosing or treating a tumour within a mammal or
CC for measuring or detecting the expression of an associated gene, as well
CC as during gene therapy. The current sequence is that of the human PRO
CC protein of the invention
XX
SQ Sequence 327 AA;

Query Match 99.5%; Score 1677; DB 6; Length 327;
Best Local Similarity 99.7%; Pred. No. 6.8e-113;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 LPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 60
Db 4 LPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 63
QY 61 PGKPISESHPILYFTNGHLIYPTGSKSKRVSLQNPPPTGVATLKLTDVHPSDTGYLCQV 120
Db 64 PGKPISESHPILYFTNGHLIYPTGSKSKRVSLQNPPPTGVATLKLTDVHPSDTGYLCQV 123
QY 121 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNWRLG 180
Db 124 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNWRLG 183
QY 181 TPTTSPGSMWQDEVSGQLILTNLSLTSSGTYRCVATNQMGSASCELTLVSVPQGRVA 240
Db 184 TPTTSPGSMWQDEVSGQLILTNLSLTSSGTYRCVATNQMGSASCELTLVSVPQGRVA 243
QY 241 GALIGVLLGVLLLSVAFAFLVRFQKRGKKPKETYGSGDLREDATAPIGISEHTCMRADSS 300
Db 244 GALIGVLLGVLLLSVAFAFLVRFQKRGKKPKETYGSGDLREDATAPIGISEHTCMRADSS 303
QY 301 KGFLERPSSASTVTTTTSKLPV 324
Db 304 KGFLERPSSASTVTTTTSKLPV 327

RESULT 11
ABJ72473
ID ABJ72473 standard; protein; 327 AA.
XX
AC ABJ72473;
XX
XX 06-NOV-2003 (first entry)
XX
DE Human PRO7154 protein.
XX
XX PRO; blood; proliferation; pericyte cell; TNF alpha; chondrocyte;
KW tumour necrosis factor; proliferation; differentiation; gene therapy;
KW dermal fibroblast.
XX
OS Homo sapiens.
XX
XX US2003027988-A1.
XX
XX 06-FEB-2003.
XX
XX 26-AUG-2002; 2002US-00227884.
XX
XX 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX

DR WPI; 2003-503301/47.
DR N-PSDB; ABT44626.
XX
PT New PRO protein encoding nucleic acid, useful for preparing PRO
PT polypeptides and anti-PRO antibodies for detecting the presence of a
PT tumour in a mammal.
XX
PS Claim 11; Fig 236; 324pp; English.
XX
CC The invention relates to a novel isolated PRO protein encoding nucleic
CC acid. The nucleic acid of the invention may be useful for preparing PRO
CC polypeptides and anti-PRO antibodies for detecting the presence of a
CC tumour in a mammal. Furthermore, the molecules of the invention may be
CC useful for stimulating proliferation or gene expression in pericyte
CC cells, the release of tumour necrosis factor (TNF)-alpha from human
CC blood, the proliferation or differentiation of chondrocyte cells and for
CC inhibiting the proliferation of normal human dermal fibroblast cells.
CC Finally, the molecules may be utilised during gene therapy. The current
CC sequence is that of the human PRO protein of the invention
XX
SQ Sequence 327 AA;

Query Match 99.5%; Score 1677; DB 6; Length 327;
Best Local Similarity 99.7%; Pred. No. 6.8e-113;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 LPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 60
Db 4 LPGPFLCGALLGFLCLSGLAWEVKVPTPLSTPLGKTAELTCTYSTVSGDSFALEWSFVQ 63
QY 61 PGKPISESHPILYFTNGHLIYPTGSKSKRVSLQNPPPTGVATLKLTDVHPSDTGYLCQV 120
Db 64 PGKPISESHPILYFTNGHLIYPTGSKSKRVSLQNPPPTGVATLKLTDVHPSDTGYLCQV 123
QY 121 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNWRLG 180
Db 124 NNPPDFYTNGLGILNLTVLVPPSNPLCSQSGQTSVGGSTALRCSSSEGAPKPVYNWRLG 183
QY 181 TPTTSPGSMWQDEVSGQLILTNLSLTSSGTYRCVATNQMGSASCELTLVSVPQGRVA 240
Db 184 TPTTSPGSMWQDEVSGQLILTNLSLTSSGTYRCVATNQMGSASCELTLVSVPQGRVA 243
QY 241 GALIGVLLGVLLLSVAFAFLVRFQKRGKKPKETYGSGDLREDATAPIGISEHTCMRADSS 300
Db 244 GALIGVLLGVLLLSVAFAFLVRFQKRGKKPKETYGSGDLREDATAPIGISEHTCMRADSS 303
QY 301 KGFLERPSSASTVTTTTSKLPV 324
Db 304 KGFLERPSSASTVTTTTSKLPV 327

RESULT 12
ABO34368
ID ABO34368 standard; protein; 327 AA.
XX
XX ABO34368;
XX
XX 19-SEP-2003 (first entry)
XX
XX Human secreted/transmembrane polypeptide PRO 7154.
XX
KW Human; chondrocyte stimulation; TNF-alpha stimulation; gene therapy;
KW human dermal fibroblast stimulation; tumour; tissue typing;
KW affinity purification.
XX
OS Homo sapiens.
XX
XX US2003044934-A1.
XX
XX 06-MAR-2003.
XX
XX 28-AUG-2002; 2002US-00230338.
XX

PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2003-492274/46.
 DR N-PSDB; ACD82293.
 XX New transmembrane polypeptides and nucleic acids encoding the
 PT polypeptides, useful in gene therapy, in chromosome identification, as
 PT chromosome markers, or in generating probes.
 XX Claim 19; Fig 236; 315pp; English.
 XX The invention relates to an isolated nucleic acid encoding a PRO
 CC polypeptide. Nucleic acids that encode PRO can be used to generate either
 CC transgenic animals or knock-out animals useful in developing and
 CC screening of therapeutically useful reagents. The nucleic acids may also
 CC be used in gene therapy for replacing defective gene, in chromosome
 CC identification, as chromosome markers, or in generating probes to isolate
 CC full length PRO cDNA. The PRO polypeptides are useful for chondrocyte
 CC stimulation, TNF-alpha stimulation, human dermal fibroblasts stimulation
 CC and for detecting the presence of tumour in an mammal. The PRO
 CC polypeptides are useful as molecular markers for protein electrophoresis
 CC and the isolated nucleic acids may be used for recombinantly expressing
 CC those markers. The PRO polypeptides and nucleic acids may also be used in
 CC tissue typing. Anti-PRO antibodies are useful in diagnostic assays for
 CC PRO and in affinity purification of PRO from recombinant cell culture or
 CC natural sources. The present sequence represents the amino acid sequence
 CC of a human secreted/transmembrane PRO polypeptide
 XX
 SQ Sequence 327 AA;
 Query Match 99.5%; Score 1677; DB 6; Length 327;
 Best Local Similarity 99.7%; Pred. No. 6.8e-113;
 Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 LFGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
 Db 4 LFGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
 QY 61 PGKPISEHPILYFTNGHLYPTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGTLYCQV 120
 Db 64 PGKPISEHPILYFTNGHLYPTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGTLYCQV 123
 QY 121 NNPPDFYTNGLGLINLTVLPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNVRLG 180
 Db 124 NNPPDFYTNGLGLINLTVLPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPYNNVRLG 183
 QY 181 TPTSPSGMVQDEVSQGLILNLSLTSSGTRVCVATNQMGASCBTLTSLVTEPPQGRVA 240
 Db 184 TPTSPSGMVQDEVSQGLILNLSLTSSGTRVCVATNQMGASCBTLTSLVTEPPQGRVA 243
 QY 241 GALIGVLLGVLLSVAACLVRFQKRGKPKETVCGSDLRDAIAPGISEHTCMRADSS 300
 Db 244 GALIGVLLGVLLSVAACLVRFQKRGKPKETVCGSDLRDAIAPGISEHTCMRADSS 303
 QY 301 KGFLERPSSASTVTTTKSKLPMVTV 324
 Db 304 KGFLERPSSASTVTTTKSKLPMVTV 327

RESULT 13
 ID ABJ72175
 XX ABJ72175 standard; protein; 327 AA.
 AC ABJ72175;
 XX
 DT 16-OCT-2003 (first entry)

XX Human membrane bound receptor/protein PRO7154 amino acid sequence.
 DE Human; PRO; membrane bound protein; membrane bound receptor;
 KW cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;
 KW differentiation factor; neurotrophin; hormone; cell receptor;
 KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.
 XX Homo sapiens.
 XX US2003065147-A1.
 XX 03-APR-2003.
 XX 29-AUG-2002; 2002US-00232224.
 XX 28-JUL-1999; 99US-0146222P.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2003-522018/49.
 DR N-PSDB; ABT43999.
 XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
 PT useful for the manufacture of a medicament for diagnosing or treating
 PT tumor.
 XX
 Claim 11; Fig 236; 315pp; English.
 XX This invention relates to one hundred and twenty two novel nucleic acids
 CC encoding human PRO membrane bound proteins or receptors. Extracellular
 CC proteins play important roles in the formation, differentiation and
 CC maintenance of multicellular organisms. The fate of many individual cells
 CC (for example proliferation, migration or differentiation) is typically
 CC governed by information received from other cells and the immediate
 CC environment. The information is often transmitted by secreted
 CC polypeptides (for example mitogenic factors, survival factors, cytotoxic
 CC factors, differentiation factors, neurotrophins and hormones) which are
 CC received and interpreted by diverse cell receptors or membrane bound
 CC proteins. These membrane bound proteins and receptors may be of use as
 CC pharmaceutical and diagnostic agents, such as in the blocking of receptor
 CC -ligand interactions. The current invention provides the amino acid
 CC sequences of novel human membrane bound receptors and proteins, along
 CC with the cDNA sequences encoding them. The novel proteins of the
 CC invention may have cytostatic activities through the stimulation of
 CC chondrocytes. The nucleic acids of the invention may be useful for the
 CC manufacture of a medicament for diagnosing or treating a tumour in a
 CC mammal. In addition, they may be useful for measuring or detecting the
 CC expression of a tumour associated gene. The present sequence is the amino
 CC acid sequence of a human PRO protein of the invention
 XX
 SQ Sequence 327 AA;
 Query Match 99.5%; Score 1677; DB 7; Length 327;
 Best Local Similarity 99.7%; Pred. No. 6.8e-113;
 Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 LFGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
 Db 4 LFGPFLCGALLGFLCLSLGLAVEVKVPTPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
 QY 61 PGKPISEHPILYFTNGHLYPTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGTLYCQV 120
 Db 64 PGKPISEHPILYFTNGHLYPTGSKSRVSLQNPPPTGVATLKLTDVHPSDTGTLYCQV 123

QY 121 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNVVRIG 180
DB 124 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNVVRIG 183
QY 181 TPTTSPGSMVQDEVSQQLILTNLSLTSSGTVRCVATNMQSGASCELTLVSVPQGRVA 240
DB 184 TPTTSPGSMVQDEVSQQLILTNLSLTSSGTVRCVATNMQSGASCELTLVSVPQGRVA 243
QY 241 GALIGVLLGVLLLSVAAFCLVRFOKRGKKPKETVGGSDLRDAIAPGISHTCMRADSS 300
DB 244 GALIGVLLGVLLLSVAAFCLVRFOKRGKKPKETVGGSDLRDAIAPGISHTCMRADSS 303
QY 301 KGFLERPSSASTVTTTKSKLPMVW 324
DB 304 KGFLERPSSASTVTTTKSKLPMVW 327

RESULT 14
ADB83726
ID ADB83726 standard; protein; 327 AA.
XX
AC ADB83726;
XX
DT 04-DEC-2003 (first entry)
XX
DE
XX
XX Novel human secreted and transmembrane protein PRO7154.
XX human; secreted and transmembrane protein; PRO; cytostatic; vulnerary;
KW antiarthritic; pericyte cell proliferation; chondrocyte cell proliferation;
KW pericyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
XX US2003073814-A1.
XX
XX 17-APR-2003.
XX
XX 12-AUG-2002; 2002US-00218849.
XX
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-644806/61.
DR N-PSDB; ADB83725.
XX
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT in gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX
XX Claim 11; Fig 236; 315pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO331, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF) -
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC

CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO3940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptide
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (III) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This is the amino acid sequence of a human secreted and
CC transmembrane PRO polypeptide.
XX
SQ Sequence 327 AA;
Query Match 99.5%; Score 1677; DB 7; Length 327;
Best Local Similarity 99.7%; Pred. No. 6.8e-113;
Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 LPGPFLCAGLLGFLCLSGLAIVEKVPTPLSGKTAELTCTYSTVSGDSFALEWSFVQ 60
DB 4 LPGPFLCAGLLGFLCLSGLAIVEKVPTPLSGKTAELTCTYSTVSGDSFALEWSFVQ 63
QY 61 PGKPISESHPILYFTNGHLYPTGSKSRVLSLQNPPTVGVATLKLTDVHPSDTGTYLCOV 120
DB 64 PGKPISESHPILYFTNGHLYPTGSKSRVLSLQNPPTVGVATLKLTDVHPSDTGTYLCOV 123
QY 121 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNVVRIG 180
DB 124 NNPPDFYTNGLGLINLTVLVPPSNPLCSQSGQTSVGGSTALRCSSEGAPKPVYNVVRIG 183
QY 181 TPTTSPGSMVQDEVSQQLILTNLSLTSSGTVRCVATNMQSGASCELTLVSVPQGRVA 240
DB 184 TPTTSPGSMVQDEVSQQLILTNLSLTSSGTVRCVATNMQSGASCELTLVSVPQGRVA 243
QY 241 GALIGVLLGVLLLSVAAFCLVRFOKRGKKPKETVGGSDLRDAIAPGISHTCMRADSS 300
DB 244 GALIGVLLGVLLLSVAAFCLVRFOKRGKKPKETVGGSDLRDAIAPGISHTCMRADSS 303
QY 301 KGFLERPSSASTVTTTKSKLPMVW 324
DB 304 KGFLERPSSASTVTTTKSKLPMVW 327

RESULT 15
ADB80832
ID ADB80832 standard; protein; 327 AA.
XX
AC ADB80832;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO7154.
XX Human; secreted and transmembrane protein; PRO; cytostatic; vulnerary;
KW antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW

KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX
 OS Homo sapiens.
 XX US2003088068-A1.
 PN
 XX 08-MAY-2003.
 XX
 XX 13-AUG-2002; 2002US-00219481.
 XX
 XX 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI: 2003-657982/62.
 DR N-PSDB; ADB80831.
 DR
 XX

US2003088068-A1.

08-MAY-2003.

13-AUG-2002; 2002US-00219481.

01-JUN-2001; 2001WO-US017800.

29-JUN-2001; 2001WO-US021066.

09-APR-2002; 2002US-00119480.

(GETH) GENENTECH INC.

Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 WPI: 2003-657982/62.
 N-PSDB; ADB80831.

One hundred and twenty two nucleic acids encoding PRO polypeptides,
 useful in gene therapy, chromosome identification, tissue typing, or as
 hybridization probes in chromosome and gene mapping.

Claim 11; Fig 236; 305pp; English.

The invention describes an isolated PRO (secreted and transmembrane)
 polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 useful for stimulating the proliferation of or gene expression in
 pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 for stimulating the proliferation or differentiation of chondrocyte
 cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 are useful for stimulating the release of tumour necrosis factor (TNF)-
 alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
 PRO1286, PRO1330, PRO1347, PRO1305, PRO1279, PRO1340, PRO1338,
 PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4344, PRO4322,
 PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 stimulating the proliferation of normal human dermal fibroblasts cells.
 PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1486, PRO4302, PRO4408,
 PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 are useful for detecting the presence of tumour in a mammal which
 involves comparing the level of expression of the above PRO polypeptides
 in a test sample of cells taken from the mammal, and a control sample of
 normal cells of the same cell type, where a higher level of expression of
 the PRO polypeptides in the test sample as compared to the control sample
 is indicative of the presence of tumour in the mammal. The tumour is lung
 tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 liver tumour. (I) is useful as molecular weight markers, for tissue
 typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 useful for chromosome and gene mapping or gene therapy. (II) is useful
 for generating transgenic animals or knock-out animals which are useful
 screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 sport injuries). This is the amino acid sequence of a human secreted and
 transmembrane PRO polypeptide.

Sequence 327 AA;

Query Match 99.5%; Score 1677; DB 7; Length 327;
 Best Local Similarity 99.7%; Pred. No. 6.8e-113;
 Matches 323; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 LPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 60
 |||||
 Db 4 LPGPFLCGALLGFLCLSLGLAVEVKVPTPEPLSTPLGKTAELTCTYSTSVGDSFALEWSFVQ 63
 |||||
 QY 61 PGKPISESHPILYFTNGHLYPTGSKSKRVSLLLQNPPTVGVATLKLTDVHPSDTGTLYLCOV 120
 |||||
 Db 64 PGKPISESHPILYFTNGHLYPTGSKSKRVSLLLQNPPTVGVATLKLTDVHPSDTGTLYLCOV 123
 |||||
 QY 121 NNPPDPFTYNGLGLINLTVLVPPSNPLCSOSGQTSVGGSTALRCSSEGAPKPVYNWVRLG 180
 |||||
 Db 124 NNPPDPFTYNGLGLINLTVLVPPSNPLCSOSGQTSVGGSTALRCSSEGAPKPVYNWVRLG 183
 |||||
 QY 181 TFTPSPFGSMVQDEVSGQLILTNLSLTSGTYRCVATNQMGSAACELTLSVTPEPPQGRVA 240
 |||||
 Db 184 TFTPSPFGSMVQDEVSGQLILTNLSLTSGTYRCVATNQMGSAACELTLSVTPEPPQGRVA 243
 |||||
 QY 241 GALIGVLLGVLLLSVAACFLVRFQKRGKKPKETYGGSDLRDAIAPGISEHTCMRADSS 300
 |||||
 Db 244 GALIGVLLGVLLLSVAACFLVRFQKRGKKPKETYGGSDLRDAIAPGISEHTCMRADSS 303
 |||||
 QY 301 KGFLERPSSASTVTTTTSKSLPMVV 324
 |||||
 Db 304 KGFLERPSSASTVTTTTSKSLPMVV 327
 |||||

Search completed: August 4, 2005, 06:07:06
 Job time : 99.8153 secs

This Page Blank (uspto)